Sentence,class,file
"Available from:   http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformation   forPatientsandProviders /ucm124713.ht m. Accessed September  25,  2014.",Non-OADS,/arxiv_data1/oa_pdf/3d/a5/dmso-8-241.PMC4445788.pdf
"Available from: http://www.fda.gov/Drugs/ DrugSafety /PostmarketDrugSafetyInformationforPatientsandProvide rs/DrugSafetyInformationforHeathcareProfessionals/ucm183764.ht m.  Accessed September  25, 2014.",Non-OADS,/arxiv_data1/oa_pdf/3d/a5/dmso-8-241.PMC4445788.pdf
"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/diabetes-metabolic-syndrome-and-obesity-targets-and-therapy-journa lDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy is  an international, peer-reviewed open-access journal committed to  the rapid publication of the latest laboratory and clinical findings  in the fields of diabetes, metabolic syndrome and obesity research.",Non-OADS,/arxiv_data1/oa_pdf/3d/a5/dmso-8-241.PMC4445788.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/3d/a5/dmso-8-241.PMC4445788.pdf
Available from: http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.,Non-OADS,/arxiv_data1/oa_pdf/3d/a5/dmso-8-241.PMC4445788.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/1a/3f/prom-6-127.PMC4445789.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph p Patient Related Outcome Measures 2015:6 127–138 Patient Related Outcome Measures Dove press submit your manuscript | www.dovepress.co m Dove press  127Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/PROM.S4958 9Optimal delivery of colorectal cancer follow-up  care: improving patient outcomes Mikaela L Jorgensen1 Jane M Y oung1,2 Michael J Solomon2,3 1Cancer epidemiology and Services  Research (C eSR), Sydney School  of Public Health, Sydney Medical  School, University of Sydney, Sydney,   NSw , Australia; 2Surgical Outcomes  Research Centre (SOuRCe), Sydney  Local Health District and University  of Sydney, Sydney, NSw , Australia;   3Discipline of Surgery, University of  Sydney, Sydney, NSw , Australia Correspondence: Jane M Young   Cancer epidemiology and Services  Research (CeSR), Level 6, The Lifehouse  (C39Z), 119-143 Missenden Road,  Camperdown, NSw 2050, Australia   Tel +61 2 8627 1559   email jane.young@sydney.edu.a uAbstract:  Colorectal cancer (CRC) is the third most commonly diagnosed cancer worldwide.",Non-OADS,/arxiv_data1/oa_pdf/1a/3f/prom-6-127.PMC4445789.pdf
Available from: http://globocan.iarc.fr/Pages/ fact_sheets_cancer.aspx .,Non-OADS,/arxiv_data1/oa_pdf/1a/3f/prom-6-127.PMC4445789.pdf
"Patient Related Outcome Measures Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/patient-related-outcome-measures-journa lPatient Related Outcome Measures is an international, peer-reviewed,  open access journal focusing on treatment outcomes specifically  relevant to patients.",Non-OADS,/arxiv_data1/oa_pdf/1a/3f/prom-6-127.PMC4445789.pdf
"Open Access This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which per- mits any noncommercial use, distribution, and reproduction in anymedium, provided you give appropriate credit to the original author(s)and the source, provide a link to the Creative Commons license, and indicate if changes were made.",Non-OADS,/arxiv_data1/oa_pdf/b4/bd/40265_2015_Article_392.PMC4445819.pdf
Available from: http://www.novartis.,Non-OADS,/arxiv_data1/oa_pdf/b4/bd/40265_2015_Article_392.PMC4445819.pdf
Available from: http://dailymed.nlm.,Non-OADS,/arxiv_data1/oa_pdf/b4/bd/40265_2015_Article_392.PMC4445819.pdf
Available from: http://www.pharma.us.novartis.com/product/pi/pdf/voltaren_xr.,Non-OADS,/arxiv_data1/oa_pdf/b4/bd/40265_2015_Article_392.PMC4445819.pdf
Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/0 21005s013lbl.pdf .,Non-OADS,/arxiv_data1/oa_pdf/b4/bd/40265_2015_Article_392.PMC4445819.pdf
Available from: http://www.accessdata.fda.gov/drugsatfda_ docs/label/2009/022122s006lbl.pdf .,Non-OADS,/arxiv_data1/oa_pdf/b4/bd/40265_2015_Article_392.PMC4445819.pdf
Available from: http://www.zipsor.com/ﬁles/PI.pdf .,Non-OADS,/arxiv_data1/oa_pdf/b4/bd/40265_2015_Article_392.PMC4445819.pdf
Available from: https://www.iroko.com/wp-content/uploads/2013/10/Zorvolex_ PI_10-18-2013.pdf .,Non-OADS,/arxiv_data1/oa_pdf/b4/bd/40265_2015_Article_392.PMC4445819.pdf
"Lake Forest: Hospira, Inc.; 1998 [updated 12/20141; cited 2015 March 17]; Available from: http://www.accessdata.fda.gov/drugsatfda_docs/ label/2014/022396lbl.pdf .",OADS,/arxiv_data1/oa_pdf/b4/bd/40265_2015_Article_392.PMC4445819.pdf
Available from: https://www.consumerreports.org/health/ resources/pdf/best-buy-drugs/Nsaids2.pdf .,Non-OADS,/arxiv_data1/oa_pdf/b4/bd/40265_2015_Article_392.PMC4445819.pdf
Avail- able from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/ 2009/022202s000chemr.pdf .,Non-OADS,/arxiv_data1/oa_pdf/b4/bd/40265_2015_Article_392.PMC4445819.pdf
Available from: https://www.google.com/patents/US5256699 .,Non-OADS,/arxiv_data1/oa_pdf/b4/bd/40265_2015_Article_392.PMC4445819.pdf
Available from: http://www.fda.gov/ Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatients andProviders/ucm150314.htm .,Non-OADS,/arxiv_data1/oa_pdf/b4/bd/40265_2015_Article_392.PMC4445819.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/54/f2/imcrj-8-103.PMC4445867.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pInternational Medical Case Reports Journal 2015:8 103–106International Medical Case Reports Journal Dove press submit your manuscript | www.dovepress.co m Dove press  103Case Repo Rtopen access to scientific and medical research open access Full text article http: //dx.doi.org/10.2147/IMCRJ.S8267 9Unilateral corneal leukoplakia   without limbal involvement Koji Hirano1 Mihoko Koide2 Y oshikazu Mizoguchi3 Yasuhiro osakabe4 Kaoru-araki sasaki5 1Department of ophthalmology, Ban  Buntane Hotokukai Hospital, school  of Medicine, Fujita Health University,   Nagoya, Japan;  2Koide Internal  Medicine and eye Clinic, Nagoya,   Japan;  3Department of pathology, Ban  Buntane Hotokukai Hospital, school  of Medicine, Fujita Health University,   Nagoya, Japan;  4Department of  Molecular p athology, tokyo Medical  University, tokyo, Japan;  5Department  of ophthalmology, Japan Health Care  organization, Hoshigaoka Medical  Center, Hirakata, Japan Correspondence: Koji Hirano   Department of ophthalmology,   Ban Buntane Hotokukai Hospital,   school of Medicine, Fujita Health  University,  3-6-10, otoubashi,  Nakagawa-ku, Nagoya  454-8509, Japan   tel +81 52 321 8171  Fax +81 52 322 4734  email kojihira@fujita-hu.ac.j pPurpose:  Leukoplakia is the term given to a white patch or plaque that is found mainly on the  oral mucus membrane.",Non-OADS,/arxiv_data1/oa_pdf/54/f2/imcrj-8-103.PMC4445867.pdf
"International Medical Case Reports Journal Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-medical-case-reports-journal-journa lThe International Medical Case Reports Journal is an international,  peer-reviewed open-access journal publishing original case reports  from all medical specialties.",Non-OADS,/arxiv_data1/oa_pdf/54/f2/imcrj-8-103.PMC4445867.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/54/f2/imcrj-8-103.PMC4445867.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/f8/ee/imcrj-8-107.PMC4445868.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pInternational Medical Case Reports Journal 2015:8 107–110International Medical Case Reports Journal Dove press submit your manuscript | www.dovepress.co m Dove press  107Case Repo Rtopen access to scientific and medical research open access Full text article http: //dx.doi.org/10.2147/IMCRJ.S8418 5Toxocara  polymerase chain reaction on ocular  fluids in bilateral granulomatous chorioretinitis Jenny Xue tian1 Stephen O’Hagan2 1Ophthalmology Department, Cairns  Base Hospital, Cairns, QLD, Australia;   2Ophthalmology, James Cook  University, Cairns, QLD, Australia Correspondence: Jenny Xue tian   Ophthalmology Department, Cairns  Base Hospital, 165 The Esplanade, Cairns  4870, QLD, Australia   tel +61 4 2427 4229   email jenny.tian@uqconnect.edu.a uAbstract:  To report a rare case of bilateral granulomatous chorioretinitis complicated by bilateral  peripapillary choroidal neovascular membranes.",Non-OADS,/arxiv_data1/oa_pdf/f8/ee/imcrj-8-107.PMC4445868.pdf
Available from: http://www.reviewofophthalmology.,Non-OADS,/arxiv_data1/oa_pdf/f8/ee/imcrj-8-107.PMC4445868.pdf
"Available from:  https://books.google.com.au/books?id=Vv59BwAAQBAJ&pg=PA3& dq=Infectious+diseases+of+Australia&hl=en&sa=X&ei=WBg7Vd2rN 6a5mwWrnoHQAw&ved=0CB0Q6AEwAA#v=onepage&q=Infectiou s%20diseases%20of%20Australia&f=fals e. Accessed April 25, 2015.",Non-OADS,/arxiv_data1/oa_pdf/f8/ee/imcrj-8-107.PMC4445868.pdf
Available from: http://informahealthcare.com/doi/abs/10.,Non-OADS,/arxiv_data1/oa_pdf/f8/ee/imcrj-8-107.PMC4445868.pdf
"Available from: http://www.pbs.gov.au/info/industry/ listing/elements/pbac-meetings/psd/2012-11/ranibizumab-lucenti s.  Accessed April 13, 2015.",Non-OADS,/arxiv_data1/oa_pdf/f8/ee/imcrj-8-107.PMC4445868.pdf
"International Medical Case Reports Journal Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-medical-case-reports-journal-journa lThe International Medical Case Reports Journal is an international,  peer-reviewed open-access journal publishing original case reports  from all medical specialties.",Non-OADS,/arxiv_data1/oa_pdf/f8/ee/imcrj-8-107.PMC4445868.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/f8/ee/imcrj-8-107.PMC4445868.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/a0/5a/ndt-11-1211.PMC4445869.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpNeuropsychiatric Disease and Treatment 2015:11 1211–1219Neuropsychiatric Disease and Treatment Dove press submit your manuscript | www.dovepress.co m Dove press  1211OrigiNal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/NDT .S8043 8Differences in gray matter volume corresponding  to delusion and hallucination in patients with  schizophrenia compared with patients who have  bipolar disorder Jinuk song1 Doug hyun han1 sun Mi Kim1 Ji sun hong1 Kyung Joon Min1 Jae hoon cheong2 Bung Nyun Kim3 1Department of Psychiatry, chung  ang University hospital, 2Uimyung  research institute for Neuroscience,   samyook University, 3Department  of Psychiatry, seoul National hospital,   seoul, south KoreaBackground:  Although schizophrenia and bipolar disorder (BD) are classified as different  disease entities, they share critical pathognomonic symptoms in terms of hallucination and  delusion.",Non-OADS,/arxiv_data1/oa_pdf/a0/5a/ndt-11-1211.PMC4445869.pdf
"Delusion is a  false belief based on an incorrect inference about external reality.2 Due to different  treatment methods and prognosis, early differential diagnosis and determination are correspondence: Doug hyun han Department of Psychiatry, chung ang  University hospital, heukseok ro 102,  seoul, 156-755, south Korea Tel +82 2 6299 3132 Fax +82 2 6298 1508 email hduk@yahoo.co m Journal name: Neuropsychiatric Disease and Treatment Article Designation: Original Research Y ear: 2015 Volume: 11 Running head verso: Song et al Running head recto: Hallucination, delusion, and gray matter DOI: http://dx.doi.org/10.2147/NDT.S80438",Non-OADS,/arxiv_data1/oa_pdf/a0/5a/ndt-11-1211.PMC4445869.pdf
Images were  reconstructed using the voxel-based morphometry toolbox  (http://dbm.neuro.uni-jena.de/vbm /).,OADS,/arxiv_data1/oa_pdf/a0/5a/ndt-11-1211.PMC4445869.pdf
"Neuropsychiatric Disease and Treatment Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/neuropsychiatric-disease-and-treatment-journa lNeuropsychiatric Disease and Treatment is an international, peer- reviewed journal of clinical therapeutics and pharmacology focusing   on concise rapid reporting of clinical or pre-clinical studies on a   range of neuropsychiatric and neurological disorders.",Non-OADS,/arxiv_data1/oa_pdf/a0/5a/ndt-11-1211.PMC4445869.pdf
Visit http://www.dovepress.com/testimonials.ph p to  read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/a0/5a/ndt-11-1211.PMC4445869.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/9a/86/ndt-11-1221.PMC4445870.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pNeuropsychiatric Disease and Treatment 2015:11 1221–1229Neuropsychiatric Disease and Treatment Dove press submit your manuscript | www.dovepress.co m Dove press  1221Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/NDT .S6051 8Comparative efficacy of alemtuzumab  and established treatment in the management  of multiple sclerosis Rachel Babij Jai S Perumal Department of Neurology, Weill  Cornell Medical College, New Y ork,   NY, USAAbstract:  Alemtuzumab is the newest disease-modifying therapy approved for the treatment  of relapsing multiple sclerosis.",Non-OADS,/arxiv_data1/oa_pdf/9a/86/ndt-11-1221.PMC4445870.pdf
"Importantly, all medications are approved for the treatment of relapsing MS.  Clinical trials have demonstrated efficacy in the relapsing forms of MS, but Correspondence: Jai S Perumal Department of Neurology, Weill Cornell  Medical College, 1305 York Avenue,  New York, NY 10021, USA Tel +1 646 962 5733 Fax +1 646 962 0390 email jsp9007@med.cornell.ed uJournal name: Neuropsychiatric Disease and Treatment Article Designation: Review Y ear: 2015 Volume: 11 Running head verso: Babij and Perumal Running head recto: Alemtuzumab in multiple sclerosis DOI: http://dx.doi.org/10.2147/NDT.S60518",Non-OADS,/arxiv_data1/oa_pdf/9a/86/ndt-11-1221.PMC4445870.pdf
"Rare cases  of lymphoproliferative disorders and lymphoma, including  mucosa-associated lymphoid tissue lymphoma, Castleman’s  disease, and a case of non-Epstein-Barr virus-associated  Burkitt’s lymphoma which was fatal following treatment  have been reported in MS patients treated with alemtu - zumab ( http://www.fda.gov/downloads/Drugs/ DrugSafety / PostmarketDrugSafetyInformationfor PatientsandProviders / UCM425409.pd f).",Non-OADS,/arxiv_data1/oa_pdf/9a/86/ndt-11-1221.PMC4445870.pdf
"As to  its order of use in the treatment sequence, while in Europe  the European Medicines Agency states that “Lemtrada is  indicated for adult patients with relapsing remitting multiple  sclerosis (RRMS) with active disease defined by clinical  or imaging features” ( http://www.ema.europa.eu/docs/ en_GB/ document_library /EPAR_- _Product_Information / human/003718/WC500150521.pd f), and hence it could be  potentially used as first-line therapy, the FDA in its approval  states that “Because of its safety profile, the use of Lemtrada  should generally be reserved for patients who have had an  inadequate response to two or more drugs indicated for the  treatment of MS.” Hence, in the USA, alemtuzumab will be  used mainly as an escalation therapy rather than as an initial  induction agent.",Non-OADS,/arxiv_data1/oa_pdf/9a/86/ndt-11-1221.PMC4445870.pdf
Available from: http://www.medscape.com/ viewarticle/83499 4.,Non-OADS,/arxiv_data1/oa_pdf/9a/86/ndt-11-1221.PMC4445870.pdf
"Available from: http://www.nationalmsso - ciety.org/Treating-MS/Medication s. Accessed April 9, 2015.",Non-OADS,/arxiv_data1/oa_pdf/9a/86/ndt-11-1221.PMC4445870.pdf
"Neuropsychiatric Disease and Treatment Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/neuropsychiatric-disease-and-treatment-journa lNeuropsychiatric Disease and Treatment is an international, peer- reviewed journal of clinical therapeutics and pharmacology focusing   on concise rapid reporting of clinical or pre-clinical studies on a   range of neuropsychiatric and neurological disorders.",Non-OADS,/arxiv_data1/oa_pdf/9a/86/ndt-11-1221.PMC4445870.pdf
Visit http://www.dovepress.com/testimonials.ph p to  read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/9a/86/ndt-11-1221.PMC4445870.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/a5/8f/ijwh-7-501.PMC4445871.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpInternational Journal of Women’s Health 2015:7 501–509International Journal of Women’s Health Dove press submit your manuscript | www.dovepress.co m Dove press  501OrIg Inal researcHopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/IJWH.S7794 2Hormone withdrawal-associated symptoms  with ethinylestradiol 20 μg/drospirenone 3 mg  (24/4 regimen) versus ethinylestradiol 20 μg/ desogestrel 150 μg (21/7 regimen) Johannes Bitzer1 Maria Jesusa Banal-silao2 Hans-Joachim ahrendt3 Jaime restrepo4 Marion Hardtke5 Ulrike Wissinger- graefenhahn6 Dietmar Trummer7 1Department of Obstetrics and   gynecology, University Hospital of  Basel, Basel, switzerland; 2University  of the Philippines college of Medicine,   Manila, Philippines; 3Praxis für  Frauenheilkunde, Klinische Forschung  und Weiterbildung ( clinical research  and Further education), Magdeburg,   germany; 4centro de Investigación  clínica, clinica Medellin Poblado,   Medellin, colombia; 5global clinical  Development Operations, Bayer  Pharma ag, Berlin, germany; 6global  Medical affairs Women’s Healthcare,   Bayer Pharma ag, Berlin, germany;   7clinical statistics europe, Bayer  Pharma ag, Berlin, germanyObjective:  To assess whether the combined oral contraceptive (COC) ethinylestradiol (EE)  20 μg/drospirenone 3 mg taken in a 24/4-day regimen (ie, 4-day hormone-free interval) is more  effective than an EE 20 μg/desogestrel (DSG) 150 μg COC taken in a 21/7-day regimen (ie, 7-day  hormone-free interval) in reducing hormone withdrawal-associated symptoms (HWAS).",Non-OADS,/arxiv_data1/oa_pdf/a5/8f/ijwh-7-501.PMC4445871.pdf
"COCs with a shortened HFI (eg, from 7 days to 5 days, 4 days,  or even 2 days) provide markedly greater suppression of ovarian activity and limit the  extent of exogenous hormonal fluctuations throughout the cycle, and have been shown correspondence: Johannes Bitzer University Hospital of Basel, Frauenklinik,  chefarzt/Vorsteher, spitalstrasse 21,  cH-4031, Basel, switzerland Tel +41 61 265 90 99 Fax +41 61 265 91 99 email johannes.bitzer@usb.c h Journal name: International Journal of Women’s Health Article Designation: Original Research Y ear: 2015 Volume: 7 Running head verso: Bitzer et al Running head recto: Hormone withdrawal-associated symptoms DOI: http://dx.doi.org/10.2147/IJWH.S77942",Non-OADS,/arxiv_data1/oa_pdf/a5/8f/ijwh-7-501.PMC4445871.pdf
"International Journal of Women’s Health Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-womens-health-journa lThe International Journal of Women’s Health is an international, peer- reviewed open-access journal publishing original research, reports,  editorials, reviews and commentaries on all aspects of women’s  healthcare including gynecology, obstetrics, and breast cancer.",Non-OADS,/arxiv_data1/oa_pdf/a5/8f/ijwh-7-501.PMC4445871.pdf
Visit http://www.dovepress.com/testimonials.ph p to read real quotes  from published authors.,Non-OADS,/arxiv_data1/oa_pdf/a5/8f/ijwh-7-501.PMC4445871.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/c7/01/oajsm-6-149.PMC4445872.pdf
Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pOpen Access Journal of Sports Medicine 2015:6 149–159Open Access Journal of Sports Medicine Dove press submit your manuscript | www.dovepress.co m Dove press  149Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/OAJSM.S7927 3what predicts performance in ultra-triathlon  races?,Non-OADS,/arxiv_data1/oa_pdf/c7/01/oajsm-6-149.PMC4445872.pdf
"The full distance of Triple Deca iron ultra-triathlon is planned for the end of 2015  in Monterrey, Mexico.Table  2 The first editions and the first women and men to finish  the distances First race First man to   finishFirst woman to  finish 1985 Double iron in   Huntsville (USA)wiseman (USA)   in 25:35 h:min1986 Montgomery  (USA) in 33:54 h:min 1988 Triple iron in   Le Fontanil (FRA)wiseman (USA)   in 39:38 h:min1989 Andonie (MeX)  in 51:53 h:min 1989 Quadruple iron   in Den Haag (NeD)Feijen (NeD) in   58:10 h:min1991 Andonie (MeX)  in 72:37 h:min 1991Quintuple iron   in Den Haag (NeD)Feijen (NeD) in   77:11 h:min1991 Andonie (MeX)  in 100:15 h:min 1992 Deca iron in   Monterrey (MeX)Feijen (NeD) in   213:41 h:min1992 Andonie (MeX)  in 249:14 h:min 1998 Double Deca   in Monterrey (MeX)Urbonas (LiT)   in 437:21 h:min1998 Andonie (MeX)  in 643:01 h:min Note:  Data from http://www.iutasport.co m.6 Abbreviations:  h, hours; min, minutes; NeD, the Netherlands; FRA, France;  LiT, Lithuania; MeX, Mexico; USA, United States of America.",Non-OADS,/arxiv_data1/oa_pdf/c7/01/oajsm-6-149.PMC4445872.pdf
"A literature search was performed with the data  base PubMed ( http://www.ncbi.nlm.nih.gov/pubmed /) using  the terms “ultra” and “triathlon” for the aspects of “ultra- triathlon”, “Ironman”, and “triathlon” for the aspects of “Iron - man triathlon”.",Non-OADS,/arxiv_data1/oa_pdf/c7/01/oajsm-6-149.PMC4445872.pdf
"Open Access Journal of Sports Medicine 2015:6Table  3 world records in ultra-triathlon Distance Men Women Athlete Race time  (h:min)Year and race Athlete Race time  (h:min)Year and race Double iron Brennwald (SUi) 19:50 2011 Neulengbach (AUT) Bischoff (USA) 22:07 1994 Huntsville (USA) Triple iron wildpanner (AUT) 31:47 2003 Lensahn (GeR) Benöhr (GeR) 37:54 1996 Lensahn (GeR) Quadruple   ironHojbjerre (DeN) 53:41 1993 Székesfehérvár (HUN) Benöhr (GeR) 59:15 1993 Székesfehérvár (HUN) Quintuple   ironConraux (FRA) 73:18 2005 Monterrey (MeX) Benöhr (GeR) 86:44 1994 Den Haag (NeD) Deca iron Lucas (FRA) 192:98 1997 Monterrey (MeX) Andonie (MeX) 249:14 1992 Monterrey (MeX) Double   Deca ironUrbonas (LiT) 437:21 1998 Monterrey (MeX) Andonie (MeX) 643:01 1998 Monterrey (MeX) Note:  Data from http://www.iutasport.co m.6 Abbreviations:  h, hours; min, minutes; AUT, Austria; DeN, Denmark; FRA, France; GeR, Germany; HUN, Hungary; LiT, Lithuania; MeX, Mexico; NeD, Netherlands; SUi,  Switzerland; USA, United States of America.",Non-OADS,/arxiv_data1/oa_pdf/c7/01/oajsm-6-149.PMC4445872.pdf
"Available  from: http://www.ironman.com/triathlon/events/americas/ironman/world- championship.aspx#axzz3UOzTj0s C. Accessed December 12, 2014.",Non-OADS,/arxiv_data1/oa_pdf/c7/01/oajsm-6-149.PMC4445872.pdf
"Open Access Journal of Sports Medicine Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/open-access-journal-of-sports-medicine-journa lOpen Access Journal of Sports Medicine is an international,  peer-reviewed, open access journal publishing original research,  reports, reviews and commentaries on all areas of sports  medicine.",Non-OADS,/arxiv_data1/oa_pdf/c7/01/oajsm-6-149.PMC4445872.pdf
Visit http://www.dovepress.com/testimonials.ph p to read real quotes  from published authors.,Non-OADS,/arxiv_data1/oa_pdf/c7/01/oajsm-6-149.PMC4445872.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/f2/48/ijn-10-3623.PMC4445873.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pInternational Journal of Nanomedicine 2015:10 3623–3640International Journal of Nanomedicine Dove press submit your manuscript | www.dovepress.co m Dove press  3623OrIg INal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/IJN.S7835 5Doxorubicin-loaded aromatic imine-contained  amphiphilic branched star polymer micelles:  synthesis, self-assembly, and drug delivery liang Qiu  chun-Yan hong  cai-Yuan Pan chinese academy of sciences Key  laboratory of soft Matter chemistry,   Department of Polymer science and  engineering, University of science and  T echnology of china, hefei, anhui,   People’s republic of chinaAbstract:  Redox- and pH-sensitive branched star polymers (BSPs), BP(DMAEMA-co- MAEBA-co-DTDMA)(PMAIGP)ns, have been successively prepared by two steps of reversible  addition–fragmentation chain transfer (RAFT) polymerization.",Non-OADS,/arxiv_data1/oa_pdf/f2/48/ijn-10-3623.PMC4445873.pdf
"Keywords:  RAFT polymerization, controlled release, doxorubicin, branched star polymer,  pH-sensitive Introduction In the past decades, various drug delivery approaches have been developed to achieve  target delivery, highly therapeutic efficacy, and minimal side effects.1 As one of the  most promising nanocarrier systems, self-assembled polymeric micelles have attracted  significant attention due to their unique features, such as enhancing aqueous solubil - ity of the drug, prolonging circulation time, reducing systemic adverse effects, and  preferential accumulation at the tumor site owing to the enhanced permeability and  retention effect.2–6 Various architectural polymers including linear polymers, dendrim - ers, hyperbranched polymers, and dendronized polymers have been utilized to construct  nanocarriers.7–11 Compared to the linear polymers, branched polymers possess some  advantages, including a number of surface groups and hollow voids of the branching  architecture, which make them attractive in drug delivery applications.12–16 correspondence: cai-Yuan Pan;   chun-Yan hong chinese academy of sciences Key  laboratory of soft Matter chemistry,  Department of Polymer science and  engineering, University of science and  Technology of china, hefei anhui  230026, People’s republic of china Tel +86 551 6360 3264;   +86 551 6360 6081 email pcy@ustc.edu.c n;   hongcy@ustc.edu.c nJournal name: International Journal of Nanomedicine Article Designation: Original Research Y ear: 2015 Volume: 10 Running head verso: Qiu et al Running head recto: Doxorubicin-loaded micelle synthesis, self-assembly, and delivery  DOI: http://dx.doi.org/10.2147/IJN.S78355",Non-OADS,/arxiv_data1/oa_pdf/f2/48/ijn-10-3623.PMC4445873.pdf
"International Journal of Nanomedicine Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-nanomedicine-journa lThe International Journal of Nanomedicine is an international, peer- reviewed journal focusing on the application of nanotechnology   in diagnostics, therapeutics, and drug delivery systems throughout   the biomedical field.",Non-OADS,/arxiv_data1/oa_pdf/f2/48/ijn-10-3623.PMC4445873.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/f2/48/ijn-10-3623.PMC4445873.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/a5/40/ijn-10-3663.PMC4445874.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pInternational Journal of Nanomedicine 2015:10 3663–3685International Journal of Nanomedicine Dove press submit your manuscript | www.dovepress.co m Dove press  3663OrIg INal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/IJN.S8013 4cetuximab-conjugated iron oxide nanoparticles  for cancer imaging and therapy shih-heng Tseng1,2 Min-Yuan chou2 I-Ming chu1 1Department of chemical engineering,   National Tsing hua University,   2Biomedical Technology and Device  research laboratories, Industrial  T echnology research Institute,   hsinchu, TaiwanAbstract:  We have developed a theranostic nanoparticle, ie, cet-PEG-dexSPIONs, by  conjugation of the anti-epidermal growth factor receptor (EGFR) monoclonal antibody, cetux - imab, to dextran-coated superparamagnetic iron oxide nanoparticles (SPIONs) via periodate  oxidation.",Non-OADS,/arxiv_data1/oa_pdf/a5/40/ijn-10-3663.PMC4445874.pdf
"Studies have also reported that high levels of EGFR expression in tumors correlate  with a poor prognosis and reduced recurrence-free or overall survival rates.2–4 Cetuximab (C225, Erbitux®) is a chimeric human/murine monoclonal antibody in  the immunoglobulin (Ig)G1 class that specifically targets the human EGFR with a 2-log  higher affinity than the natural ligands, transforming growth factor- α and epidermal  growth factor.5 The US Food and Drug Administration has approved cetuximab as  first-line treatment for K-ras  wild-type EGFR-expressing metastatic colorectal cancer  in combination with FOLFIRI (irinotecan, 5-fluorouracil, and leucovorin).6,7 Cetuximab  is also indicated for the treatment of locally advanced squamous cell carcinoma of  the head and neck in combination with radiation therapy and for treatment of recur - rent or metastatic squamous cell carcinoma of the head and neck as a single agent.8  correspondences: Min-Yuan chou Biomedical Technology and Device  research laboratories, Industrial  Technology research Institute,  195, section 4, chung hsing road,  chutung, hsinchu 31040, Taiwan Tel +886 3591 2144 Fax +886 3591 0097 email minyuanc@itri.org.t w I-Ming chu Department of chemical engineering,  National Tsing hua University,  101 section 2, Kuang-Fu road,  hsinchu 30013, Taiwan Tel +886 3571 3704 Fax +886 3571 5408 email chuiming123@gmail.co mJournal name: International Journal of Nanomedicine Article Designation: Original Research Y ear: 2015 Volume: 10 Running head verso: Tseng et al Running head recto: Cet-PEG-dexSPIONs for cancer imaging and therapy DOI: http://dx.doi.org/10.2147/IJN.S80134",Non-OADS,/arxiv_data1/oa_pdf/a5/40/ijn-10-3663.PMC4445874.pdf
"International Journal of Nanomedicine Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-nanomedicine-journa lThe International Journal of Nanomedicine is an international, peer- reviewed journal focusing on the application of nanotechnology   in diagnostics, therapeutics, and drug delivery systems throughout   the biomedical field.",Non-OADS,/arxiv_data1/oa_pdf/a5/40/ijn-10-3663.PMC4445874.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/a5/40/ijn-10-3663.PMC4445874.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/1d/37/jmdh-8-217.PMC4445875.pdf
Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pJournal of Multidisciplinary Healthcare 2015:8 217–228Journal of Multidisciplinary Healthcare Dove press submit your manuscript | www.dovepress.co m Dove press  217Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/JMDH.S7452 9Use of oral anticoagulants in African-American  and Caucasian patients with atrial fibrillation:   is there a treatment disparity?,Non-OADS,/arxiv_data1/oa_pdf/1d/37/jmdh-8-217.PMC4445875.pdf
"Available  from: http://www.heart.org/idc/groups/heart-public/@wcm/@hcm/   documents/downloadable/ucm_300294.pd f. Accessed October 30, 2013.",Non-OADS,/arxiv_data1/oa_pdf/1d/37/jmdh-8-217.PMC4445875.pdf
"Available  from: http://kff.org/medicare/report/examining-sources-of- supplemental- insurance-and-prescriptio n. Accessed December 9, 2014.",Non-OADS,/arxiv_data1/oa_pdf/1d/37/jmdh-8-217.PMC4445875.pdf
"Available from: http://packageinserts.bms.com/pi/pi_coumadin.pd f.  Accessed October 11, 2013.",OADS,/arxiv_data1/oa_pdf/1d/37/jmdh-8-217.PMC4445875.pdf
"Available from http://www.accessdata.fda.gov/drugsatfda_docs/ label/2015/206316lbl.pd f. Accessed January 22, 2015.",Non-OADS,/arxiv_data1/oa_pdf/1d/37/jmdh-8-217.PMC4445875.pdf
Available from: http://www.accessdata.,OADS,/arxiv_data1/oa_pdf/1d/37/jmdh-8-217.PMC4445875.pdf
"Available from: http://packageinserts.bms.com/ pi/pi_eliquis.pd f. Accessed March 20, 2014.",Non-OADS,/arxiv_data1/oa_pdf/1d/37/jmdh-8-217.PMC4445875.pdf
"Journal of Multidisciplinary Healthcare Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/journal-of-multidisciplinary-healthcare-journa lThe Journal of Multidisciplinary Healthcare is an international, peer- reviewed open-access journal that aims to represent and publish research  in healthcare areas delivered by practitioners of different disciplines.",Non-OADS,/arxiv_data1/oa_pdf/1d/37/jmdh-8-217.PMC4445875.pdf
Visit http://www.dove - press.com/testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/1d/37/jmdh-8-217.PMC4445875.pdf
Available from: http://www.xareltohcp.com/sites/ default/files/pdf/xarelto_0.pdf#zoom=10 0.,OADS,/arxiv_data1/oa_pdf/1d/37/jmdh-8-217.PMC4445875.pdf
Available from: http://clinicaltrials.gov/show/ NCT0168883 0.,Non-OADS,/arxiv_data1/oa_pdf/1d/37/jmdh-8-217.PMC4445875.pdf
"Available  from: http://perosphere.com/content/research/per977.ht m. Accessed  June 6, 2013.",OADS,/arxiv_data1/oa_pdf/1d/37/jmdh-8-217.PMC4445875.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/4d/a9/ijn-10-3651.PMC4445876.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pInternational Journal of Nanomedicine 2015:10 3651–3662International Journal of Nanomedicine Dove press submit your manuscript | www.dovepress.co m Dove press  3651OrIg INal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/IJN.S81395Dual-color immunofluorescent labeling with  quantum dots of the diabetes-associated proteins  aldose reductase and T oll-like receptor 4  in the kidneys of diabetic rats Xiaomin liu1,* rui hu2,* Hongwei Lian1,3 Yang Liu4 Jing Liu1 Jianwei liu1 guimiao lin5 liwei liu6 Xiaojian Duan1 Ken-Tye Y ong2 Ling Ye1 1Institute of Gerontology and Geriatrics,   Chinese PLA General Hospital, Beijing Key  Lab of Aging and Geriatrics, Beijing, People’s  Republic of China; 2School of Electrical  and Electronic Engineering, Nanyang  T echnological University, Singapore,   Singapore; 3Department of Emergency  Medicine, Peking University Third  Hospital, Beijing, 4Department of geriatric  Nephrology, Chinese PLA General Hospital,   Beijing, 5Key Lab of Biomedical Engineering,   School of Medical Sciences, Shenzhen  University, Shenzhen, 6School of Science,   Changchun University of Science and  Technology, Changchun, People’s Republic  of China *These authors contributed equally to  this  workAbstract:  Diabetes is one of the major chronic diseases diagnosed worldwide with a common  complication of diabetic nephropathy (DN).",Non-OADS,/arxiv_data1/oa_pdf/4d/a9/ijn-10-3651.PMC4445876.pdf
"Aldose  reductase (AR) is a key enzyme in the polyol pathway that catalyzes the nicotinamide  adenine dinucleotide phosphate, reduced (NADPH)-dependent conversion of glucose Correspondences: Ling Ye Institute of Gerontology and Geriatrics,  Chinese PLA General Hospital, Beijing Key  Lab of Aging and Geriatrics, Beijing 100853,  People’s Republic of China Tel +86 10 6687 6418 email lye_301@163.co m  Ken-Tye Yong School of Electrical and Electronic Engineering,  Nanyang Technological University, 50 Nanyang  Avenue, Singapore 639798, Singapore Tel +65 6790 5444 email ktyong@ntu.edu.s g Journal name: International Journal of Nanomedicine Article Designation: Original Research Y ear: 2015 Volume: 10 Running head verso: Liu et al Running head recto: AR and TLR4 labeled with dual-color QDs DOI: http://dx.doi.org/10.2147/IJN.S81395",Non-OADS,/arxiv_data1/oa_pdf/4d/a9/ijn-10-3651.PMC4445876.pdf
"International Journal of Nanomedicine Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-nanomedicine-journa lThe International Journal of Nanomedicine is an international, peer- reviewed journal focusing on the application of nanotechnology   in diagnostics, therapeutics, and drug delivery systems throughout   the biomedical field.",Non-OADS,/arxiv_data1/oa_pdf/4d/a9/ijn-10-3651.PMC4445876.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/4d/a9/ijn-10-3651.PMC4445876.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/f0/4c/main.PMC4445878.pdf
http://dx.doi.org/10.1016/j.ebiom.2015.03.001 2352-3964/© 2015 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/f0/4c/main.PMC4445878.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/f0/4c/main.PMC4445878.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/a3/16/main.PMC4445889.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/a3/16/main.PMC4445889.pdf
http://dx.doi.org/10.1016/j.eucr.2015.03.003Urology Case Reports 3 (2015) 59 e62,Non-OADS,/arxiv_data1/oa_pdf/a3/16/main.PMC4445889.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/87/6d/ijwh-7-539.PMC4445944.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pInternational Journal of Women’s Health 2015:7 539–550International Journal of Women’s Health Dove press submit your manuscript | www.dovepress.co m Dove press  539RevIeWopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/IJWH.S8204 6Updated guidelines on screening for gestational  diabetes Yashdeep Gupta1 Bharti Kalra2 Manash P Baruah3 Rajiv Singla4 Sanjay Kalra2 1Department of Medicine,   Government Medical College and  Hospital, Chandigarh, India; 2Bharti  Hospital, Karnal, Haryana, India; 3excel  Center, Guwahati, Assam, India; 4Saket  City Hospital, New Delhi, IndiaAbstract:  Gestational diabetes mellitus (GDM) is associated with an increased risk of  complications for both mother and baby during pregnancy as well as in the postpartum period.",Non-OADS,/arxiv_data1/oa_pdf/87/6d/ijwh-7-539.PMC4445944.pdf
"Recently, the recommendations from IADPSG attempt  to redefine GDM in terms of adverse pregnancy outcomes, based on Hyperglycemia  and Adverse Pregnancy Outcome (HAPO) study results.6 But, we are still far from  attaining a holistic criteria which is based on both short and long-term outcomes.Correspondence: Yashdeep Gupta Department of Medicine, Government  Medical College and Hospital, Sector 32,  Chandigarh 160030, India Tel +91 96 4612 1573 email yash_deep_gupta@yahoo.co.i n Journal name: International Journal of Women’s Health Article Designation: Review Y ear: 2015 Volume: 7 Running head verso: Gupta et al Running head recto: Screening for gestational diabetes DOI: http://dx.doi.org/10.2147/IJWH.S82046",Non-OADS,/arxiv_data1/oa_pdf/87/6d/ijwh-7-539.PMC4445944.pdf
"Available from: http://www.bhs.org.au/airapps/Services/ au/org/bhs/govdoc/files/references/14440.pd f. Accessed January 27,  2015.",OADS,/arxiv_data1/oa_pdf/87/6d/ijwh-7-539.PMC4445944.pdf
"International Journal of Women’s Health Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-womens-health-journa lThe International Journal of Women’s Health is an international, peer- reviewed open-access journal publishing original research, reports,  editorials, reviews and commentaries on all aspects of women’s  healthcare including gynecology, obstetrics, and breast cancer.",Non-OADS,/arxiv_data1/oa_pdf/87/6d/ijwh-7-539.PMC4445944.pdf
Visit http://www.dovepress.com/testimonials.ph p to read real quotes  from published authors.,Non-OADS,/arxiv_data1/oa_pdf/87/6d/ijwh-7-539.PMC4445944.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/8d/ef/ijgm-8-203.PMC4445945.pdf
"Information on how to  request permission may be found at: http://www.dovepress.com/permissions.ph pInternational Journal of General Medicine 2015:8 203–210International Journal of General Medicine Dove press submit your manuscript | www.dovepress.co m Dove press  203OrIGInal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/IJGM.S8193 8a combined continuous and interval aerobic  training improves metabolic syndrome risk   factors in men Vahid sari-sarraf1 akbar aliasgarzadeh2 Mohammad-Mahdi  naderali3 hamid esmaeili1 ebrahim K naderali4 1Department of exercise Physiology,   Faculty of Physical education and  sport sciences, University of Tabriz,   2Bone research centre, endocrine  Unit, Department of Medicine, Tabriz  University of Medical sciences, Tabriz,   Iran; 3The school of Pharmacy and  Biomolecular sciences, liverpool John  Moores University, liverpool, 4Faculty  of science, liverpool hope University,   liverpool, UK correspondence: ebrahim K naderali   Faculty of science, liverpool hope  University, hope Park campus,   liverpool l16 9JD, UK   Tel +44 151 291 3439   Fax +44 151 291 3414   email naderae@hope.ac.u kAbstract:  Individuals with metabolic syndrome have significantly higher risk of cardiovascular  disease and type 2 diabetes leading to premature death mortality.",Non-OADS,/arxiv_data1/oa_pdf/8d/ef/ijgm-8-203.PMC4445945.pdf
Available from: http://www.world- heart-federation.org/ cardiovascular -health/cardiovascular-disease-risk- factors/obesity /.,Non-OADS,/arxiv_data1/oa_pdf/8d/ef/ijgm-8-203.PMC4445945.pdf
"International Journal of General Medicine Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-general-medicine-journa lThe International Journal of General Medicine is an international,  peer-reviewed open-access journal that focuses on general and internal  medicine, pathogenesis, epidemiology, diagnosis, monitoring and treat - ment protocols.",Non-OADS,/arxiv_data1/oa_pdf/8d/ef/ijgm-8-203.PMC4445945.pdf
Visit http://www.dovepress.com/   testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/8d/ef/ijgm-8-203.PMC4445945.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/5d/52/hmer-7-021.PMC4445946.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pHepatic Medicine: Evidence and Research 2015:7 21–27Hepatic Medicine: Evidence and Research Dove press submit your manuscript | www.dovepress.co m Dove press  21CasE sERiEsopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/HMER.S6794 0Percutaneous hepatic radiofrequency   for hepatocellular carcinoma: results   and outcome of 46 patients Julie Bertrand1 Fabrice Caillol1 Patrick Borentain2 Jean-Luc Raoul1 Laurent Heyries2 Erwan Bories1 Christian Pesenti1 Jean-Philippe Ratone2 Jean-Paul Bernard2 René Gerolami2 Marc Giovannini1 1Endoscopy Unit, Paoli Calmettes  institute, Marseille, France;   2Department of Hepato- Gastroenterology, Conception  Hospital, Marseille, France Correspondence: Fabrice Caillol   Endoscopy Unit, Paoli-Calmettes  institute, 232 bd ste Marguerite,  Marseille 13009, France   Email fcaillol@free.f rAbstract:  Radiofrequency ablation (RFA) is a curative option for hepatocellular carcinoma  (HCC), the most common primary malignancy of the liver.",Non-OADS,/arxiv_data1/oa_pdf/5d/52/hmer-7-021.PMC4445946.pdf
"Hepatic Medicine: Evidence and Research Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/hepatic-medicine-evidence-and-research-journa lHepatic Medicine: Evidence and Research is an international, peer- reviewed, open access journal covering all aspects of adult and pedi - atric hepatology in the clinic and laboratory including the following  topics: Pathology, pathophysiology of hepatic disease; Investigation  and treatment of hepatic disease; Pharmacology of drugs used for the treatment of hepatic disease.",Non-OADS,/arxiv_data1/oa_pdf/5d/52/hmer-7-021.PMC4445946.pdf
Visit http://www.dovepress.com/   testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/5d/52/hmer-7-021.PMC4445946.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/b4/93/jmdh-8-229.PMC4445947.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pJournal of Multidisciplinary Healthcare 2015:8 229–236Journal of Multidisciplinary Healthcare Dove press submit your manuscript | www.dovepress.co m Dove press  229Original researcHopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/JMDH.S8056 0nonpharmacological therapies and provision of  aids in outpatient dementia networks in germany:  utilization rates and associated factors Markus Wübbeler1 Jochen rené Thyrian1 Bernhard Michalowsky2 Johannes Hertel2 Franziska laporte Uribe3 Karin Wolf-Ostermann4 susanne schäfer-Walkmann6 Wolfgang Hoffmann2,5 1interventional Health care  research group, german center  for neurodegenerative Diseases  (DZne) rostock/ greifswald,  2german  center for neurodegenerative  Diseases (DZne) rostock/ greifswald, greifswald, germany;   3implementation and Dissemination  research group, german center for  neurodegenerative Diseases (DZne),  Witten, germany;  4Department of  Human and Health science, University  of Bremen, Bremen, germany;   5epidemiology of Health care  and community Health, institute  for community Medicine, ernst- Moritz-arndt-University greifswald,  greifswald, germany;  6institute for  applied social sciences, stuttgart,  germany correspondence: Markus Wübbeler   research group “interventional Health  care research”, german center  for neurodegenerative Diseases  (DZne), site rostock/greifswald,  ellernholzstrasse  1-2, greifswald  D-17489, germany   Tel +49 3834 86 7506   Fax +49 3834 86 19551  email markus.wuebbeler@dzne.d eBackground:  Nonpharmacological therapies and the provision of aids are described to be sup - portive in the treatment of persons with dementia (PWDs).",Non-OADS,/arxiv_data1/oa_pdf/b4/93/jmdh-8-229.PMC4445947.pdf
"Journal of Multidisciplinary Healthcare Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/journal-of-multidisciplinary-healthcare-journa lThe Journal of Multidisciplinary Healthcare is an international, peer- reviewed open-access journal that aims to represent and publish research  in healthcare areas delivered by practitioners of different disciplines.",Non-OADS,/arxiv_data1/oa_pdf/b4/93/jmdh-8-229.PMC4445947.pdf
Visit http://www.dove - press.com/testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/b4/93/jmdh-8-229.PMC4445947.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/19/b5/opth-9-885.PMC4445948.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pClinical Ophthalmology 2015:9 885–887Clinical Ophthalmology Dove press submit your manuscript | www.dovepress.co m Dove press  885Case repO rtopen access to scientific and medical research Open access Full text article http: //dx.doi.org/10.2147/OPTH.S8421 4Central retinal vein occlusion resulting  from anomalous retinal vascular anatomy  in a 24-year-old man shaheen C Kavoussi James e Kempton John J Huang Yale University Department of  Ophthalmology and Visual science,   New Haven, Ct , UsaAbstract:  An otherwise healthy 24-year-old man presented with a painless decrease of vision  in the left eye for 2 days.",Non-OADS,/arxiv_data1/oa_pdf/19/b5/opth-9-885.PMC4445948.pdf
"Com - pressive, autoimmune, and hematologic work-up including complete blood count, a  full lipid profile, antinuclear antibody, anti-neutrophil cytoplasmic antibody, ACE,  homocysteine, syphilis studies, PROC and PROS levels, anti-cardiolipin and anti- phospholipid antibodies, Factor V Leiden, ATIII, and magnetic resonance imaging  (MRI) of the brain and orbits were negative.Correspondence: shaheen C Kavoussi Yale University Department of  Ophthalmology and Visual science,  40 temple street, 3rd Floor,   New Haven, Ct 06510, Usa tel +1 203 785 2020 Fax +1 203 785 6123 email shaheen.kavoussi@yale.ed u Journal name: Clinical Ophthalmology Article Designation: Case report Y ear: 2015 Volume: 9 Running head verso: Kavoussi et al Running head recto: CRVO resulting from anomalous retinal vascular anatomy DOI: http://dx.doi.org/10.2147/OPTH.S84214",Non-OADS,/arxiv_data1/oa_pdf/19/b5/opth-9-885.PMC4445948.pdf
"Clinical Ophthalmology Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-ophthalmology-journa lClinical Ophthalmology is an international, peer-reviewed journal  covering all subspecialties within ophthalmology.",Non-OADS,/arxiv_data1/oa_pdf/19/b5/opth-9-885.PMC4445948.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/19/b5/opth-9-885.PMC4445948.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/d2/ab/ijn-10-3699.PMC4445949.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pInternational Journal of Nanomedicine 2015:10 3699–3717International Journal of Nanomedicine Dove press submit your manuscript | www.dovepress.co m Dove press  3699OrIg INal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/IJN.S8165 0Efficacy and mechanism of tanshinone IIA  liquid nanoparticles in preventing experimental  postoperative peritoneal adhesions in vivo  and in vitro Fei Qin1,* Yun Ma1,* Xiao li2 Xian Wang1 Yuanyi Wei1 Chuqi Hou3 si lin1 lianbing hou1 Chengxi Wang4 1Department of Pharmacy, Nanfang  Hospital, Southern Medical University,   Guangzhou, 2Department of Pharmacy,   the Affiliated Hospital of Qingdao  University, Qingdao, Shandong,   3Department of Pharmacology,   Southern Medical University,   4Department of Pharmacology,   Guangdong Pharmaceutical University,   Guangzhou, People’s Republic  of China *These authors contributed equally  to this workAbstract:  Up to 90% of patients develop adhesion following laparotomy.",Non-OADS,/arxiv_data1/oa_pdf/d2/ab/ijn-10-3699.PMC4445949.pdf
"Studies have shown that peritoneal trauma initiates the persistence of a fibrin-rich exu - date at the site of injury and forms bands between adjacent organs.3–7 Fibrin is principally correspondences: lianbing hou Department of Pharmacy, Nanfang Hospital,  Southern Medical University, No 1838,  Guangzhou Boulevard (North), Guangzhou  510515, People’s Republic of China Tel +86 20 6164 2175 Fax +86 20 8770 1797 email smuhlianbing@hotmail.co m Chengxi Wang Department of Pharmacology,  Guangdong Pharmaceutical University,  280 Wai Huan Dong Road, Mega Center,  Guangzhou 510006, People’s Republic of  China Tel +86 20 3470 2826 Fax +86 20 3470 2826 email gdpuwcx@163.co m Journal name: International Journal of Nanomedicine Article Designation: Original Research Y ear: 2015 Volume: 10 Running head verso: Qin et al Running head recto: Tanshinone IIA liquid NPs and postoperative peritoneal adhesions DOI: http://dx.doi.org/10.2147/IJN.S81650",Non-OADS,/arxiv_data1/oa_pdf/d2/ab/ijn-10-3699.PMC4445949.pdf
"International Journal of Nanomedicine Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-nanomedicine-journa lThe International Journal of Nanomedicine is an international, peer- reviewed journal focusing on the application of nanotechnology   in diagnostics, therapeutics, and drug delivery systems throughout   the biomedical field.",Non-OADS,/arxiv_data1/oa_pdf/d2/ab/ijn-10-3699.PMC4445949.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/d2/ab/ijn-10-3699.PMC4445949.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/f5/b8/opth-9-903.PMC4445950.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pClinical Ophthalmology 2015:9 903–906Clinical Ophthalmology Dove press submit your manuscript | www.dovepress.co m Dove press  903Case seriesopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OPTH.S8186 1aqueous misdirection following pars plana  vitrectomy and silicone oil injection Hammouda H Ghoraba1,2 ali ahmed Ghali3 Hosam Othman Mansour2,3 1Tanta University, Tanta, egypt;   2Magrabi eye Hospital, Cairo, egypt;   3al-azhar University, Cairo, egyptPurpose:  To report a retrospective series of seven phakic eyes of seven patients suffering  from a malignant glaucoma-like syndrome following pars plana vitrectomy and silicone oil  (SO) injection.",Non-OADS,/arxiv_data1/oa_pdf/f5/b8/opth-9-903.PMC4445950.pdf
"A recent study found a lower incidence  (11%) of glaucoma after PPV with injection of highly purified SO (5,000 centistokes).3  Topical and systemic anti-glaucoma medications achieve effective control of IOP in  the majority of patients, and topical steroids are often administered after surgery to Correspondence: Hosam Othman  Mansour Department of Ophthalmology, al-azhar  University, autostrad st, Nasr City,   Cairo 020, egypt email drhmansor@yahoo.com Journal name: Clinical Ophthalmology Article Designation: Case Series Y ear: 2015 Volume: 9 Running head verso: Ghoraba et al Running head recto: Aqueous misdirection following vitrectomy and S.O DOI: http://dx.doi.org/10.2147/OPTH.S81861",Non-OADS,/arxiv_data1/oa_pdf/f5/b8/opth-9-903.PMC4445950.pdf
"Clinical Ophthalmology Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-ophthalmology-journa lClinical Ophthalmology is an international, peer-reviewed journal  covering all subspecialties within ophthalmology.",Non-OADS,/arxiv_data1/oa_pdf/f5/b8/opth-9-903.PMC4445950.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/f5/b8/opth-9-903.PMC4445950.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/b8/63/opth-9-877.PMC4445951.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pClinical Ophthalmology 2015:9 877–884Clinical Ophthalmology Dove press submit your manuscript | www.dovepress.co m Dove press  877Original researChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OPTH.S8095 4Thymosin beta 4 ophthalmic solution for dry eye:  a randomized, placebo-controlled, Phase ii clinical  trial conducted using the controlled adverse  environment (C ae™) model gabriel sosne1 george W Ousler2 1Kresge eye institute, Wayne state  University, Detroit, M i, 2Ora inc,   andover, M a, UsaBackground:  The purpose of this study was to evaluate the safety and efficacy of thymosin  beta 4 ophthalmic solution (RGN-259; T β4) in subjects with moderate to severe dry eye using  the CAE™ model.",Non-OADS,/arxiv_data1/oa_pdf/b8/63/opth-9-877.PMC4445951.pdf
"A therapeutic agent that could reduce inflammation and  accelerate ocular surface healing would reduce the risk of permanent injury, improve  vision, and provide improved comfort for those with dry eye.Correspondence: gabriel sosne Departments of Ophthalmology and  anatomy and Cell Biology, Kresge eye  institute, Wayne state University school  of Medicine, 4717 st antoine Detroit,  Mi 48201, Usa Tel +1 313 577 1356 Fax +1 313 577 3125 email gsosne@med.wayne.ed u Journal name: Clinical Ophthalmology Article Designation: Original Research Y ear: 2015 Volume: 9 Running head verso: Sosne and Ousler Running head recto: T β4 ophthalmic solution for dry eye DOI: http://dx.doi.org/10.2147/OPTH.S80954",Non-OADS,/arxiv_data1/oa_pdf/b8/63/opth-9-877.PMC4445951.pdf
"Clinical Ophthalmology Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-ophthalmology-journa lClinical Ophthalmology is an international, peer-reviewed journal  covering all subspecialties within ophthalmology.",Non-OADS,/arxiv_data1/oa_pdf/b8/63/opth-9-877.PMC4445951.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/b8/63/opth-9-877.PMC4445951.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/1a/17/oajsm-6-161.PMC4445952.pdf
"Information on how to  request permission may be found at: http://www.dovepress.com/permissions.ph pOpen Access Journal of Sports Medicine 2015:6 161–172Open Access Journal of Sports Medicine Dove press submit your manuscript | www.dovepress.co m Dove press  161OriginAl reSeArchopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/OAJSM.S7561 2The connection between typological complexes   of properties of the nervous system, temperaments,  and personality types in the professions and sports Aleksandr K Drozdovski Sports Training center for russian  T eams, Moscow, russia correspondence: Aleksandr K Drozdovski   Sports Training center for russian  Teams, Kazakova street, 18-8, ul Frunze  16 -104, St Petersburg 196135, russia   email drozd53@bk.r uAbstract:  Based on experimental studies in education, professions and sports, an attempt was  made to combine the following two historically disconnected research directions in the study  of the natural human traits into a single coordinate system: Pavlov’ s theory on the properties  of the nervous system, as well as the types of higher nervous activity, and Jung’ s theory on  psychological types.",Non-OADS,/arxiv_data1/oa_pdf/1a/17/oajsm-6-161.PMC4445952.pdf
"Open Access Journal of Sports Medicine Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/open-access-journal-of-sports-medicine-journa lOpen Access Journal of Sports Medicine is an international,  peer-reviewed, open access journal publishing original research,  reports, reviews and commentaries on all areas of sports  medicine.",Non-OADS,/arxiv_data1/oa_pdf/1a/17/oajsm-6-161.PMC4445952.pdf
Visit http://www.dovepress.com/testimonials.ph p to read real quotes  from published authors.,Non-OADS,/arxiv_data1/oa_pdf/1a/17/oajsm-6-161.PMC4445952.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/81/bc/ijn-10-3687.PMC4445953.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpInternational Journal of Nanomedicine 2015:10 3687–3697International Journal of Nanomedicine Dove press submit your manuscript | www.dovepress.co m Dove press  3687OrIg INal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/IJN.S8263 7Effects of carbon nanofiber on physiology of  Drosophila Shin-Hae Lee1,* Hye-Yeon Lee1,* Eun-Ji Lee1,* Dongwoo Khang2 Kyung-Jin Min1 1Department of Biological Sciences,   Inha University, Incheon, Republic  of Korea; 2Department of Molecular  Medicine, Graduate School of  Medicine, Gachon University, Incheon,   Republic of Korea *These authors contributed equally  to this workAbstract:  As nanomaterials are now widely utilized in a wide range of fields for both medical  and industrial applications, concerns over their potential toxicity to human health and the envi - ronment have increased.",Non-OADS,/arxiv_data1/oa_pdf/81/bc/ijn-10-3687.PMC4445953.pdf
"Concerns over the toxicity of fibrous nanomaterials have been raised  due to their structural similarity with asbestos, although their chemical composition  and physic-mechanical properties are reported to be very different from asbestos.6 In  addition, CNFs possess distinct properties from carbon nanotubes.7 Structurally, single- walled carbon nanotubes are composed of a rolled-up cylindrical sheet of graphene,  whereas CNFs are formed from stacked graphene nanocones.8 CNFs are strong and  flexible filaments ranging from 70 to 200 nm in diameter and 10–100 μm in length,  and they are usually used in advanced composite materials to improve strength, stiff - ness, durability, electrical conductivity, and heat resistance.9 CNFs are cost-effective  compared to carbon nanotubes, and thus their commercial applicability has grown Correspondence: Kyung-Jin Min Department of Biological Sciences, 100  Inha Street, Inha University, Incheon  402-751, Republic of Korea Tel +82 32 860 8193 Fax +82 32 860 7690 email minkj@inha.ac.k r Journal name: International Journal of Nanomedicine Article Designation: Original Research Y ear: 2015 Volume: 10 Running head verso: Lee et al Running head recto: Effects of CNF on Drosophila  physiology DOI: http://dx.doi.org/10.2147/IJN.S82637",Non-OADS,/arxiv_data1/oa_pdf/81/bc/ijn-10-3687.PMC4445953.pdf
"International Journal of Nanomedicine Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-nanomedicine-journa lThe International Journal of Nanomedicine is an international, peer- reviewed journal focusing on the application of nanotechnology   in diagnostics, therapeutics, and drug delivery systems throughout   the biomedical field.",Non-OADS,/arxiv_data1/oa_pdf/81/bc/ijn-10-3687.PMC4445953.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/81/bc/ijn-10-3687.PMC4445953.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/a6/a7/idr-8-129.PMC4445954.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pInfection and Drug Resistance 2015:8 129–145Infection and Drug Resistance Dove press submit your manuscript | www.dovepress.co m Dove press  129 RevIewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/IDR.S7479 5Corynebacterium urealyticum:  a comprehensive  review of an understated organism Nagla Salem1 Lamyaa Salem2 Sally Saber2 Ghada Ismail2 Martin H Bluth1 1Department of Pathology, wayne  State University School of Medicine,   Detroit, MI, USA; 2Department  of Clinical and Chemical Pathology,   Ain Shams  University, Cairo, egypt Correspondence: Nagla Salem   Department of Pathology, wayne  State University School of Medicine,  540 East Canfield Street,   Detroit, MI 48201, USA   email nsale@med.wayne.ed u;  dr.nagla.81@gmail.co mAbstract:  Corynebacterium urealyticum  is a Gram positive, slow-growing, lipophilic, multi- drug resistant, urease positive micro-organism with diphtheroid morphology.",Non-OADS,/arxiv_data1/oa_pdf/a6/a7/idr-8-129.PMC4445954.pdf
"Infection and Drug Resistance Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/infection-and-drug-resistance-journa lInfection and Drug Resistance is an international, peer-reviewed open- access journal that focuses on the optimal treatment of infection (bacte - rial, fungal and viral) and the development and institution of preventive  strategies to minimize the development and spread of resistance.",Non-OADS,/arxiv_data1/oa_pdf/a6/a7/idr-8-129.PMC4445954.pdf
Visit http://www.dovepress.com/   testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/a6/a7/idr-8-129.PMC4445954.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/69/e8/opth-9-889.PMC4445955.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpClinical Ophthalmology 2015:9 889–901Clinical Ophthalmology Dove press submit your manuscript | www.dovepress.co m Dove press  889Original researChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OPTH.S8097 2epidemiology of uveitis in the mid-atlantic  United states Correspondence: ashvini K reddy Department of Ophthalmology,  University of Virginia, 1300 Jefferson Park  avenue, Charlottesville, Va 22908, Usa Tel +1 434 243 5890 Fax +1 434 924 5180 email ash.vee.knee@gmail.co m asima Bajwa1 Diba Osmanzada1 susan Osmanzada1 irfan Khan1 Jim Patrie2 Wenjun Xin2 ashvini K reddy1 1Department of Ophthalmology,   2Department of Public health  sciences, University of Virginia,   Charlottesville, V a, UsaPurpose:  To demonstrate the demographic, anatomic, and diagnostic classification of patients  with uveitis seen in a tertiary care center in central Virginia.",Non-OADS,/arxiv_data1/oa_pdf/69/e8/opth-9-889.PMC4445955.pdf
"Keywords:  mid-Atlantic United States, central Virginia, demographics Introduction Uveitis is a leading cause of visual morbidity and causes approximately 30,000 new  cases of legal blindness annually in the United States alone.1,2 Because uveitis encom - passes many heterogeneous disorders, factors that vary regionally, such as age, sex,  ethnicity, environmental exposures, and genetics, influence ocular inflammation in  ways that are incompletely understood.3,4 Worldwide, epidemiologic reports on uveitis have led to the identification of new  entities, contributed to monitoring of shifting patterns of uveitis, and guided diagnostic  and therapeutic approaches.5–12 Infectious uveitides, for example, are strongly associated Journal name: Clinical Ophthalmology Article Designation: Original Research Y ear: 2015 Volume: 9 Running head verso: Bajwa et al Running head recto: Epidemiology of uveitis in Virginia DOI: http://dx.doi.org/10.2147/OPTH.S80972",Non-OADS,/arxiv_data1/oa_pdf/69/e8/opth-9-889.PMC4445955.pdf
Available from: http://quickfacts.census.gov/qfd/states/00000.,OADS,/arxiv_data1/oa_pdf/69/e8/opth-9-889.PMC4445955.pdf
"Clinical Ophthalmology Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-ophthalmology-journa lClinical Ophthalmology is an international, peer-reviewed journal  covering all subspecialties within ophthalmology.",Non-OADS,/arxiv_data1/oa_pdf/69/e8/opth-9-889.PMC4445955.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/69/e8/opth-9-889.PMC4445955.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/94/20/ott-8-1143.PMC4446009.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pOncoTargets and Therapy 2015:8 1143–1147OncoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  1143Case repO rTopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OTT .S7729 7anaplastic lymphoma kinase-positive anaplastic  large-cell lymphoma with involvement of the urinary  bladder: a case report and review of literature Xiaoqin Liang1,2 Yingmei Wang1 Jinsong Zhang3 Hong Cheng1 Jinsui Wang2 Yamei Dang2 Haomin Li1,4 ru Zhou1 Jing Zhang1 Qing Qiao5 1state Key Laboratory of Tumor  Biology, Department of pathology,   Xijing Hospital, The Fourth Military  Medical University, Xi’an, shaanxi,   people’s republic of China;  2Department of pathology, Gansu  provincial p eople’s Hospital, Lanzhou,   Gansu, people’s republic of China;   3Department of radiology, Xijing  Hospital, The Fourth Military Medical  University, Xi’an, shaanxi, people’s  republic of China; 4Department of  Neurosurgery, First affiliated Hospital,   China Medical University, shenyang,   Liaoning, people’s republic of China;   5Department of General surgery,   Tangdu Hospital, The Fourth Military  Medical University, Xi’an, shaanxi,   people’s republic of ChinaAbstract:  We report a unique case of anaplastic large-cell lymphoma (ALCL) involving the  urinary bladder in a 22-year-old man.",Non-OADS,/arxiv_data1/oa_pdf/94/20/ott-8-1143.PMC4446009.pdf
"A computed tomography (CT) scan showed an exophytic mass in the urinary bladder Correspondence: Qing Qiao Department of General surgery, Tangdu  Hospital, The Fourth Military Medical  University, No 1 Xinsi road, Xi’an, shaanxi 710038, people’s republic of China Tel +86 29 84777731 Fax +86 29 84773624 email qqing44@fmmu.edu.c n Journal name: OncoTargets and Therapy Article Designation: Case report Y ear: 2015 Volume: 8 Running head verso: Liang et al Running head recto: ALK-positive anaplastic large-cell lymphoma involving the urinary bladder  DOI: http://dx.doi.org/10.2147/OTT.S77297",Non-OADS,/arxiv_data1/oa_pdf/94/20/ott-8-1143.PMC4446009.pdf
"OncoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncotargets-and-therapy-journa lOncoTargets and Therapy is an international, peer-reviewed, open  access journal focusing on the pathological basis of all cancers, potential  targets for therapy and treatment protocols employed to improve the  management of cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/94/20/ott-8-1143.PMC4446009.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/94/20/ott-8-1143.PMC4446009.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/5a/26/ott-8-1137.PMC4446010.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpOncoTargets and Therapy 2015:8 1137–1142OncoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  1137Case seriesopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OTT .S7538 8Combination of afatinib with cetuximab  in patients with eGFr-mutant non-small-cell  lung cancer resistant to eGFr inhibitors Jéssica ribeiro Gomes  Marcelo rocha s Cruz antonio ermirio de Moraes Oncology  Center, são Paulo-BrazilAbstract:  Tyrosine kinase inhibitors (TKIs) targeting the epidermal growth factor receptor  (EGFR) have shown effectiveness for advanced non-small-cell lung cancer (NSCLC) with acti - vating mutations in the EGFR  gene.",Non-OADS,/arxiv_data1/oa_pdf/5a/26/ott-8-1137.PMC4446010.pdf
"The Phase III trial LUX-Lung 3 yielded an increase in median PFS  in patients with mutated EGFR treated with afatinib when compared with cisplatin and  pemetrexed as first-line therapy: 11.1 months and 6.9 months, respectively (hazard Correspondence: Marcelo rocha s Cruz rua Martiniano de Carvalho, 951 Bela Vista, são Paulo-sP, Brazil CeP 01321-001 email marcelo.cruz.md@gmail.co mJournal name: OncoTargets and Therapy Article Designation: Case Series Y ear: 2015 Volume: 8 Running head verso: Ribeiro Gomes and Cruz Running head recto: Afatinib and cetuximab in patients with EGFR-mutant NSCLC DOI: http://dx.doi.org/10.2147/OTT.S75388",Non-OADS,/arxiv_data1/oa_pdf/5a/26/ott-8-1137.PMC4446010.pdf
"Available from: http://seer.cancer.gov/statfacts/html/lungb.htm l.  Accessed January 1, 2014.",Non-OADS,/arxiv_data1/oa_pdf/5a/26/ott-8-1137.PMC4446010.pdf
Available  from: http://www.nccn.org /.,Non-OADS,/arxiv_data1/oa_pdf/5a/26/ott-8-1137.PMC4446010.pdf
"OncoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncotargets-and-therapy-journa lOncoTargets and Therapy is an international, peer-reviewed, open  access journal focusing on the pathological basis of all cancers, potential  targets for therapy and treatment protocols employed to improve the  management of cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/5a/26/ott-8-1137.PMC4446010.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/5a/26/ott-8-1137.PMC4446010.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/72/1e/ott-8-1119.PMC4446011.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpOncoTargets and Therapy 2015:8 1119–1127OncoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  1119Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OTT .S7586 4Knockdown of immature colon carcinoma  transcript-1 inhibits proliferation of glioblastoma  multiforme cells through gap 2/mitotic  phase arrest rong Xie* Yichao Zhang* chao shen Xiaoyun cao shixin gu* Xiaoming che* Department of n eurosurgery,   huashan hospital, Fudan University,   shanghai, People’s republic of china *These authors contributed equally  to this workAbstract:  “Glioblastoma multiforme” (GBM) is the frequent form of malignant glioma.",Non-OADS,/arxiv_data1/oa_pdf/72/1e/ott-8-1119.PMC4446011.pdf
"Immature colon carcinoma transcript-1 (ICT1) was originally reported as   a transcript downregulated during in vitro differentiation of colon carcinoma cell  line HT29-D4.7,8 Subsequent research identified ICT1 to be associated with mito - chondrial ribosome recycling factor.9 Richter et al further showed that ICT1 is a  component of the human mitoribosome and has codon-independent peptidyl-transfer  RNA hydrolysis activity via its conserved GGQ motif.10 Depletion of ICT1 causes correspondence: shixin gu; Xiaoming  che Department of neurosurgery, huashan  hospital, Fudan University, 12 Middle  Wulumuqi road, shanghai 200040,  People’s republic of china Tel +86 21 5288 9999 Fax +86 21 5288 7030 email gushi_xin@yeah.ne t;   xiao_mingche@163.co m Journal name: OncoTargets and Therapy Article Designation: Original Research Y ear: 2015 Volume: 8 Running head verso: Xie et al Running head recto: ICT1 promotes GBM cell growth DOI: http://dx.doi.org/10.2147/OTT.S75864",Non-OADS,/arxiv_data1/oa_pdf/72/1e/ott-8-1119.PMC4446011.pdf
"OncoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncotargets-and-therapy-journa lOncoTargets and Therapy is an international, peer-reviewed, open  access journal focusing on the pathological basis of all cancers, potential  targets for therapy and treatment protocols employed to improve the  management of cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/72/1e/ott-8-1119.PMC4446011.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/72/1e/ott-8-1119.PMC4446011.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/86/40/ndt-11-1231.PMC4446012.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpNeuropsychiatric Disease and Treatment 2015:11 1231–1238Neuropsychiatric Disease and Treatment Dove press submit your manuscript | www.dovepress.co m Dove press  1231OrigiNal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/NDT .S7688 2Efficacy and safety of intravenous nimodipine  administration for treatment of hypertension  in patients with intracerebral hemorrhage Yuqian li1,* Wei Fang1,* lei Tao2,* Min li1 Yanlong Yang1 Yafei gao1 shunnan ge1 li gao1 Bin Zhang1 Zhihong li1 Wei Zhou1 Boliang Wang3 lihong li1 1Department of Neurosurgery,   2Department of anesthesiology,   3Department of emergency, Tangdu  hospital, The Fourth Military Medical  University, Xi’an, shaanxi, People’s  republic of china *These authors contributed equally  to this studyBackground:  Nicardipine (NC) is the most commonly used antihypertensive drug in  neurological patients with hypertension.",Non-OADS,/arxiv_data1/oa_pdf/86/40/ndt-11-1231.PMC4446012.pdf
"Since intravenous (IV) nicardipine (NC) is feasible correspondence: lihong li Department of Neurosurgery, Tangdu  hospital, The Fourth Military Medical  University, Xi’an, shaanxi, 710038,  People’s republic of china Tel +86 181 8267 9050 email lihongliaaa@126.co m Boliang Wang Department of emergency, Tangdu  hospital, The Fourth Military Medical  University, Xi’an, shaanxi, 710038,  People’s republic of china Tel +86 135 7213 3002 email wang.fmmu@gmail.co m Journal name: Neuropsychiatric Disease and Treatment Article Designation: Original Research Y ear: 2015 Volume: 11 Running head verso: Li et al Running head recto: Nimodipine controls hypertension DOI: http://dx.doi.org/10.2147/NDT.S76882",Non-OADS,/arxiv_data1/oa_pdf/86/40/ndt-11-1231.PMC4446012.pdf
"Neuropsychiatric Disease and Treatment Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/neuropsychiatric-disease-and-treatment-journa lNeuropsychiatric Disease and Treatment is an international, peer- reviewed journal of clinical therapeutics and pharmacology focusing   on concise rapid reporting of clinical or pre-clinical studies on a   range of neuropsychiatric and neurological disorders.",Non-OADS,/arxiv_data1/oa_pdf/86/40/ndt-11-1231.PMC4446012.pdf
Visit http://www.dovepress.com/testimonials.ph p to  read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/86/40/ndt-11-1231.PMC4446012.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/c3/c1/ott-8-1083.PMC4446013.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpOncoTargets and Therapy 2015:8 1083–1090OncoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  1083Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OTT .S7910 9comparison of tumor markers using different  detection devices rong Tao shaohua T u chong liu Qi Yang Min Zhu Jiangfan shen nuclear Medicine, Putuo District  center hospital, shanghai, People’s  republic of chinaBackground:  With the development of proteomics, tumor markers have attracted increasing  attention for the early diagnosis and treatment of lung cancer.",Non-OADS,/arxiv_data1/oa_pdf/c3/c1/ott-8-1083.PMC4446013.pdf
"Low-dose spiral correspondence: Jiangfan shen nuclear Medicine, Putuo District center  hospital, shanghai 200062, People’s  republic of china email sjf@ibhsedu.co m Journal name: OncoTargets and Therapy Article Designation: Original Research Y ear: 2015 Volume: 8 Running head verso: Tao et al Running head recto: Detection of multiple tumor markers DOI: http://dx.doi.org/10.2147/OTT.S79109",Non-OADS,/arxiv_data1/oa_pdf/c3/c1/ott-8-1083.PMC4446013.pdf
"OncoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncotargets-and-therapy-journa lOncoTargets and Therapy is an international, peer-reviewed, open  access journal focusing on the pathological basis of all cancers, potential  targets for therapy and treatment protocols employed to improve the  management of cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/c3/c1/ott-8-1083.PMC4446013.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/c3/c1/ott-8-1083.PMC4446013.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/c6/44/ppa-9-675.PMC4446014.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pPatient Preference and Adherence 2015:9 675–684Patient Preference and Adherence Dove press submit your manuscript | www.dovepress.co m Dove press  675Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/PPA.S2079 1An update on the use of natalizumab in the  treatment of multiple sclerosis: appropriate  patient selection and special considerations Barbara Kornek Department of Neurology, Medical  University of vienna, vienna, AustriaAbstract:  In the context of an increasing repertoire of multiple sclerosis (MS) therapeutics,  choosing the appropriate treatment for an individual patient is becoming increasingly challenging.",Non-OADS,/arxiv_data1/oa_pdf/c6/44/ppa-9-675.PMC4446014.pdf
"Keywords:  safety, long-term outcome, pediatric multiple sclerosis, adherence, PML, treatment  discontinuation Introduction Multiple sclerosis (MS) is a chronic disabling disease of the central nervous system  (CNS), affecting .2 million people worldwide.1,2 The disease usually starts in early  adulthood, but the age range for disease onset is wide, with both pediatric cases and new  onset of disease above the age of 50 years;3,4 85%–90% of people with MS experience  relapses and remissions of neurologic symptoms (relapsing–remitting MS [RRMS]),  particularly early in the disease, and clinical events are usually associated with areas of  CNS inflammation.5,6 Over time, the majority of untreated patients develops a pattern  of progressive worsening with or without superimposed relapses; after 20–25 years,  approximately 90% of untreated RRMS patients will have secondary progressive MS.7  Compared to the normal population, life expectancy is reduced by 8–12 years in the  MS population untreated with a disease-modifying therapy.8 The unpredictable disease course, as well as the progressive nature of the disease  with ongoing physical and mental impairment, significantly impacts patients’ quality  of life,9 social10 and family lives,11 and employment status.12 Although quality-of-life Correspondence: Barbara Kornek Department of Neurology, Medical  University of vienna, waehringer Guertel  18-20, A-1090, vienna, Austria Tel +43 1 40400 31450 Fax +43 1 40400 31410 email barbara.bajer-kornek@ meduniwien.ac.a t Journal name: Patient Preference and Adherence Article Designation: Review Y ear: 2015 Volume: 9 Running head verso: Kornek Running head recto: Natalizumab in the treatment of MS DOI: http://dx.doi.org/10.2147/PPA.S20791",Non-OADS,/arxiv_data1/oa_pdf/c6/44/ppa-9-675.PMC4446014.pdf
Available from: http://www.ema.europa.eu.,Non-OADS,/arxiv_data1/oa_pdf/c6/44/ppa-9-675.PMC4446014.pdf
Available from: http://www.FDA.gov.,Non-OADS,/arxiv_data1/oa_pdf/c6/44/ppa-9-675.PMC4446014.pdf
Available from: http://www.ema.europa.eu.,Non-OADS,/arxiv_data1/oa_pdf/c6/44/ppa-9-675.PMC4446014.pdf
Available from: http://www.fda.gov.,Non-OADS,/arxiv_data1/oa_pdf/c6/44/ppa-9-675.PMC4446014.pdf
Available from: http://www.ema.europa.eu.,Non-OADS,/arxiv_data1/oa_pdf/c6/44/ppa-9-675.PMC4446014.pdf
Available from: http://www.fda.org.,Non-OADS,/arxiv_data1/oa_pdf/c6/44/ppa-9-675.PMC4446014.pdf
"Patient Preference and Adherence Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/patient-preference-and-adherence-journa lPatient Preference and Adherence is an international, peer-reviewed,  open access journal that focuses on the growing importance of patient   preference  and adherence throughout the therapeutic continuum.",Non-OADS,/arxiv_data1/oa_pdf/c6/44/ppa-9-675.PMC4446014.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/17/14/ott-8-1129.PMC4446015.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pOncoTargets and Therapy 2015:8 1129–1136OncoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  1129Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OTT .S7943 3Transforming growth factor-beta-1 is a serum  biomarker of radiation-induced pneumonitis in   esophageal cancer patients treated with thoracic  radiotherapy: preliminary results of a prospective  study Jingxia li1,* shuangfeng Mu1,* lixiang Mu1 Xiaohui Zhang1 ranran Pang1 shegan gao2 1radiation Oncology Department,   2Department of Oncology, the First  affiliated hospital, henan University  of science and T echnology, luoyang,   People’s republic of china *These authors contributed equally  to this workObjective:  To examine the relationship between cytokine levels of transforming growth factor- beta-1 (TGF- β1), interleukin-1 beta (IL-1 β), and angiotensin-converting enzyme (ACE) in the  plasma of esophageal carcinoma patients and radiation-induced pneumonitis (RP).",Non-OADS,/arxiv_data1/oa_pdf/17/14/ott-8-1129.PMC4446015.pdf
"Approximately 13%–37% of patients that received radical RT developed symptomatic  radiation-induced pneumonitis (RP).1 Recent studies have shown that each Gy above  the conventional prescription dose of 60–70 Gy would improve the 3- to 5-year sur - vival rate by approximately 1%, and it would reduce cancer-associated mortality by  approximately 3%.2 The conventional radiation dose was determined based on the risk  estimates for the general human population, so as to limit the toxicity rate to 5%–15%.2–5 correspondence: shegan gao Department of Oncology, the First  Affiliated Hospital, Henan University of  science and Technology, luoyang 471003,  People’s republic of china Tel +86 379 6481 5350 Fax +86 379 6481 5350 email gsg112258@163.co m Journal name: OncoTargets and Therapy Article Designation: Original Research Y ear: 2015 Volume: 8 Running head verso: Li et al Running head recto: TGF- β1 as a biomarker of pneumonitis DOI: http://dx.doi.org/10.2147/OTT.S79433",Non-OADS,/arxiv_data1/oa_pdf/17/14/ott-8-1129.PMC4446015.pdf
"OncoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncotargets-and-therapy-journa lOncoTargets and Therapy is an international, peer-reviewed, open  access journal focusing on the pathological basis of all cancers, potential  targets for therapy and treatment protocols employed to improve the  management of cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/17/14/ott-8-1129.PMC4446015.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/17/14/ott-8-1129.PMC4446015.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/2f/b2/jir-8-097.PMC4446016.pdf
"Information on how to  request permission may be found at: http://www.dovepress.com/permissions.ph pJournal of Inflammation Research 2015:8 97–106Journal of Inflammation Research Dove press submit your manuscript | www.dovepress.co m Dove press  97ORIg Inal ReseaRchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/JIR.S8220 2Regulation of indoleamine  2,3-dioxygenase  in  primary human saphenous vein endothelial cells Petros Xe Mouratidis* andrew JT george* Department of Immunology, Imperial  college london, london, UK *These authors contributed equally to  this work correspondence: Petros Xe Mouratidis   Division of Radiotherapy and Imaging,  The Institute of cancer Research,   sutton, surrey, sM25ng, UK   Tel +44 20 8722 4406   email pmouratidis@hotmail.co mBackground:  Indoleamine  2,3-dioxygenase (IDO) is an enzyme associated with the regulation  of immune responses.",Non-OADS,/arxiv_data1/oa_pdf/2f/b2/jir-8-097.PMC4446016.pdf
"Journal of Inflammation Research Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/journal-of-inflammation-research-journa lThe Journal of Inflammation Research is an international, peer-reviewed  open-access journal that welcomes laboratory and clinical findings on the  molecular basis, cell biology and pharmacology of inflammation including  original research, reviews, symposium reports, hypothesis formation and  commentaries on: acute/chronic inflammation; mediators of inflamma -tion; cellular processes; molecular mechanisms; pharmacology and novel  anti-inflammatory drugs; clinical conditions involving inflammation.",Non-OADS,/arxiv_data1/oa_pdf/2f/b2/jir-8-097.PMC4446016.pdf
Visit http://www.dovepress.com/   testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/2f/b2/jir-8-097.PMC4446016.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/99/df/ott-8-1165.PMC4446017.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpOncoTargets and Therapy 2015:8 1165–1173OncoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  1165Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OTT .S8379 4DDM c-p53 gene therapy with or without cisplatin  and microwave ablation Wolfgang hohenforst- schmidt1 Paul Zarogoulidis2 Joshua stopek3 Thomas Vogl4 Frank hübner1 J Francis T urner5,6 robert Browning7 Konstantinos Zarogoulidis2 antonis Drevelegas8 Konstantinos Drevelegas8 Kaid Darwiche9 lutz Freitag9 harald rittger10 1ii Medical clinic, coburg hospital,   University of Wuerzburg, coburg, germany;   2Pulmonary Department-Oncology  Unit, g Papanikolaou general hospital,   aristotle University of Thessaloniki,   Thessaloniki, greece; 3covidien, Jersey city,   nJ, Usa; 4Department of Diagnostic and  interventional radiology, goethe University  of Frankfurt, Frankfurt, germany; 5Division  of interventional Pulmonology, 6Medical  Oncology, cancer Treatment centers of  america, Western regional Medical center,   goodyear, aZ, 7Pulmonary and critical  care Medicine, interventional Pulmonology,   national naval Medical center, Walter  reed army Medical center, Bethesda, MD,   Usa; 8radiology Department, interbalkan  european Medical center, Thessaloniki,   greece; 9Department of interventional  Pneumology, ruhrlandklinik, University  hospital essen, University of essen- Duisburg, essen, germany; 10Medical  clinic i, ‘Fuerth hospital, University of  erlangen, erlangen, germanyAbstract:  Lung cancer remains the leading cause of death in cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/99/df/ott-8-1165.PMC4446017.pdf
"Passive and active transport are the two major methods via which a  drug diffuses within tissue.33 Passive transport depends on the physical ability of each correspondence: Paul Zarogoulidis Pulmonary Department-Oncology  Unit, g Papanikolaou general hospital,  aristotle University of Thessaloniki,  Thessaloniki, greece Fax +30 23 1099 2424 email pzarog@hotmail.co m Journal name: OncoTargets and Therapy Article Designation: Original Research Y ear: 2015 Volume: 8 Running head verso: Hohenforst-Schmidt et al Running head recto: DDMC-p53 gene therapy ± cisplatin and microwave ablation DOI: http://dx.doi.org/10.2147/OTT.S83794",Non-OADS,/arxiv_data1/oa_pdf/99/df/ott-8-1165.PMC4446017.pdf
"As indicated by the manufacturer  (http://surgical.covidien.com/products/ablation-systems/ microwave-ablation/evident-mwa-antenna s), there is no need  to insert an additional spike for this tumor diameter.",Non-OADS,/arxiv_data1/oa_pdf/99/df/ott-8-1165.PMC4446017.pdf
"Therefore, in many cases,  more than two spikes 1 cm apart are inserted in the tumor  in order to enhance the effect ( http://surgical.covidien.com/ products/ablation-systems/microwave-ablation/evident-mwa- antenna s).79 Computed tomography has been used until now,  but novel studies are currently investigating the use of ultra - sound for correct insertion of spikes into the tumor lesion.80  The thermal effect of microwave ablation has been shown to  be effective for lesions ,3 cm, distant to vessels.",Non-OADS,/arxiv_data1/oa_pdf/99/df/ott-8-1165.PMC4446017.pdf
"OncoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncotargets-and-therapy-journa lOncoTargets and Therapy is an international, peer-reviewed, open  access journal focusing on the pathological basis of all cancers, potential  targets for therapy and treatment protocols employed to improve the  management of cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/99/df/ott-8-1165.PMC4446017.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/99/df/ott-8-1165.PMC4446017.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/2b/c3/ndt-11-1239.PMC4446018.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pNeuropsychiatric Disease and Treatment 2015:11 1239–1246Neuropsychiatric Disease and Treatment Dove press submit your manuscript | www.dovepress.co m Dove press  1239OrigiNal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/NDT .S8232 8assessment of knowledge, attitude, and  practice related to epilepsy: a community- based study correspondence: Zewdu shewangizaw college of Medicine and health sciences,  arba Minch University, PO Box 21,  arba Minch, ethiopia Tel +251 91 374 9690   email hweret@gmail.co m Jalle T eferi1 Zewdu shewangizaw2 1addis ababa health Bureau,   Zewuditu specialized hospital, addis  ababa, ethiopia; 2college of Medicine  and health sciences, arba Minch  University, arba Minch, ethiopiaAbstract:  Religious and sociocultural beliefs influence the nature of treatment and care  received by people with epilepsy.",Non-OADS,/arxiv_data1/oa_pdf/2b/c3/ndt-11-1239.PMC4446018.pdf
"The discharge results in an almost instantaneous disturbance of sensation,  loss of consciousness or psychic function, convulsive movements, or combinations of  these.1,2 Persons with epilepsy are at a risk of developing a variety of psychological  problems, including depression and anxiety, and psychosis.3 Previous studies show that  the prevalence of active epilepsy in developing countries range from 5 to 10 per 1,000  people.4 However, the worldwide prevalence rate of epilepsy varies from 2.8 to 19.5 per   1,000 of the general population and is more prevalent among children.5 In Nigeria, the  estimated prevalence of epilepsy is 8–13 per 1,000 people.6 In developing countries,  the disorder is to a significant degree associated with a host of parasitic and bacterial  infectious diseases that are largely absent in industrialized countries.7 Sociocultural attitudes continue to cause a negative impact on the manage - ment of epilepsy in many African nations.8 The disorder is enrobed in superstition, Journal name: Neuropsychiatric Disease and Treatment Article Designation: Original Research Y ear: 2015 Volume: 11 Running head verso: Teferi and Shewangizaw Running head recto: Assessment of knowledge, attitude, and practice related to epilepsy DOI: http://dx.doi.org/10.2147/NDT.S8232 8",Non-OADS,/arxiv_data1/oa_pdf/2b/c3/ndt-11-1239.PMC4446018.pdf
"Neuropsychiatric Disease and Treatment Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/neuropsychiatric-disease-and-treatment-journa lNeuropsychiatric Disease and Treatment is an international, peer- reviewed journal of clinical therapeutics and pharmacology focusing   on concise rapid reporting of clinical or pre-clinical studies on a   range of neuropsychiatric and neurological disorders.",Non-OADS,/arxiv_data1/oa_pdf/2b/c3/ndt-11-1239.PMC4446018.pdf
Visit http://www.dovepress.com/testimonials.ph p to  read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/2b/c3/ndt-11-1239.PMC4446018.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/d3/ee/jir-8-107.PMC4446019.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pJournal of Inflammation Research 2015:8 107–116Journal of Inflammation Research Dove press submit your manuscript | www.dovepress.co m Dove press  107ORIg Inal ReseaRchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/JIR.S7630 4association of inflammatory markers and poor  outcome in diabetic patients presenting with sT  segment elevation myocardial infarction Yulia Belenkova1,2 Viktoria Karetnikova1,2 aleksey Diachenko2 Olga gruzdeva1 Olga Blagoveshchenskaya3 Tatiana Molodtsova3 evgenya Uchasova1 Olga Barbarash1,2 1Federal state Budgetary Institution  Research Institute for complex Issues  of cardiovascular Diseases, siberian  Branch of the Russian academy of  Medical sciences, 2state Budgetary  educational Institution of higher  Professional education Kemerovo  state Medical academy of the Russian  Ministry of health, 3state Budgetary  healthcare Institution Kemerovo  Regional clinical hospital, Kemerovo,   Russian Federation correspondence: evgenya Uchasova   Federal state Budgetary Institution  Research Institute for complex Issues  of cardiovascular Diseases, sciences,  6 sosnovy Boulevard, Kemerovo 650002,  Russian Federation   email evg.uchasova@yandex.r uObjective:  Carbohydrate metabolism disorders (CMD) significantly impact the development  and progression of all forms of ischemic heart disease, and inflammation is regarded as a general  pathogenetic link between CMD and ischemic heart disease.",Non-OADS,/arxiv_data1/oa_pdf/d3/ee/jir-8-107.PMC4446019.pdf
"A vailable from:  http://www.syntaxscore.com/calc/start.ht m. Accessed October 23, 2014.",Non-OADS,/arxiv_data1/oa_pdf/d3/ee/jir-8-107.PMC4446019.pdf
"Available from: http://www.timi.org/index.php?page=calculator s.  Accessed October 23, 2014.",Non-OADS,/arxiv_data1/oa_pdf/d3/ee/jir-8-107.PMC4446019.pdf
"Journal of Inflammation Research Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/journal-of-inflammation-research-journa lThe Journal of Inflammation Research is an international, peer-reviewed  open-access journal that welcomes laboratory and clinical findings on the  molecular basis, cell biology and pharmacology of inflammation including  original research, reviews, symposium reports, hypothesis formation and  commentaries on: acute/chronic inflammation; mediators of inflamma -tion; cellular processes; molecular mechanisms; pharmacology and novel  anti-inflammatory drugs; clinical conditions involving inflammation.",Non-OADS,/arxiv_data1/oa_pdf/d3/ee/jir-8-107.PMC4446019.pdf
Visit http://www.dovepress.com/   testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/d3/ee/jir-8-107.PMC4446019.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/75/4a/ndt-11-1247.PMC4446020.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpNeuropsychiatric Disease and Treatment 2015:11 1247–1253Neuropsychiatric Disease and Treatment Dove press submit your manuscript | www.dovepress.co m Dove press  1247OrigiNal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/NDT .S8356 9comprehensive family therapy: an effective  approach for cognitive rehabilitation  in schizophrenia Jun cai1 Yi Zhu1 Weibo Zhang1 Yanfeng Wang1 chen Zhang2 1center for Disease control  and Prevention, shanghai Mental  health center, 2schizophrenia  Program, shanghai Mental health  center, shanghai Jiao T ong University  school of Medicine, shanghai, People’s  republic of chinaBackground:  Antipsychotic medication has limited abilities to improve the cognitive  impairments that accompany schizophrenia.",Non-OADS,/arxiv_data1/oa_pdf/75/4a/ndt-11-1247.PMC4446020.pdf
"Moreover, around 80%  of patients with the disease struggle with a variety of neurocognitive deficiencies, including  speed of processing, attention/vigilance, working memory, verbal learning, reasoning, and  problem solving.3 A growing number of studies have indicated that cognitive dysfunction  is among the most important factors in contributing to the social deficits and the func - tional outcome of schizophrenia patients;4 moreover, our previous work demonstrated a  wide range of cognitive functions that were substantially impaired among antipsychotic- naïve patients with first-episode schizophrenia,5,6 which supports the view that cognitive correspondence: chen Zhang schizophrenia Program, shanghai Mental  health center, shanghai Jiao Tong  University school of Medicine, 600  Wan Ping Nan road, shanghai 200030,  People’s republic of china Tel +86 21 6438 7250 email zhangchen645@gmail.co m Journal name: Neuropsychiatric Disease and Treatment Article Designation: Original Research Y ear: 2015 Volume: 11 Running head verso: Cai et al Running head recto: Comprehensive family therapy and schizophrenia DOI: http://dx.doi.org/10.2147/NDT.S83569",Non-OADS,/arxiv_data1/oa_pdf/75/4a/ndt-11-1247.PMC4446020.pdf
"Neuropsychiatric Disease and Treatment Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/neuropsychiatric-disease-and-treatment-journa lNeuropsychiatric Disease and Treatment is an international, peer- reviewed journal of clinical therapeutics and pharmacology focusing   on concise rapid reporting of clinical or pre-clinical studies on a   range of neuropsychiatric and neurological disorders.",Non-OADS,/arxiv_data1/oa_pdf/75/4a/ndt-11-1247.PMC4446020.pdf
Visit http://www.dovepress.com/testimonials.ph p to  read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/75/4a/ndt-11-1247.PMC4446020.pdf
"creativecommons.org/licenses/by-nc/3.0/) which permits non-commercial use, reproduction and distribution of the work without further permiss ion provided the original work is attributed as specified on the SAGE and Open Access page (http://www.uk.sagepub.com/aboutus/openaccess.htm).",Non-OADS,/arxiv_data1/oa_pdf/ed/4e/10.1177_2047981614568910.PMC4446225.pdf
- Korean J Orthod 2014;44:320-329  http://dx.doi.org/10.4041/kjod.2015.45.3.103103www.e-kjo.orgpISSN 2234-7518 eISSN 2005-372X,Non-OADS,/arxiv_data1/oa_pdf/db/d4/kjod-45-103.PMC4446370.pdf
"Biochem Biophys Res Commun 2006;348:1167-73.  www.e-kjo.org http://dx.doi.org/10.4041/kjod.2015.45.3.103This is an Open Access article distributed under the terms of the  Creative Commons Attribution Non-Commercial License (http:// creativecommons.org/licenses/by-nc/4.0) which permits unrestricted  non-commercial use, distribution, and reproduction in any medium,  provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/db/d4/kjod-45-103.PMC4446370.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License  (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and  reproduction in any medium, provided the original work is properly cited.THE KOREAN JOURNAL of  ORTHODONTICS Original Article pISSN 2234-7518 • eISSN 2005-372X http://dx.doi.org/10.4041/kjod.2015.45.3.105",Non-OADS,/arxiv_data1/oa_pdf/2c/3f/kjod-45-105.PMC4446371.pdf
"Kim et al • Evaluation of 3D facial scanning www.e-kjo.org 106 http://dx.doi.org/10.4041/kjod.2015.45.3.105 INTRODUCTION   Acquiring patient data, including facial images of the  head and neck region, is an integral step in the diag- nosis, treatment planning, and evaluation of orthodontic  treatment and orthognathic surgery.",Non-OADS,/arxiv_data1/oa_pdf/2c/3f/kjod-45-105.PMC4446371.pdf
Kim et al • Evaluation of 3D facial scanning www.e-kjo.org 107 http://dx.doi.org/10.4041/kjod.2015.45.3.105 1310-1).,OADS,/arxiv_data1/oa_pdf/2c/3f/kjod-45-105.PMC4446371.pdf
Kim et al • Evaluation of 3D facial scanning www.e-kjo.org 108 http://dx.doi.org/10.4041/kjod.2015.45.3.105 evaluate linear measurements on the subject’s forehead.,OADS,/arxiv_data1/oa_pdf/2c/3f/kjod-45-105.PMC4446371.pdf
Kim et al • Evaluation of 3D facial scanning www.e-kjo.org 109 http://dx.doi.org/10.4041/kjod.2015.45.3.105 Table 3.,OADS,/arxiv_data1/oa_pdf/2c/3f/kjod-45-105.PMC4446371.pdf
"Kim et al • Evaluation of 3D facial scanning www.e-kjo.org 110 http://dx.doi.org/10.4041/kjod.2015.45.3.105 (1.1 mm), and La1-La2 (1.0 mm).",OADS,/arxiv_data1/oa_pdf/2c/3f/kjod-45-105.PMC4446371.pdf
"Kim et al • Evaluation of 3D facial scanning www.e-kjo.org 111 http://dx.doi.org/10.4041/kjod.2015.45.3.105 and En, and the subjects usually constricted the muscles  around the eyes as the digital caliper approached.",Non-OADS,/arxiv_data1/oa_pdf/2c/3f/kjod-45-105.PMC4446371.pdf
Kim et al • Evaluation of 3D facial scanning www.e-kjo.org 112 http://dx.doi.org/10.4041/kjod.2015.45.3.105 Maxillofac Surg 2008;37:641-6.,OADS,/arxiv_data1/oa_pdf/2c/3f/kjod-45-105.PMC4446371.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License  (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and  reproduction in any medium, provided the original work is properly cited.THE KOREAN JOURNAL of  ORTHODONTICS Original Article pISSN 2234-7518 • eISSN 2005-372X http://dx.doi.org/10.4041/kjod.2015.45.3.113",Non-OADS,/arxiv_data1/oa_pdf/5b/ba/kjod-45-113.PMC4446372.pdf
Lee et al • Comparison of occlusal contact areas www.e-kjo.org 114 http://dx.doi.org/10.4041/kjod.2015.45.3.113 INTRODUCTION   Molar occlusal relationships are evaluated from the  buccal aspect.,OADS,/arxiv_data1/oa_pdf/5b/ba/kjod-45-113.PMC4446372.pdf
Lee et al • Comparison of occlusal contact areas www.e-kjo.org 115 http://dx.doi.org/10.4041/kjod.2015.45.3.113 which showed the same molar relationships at the initial  visit and had only the maxillary first premolars extracted.,Non-OADS,/arxiv_data1/oa_pdf/5b/ba/kjod-45-113.PMC4446372.pdf
"Lee et al • Comparison of occlusal contact areas www.e-kjo.org 116 http://dx.doi.org/10.4041/kjod.2015.45.3.113 the occlusal contact area of the posterior segment, based  on maxillary teeth, was calculated as the sum of right  and left second molars, the sum of right and left first  molars, and the sum of right and left second premolars,  excluding the first premolar; the occlusal contact area  of the individual teeth, based on maxillary teeth, was  calculated as the sum of right and left second molars (no.",OADS,/arxiv_data1/oa_pdf/5b/ba/kjod-45-113.PMC4446372.pdf
Lee et al • Comparison of occlusal contact areas www.e-kjo.org 117 http://dx.doi.org/10.4041/kjod.2015.45.3.113 class I and II finishings.,OADS,/arxiv_data1/oa_pdf/5b/ba/kjod-45-113.PMC4446372.pdf
Lee et al • Comparison of occlusal contact areas www.e-kjo.org 118 http://dx.doi.org/10.4041/kjod.2015.45.3.113 Occlusal contact areas of the posterior segment of the  initial models were greater than those of the set-up  and final models according to the Bonferroni test.,OADS,/arxiv_data1/oa_pdf/5b/ba/kjod-45-113.PMC4446372.pdf
Lee et al • Comparison of occlusal contact areas www.e-kjo.org 119 http://dx.doi.org/10.4041/kjod.2015.45.3.113 of the class II finishing showed a cusp-to-marginal ridge  relationship.,OADS,/arxiv_data1/oa_pdf/5b/ba/kjod-45-113.PMC4446372.pdf
Lee et al • Comparison of occlusal contact areas www.e-kjo.org 120 http://dx.doi.org/10.4041/kjod.2015.45.3.113 at restriction of maxillary growth.,OADS,/arxiv_data1/oa_pdf/5b/ba/kjod-45-113.PMC4446372.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License  (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and  reproduction in any medium, provided the original work is properly cited.THE KOREAN JOURNAL of  ORTHODONTICS Original Article pISSN 2234-7518 • eISSN 2005-372X http://dx.doi.org/10.4041/kjod.2015.45.3.121 Received September 18, 2014; Revised December 1, 2014; Accepted December 4, 2014.",Non-OADS,/arxiv_data1/oa_pdf/b0/e9/kjod-45-121.PMC4446373.pdf
Gorucu Coskuner et al • Assessment of tempormandibular joint and mandible www.e-kjo.org 122 http://dx.doi.org/10.4041/kjod.2015.45.3.121 INTRODUCTION   Class II malocclusion is a common clinical entity and  is categorized into Class II division 1 and Class II di- vision 2 malocclusions.,Non-OADS,/arxiv_data1/oa_pdf/b0/e9/kjod-45-121.PMC4446373.pdf
"Gorucu Coskuner et al • Assessment of tempormandibular joint and mandible www.e-kjo.org 123 http://dx.doi.org/10.4041/kjod.2015.45.3.121 munications in Medicine files and processed in the OsiriX  medical imaging software program (Open-Source, OsiriX  Medical Imaging Software, www.osirix-viewer.com), as  described by Leonardi et al.23 By determining the long  axis of the condyle in the coronal and axial sections, a  sagittal image (Figure 1) was constructed.",OADS,/arxiv_data1/oa_pdf/b0/e9/kjod-45-121.PMC4446373.pdf
"Gorucu Coskuner et al • Assessment of tempormandibular joint and mandible www.e-kjo.org 124 http://dx.doi.org/10.4041/kjod.2015.45.3.121 stage, and mean treatment duration between the two  groups ( p < 0.05).",OADS,/arxiv_data1/oa_pdf/b0/e9/kjod-45-121.PMC4446373.pdf
"Gorucu Coskuner et al • Assessment of tempormandibular joint and mandible www.e-kjo.org 125 http://dx.doi.org/10.4041/kjod.2015.45.3.121 angle between the long axis of the mandibular condylar  process and the midsagittal plane, and the vertical  distance from the geometric centers of the condyles to  the midsagittal plane ( p > 0.0125).",OADS,/arxiv_data1/oa_pdf/b0/e9/kjod-45-121.PMC4446373.pdf
Gorucu Coskuner et al • Assessment of tempormandibular joint and mandible www.e-kjo.org 126 http://dx.doi.org/10.4041/kjod.2015.45.3.121 maxillary expansion with a control group of 50 subjects.,Non-OADS,/arxiv_data1/oa_pdf/b0/e9/kjod-45-121.PMC4446373.pdf
"Gorucu Coskuner et al • Assessment of tempormandibular joint and mandible www.e-kjo.org 127 http://dx.doi.org/10.4041/kjod.2015.45.3.121 group II, SNB and the facial depth angles as well as the  Pog-NB and Ar-Go distances also showed statistically  significant increases, indicating that in patients with  Class II division 2 malocclusion, the elimination of  maxillary interferences may lead to a greater increase in  the mandibular dimensions.",Non-OADS,/arxiv_data1/oa_pdf/b0/e9/kjod-45-121.PMC4446373.pdf
"Gorucu Coskuner et al • Assessment of tempormandibular joint and mandible www.e-kjo.org 128 http://dx.doi.org/10.4041/kjod.2015.45.3.121 changes related to physiological growth, further studies  assessing temporomandibular joint images at more  frequent intervals are necessary.",Non-OADS,/arxiv_data1/oa_pdf/b0/e9/kjod-45-121.PMC4446373.pdf
Gorucu Coskuner et al • Assessment of tempormandibular joint and mandible www.e-kjo.org 129 http://dx.doi.org/10.4041/kjod.2015.45.3.121 7.,OADS,/arxiv_data1/oa_pdf/b0/e9/kjod-45-121.PMC4446373.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License  (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and  reproduction in any medium, provided the original work is properly cited.THE KOREAN JOURNAL of  ORTHODONTICS Original Article pISSN 2234-7518 • eISSN 2005-372X http://dx.doi.org/10.4041/kjod.2015.45.3.130 130",Non-OADS,/arxiv_data1/oa_pdf/f7/84/kjod-45-130.PMC4446374.pdf
Inami et al • Color stability of GFRP esthetic wires www.e-kjo.org 131 http://dx.doi.org/10.4041/kjod.2015.45.3.130 INTRODUCTION   Orthodontic wires are widely used as part of ortho- dontic appliances throughout treatment.,Non-OADS,/arxiv_data1/oa_pdf/f7/84/kjod-45-130.PMC4446374.pdf
"Inami et al • Color stability of GFRP esthetic wires www.e-kjo.org 132 http://dx.doi.org/10.4041/kjod.2015.45.3.130 GFRP wires with such small diameters was impossible;  samples with a total width of at least 3 mm are requ - ired so that the color can be properly measured by colo- rimetry, as described later.",OADS,/arxiv_data1/oa_pdf/f7/84/kjod-45-130.PMC4446374.pdf
Inami et al • Color stability of GFRP esthetic wires www.e-kjo.org 133 http://dx.doi.org/10.4041/kjod.2015.45.3.130 RESULTS   Figure 3 shows photographs of the GFRP wires before  and after 4 weeks of immersion in the coffee solution.,OADS,/arxiv_data1/oa_pdf/f7/84/kjod-45-130.PMC4446374.pdf
"Inami et al • Color stability of GFRP esthetic wires www.e-kjo.org 134 http://dx.doi.org/10.4041/kjod.2015.45.3.130 orthodontic appliances according to ΔE* units has not  yet been clearly defined, the relatively low ΔE* values  for the present GFRPs suggest that discoloration will not  occur during orthodontic treatment.",Non-OADS,/arxiv_data1/oa_pdf/f7/84/kjod-45-130.PMC4446374.pdf
Inami et al • Color stability of GFRP esthetic wires www.e-kjo.org 135 http://dx.doi.org/10.4041/kjod.2015.45.3.130 2013;83:994-1001.,OADS,/arxiv_data1/oa_pdf/f7/84/kjod-45-130.PMC4446374.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License  (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and  reproduction in any medium, provided the original work is properly cited.THE KOREAN JOURNAL of  ORTHODONTICS Case Report pISSN 2234-7518 • eISSN 2005-372X http://dx.doi.org/10.4041/kjod.2015.45.3.136 136",Non-OADS,/arxiv_data1/oa_pdf/5c/b0/kjod-45-136.PMC4446375.pdf
"Arai et al • Management of open bite www.e-kjo.org 137 http://dx.doi.org/10.4041/kjod.2015.45.3.136 INTRODUCTION   Patients with internal derangement (ID) and osteoar- thritis (OA) of the temporomandibular joint (TMJ) pri- marily undergo serial non-surgical treatfment, including  physiotherapy, occlusal splint therapy, and medication,  to relieve functional TMJ pain.1,2 However, surgical pro- cedures are sometimes required if the symptoms do not  improve after nonsurgical treatment and/or are caused  by degenerative changes in the condyle.3-6    However, even after symptom resolution, morphological  changes of the condyle persist in these patients.",Non-OADS,/arxiv_data1/oa_pdf/5c/b0/kjod-45-136.PMC4446375.pdf
Arai et al • Management of open bite www.e-kjo.org 138 http://dx.doi.org/10.4041/kjod.2015.45.3.136 correction of open bite.,OADS,/arxiv_data1/oa_pdf/5c/b0/kjod-45-136.PMC4446375.pdf
"Arai et al • Management of open bite www.e-kjo.org 139 http://dx.doi.org/10.4041/kjod.2015.45.3.136 cephalometric analysis showed the following values: ANB  angle, 4.5o; FMA, 46.7o; U1-SN, 95.8o; L1-MP, 83.7o  (Table 1, Figure 5B).",OADS,/arxiv_data1/oa_pdf/5c/b0/kjod-45-136.PMC4446375.pdf
"Arai et al • Management of open bite www.e-kjo.org 140 http://dx.doi.org/10.4041/kjod.2015.45.3.136 TREATMENT ALTERNATIVES   To achieve the treatment objectives, particularly open  bite correction, we suggested two treatment plans.",Non-OADS,/arxiv_data1/oa_pdf/5c/b0/kjod-45-136.PMC4446375.pdf
Arai et al • Management of open bite www.e-kjo.org 141 http://dx.doi.org/10.4041/kjod.2015.45.3.136 and lingual arch were removed from the mandible.,Non-OADS,/arxiv_data1/oa_pdf/5c/b0/kjod-45-136.PMC4446375.pdf
Arai et al • Management of open bite www.e-kjo.org 142 http://dx.doi.org/10.4041/kjod.2015.45.3.136 of improvement (Figure 10A).,OADS,/arxiv_data1/oa_pdf/5c/b0/kjod-45-136.PMC4446375.pdf
"Arai et al • Management of open bite www.e-kjo.org 143 http://dx.doi.org/10.4041/kjod.2015.45.3.136 open bite correction, although stability of the treatment  outcomes remains debatable.",Non-OADS,/arxiv_data1/oa_pdf/5c/b0/kjod-45-136.PMC4446375.pdf
Arai et al • Management of open bite www.e-kjo.org 144 http://dx.doi.org/10.4041/kjod.2015.45.3.136 sequence of excessive lingual movement of the man- dibular anterior teeth.,Non-OADS,/arxiv_data1/oa_pdf/5c/b0/kjod-45-136.PMC4446375.pdf
Arai et al • Management of open bite www.e-kjo.org 145 http://dx.doi.org/10.4041/kjod.2015.45.3.136 intrusion of the molars is a safer and less stressful alter- native for the management of open bite due to bilateral  condylar degeneration secondary to ID and OA of TMJ.,Non-OADS,/arxiv_data1/oa_pdf/5c/b0/kjod-45-136.PMC4446375.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License  (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and  reproduction in any medium, provided the original work is properly cited.THE KOREAN JOURNAL of  ORTHODONTICS Brief Report pISSN 2234-7518 • eISSN 2005-372X http://dx.doi.org/10.4041/kjod.2015.45.3.146 146",Non-OADS,/arxiv_data1/oa_pdf/13/7c/kjod-45-146.PMC4446376.pdf
Choi et al • Revision of miniscrew scars  www.e-kjo.org 147 http://dx.doi.org/10.4041/kjod.2015.45.3.146 INTRODUCTION   Favored implantation sites for orthodontic miniscrews  are the interdental alveolar bone within the attached  gingiva and the palate.,Non-OADS,/arxiv_data1/oa_pdf/13/7c/kjod-45-146.PMC4446376.pdf
"Choi et al • Revision of miniscrew scars  www.e-kjo.org 148 http://dx.doi.org/10.4041/kjod.2015.45.3.146 gingival junction, to apply intrusive force similar to  that of J-hook headgear (Figure 2B).8 After 4 months,  appliances were removed following gingivectomy (Figure  2C).",Non-OADS,/arxiv_data1/oa_pdf/13/7c/kjod-45-146.PMC4446376.pdf
Choi et al • Revision of miniscrew scars  www.e-kjo.org 149 http://dx.doi.org/10.4041/kjod.2015.45.3.146 DISCUSSION   The removal of miniscrews is generally not considered  a traumatic procedure.,Non-OADS,/arxiv_data1/oa_pdf/13/7c/kjod-45-146.PMC4446376.pdf
Choi et al • Revision of miniscrew scars  www.e-kjo.org 150 http://dx.doi.org/10.4041/kjod.2015.45.3.146 molecular mechanism of hypertrophic scar.,OADS,/arxiv_data1/oa_pdf/13/7c/kjod-45-146.PMC4446376.pdf
Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Di seases This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ) http://dx.doi.org/10.1016/j.nmni.2015.02.007,Non-OADS,/arxiv_data1/oa_pdf/2d/77/main.PMC4446399.pdf
"Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Di seases, NMNI ,6,2 2–29 This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ )",Non-OADS,/arxiv_data1/oa_pdf/2d/77/main.PMC4446399.pdf
The latest ECDC report on antimi- crobial resistance surveillance in Europe ( http://www.ecdc.,Non-OADS,/arxiv_data1/oa_pdf/2d/77/main.PMC4446399.pdf
"Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Di seases, NMNI ,6,2 2–29 This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ )",Non-OADS,/arxiv_data1/oa_pdf/2d/77/main.PMC4446399.pdf
"Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Di seases, NMNI ,6,2 2–29 This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ )",Non-OADS,/arxiv_data1/oa_pdf/2d/77/main.PMC4446399.pdf
"Initiatives such as the 10 × ’20 Initiative, promoted by the Infectious Diseases Society of America (IDSA), that attempts to produce ten new systemic antibiotics by the year 2020 [32], or the European Innovative Medicine Initiative ( http://www.imi.europa.eu ), supporting collaborative research projects between the pharmaceutical industry and theacademia, combine public and private funding to invigorate antimicrobial drug research.",Non-OADS,/arxiv_data1/oa_pdf/2d/77/main.PMC4446399.pdf
"Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Di seases, NMNI ,6,2 2–29 This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ )",Non-OADS,/arxiv_data1/oa_pdf/2d/77/main.PMC4446399.pdf
"Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Di seases, NMNI ,6,2 2–29 This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ )",Non-OADS,/arxiv_data1/oa_pdf/2d/77/main.PMC4446399.pdf
Available at: http://www.efsa.europa.eu/en/ scdocs/doc/1372.pdf [accessed 8.5.15].,Non-OADS,/arxiv_data1/oa_pdf/2d/77/main.PMC4446399.pdf
Available at: http://www.who.int/ foodsafety/publications/antimicrobials-third/en/ [accessed 8.5.15].,Non-OADS,/arxiv_data1/oa_pdf/2d/77/main.PMC4446399.pdf
"2013.Available at:, http://ecdc.europa.eu/en/publications/Publications/antimi crobial-resistance-surveillance-europe-2012.pdf [accessed 8.5.15].",Non-OADS,/arxiv_data1/oa_pdf/2d/77/main.PMC4446399.pdf
"Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Di seases, NMNI ,6,2 2–29 This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ )",Non-OADS,/arxiv_data1/oa_pdf/2d/77/main.PMC4446399.pdf
"Available at:, http://www.ema.europa.eu/ docs/en_GB/document_library/Report/2009/11/WC500008770.pdf [accessed 8.5.15].",Non-OADS,/arxiv_data1/oa_pdf/2d/77/main.PMC4446399.pdf
"Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Di seases, NMNI ,6,2 2–29 This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ )",Non-OADS,/arxiv_data1/oa_pdf/2d/77/main.PMC4446399.pdf
File con- versionusingMSConvert( http://proteowizard.sourceforge.,OADS,/arxiv_data1/oa_pdf/47/02/gkv145.PMC4446411.pdf
The soft- ware can be downloaded at http://bearcatms.uc.edu/new/ limbachgroup publication/ .,Non-OADS,/arxiv_data1/oa_pdf/47/02/gkv145.PMC4446411.pdf
MATERIALS AND METHODS Identifying TALEN-binding sites TALENSeek was generated as a script in the R program- ming language (available at http://geschwindlab.neurology.,OADS,/arxiv_data1/oa_pdf/c8/9e/gkv164.PMC4446412.pdf
"We finally kept regions with at most 10 −7unadjusted P-value, provided that they were not lo- cated on a mitochondrial chromosome; and they did not belong to the blacklist published in the context of the EN- CODEproject( 33)availableat https://sites.google.com/site/ anshulkundaje/projects/blacklists .",Non-OADS,/arxiv_data1/oa_pdf/cd/b6/gkv370.PMC4446430.pdf
"( A)TimecourseanalysisofRAR(green)andRXR(red)bindingprofilesinthe HoxalocusafterRA stimulationofF9ECcells.Ascreenshot( http://genome.ucsc.edu )oftheRARandRXRbindingsignalatthedifferenttimepointsafterRAstimulation,is shown.",OADS,/arxiv_data1/oa_pdf/cd/b6/gkv370.PMC4446430.pdf
( B)EffectofEsrrbKD onRARbindingintensity.Upperpanelsshowascreenshot( http://genome.ucsc.edu )ofRARandESRRBbindingsignalonthegenomiclocianalyzedin wild-type F9 cells and ES cells respectively.,OADS,/arxiv_data1/oa_pdf/cd/b6/gkv370.PMC4446430.pdf
Upper panels show a screenshot ( http://genome.ucsc.edu ) of RAR and SOX17 bindingsignalonthegenomiclocianalyzedinuntreatedandRAtreatedwild-typeF9cells.PredictedRAREmotifspresentunderthepeakareindicated .,Non-OADS,/arxiv_data1/oa_pdf/cd/b6/gkv370.PMC4446430.pdf
DATA ACCESS The data have been submitted to the NCBI Gene Expres- sion Omnibus (GEO) ( http://www.ncbi.nlm.nih.gov/geo/ ) under accession No.GSE56893.,OADS,/arxiv_data1/oa_pdf/cd/b6/gkv370.PMC4446430.pdf
"http://www.espcr.org/micemut ),thussuggestingapotential relevanceoftheseadditionalproteinbindingsiteswithintheTyr5 /primeregulatory element.",OADS,/arxiv_data1/oa_pdf/14/2e/gkv375.PMC4446435.pdf
Convergence of the runs was verified using the Tracer tool(http://beast.bio.ed.ac.uk/tracer ).,OADS,/arxiv_data1/oa_pdf/dc/a8/gkv378.PMC4446436.pdf
Analysis of COCO-VAtoggling by BayesTraits Evolution of non-synonymous replacements at the codon- constrained Val-Ala (COCO-VA) site of ORF5 was analysed by BayesTraits package using the Multistatemodel ( http://www.evolution.rdg.ac.uk/BayesTraits.html ) (53).,OADS,/arxiv_data1/oa_pdf/dc/a8/gkv378.PMC4446436.pdf
Statistical significance of differences in Ala-Val exchange rates was assessed using log Bayes Factors that was calculated with the R package Bayes Factor ( http://bayesfactorpcl.r-forge.r-project.org/ ).,OADS,/arxiv_data1/oa_pdf/dc/a8/gkv378.PMC4446436.pdf
"4804NucleicAcidsResearch,2015,Vol.43,No.10 (66)a n dP S I P r e d( 67)(http://www-nmr.cabm.rutgers.edu/ bioinformatics/disorder/ ).",OADS,/arxiv_data1/oa_pdf/dc/a8/gkv378.PMC4446436.pdf
"For structure prediction the defaultRNAz parameters of ‘Standard Analysis’ were utilized, which scored in the overlapping windows of 120 alignment columns with step-size of 40 nt ( http://rna.tbi.univie.ac.at/ cgi-bin/RNAz.cgi?PAGE=1&TYPE=S ).",OADS,/arxiv_data1/oa_pdf/dc/a8/gkv378.PMC4446436.pdf
"(2012) VirusTaxonomy:NinthReportoftheInternationalCommitteeon TaxonomyofViruses .AcademicPress,London, http://www.sciencedirect.com/science/book/9780123846846 .",Non-OADS,/arxiv_data1/oa_pdf/dc/a8/gkv378.PMC4446436.pdf
"Open Access This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which per-mits any noncommercial use, distribution, and reproduction in anymedium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.",Non-OADS,/arxiv_data1/oa_pdf/21/3a/40264_2015_Article_288.PMC4446523.pdf
Available at: http://www.who.int/mediacentre/factsheets/fs363/ en/.,Non-OADS,/arxiv_data1/oa_pdf/21/3a/40264_2015_Article_288.PMC4446523.pdf
Available at: http://www.ema.,Non-OADS,/arxiv_data1/oa_pdf/21/3a/40264_2015_Article_288.PMC4446523.pdf
Available at: http://ec.europa.eu/health/ﬁles/pharmacos/ docs/doc2002/feb/cd_pediatrics_en.pdf .,Non-OADS,/arxiv_data1/oa_pdf/21/3a/40264_2015_Article_288.PMC4446523.pdf
Available at: http://www.gpo.gov/fdsys/pkg/PLAW-108publ155/html/PLAW-108publ155.htm .,Non-OADS,/arxiv_data1/oa_pdf/21/3a/40264_2015_Article_288.PMC4446523.pdf
Available at: http://www.fda.gov/Regulatory Information/Legislation/FederalFoodDrugandCosmeticActFDCAct/SigniﬁcantAmendmentstotheFDCAct/FDASIA/ .,OADS,/arxiv_data1/oa_pdf/21/3a/40264_2015_Article_288.PMC4446523.pdf
Available at:http://www.who.int/selection_medicines/list/WMFc_2010.pdf .,Non-OADS,/arxiv_data1/oa_pdf/21/3a/40264_2015_Article_288.PMC4446523.pdf
Avail- able at: http://www.accessdata.fda.gov/scripts/sda/sdNavigation.,Non-OADS,/arxiv_data1/oa_pdf/21/3a/40264_2015_Article_288.PMC4446523.pdf
Available at: http://www.ema.,Non-OADS,/arxiv_data1/oa_pdf/21/3a/40264_2015_Article_288.PMC4446523.pdf
Available at: http://www.ema.europa.eu/docs/en_GB/ document_library/Scientiﬁc_guideline/2009/09/WC500003807.pdf.,Non-OADS,/arxiv_data1/oa_pdf/21/3a/40264_2015_Article_288.PMC4446523.pdf
Both the Medicines and Healthcare Products Regulatory Agency Contents lists available at ScienceDirect Annals of Medicine and Surgery journal homepage: www.annalsjournal.com Annals of Medicine and Surgery 4 (2015) 187 e188 http://dx.doi.org/10.1016/j.amsu.2015.05.005 2049-0801/ ©2015 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/03/3a/main.PMC4446552.pdf
"pISSN: 1011-8942  eISSN: 2092-9382Korean J Ophthalmol 2015;29(3):147-154 http://dx.doi.org/10.3341/kjo.2015.29.3.147 © 2015 The Korean Ophthalmological Society This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses  /by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.147 Original ArticleCombined Cataract Extraction and Vitrectomy for Macula-sparing  Retinal Detachment: Visual Outcomes and Complications Kyoung-Nam Kim1,2, Haeng-Jin Lee1, Dong-Won Heo1, Young-Joon Jo1,2, Ju ng-Yeul K i m1,2 1Department of Ophthalmology, Chungnam National University Hospital, Daejeon, Korea  2Department of Ophthalmology, Chungnam National University College of Medicine, Daejeon, Korea  Purpose:  To evaluate the visual outcome of combined phacoemulsification, intraocular lens implantation, and  vitrectomy for macula-sparing rhegmatogenous retinal detachment.",Non-OADS,/arxiv_data1/oa_pdf/ef/f7/kjo-29-147.PMC4446553.pdf
"pISSN: 1011-8942  eISSN: 2092-9382Korean J Ophthalmol 2015;29(3):155-159 http://dx.doi.org/10.3341/kjo.2015.29.3.155 © 2015 The Korean Ophthalmological Society This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses  /by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.155 Original ArticleDemographic Features of Idiopathic Macular Telangiectasia in   Korean Patients Sung Hyun Kim1, Jaeryung Oh2, Soh-Eun Ahn2, Choul Yong Park1, Jong-Hyun Oh1 1Department of Ophthalmology, Dongguk University Ilsan Hospital, Goyang, Korea 2Department of Ophthalmology, Korea University College of Medicine, Seoul, Korea Purpose:  To investigate the clinical and demographic features of idiopathic macular telangiectasia (MacTel) in  Korean patients since the introduction of spectral domain optical coherence tomography (SD-OCT).",Non-OADS,/arxiv_data1/oa_pdf/6b/f9/kjo-29-155.PMC4446554.pdf
"Additionally, increased awareness for the  disease through recent promotion activities of the MacTel  study group (http://www.mactelresearch.com) possibly af - fected the higher prevalence of type 2 MacTel in the pres - ent study [13].",Non-OADS,/arxiv_data1/oa_pdf/6b/f9/kjo-29-155.PMC4446554.pdf
"pISSN: 1011-8942  eISSN: 2092-9382Korean J Ophthalmol 2015;29(3):160-167 http://dx.doi.org/10.3341/kjo.2015.29.3.160 © 2015 The Korean Ophthalmological Society This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses  /by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.160 Original ArticleThe Association between Choroidal Thickness Variations and  Response to Intravitreal Bevacizumab in Central   Serous Chorioretinopathy Dong Yoon Kim1, Soo Geun Joe1, Sung Jae Yang2, Joo Yong Lee1, June-Gone Kim1, You ng Hee Yoon1 1Department of Ophthalmology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea 2Department of Ophthalmology, Gangneung Asan Hospital, University of Ulsan College of Medicine, Gangneung, Korea Purpose:  To analyze differences in the subfoveal choroidal thickness (SFChT) between bevacizumab respond - ers (BevRs) and nonresponders (BevNRs) in patients with idiopathic central serous chorioretinopathy (CSC).",Non-OADS,/arxiv_data1/oa_pdf/ac/bc/kjo-29-160.PMC4446555.pdf
"pISSN: 1011-8942  eISSN: 2092-9382Korean J Ophthalmol 2015;29(3):168-172 http://dx.doi.org/10.3341/kjo.2015.29.3.168 © 2015 The Korean Ophthalmological Society This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses  /by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.168 Original ArticleSimplified Correction of Ischemic Index in Diabetic Retinopathy  Evaluated by Ultra-widefield Fluorescein Angiography Jeong Hee Kim, Hyeong-Gi Jung, Hye Jin Chung, Kyungmin Lee, Joonhong Sohn HanGil Eye Hospital, Incheon, Korea Purpose:  To develop a novel, simplified method for correcting the ischemic index of nonperfused areas in dia - betic retinopathy (DR).",Non-OADS,/arxiv_data1/oa_pdf/d8/ef/kjo-29-168.PMC4446556.pdf
"pISSN: 1011-8942  eISSN: 2092-9382Korean J Ophthalmol 2015;29(3):173-177 http://dx.doi.org/10.3341/kjo.2015.29.3.173 © 2015 The Korean Ophthalmological Society This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses  /by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.173 Original ArticleRelationship between Control Grade, Stereoacuity and Surgical  Success in Basic Intermittent Exotropia Kyung Tae Kang, Se Youp Lee Department of Ophthalmology, Keimyung University School of Medicine, Daegu, Korea Purpose:  This study was conducted to identify the relationship between control grade, stereoacuity and surgical  success in basic intermittent exotropia.",Non-OADS,/arxiv_data1/oa_pdf/02/6c/kjo-29-173.PMC4446557.pdf
"pISSN: 1011-8942  eISSN: 2092-9382Korean J Ophthalmol 2015;29(3):178-184 http://dx.doi.org/10.3341/kjo.2015.29.3.178 © 2015 The Korean Ophthalmological Society This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses  /by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.178 Original ArticleComparison of the Refractive Measurements with Hand-held  Autorefractometer, Table-mounted Autorefractometer and   Cycloplegic Retinoscopy in Children Handan A kil1, Soner K eskin2, Cemal Ç avdarli3 1Op.",Non-OADS,/arxiv_data1/oa_pdf/8a/c5/kjo-29-178.PMC4446558.pdf
"pISSN: 1011-8942  eISSN: 2092-9382Korean J Ophthalmol 2015;29(3):185-189 http://dx.doi.org/10.3341/kjo.2015.29.3.185 © 2015 The Korean Ophthalmological Society This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses  /by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.185 Original ArticleThe Parameters of Pattern Visual Evoked Potential in the Severe  Visual Loss Patients in Korean Min Kyung Kim1, Ungsoo Samuel Kim1,2     1Department of Ophthalmology, Kim ’s Eye Hospital, Seoul, Korea    2 Department of Ophthalmology, Konyang University College of Medicine, Daejeon, Korea Purpose:  To compare  the characteristics of the pattern visual evoked potential (PVEP) in patients with severe  visual loss  and normal controls , and to demonstrate the range of PVEP parameters in normal Koreans .",Non-OADS,/arxiv_data1/oa_pdf/f3/80/kjo-29-185.PMC4446559.pdf
"pISSN: 1011-8942  eISSN: 2092-9382Korean J Ophthalmol 2015;29(3):190-194 http://dx.doi.org/10.3341/kjo.2015.29.3.190 © 2015 The Korean Ophthalmological Society This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses  /by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.190 Original ArticleAssessment of Patient Pain Experience during Intravitreal 27 -Gauge  Bevacizumab and 30 -Gauge Ranibizumab Injection Mete Güler1, Burak Bilgin2, Musa Çapkın1, Ali Şimşek1, Şemsettin Bilak1 1Department of Ophthalmology, Adıyaman University School of Medicine, Adiyaman, Turkey  2Department of Ophthalmology, Adıyaman University Education and Research Hospital, Adiyaman, Turkey Purpose:  To compare pain scores of patients during intravitreal 27-gauge bevacizumab and 30-gauge ranibi - zumab injection procedures.",Non-OADS,/arxiv_data1/oa_pdf/14/ce/kjo-29-190.PMC4446560.pdf
"pISSN: 1011-8942  eISSN: 2092-9382Korean J Ophthalmol 2015;29(3):195-202 http://dx.doi.org/10.3341/kjo.2015.29.3.195 © 2015 The Korean Ophthalmological Society This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses  /by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.195 Original ArticleEstimation of Intraocular Lens Power Calculation after Myopic  Corneal Refractive Surgery: Using Corneal Height in Anterior  Segment Optical Coherence Tomography Dong Hyun Kim1,2, Mee Kum Kim1,2, Won Ryang Wee1,2 1Department of Ophthalmology, Seoul National University College of Medicine, Seoul, Korea 2Laboratory of Ocular Regenerative Medicine and Immunology, Seoul Artificial Eye Center, Seoul National University Hospital  Clinical Research Institute, Seoul, Korea Purpose:  To investigate the feasibility of estimating effective lens position (ELP) and calculating intraocular lens  power  using corneal height (CH), as measured using anterior segment optical coherence tomography (AS- OCT), in patients who have undergone corneal refractive surgery.",Non-OADS,/arxiv_data1/oa_pdf/88/91/kjo-29-195.PMC4446561.pdf
"pISSN: 1011-8942  eISSN: 2092-9382 © 2015 The Korean Ophthalmological Society This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses  /by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.203Pathophysiology of Transient Cor - neal Edema and Pseudophakic  Cystoid Macular Edema  Dear Editor, We read with interest the article titled “Transient corneal  edema is a predictive factor for pseudophakic cystoid mac - ular edema after uncomplicated cataract surgery” [1], in  which the authors found that transient corneal edema  (TCE) following cataract surgery is a predictive factor of  pseudophakic cystoid macular edema (PCME).",Non-OADS,/arxiv_data1/oa_pdf/78/58/kjo-29-203.PMC4446562.pdf
"Sang Beom Han, Moosang Kim, Seung-Jun Lee  Department of Ophthalmology, Kangwon National University  Hospital, Kangwon National University Graduate School of  Medicine, Chuncheon, Korea E-mail(Sang Beom Han): m.sangbeom.han@gmail.comKorean J Ophthalmol 2015;29(3):203-205 http://dx.doi.org/10.3341/kjo.2015.29.3.203Correspondence",Non-OADS,/arxiv_data1/oa_pdf/78/58/kjo-29-203.PMC4446562.pdf
"The exact  mechanism of SO is not clear, but it is hypothesized that SO Korean J Ophthalmol 2015;29(3):205-207 http://dx.doi.org/10.3341/kjo.2015.29.3.205",Non-OADS,/arxiv_data1/oa_pdf/78/58/kjo-29-203.PMC4446562.pdf
"The exact  mechanism of SO is not clear, but it is hypothesized that SO Korean J Ophthalmol 2015;29(3):205-207 http://dx.doi.org/10.3341/kjo.2015.29.3.205",Non-OADS,/arxiv_data1/oa_pdf/eb/f9/kjo-29-205.PMC4446563.pdf
"In conclusion, ONHD should be considered in the pres - ence of peripapillary masses, and SD-OCT can be helpful Korean J Ophthalmol 2015;29(3):207-208 http://dx.doi.org/10.3341/kjo.2015.29.3.207",Non-OADS,/arxiv_data1/oa_pdf/eb/f9/kjo-29-205.PMC4446563.pdf
"In conclusion, ONHD should be considered in the pres - ence of peripapillary masses, and SD-OCT can be helpful Korean J Ophthalmol 2015;29(3):207-208 http://dx.doi.org/10.3341/kjo.2015.29.3.207",Non-OADS,/arxiv_data1/oa_pdf/57/a8/kjo-29-207.PMC4446564.pdf
Korean J Ophthalmol 2015;29(3):209-211 http://dx.doi.org/10.3341/kjo.2015.29.3.209,Non-OADS,/arxiv_data1/oa_pdf/3c/8e/kjo-29-209.PMC4446565.pdf
"ISSN 2234-3806 • eISSN 2234-3814  http://dx.doi.org/10.3343/alm.2015.35.4.391 www.annlabmed.org  391Ann Lab Med 2015;35:391-398 http://dx.doi.org/10.3343/alm.2015.35.4.391Original Article Clinical Chemistry A Novel Simultaneous Determination of Sarpogrelate  and its Active Metabolite (M-1) in Human Plasma,  Using Liquid Chromatography-Tandem Mass  Spectrometry: Clinical Application Jeong-Soo Yang, Ph.D.1,*, Jung-Ryul Kim, M.D.2,3,*, EunGi Cho, B.S.1, Wooseong Huh, M.D.2, Jae-Wook Ko, M.D.2,   and Soo-Youn Lee, M.D.2,4 Clinical Trial Center1, Clinical Research Institute, Samsung Medical Center; Department of Clinical Pharmacology and Therapeutics2, Samsung Medical  Center; Department of Clinical Research Design and Evaluation3, SAIHST, Sungkyunkwan University; Department of Laboratory Medicine and Genetics4,  Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea Background:  This study describes a novel analytical method for simultaneously determin - ing sarpogrelate and its metabolite (M-1) in human plasma, using liquid chromatography  coupled with tandem mass spectrometry, with electrospray ionization in the positive ion  mode.",Non-OADS,/arxiv_data1/oa_pdf/5f/df/alm-35-391.PMC4446576.pdf
Sarpogrelate and its active metabolite (M-1) assay 392  www.annlabmed.org http://dx.doi.org/10.3343/alm.2015.35.4.391and both sarpogrelate and M-1 inhibit the 5-HT2A receptor.,Non-OADS,/arxiv_data1/oa_pdf/5f/df/alm-35-391.PMC4446576.pdf
Sarpogrelate and its active metabolite (M-1) assay http://dx.doi.org/10.3343/alm.2015.35.4.391 www.annlabmed.org  393jection of standard solutions of analytes and IS onto the LC-MS/ MS.,Non-OADS,/arxiv_data1/oa_pdf/5f/df/alm-35-391.PMC4446576.pdf
Sarpogrelate and its active metabolite (M-1) assay 394  www.annlabmed.org http://dx.doi.org/10.3343/alm.2015.35.4.391without interference from endogenous substances derived from  plasma matrices.,Non-OADS,/arxiv_data1/oa_pdf/5f/df/alm-35-391.PMC4446576.pdf
"Sarpogrelate and its active metabolite (M-1) assay http://dx.doi.org/10.3343/alm.2015.35.4.391 www.annlabmed.org  395grelate, m/z 330.0 for M-1, and m/z 433.2 for the IS.",Non-OADS,/arxiv_data1/oa_pdf/5f/df/alm-35-391.PMC4446576.pdf
Sarpogrelate and its active metabolite (M-1) assay 396  www.annlabmed.org http://dx.doi.org/10.3343/alm.2015.35.4.391accurate and precise owing to the RSD and RE values falling  within the acceptance criteria.,Non-OADS,/arxiv_data1/oa_pdf/5f/df/alm-35-391.PMC4446576.pdf
"Sarpogrelate and its active metabolite (M-1) assay http://dx.doi.org/10.3343/alm.2015.35.4.391 www.annlabmed.org  397the pharmacokinetic parameters of sarpogrelate and M-1, with  coefficients of variation >50%.",Non-OADS,/arxiv_data1/oa_pdf/5f/df/alm-35-391.PMC4446576.pdf
"Sarpogrelate and its active metabolite (M-1) assay 398  www.annlabmed.org http://dx.doi.org/10.3343/alm.2015.35.4.391profiles of R-96544, the active form of a novel 5-HT2A receptor antago - nist R-102444.",Non-OADS,/arxiv_data1/oa_pdf/5f/df/alm-35-391.PMC4446576.pdf
http://www.fda.gov/downloads/Drugs/GuidanceCom - plianceRegulatoryInformation/Guidances/UCM368107.pdf .,Non-OADS,/arxiv_data1/oa_pdf/5f/df/alm-35-391.PMC4446576.pdf
"ISSN 2234-3806 • eISSN 2234-3814  http://dx.doi.org/10.3343/alm.2015.35.4.399 www.annlabmed.org  399Ann Lab Med 2015;35:399-403 http://dx.doi.org/10.3343/alm.2015.35.4.399Original Article Clinical Microbiology Accessory Gene Regulator Polymorphism and  Vancomycin Minimum Inhibitory Concentration in  Methicillin-Resistant Staphylococcus aureus Min-Jeong Park, M.D., Han-Sung Kim, M.D., Hyun Soo Kim, M.D., Jae-Seok Kim, M.D., Wonkeun Song, M.D.,   Mi Young Kim, M.D., Young Kyung Lee, M.D., and Hee Jung Kang, M.D.",Non-OADS,/arxiv_data1/oa_pdf/81/40/alm-35-399.PMC4446577.pdf
Agr polymorphism and vancomycin MIC in MRSA 400  www.annlabmed.org http://dx.doi.org/10.3343/alm.2015.35.4.399 Accessory gene regulator ( agr) operon participates in the reg - ulation of virulence factors of S. aureus .,Non-OADS,/arxiv_data1/oa_pdf/81/40/alm-35-399.PMC4446577.pdf
Agr polymorphism and vancomycin MIC in MRSA http://dx.doi.org/10.3343/alm.2015.35.4.399 www.annlabmed.org  401lates belonged to agr group III.,Non-OADS,/arxiv_data1/oa_pdf/81/40/alm-35-399.PMC4446577.pdf
Agr polymorphism and vancomycin MIC in MRSA 402  www.annlabmed.org http://dx.doi.org/10.3343/alm.2015.35.4.399present results support those of a previous study that reported  an association between agr group II and failure of vancomycin  therapy [8].,Non-OADS,/arxiv_data1/oa_pdf/81/40/alm-35-399.PMC4446577.pdf
"Agr polymorphism and vancomycin MIC in MRSA http://dx.doi.org/10.3343/alm.2015.35.4.399 www.annlabmed.org  403kum A.Population studies of methicillin-resistant and -sensitive Staphy - lococcus aureus  strains reveal a lack of variability in the agr D gene, en - coding a staphylococcal autoinducer peptide.",Non-OADS,/arxiv_data1/oa_pdf/81/40/alm-35-399.PMC4446577.pdf
"ISSN 2234-3806 • eISSN 2234-3814  404  www.annlabmed.org http://dx.doi.org/10.3343/alm.2015.35.4.404Ann Lab Med 2015;35:404-409 http://dx.doi.org/10.3343/alm.2015.35.4.404Original Article Clinical Microbiology Isolation and Identification of Clostridium difficile   Using ChromID C. difficile  Medium Combined With  Gram Staining and PRO Disc Testing: A Proposal for a  Simple Culture Process  Kyung Sun Park, M.D.",Non-OADS,/arxiv_data1/oa_pdf/b2/b9/alm-35-404.PMC4446578.pdf
"C. difficile  with CDIF, Gram stain and PRO disc test http://dx.doi.org/10.3343/alm.2015.35.4.404 www.annlabmed.org  405cepted as the standard because culture is the most sensitive  method [1].",Non-OADS,/arxiv_data1/oa_pdf/b2/b9/alm-35-404.PMC4446578.pdf
"C. difficile  with CDIF, Gram stain and PRO disc test 406  www.annlabmed.org http://dx.doi.org/10.3343/alm.2015.35.4.404NK11, and NK104/NK105 primers were used.",Non-OADS,/arxiv_data1/oa_pdf/b2/b9/alm-35-404.PMC4446578.pdf
"Statistical analysis Statistical analysis was performed by using MedCalc software  version 15.2.2 (MedCalc Software bvba, Ostend, Belgium;  http://www.medcalc.org; 2015).",OADS,/arxiv_data1/oa_pdf/b2/b9/alm-35-404.PMC4446578.pdf
"C. difficile  with CDIF, Gram stain and PRO disc test http://dx.doi.org/10.3343/alm.2015.35.4.404 www.annlabmed.org  407RESULTS A total of 1,402 prospectively collected stool specimens were  tested and 650 (46.4%) were positive by CDIF culture (Fig.",Non-OADS,/arxiv_data1/oa_pdf/b2/b9/alm-35-404.PMC4446578.pdf
"C. difficile  with CDIF, Gram stain and PRO disc test 408  www.annlabmed.org http://dx.doi.org/10.3343/alm.2015.35.4.404difficile  by direct sequencing of the 16S rDNA or tpi genes.",Non-OADS,/arxiv_data1/oa_pdf/b2/b9/alm-35-404.PMC4446578.pdf
"C. difficile  with CDIF, Gram stain and PRO disc test http://dx.doi.org/10.3343/alm.2015.35.4.404 www.annlabmed.org  409REFERENCES 1.",Non-OADS,/arxiv_data1/oa_pdf/b2/b9/alm-35-404.PMC4446578.pdf
"ISSN 2234-3806 • eISSN 2234-3814  410  www.annlabmed.org http://dx.doi.org/10.3343/alm.2015.35.4.410Ann Lab Med 2015;35:410-415 http://dx.doi.org/10.3343/alm.2015.35.4.410Original Article Clinical Microbiology Characterization of Mucoid and Non-Mucoid  Streptococcus pneumoniae  Isolated From Outpatients Shinji Ogihara, B.S.1, Ryoichi Saito, Ph.D.2, Teru Akikura, B.S.3, Akiko Iwama, B.S.3, Yukari Adachi, B.S.3, Daiki Kaji, B.S.3,  Kyoka Kakinuma, B.S.3, and Hiroshi Takahashi, B.S.3 Department of Clinical Laboratory1, Tokyo Medical and Dental University Hospital of Medicine, Tokyo; Department of Microbiology and Immunology2,  Graduate School of Health Care Sciences, Tokyo Medical and Dental University, Tokyo; Department of Clinical Laboratory3, Kimitsu Central Hospital, Chiba,  Japan Background:  Streptococcus pneumoniae  causes pneumonia, sepsis, and meningitis.",Non-OADS,/arxiv_data1/oa_pdf/95/99/alm-35-410.PMC4446579.pdf
Characterization of phenotypes of S. pneumoniae http://dx.doi.org/10.3343/alm.2015.35.4.410 www.annlabmed.org  411aeruginosa  [7].,Non-OADS,/arxiv_data1/oa_pdf/95/99/alm-35-410.PMC4446579.pdf
"Characterization of phenotypes of S. pneumoniae 412  www.annlabmed.org http://dx.doi.org/10.3343/alm.2015.35.4.410clavulanate, cefotaxime, ceftriaxone, cefepime, meropenem,  and vancomycin, did not differ significantly between the two  phenotypes (Table 1).",Non-OADS,/arxiv_data1/oa_pdf/95/99/alm-35-410.PMC4446579.pdf
"Characterization of phenotypes of S. pneumoniae http://dx.doi.org/10.3343/alm.2015.35.4.410 www.annlabmed.org  413and abscess exudate, and eye discharge was significantly higher  than that of non-mucoid isolates ( P<0.05) (Table 2).",OADS,/arxiv_data1/oa_pdf/95/99/alm-35-410.PMC4446579.pdf
Characterization of phenotypes of S. pneumoniae 414  www.annlabmed.org http://dx.doi.org/10.3343/alm.2015.35.4.410Table 5.,Non-OADS,/arxiv_data1/oa_pdf/95/99/alm-35-410.PMC4446579.pdf
Characterization of phenotypes of S. pneumoniae http://dx.doi.org/10.3343/alm.2015.35.4.410 www.annlabmed.org  4159.,Non-OADS,/arxiv_data1/oa_pdf/95/99/alm-35-410.PMC4446579.pdf
"ISSN 2234-3806 • eISSN 2234-3814  416  www.annlabmed.org http://dx.doi.org/10.3343/alm.2015.35.4.416Ann Lab Med 2015;35:416-422 http://dx.doi.org/10.3343/alm.2015.35.4.416Original Article Clinical Microbiology Direct Identification of Urinary Tract Pathogens From  Urine Samples Using the Vitek MS System Based on  Matrix-Assisted Laser Desorption Ionization–Time of  Flight Mass Spectrometry Yeongsic Kim, M.D.1, Kang Gyun Park, M.T.1, Kyungwon Lee, M.D.2, and Yeon-Joon Park, M.D.1 Department of Laboratory Medicine1, College of Medicine, The Catholic University of Korea, Seoul; Department of Laboratory Medicine2, Yonsei University  College of Medicine, Seoul, Korea Background:  We evaluated the coincidence rate between Vitek MS system (bioMérieux,  France) and Vitek 2 in identifying uropathogens directly from urine specimens.",OADS,/arxiv_data1/oa_pdf/dd/6f/alm-35-416.PMC4446580.pdf
"Identification of uropathogens by MALDI-TOF MS http://dx.doi.org/10.3343/alm.2015.35.4.416 www.annlabmed.org  417organisms found in blood cultures are E. coli , Candida  spp.,  Klebsiella  spp., Acinetobacter  spp., and Staphylococcus aureus   [2].",Non-OADS,/arxiv_data1/oa_pdf/dd/6f/alm-35-416.PMC4446580.pdf
Identification of uropathogens by MALDI-TOF MS 418  www.annlabmed.org http://dx.doi.org/10.3343/alm.2015.35.4.416the database (“no ID”) [4].,OADS,/arxiv_data1/oa_pdf/dd/6f/alm-35-416.PMC4446580.pdf
"Identification of uropathogens by MALDI-TOF MS http://dx.doi.org/10.3343/alm.2015.35.4.416 www.annlabmed.org  419two Acinetobacter  baumannii  complex, one Klebsiella  pneu - moniae , one Morganella morganii , and one Streptococcus  aga- lactiae ).",OADS,/arxiv_data1/oa_pdf/dd/6f/alm-35-416.PMC4446580.pdf
"Identification of uropathogens by MALDI-TOF MS 420  www.annlabmed.org http://dx.doi.org/10.3343/alm.2015.35.4.416edge, this is the first such study that used Vitek MS and in - cluded specimens with yeasts.",Non-OADS,/arxiv_data1/oa_pdf/dd/6f/alm-35-416.PMC4446580.pdf
"Identification of uropathogens by MALDI-TOF MS http://dx.doi.org/10.3343/alm.2015.35.4.416 www.annlabmed.org  421 For urine specimens with ≥105 CFU/mL, the identification  rate differed according to the microorganisms involved.",OADS,/arxiv_data1/oa_pdf/dd/6f/alm-35-416.PMC4446580.pdf
Identification of uropathogens by MALDI-TOF MS 422  www.annlabmed.org http://dx.doi.org/10.3343/alm.2015.35.4.416of urinary tract pathogens from urine samples by matrix-assisted laser  desorption ionization-time of flight mass spectrometry.,OADS,/arxiv_data1/oa_pdf/dd/6f/alm-35-416.PMC4446580.pdf
"ISSN 2234-3806 • eISSN 2234-3814  http://dx.doi.org/10.3343/alm.2015.35.4.423 www.annlabmed.org  423Ann Lab Med 2015;35:423-428 http://dx.doi.org/10.3343/alm.2015.35.4.423Original Article Diagnostic Immunology Comparison of FcR γ-Deficient and CD57+ Natural  Killer Cells Between Cord Blood and Adult Blood in  the Cytomegalovirus-Endemic Korean Population Hee Jo Baek, M.D.1, Da-Woon Kim, M.D.2,3, Minh-Trang Thi Phan, M.S.2,4,5, Ju-Sun Kim, M.S.5, Ji-Hoon Yang, M.S.6,   Jeong Il Choi, M.D.6, Je-Jung Lee, M.D.5, Myung-Geun Shin, M.D.2, Dong-Wook Ryang, M.D.2, Sang-Ki Kim, D.V.M.7,   Seung-Hwan Lee, Ph.D.8, Hoon Kook, M.D.1, and Duck Cho, M.D.2,4,5,* Department of Pediatrics1, Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Gwangju; Department of  Laboratory Medicine2, Chonnam National University Medical School, Gwangju; Department of Laboratory Medicine3, KS Hospital, Gwangju; Center for  Creative Biomedical Scientists4, Chonnam National University, Gwangju; Research Center for Cancer Immunotherapy5, Chonnam National University  Hwasun Hospital, Hwasun; Department of Anesthesiology and Pain Medicine6, Chonnan National University Medical School and Hospital, Gwangju;  Department of Companion & Laboratory Animal Science7, Kongju National University, Yesan, Korea; Department of Biochemistry, Microbiology and  Immunology8, University of Ottawa, Ottawa, Canada Background:  FcRγ-deficient natural killer (NK) cells (g¯NK cells) have been associated  with cytomegalovirus (CMV) infection.",Non-OADS,/arxiv_data1/oa_pdf/c0/c6/alm-35-423.PMC4446581.pdf
FcRγ-deficient NK cells in CMV endemic population 424  www.annlabmed.org http://dx.doi.org/10.3343/alm.2015.35.4.423INTRODUCTION Natural killer (NK) cells are innate immune cells that are an in - tegral part of the immune response to certain microbial infec - tions and tumors.,Non-OADS,/arxiv_data1/oa_pdf/c0/c6/alm-35-423.PMC4446581.pdf
FcRγ-deficient NK cells in CMV endemic population http://dx.doi.org/10.3343/alm.2015.35.4.423 www.annlabmed.org  425used CB in their study to avoid confounding effects from adult  donors who may have encountered CMV previously.,Non-OADS,/arxiv_data1/oa_pdf/c0/c6/alm-35-423.PMC4446581.pdf
FcRγ-deficient NK cells in CMV endemic population 426  www.annlabmed.org http://dx.doi.org/10.3343/alm.2015.35.4.423ing from 50.5% to 82.0%.,Non-OADS,/arxiv_data1/oa_pdf/c0/c6/alm-35-423.PMC4446581.pdf
FcRγ-deficient NK cells in CMV endemic population http://dx.doi.org/10.3343/alm.2015.35.4.423 www.annlabmed.org  427 Fig.,Non-OADS,/arxiv_data1/oa_pdf/c0/c6/alm-35-423.PMC4446581.pdf
FcRγ-deficient NK cells in CMV endemic population 428  www.annlabmed.org http://dx.doi.org/10.3343/alm.2015.35.4.423that CD56dim NK cells derived from CB almost completely lacked  surface expression of CD57 [20].,Non-OADS,/arxiv_data1/oa_pdf/c0/c6/alm-35-423.PMC4446581.pdf
"ISSN 2234-3806 • eISSN 2234-3814  http://dx.doi.org/10.3343/alm.2015.35.4.429 www.annlabmed.org  429Ann Lab Med 2015;35:429-435 http://dx.doi.org/10.3343/alm.2015.35.4.429Original Article Diagnostic Immunology Allele and Haplotype Frequencies of Human Leukocyte  Antigen-A, -B, -C, -DRB1, and -DQB1 From Sequence- Based DNA Typing Data in Koreans Ji Won In, M.D.1, Eun Youn Roh, M.D.1, Sohee Oh, Ph.D.2, Sue Shin, M.D.1, Kyoung Un Park, M.D.1,   and Eun Young Song, M.D.1,3 Department of Laboratory Medicine1, Seoul National University College of Medicine; Department of Biostatistics2, Seoul National University Boramae Medical  Center; Department of Molecular Medicine and Biopharmaceutical Sciences3, Graduate School of Convergence Science and Technology and College of  Medicine, Medical Research Center, Seoul National University, Seoul, Korea Background:  Data on allele frequencies (AFs) and haplotype frequencies (HFs) of HLA-C  and -DQB1 are limited in Koreans.",Non-OADS,/arxiv_data1/oa_pdf/94/42/alm-35-429.PMC4446582.pdf
"HLA-A, -B, -C, -DRB1, and -DQB1 in Koreans 430  www.annlabmed.org http://dx.doi.org/10.3343/alm.2015.35.4.429-DQB1 matches are important for hematopoietic stem cell and  organ transplantations [8-12].",Non-OADS,/arxiv_data1/oa_pdf/94/42/alm-35-429.PMC4446582.pdf
"HLA-A, -B, -C, -DRB1, and -DQB1 in Koreans http://dx.doi.org/10.3343/alm.2015.35.4.429 www.annlabmed.org  431mon alleles, followed by B*58:01 , B*35:01 , B*54:01 , and  B*46:01  (AF ≥5%).",Non-OADS,/arxiv_data1/oa_pdf/94/42/alm-35-429.PMC4446582.pdf
"HLA-A, -B, -C, -DRB1, and -DQB1 in Koreans 432  www.annlabmed.org http://dx.doi.org/10.3343/alm.2015.35.4.429Table 2.",Non-OADS,/arxiv_data1/oa_pdf/94/42/alm-35-429.PMC4446582.pdf
"HLA-A, -B, -C, -DRB1, and -DQB1 in Koreans http://dx.doi.org/10.3343/alm.2015.35.4.429 www.annlabmed.org  433higher and those of C*02:02 , C*04:01 , C*07:01/06 , C*12:03 ,  and C*16:01  were lower than those in Caucasians ( Pc<0.001;  Table 4).",OADS,/arxiv_data1/oa_pdf/94/42/alm-35-429.PMC4446582.pdf
"HLA-A, -B, -C, -DRB1, and -DQB1 in Koreans 434  www.annlabmed.org http://dx.doi.org/10.3343/alm.2015.35.4.429cant χ2 values (83.6 and 301.3, respectively).",OADS,/arxiv_data1/oa_pdf/94/42/alm-35-429.PMC4446582.pdf
"HLA-A, -B, -C, -DRB1, and -DQB1 in Koreans http://dx.doi.org/10.3343/alm.2015.35.4.429 www.annlabmed.org  435AF of DQB1*06:01  was higher in Koreans (9.4%) than in Cau - casians (0.2%), which might cause false reaction while using  commercial kits developed in the United States [22].",Non-OADS,/arxiv_data1/oa_pdf/94/42/alm-35-429.PMC4446582.pdf
http://cran.us.r-project.org/  (Updated on Oct 2014).,Non-OADS,/arxiv_data1/oa_pdf/94/42/alm-35-429.PMC4446582.pdf
ISSN 2234-3806 • eISSN 2234-3814  436  www.annlabmed.org http://dx.doi.org/10.3343/alm.2015.35.4.436Ann Lab Med 2015;35:436-444 http://dx.doi.org/10.3343/alm.2015.35.4.436Original Article Transfusion Medicine Red Blood Cell Transfusion in Patients With  Autoantibodies: Is It Effective and Safe Without  Increasing Hemolysis Risk?,Non-OADS,/arxiv_data1/oa_pdf/dc/36/alm-35-436.PMC4446583.pdf
"RBC transfusion in patients with autoantibodies http://dx.doi.org/10.3343/alm.2015.35.4.436 www.annlabmed.org  437the increased oxygen-carrying capacity provided by the trans - fused RBCs may satisfy a patient’s need until other treatment  options become effective, particularly in those with symptomatic  cardiovascular diseases for which sufficient oxygen supply is  important [1, 4, 9].",Non-OADS,/arxiv_data1/oa_pdf/dc/36/alm-35-436.PMC4446583.pdf
RBC transfusion in patients with autoantibodies 438  www.annlabmed.org http://dx.doi.org/10.3343/alm.2015.35.4.436Table 1.,Non-OADS,/arxiv_data1/oa_pdf/dc/36/alm-35-436.PMC4446583.pdf
RBC transfusion in patients with autoantibodies http://dx.doi.org/10.3343/alm.2015.35.4.436 www.annlabmed.org  4391.51.6 1.31.7 1.32.45 1.51.75 1.15 0.8P* = 0.090P* < 0.001 5.,Non-OADS,/arxiv_data1/oa_pdf/dc/36/alm-35-436.PMC4446583.pdf
RBC transfusion in patients with autoantibodies 440  www.annlabmed.org http://dx.doi.org/10.3343/alm.2015.35.4.4365.,Non-OADS,/arxiv_data1/oa_pdf/dc/36/alm-35-436.PMC4446583.pdf
"RBC transfusion in patients with autoantibodies http://dx.doi.org/10.3343/alm.2015.35.4.436 www.annlabmed.org  44138.1°C, and 37.7°C peak temperatures) within 24 hrs of trans - fusion; however, the patients had pneumonia and showed no  evidence of hemolytic transfusion reaction (Table 1).",Non-OADS,/arxiv_data1/oa_pdf/dc/36/alm-35-436.PMC4446583.pdf
"RBC transfusion in patients with autoantibodies 442  www.annlabmed.org http://dx.doi.org/10.3343/alm.2015.35.4.436strength, and steroid therapy status with hemoglobin changes at  day 1 and day 7 after transfusion were not evident.",Non-OADS,/arxiv_data1/oa_pdf/dc/36/alm-35-436.PMC4446583.pdf
"RBC transfusion in patients with autoantibodies http://dx.doi.org/10.3343/alm.2015.35.4.436 www.annlabmed.org  443DISCUSSION RBC transfusion to patients with autoantibodies was classically  regarded to be therapeutically non-beneficial owing to the diffi - culties of finding compatible blood donor and increased risk of  transfusion reactions [4, 11].",Non-OADS,/arxiv_data1/oa_pdf/dc/36/alm-35-436.PMC4446583.pdf
RBC transfusion in patients with autoantibodies 444  www.annlabmed.org http://dx.doi.org/10.3343/alm.2015.35.4.436compatible RBCs and found no evidence of acute hemolytic  transfusion reaction within 24 hr of transfusion.,Non-OADS,/arxiv_data1/oa_pdf/dc/36/alm-35-436.PMC4446583.pdf
"ISSN 2234-3806 • eISSN 2234-3814  http://dx.doi.org/10.3343/alm.2015.35.4.445 www.annlabmed.org  445Ann Lab Med 2015;35:445-448 http://dx.doi.org/10.3343/alm.2015.35.4.445Brief Communication Clinical Microbiology Evaluation of Modified Formalin-Ether Concentration  Method Using Para Tube in Clinical Settings Eun Jeong Won, M.D.1, Jin Kim, M.D.2, and Dong Wook Ryang, M.D.1 Department of Laboratory Medicine1, Chonnam National University Hospital, Gwangju; Department of Parasitology2, College of Medicine, Seonam University,  Namwon, Korea Conventional formalin-ether concentration method is a gold standard for the diagnosis of  parasite infection.",Non-OADS,/arxiv_data1/oa_pdf/96/9c/alm-35-445.PMC4446584.pdf
"Modified formalin-ether concentration with ParaTube 446  www.annlabmed.org http://dx.doi.org/10.3343/alm.2015.35.4.445tain a concentration of 10 ova/10 µL, and G. lamblia  cysts were  diluted in 200 µL distilled water to obtain a concentration of 80  cysts/10 µL.",Non-OADS,/arxiv_data1/oa_pdf/96/9c/alm-35-445.PMC4446584.pdf
Modified formalin-ether concentration with ParaTube http://dx.doi.org/10.3343/alm.2015.35.4.445 www.annlabmed.org  447compare the time for each procedure.,Non-OADS,/arxiv_data1/oa_pdf/96/9c/alm-35-445.PMC4446584.pdf
"Modified formalin-ether concentration with ParaTube 448  www.annlabmed.org http://dx.doi.org/10.3343/alm.2015.35.4.445pensive than the conventional conical tube ($0.8 for the Para  Tube vs. $0.4 for the conventional tube), it is still affordable and  within the range of the test fee.",Non-OADS,/arxiv_data1/oa_pdf/96/9c/alm-35-445.PMC4446584.pdf
"ISSN 2234-3806 • eISSN 2234-3814  http://dx.doi.org/10.3343/alm.2015.35.4.449 www.annlabmed.org  449Ann Lab Med 2015;35:449-453 http://dx.doi.org/10.3343/alm.2015.35.4.449Brief Communication Clinical Microbiology Seroepidemiology of Toxocariasis and Its Clinical  Implications in Gwangju and Jeonnam-province, Korea Eun Jeong Won, M.D.1,2, Jin Kim, M.D.3, Myung-Geun Shin, M.D.2, Jong Hee Shin, M.D.1, Soon Pal Suh, M.D.1,   and Dong Wook Ryang, M.D.1 Department of Laboratory Medicine1, Chonnam National University Hospital, Gwangju; Department of Laboratory Medicine2, Chonnam National University  Hwasun Hospital, Hwasun; Department of Parasitology3, College of Medicine, Seonam University, Namwon, Korea We investigated the seroepidemiological, clinical, and laboratory characteristics of patients  suspected to have toxocariasis in Gwangju and Jeonnam-province, Korea.",Non-OADS,/arxiv_data1/oa_pdf/c3/ee/alm-35-449.PMC4446585.pdf
"Seroepidemiology of toxocariasis, Gwangju-Jeonnam 450  www.annlabmed.org http://dx.doi.org/10.3343/alm.2015.35.4.449and vi) other parasitic infections (clonorchiasis, paragonimiasis,  cysticercosis, or sparganosis).",Non-OADS,/arxiv_data1/oa_pdf/c3/ee/alm-35-449.PMC4446585.pdf
"Seroepidemiology of toxocariasis, Gwangju-Jeonnam http://dx.doi.org/10.3343/alm.2015.35.4.449 www.annlabmed.org  451of IgG showed a weak correlation with eosinophil counts  (r=0.234, P<0.001) and the duration of eosinophilia (r=0.155, P=0.019; Supplemental Data Figure S1).",OADS,/arxiv_data1/oa_pdf/c3/ee/alm-35-449.PMC4446585.pdf
"Seroepidemiology of toxocariasis, Gwangju-Jeonnam 452  www.annlabmed.org http://dx.doi.org/10.3343/alm.2015.35.4.449eosinophilia (r=0.585, P<0.001; data not shown).",OADS,/arxiv_data1/oa_pdf/c3/ee/alm-35-449.PMC4446585.pdf
"Seroepidemiology of toxocariasis, Gwangju-Jeonnam http://dx.doi.org/10.3343/alm.2015.35.4.449 www.annlabmed.org  453REFERENCES 1.",Non-OADS,/arxiv_data1/oa_pdf/c3/ee/alm-35-449.PMC4446585.pdf
"ISSN 2234-3806 • eISSN 2234-3814  454  www.annlabmed.org http://dx.doi.org/10.3343/alm.2015.35.4.454Ann Lab Med 2015;35:454-457 http://dx.doi.org/10.3343/alm.2015.35.4.454Brief Communication Clinical Microbiology Direct Identification of Staphylococcus aureus  and  Determination of Methicillin Susceptibility From  Positive Blood-Culture Bottles in a Bact/ALERT System  Using Binax Now S. aureus  and PBP2a Tests Sandrine Heraud, Pharm.D.1, Anne-Marie Freydiere, Pharm.D.1,2,3,4, Anne Doleans-Jordheim, Ph.D.1,5,   Michèle Bes, Ph.D. 1,2,3, Anne Tristan, Ph.D.1,2,3,4, François Vandenesch, M.D.1,2,3,4, Frederic Laurent, Ph.D.2,3,4,6,*,  and Olivier Dauwalder, Ph.D.1,2,3,4,* Hospices Civils de Lyon1, Laboratoire de Bactériologie, Centre de Biologie et de Pathologie Est, Bron; Hospices Civils de Lyon2, Centre National de Référence  des Staphylocoques, Centre de Biologie et de Pathologie Est, Bron; International Center for Research in Infectiology3, INSERM U 1111, Lyon; Université de  Lyon4, Faculté de Médecine Lyon Est, Domaine de la Buire, Lyon; Research group on «Bacterial Opportunistic Pathogens and Environment»5, UMR 5557  Ecologie Microbienne, CNRS, Université Lyon 1, ENVL, Université de Lyon, Lyon; Hospices Civils de Lyon6, Laboratoire de Bactériologie, Centre de Biologie  et Pathologie Nord, Lyon, France Staphylococcus aureus  bacteremia is associated with high mortality and morbidity, requir - ing prompt and appropriate antimicrobial treatment.",Non-OADS,/arxiv_data1/oa_pdf/75/7a/alm-35-454.PMC4446586.pdf
"Direct SA/MRSA identification from blood cultures  http://dx.doi.org/10.3343/alm.2015.35.4.454 www.annlabmed.org  455PBP2a (BNPBP2a; Alere SAS, Jouy-en-Josas, France) for de - termining methicillin resistance.",Non-OADS,/arxiv_data1/oa_pdf/75/7a/alm-35-454.PMC4446586.pdf
"Direct SA/MRSA identification from blood cultures  456  www.annlabmed.org http://dx.doi.org/10.3343/alm.2015.35.4.454six mixed SA/CNS BC, three tested negative for S. aureus  using  BNSA, suggesting the inoculum was too low.",Non-OADS,/arxiv_data1/oa_pdf/75/7a/alm-35-454.PMC4446586.pdf
"Direct SA/MRSA identification from blood cultures  http://dx.doi.org/10.3343/alm.2015.35.4.454 www.annlabmed.org  457methods, and type of BC bottles that are included in the pro - cess [7].",Non-OADS,/arxiv_data1/oa_pdf/75/7a/alm-35-454.PMC4446586.pdf
"ISSN 2234-3806 • eISSN 2234-3814  458  www.annlabmed.org http://dx.doi.org/10.3343/alm.2015.35.4.458Ann Lab Med 2015;35:458-462 http://dx.doi.org/10.3343/alm.2015.35.4.458Brief Communication Diagnostic Genetics Biochemical and Genetic Analysis of Seven Korean  Individuals With Suspected Metachromatic  Leukodystrophy Minje Han, M.D.1,2, Sun-Hee Jun, M.T.3, Yun-Jin Lee, M.D.4, Baik-Lin Eun, M.D.5, Seung Jun Lee, M.D.1,2,   Moon-Woo Seong, M.D.1,2, Sung Sup Park, M.D.1,2, Sang Hoon Song, M.D.1,2, Hyung-Doo Park, M.D.6,   and Junghan Song, M.D.1,3 Department of Laboratory Medicine1, Seoul National University College of Medicine, Seoul; Department of Laboratory Medicine2, Seoul National University  Hospital, Seoul; Department of Laboratory Medicine3, Seoul National University Bundang Hospital, Seongnam; Department of Pediatrics4, Pusan National  University Children’s Hospital, Pusan National University School of Medicine, Yangsan; Department of Pediatrics5, Korea University College of Medicine,  Seoul; Department of Laboratory Medicine & Genetics6, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea Metachromatic leukodystrophy (MLD) is an autosomal recessive disease caused by a de - ficiency in arylsulfatase A (ARSA).",Non-OADS,/arxiv_data1/oa_pdf/14/7b/alm-35-458.PMC4446587.pdf
"Genetic analysis of Korean patients with MLD http://dx.doi.org/10.3343/alm.2015.35.4.458 www.annlabmed.org  459mutations, such as c.1107+1G>T and c.302G>A, have been  reported in Koreans thus far [9-11].",Non-OADS,/arxiv_data1/oa_pdf/14/7b/alm-35-458.PMC4446587.pdf
"Genetic analysis of Korean patients with MLD 460  www.annlabmed.org http://dx.doi.org/10.3343/alm.2015.35.4.458tion by using TRIzol Reagent (Life Technologies, Carlsbad, CA,  USA), and cDNA was generated by using SuperScript III Reverse  Transcriptase (Life Technologies), according to the manufactur - er’s instructions.",OADS,/arxiv_data1/oa_pdf/14/7b/alm-35-458.PMC4446587.pdf
Mutation nomenclature used in this study  follows the recommendations of the Human Genome Variation  Society (http://www.hgvs.org/mutnomen/) [13].,Non-OADS,/arxiv_data1/oa_pdf/14/7b/alm-35-458.PMC4446587.pdf
Genetic analysis of Korean patients with MLD http://dx.doi.org/10.3343/alm.2015.35.4.458 www.annlabmed.org  461(Fig.,Non-OADS,/arxiv_data1/oa_pdf/14/7b/alm-35-458.PMC4446587.pdf
"“HGMD Muta - tion Result,” https://portal.biobase-international.com/hgmd/pro/allmut.",OADS,/arxiv_data1/oa_pdf/14/7b/alm-35-458.PMC4446587.pdf
http://www.ncbi.,Non-OADS,/arxiv_data1/oa_pdf/14/7b/alm-35-458.PMC4446587.pdf
Genetic analysis of Korean patients with MLD 462  www.annlabmed.org http://dx.doi.org/10.3343/alm.2015.35.4.4587.,Non-OADS,/arxiv_data1/oa_pdf/14/7b/alm-35-458.PMC4446587.pdf
"http://www.hgvs.org/mutnomen/ (Accessed on Apr  24, 2015).",Non-OADS,/arxiv_data1/oa_pdf/14/7b/alm-35-458.PMC4446587.pdf
"ISSN 2234-3806 • eISSN 2234-3814  http://dx.doi.org/10.3343/alm.2015.35.4.463 www.annlabmed.org  463Ann Lab Med 2015;35:463-465 http://dx.doi.org/10.3343/alm.2015.35.4.463Letter to the Editor  Diagnostic Hematology Concurrent Hematologic and Metastatic Epithelial  Malignancies in the Bone Marrow: Report of Three  Cases  Jeonghyun Chang, M.D.1, Young-Uk Cho, M.D.1, Eun-Jung Cho, M.D.1, Seongsoo Jang, M.D.",OADS,/arxiv_data1/oa_pdf/d9/eb/alm-35-463.PMC4446588.pdf
"This is an Open Access article distributed under the terms of the Creative Commons  Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/d9/eb/alm-35-463.PMC4446588.pdf
Three cases of concurrent malignancies in bone marrow 464  www.annlabmed.org http://dx.doi.org/10.3343/alm.2015.35.4.463like lesion at the gall bladder neck and multiple hepatic masses.,Non-OADS,/arxiv_data1/oa_pdf/d9/eb/alm-35-463.PMC4446588.pdf
Three cases of concurrent malignancies in bone marrow http://dx.doi.org/10.3343/alm.2015.35.4.463 www.annlabmed.org  465Table 1.,Non-OADS,/arxiv_data1/oa_pdf/d9/eb/alm-35-463.PMC4446588.pdf
"ISSN 2234-3806 • eISSN 2234-3814  466  www.annlabmed.org http://dx.doi.org/10.3343/alm.2015.35.4.466Ann Lab Med 2015;35:466-468 http://dx.doi.org/10.3343/alm.2015.35.4.466Letter to the Editor  Diagnostic Hematology  An Unusual Case of Myeloperoxidase-Positive Acute  Megakaryoblastic Leukemia Hyeyoung Lee, M.D.1, Yonggoo Kim, M.D.1, Yoo-Jin Kim, M.D.2, and Kyungja Han, M.D.1 Departments of Laboratory Medicine1 and Internal Medicine2, College of Medicine, The Catholic University of Korea, Seoul, Korea Dear Editor We report an unusual case of myeloperoxidase (MPO)-positive  acute megakaryoblastic leukemia (AMKL).",Non-OADS,/arxiv_data1/oa_pdf/12/01/alm-35-466.PMC4446589.pdf
"This is an Open Access article distributed under the terms of the Creative Commons  Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/12/01/alm-35-466.PMC4446589.pdf
MPO-positive acute megakaryoblastic leukemia http://dx.doi.org/10.3343/alm.2015.35.4.466 www.annlabmed.org  467the Golgi [4].,Non-OADS,/arxiv_data1/oa_pdf/12/01/alm-35-466.PMC4446589.pdf
"MPO-positive acute megakaryoblastic leukemia 468  www.annlabmed.org http://dx.doi.org/10.3343/alm.2015.35.4.466megakaryoblastic lineage, few MPO-positive AMKL cases have  been reported [5-7].",Non-OADS,/arxiv_data1/oa_pdf/12/01/alm-35-466.PMC4446589.pdf
"ISSN 2234-3806 • eISSN 2234-3814  http://dx.doi.org/10.3343/alm.2015.35.4.469 www.annlabmed.org  469Ann Lab Med 2015;35:469-471 http://dx.doi.org/10.3343/alm.2015.35.4.469Letter to the Editor  Diagnostic Hematology Identification of Mixed Lineage Leukemia Gene ( MLL)/ MLLT10  Fusion Transcripts by Reverse Transcription- PCR and Sequencing in a Case of AML With a FISH- Negative Cryptic MLL Rearrangement Kiwoong Ko, M.D.1,*, Min-Jung Kwon, M.D.1,*, Hee-Yeon Woo, M.D.1, Hyosoon Park, M.D.1, Chang-Hun Park, M.D.2,   Seung-Tae Lee, M.D.2, and Sun-Hee Kim, M.D.2 Department of Laboratory Medicine1, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine; Department of Laboratory Medicine and  Genetics2, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea Dear Editor The mixed lineage leukemia gene ( MLL) on chromosome 11q23  is a frequent target of chromosomal translocations and rear - rangements in childhood leukemia and adult therapy-related  leukemia [1].",Non-OADS,/arxiv_data1/oa_pdf/9a/92/alm-35-469.PMC4446590.pdf
"This is an Open Access article distributed under the terms of the Creative Commons  Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/9a/92/alm-35-469.PMC4446590.pdf
FISH-negative cryptic MLL rearrangement in AML 470  www.annlabmed.org http://dx.doi.org/10.3343/alm.2015.35.4.469via two orphan nucleotides (Fig.,Non-OADS,/arxiv_data1/oa_pdf/9a/92/alm-35-469.PMC4446590.pdf
"FISH-negative cryptic MLL rearrangement in AML http://dx.doi.org/10.3343/alm.2015.35.4.469 www.annlabmed.org  471rays or re-testing with different FISH probes (i.e., from a differ - ent manufacturer) or LDI-PCR because of insufficient speci - mens.",Non-OADS,/arxiv_data1/oa_pdf/9a/92/alm-35-469.PMC4446590.pdf
"ISSN 2234-3806 • eISSN 2234-3814  472  www.annlabmed.org http://dx.doi.org/10.3343/alm.2015.35.4.472Ann Lab Med 2015;35:472-473 http://dx.doi.org/10.3343/alm.2015.35.4.472Letter to the Editor  Clinical Microbiology Multidrug-Resistant Corynebacterium striatum   Bacteremia: First Case in Korea Gilsung Yoo, M.D., Juwon Kim, M.D., Young Uh, M.D., Hyeun Gyeo Lee, M.T., Gyu Yel Hwang, M.S., and Kap Joon Yoon, M.D.",Non-OADS,/arxiv_data1/oa_pdf/a3/58/alm-35-472.PMC4446591.pdf
"This is an Open Access article distributed under the terms of the Creative Commons  Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/a3/58/alm-35-472.PMC4446591.pdf
Corynebacterium striatum  bacteremia http://dx.doi.org/10.3343/alm.2015.35.4.472 www.annlabmed.org  473blood cultures performed on the 6th day of admission revealed  C. striatum  growth.,Non-OADS,/arxiv_data1/oa_pdf/a3/58/alm-35-472.PMC4446591.pdf
"ISSN 2234-3806 • eISSN 2234-3814  474  www.annlabmed.org http://dx.doi.org/10.3343/alm.2015.35.4.474Ann Lab Med 2015;35:474-476 http://dx.doi.org/10.3343/alm.2015.35.4.474Letter to the Editor  Diagnostic Genetics Isodicentric Chromosome 15 Syndrome in a Korean  Patient With Café-au-lait Spots John Hoon Rim, M.D.1, Hee Jung Chung, M.D.2, Saeam Shin, M.D.1, Seo-Jin Park, M.D.1, and Jong Rak Choi, M.D.1 Departments of Laboratory Medicine1 and Pediatrics2, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea Dear Editor Isodicentric chromosome 15 [idic(15) or inv dup(15)] syndrome  is a rare condition with distinctive clinical features, including de - velopmental delay, hypotonia, epilepsy, and autism or autistic- like behavior [1].",Non-OADS,/arxiv_data1/oa_pdf/ec/1a/alm-35-474.PMC4446592.pdf
"This is an Open Access article distributed under the terms of the Creative Commons  Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)  which permits unrestricted non-commercial use, distribution, and reproduction in any  medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/ec/1a/alm-35-474.PMC4446592.pdf
A case of idic(15) syndrome with Café-au-lait spots  http://dx.doi.org/10.3343/alm.2015.35.4.474 www.annlabmed.org  475autism or autistic-like behavior [6].,Non-OADS,/arxiv_data1/oa_pdf/ec/1a/alm-35-474.PMC4446592.pdf
"A case of idic(15) syndrome with Café-au-lait spots  476  www.annlabmed.org http://dx.doi.org/10.3343/alm.2015.35.4.474some 15 abnormalities, which supports the notion that the long  arm of chromosome 15 is an autism candidate region [6, 7].",Non-OADS,/arxiv_data1/oa_pdf/ec/1a/alm-35-474.PMC4446592.pdf
"ISSN 2234-3806 • eISSN 2234-3814  http://dx.doi.org/10.3343/alm.2015.35.4.477 www.annlabmed.org  477This erratum is being published to correct the printing errors on page 159 of the article entitled ‘Two Cases of  Acute Lymphoblastic Leukemia With an e 1a3 BCR-ABL 1 Fusion Transcript ’ by Sang-Yong Shin, Jin-Hee Cho,  Hee-Jin Kim, Jun-Ho Jang, Seung-Tae Lee, and Sun-Hee Kim in Ann Lab Med 2015;35:159-161, doi/ alm.2015.35.1.159.",Non-OADS,/arxiv_data1/oa_pdf/55/44/alm-35-477.PMC4446593.pdf
"An e1a2-type BCR-ABL 1 fusion tran - script is found in about 70% of cases, and major breakpoint transcripts (e 13a2, e14a2) are found in about  30% of cases.Ann Lab Med 2015;35:477-477 http://dx.doi.org/10.3343/alm.2015.35.4.477Erratum",Non-OADS,/arxiv_data1/oa_pdf/55/44/alm-35-477.PMC4446593.pdf
"© Copyright The Korean Academy of Asthma, Allergy and Clinical Immunology • The Korean Academy of Pediatric Allergy and Respiratory Disease309 http://e-aair.orgIn daily clinical practice, it is not so easy to make a confirma - tive diagnosis of food allergy.",Non-OADS,/arxiv_data1/oa_pdf/b5/6a/aair-7-309.PMC4446628.pdf
"Tae Won Song Department of Pediatrics, Ilsan Paik Hospital, Inje University College of Medicine, Goyang, Korea This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits  unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/b5/6a/aair-7-309.PMC4446628.pdf
2015 July;7(4):309-311. http://dx.doi.org/10.4168/aair.2015.7.4.309 pISSN 2092-7355 • eISSN 2092-7363,Non-OADS,/arxiv_data1/oa_pdf/b5/6a/aair-7-309.PMC4446628.pdf
"2015 July;7(4):309-311. http://dx.doi.org/10.4168/aair.2015.7.4.309 Volume 7, Number 4, July 2015 310 http://e-aair.orgcians should consider patient age, natural history of concerned  food allergy, severity of previous symptoms, and reduction in  the food-sIgE level in an individual patient.4 Challenge tests can  be performed in children when their food-sIgE level decreases  to about one-fourth of the diagnostic decision point, unless they have experienced any recent allergic reaction.2 Ando et  al.13 have reported that negative predictive value (NPV 84%),  based on 95% sensitivity, is 0.6 kU A/L for egg white.",Non-OADS,/arxiv_data1/oa_pdf/b5/6a/aair-7-309.PMC4446628.pdf
"2015 July;7(4):309-311. http://dx.doi.org/10.4168/aair.2015.7.4.309 AAIR 311 http://e-aair.org3.45 kU A/L yield a NPV of 93.6% in children <24 months of age,  while a NPV of 1.80 kU A/L yield a NPV of 99.2% in those ≥24  months of age.",Non-OADS,/arxiv_data1/oa_pdf/b5/6a/aair-7-309.PMC4446628.pdf
"© Copyright The Korean Academy of Asthma, Allergy and Clinical Immunology • The Korean Academy of Pediatric Allergy and Respiratory Disease312 http://e-aair.orgINTRODUCTION Since the first non-steroidal anti-inflammatory drugs (NSAIDs)  (antypiryne and aspirin) were synthesized at the end of the XIX  century, dozens of new compounds with similar anti-inflamma - tory activity have been developed and introduced to clinical  practice for the treatment of chronic inflammatory disorders,  pain, and fever.",Non-OADS,/arxiv_data1/oa_pdf/1c/27/aair-7-312.PMC4446629.pdf
"Marek L. Kowalski,* Joanna S. Makowska Department of Immunology, Rheumatology and Allergy, Medical University of Lodz, Lodz, Poland   This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits  unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/1c/27/aair-7-312.PMC4446629.pdf
2015 July;7(4):312-320. http://dx.doi.org/10.4168/aair.2015.7.4.312 pISSN 2092-7355 • eISSN 2092-7363,Non-OADS,/arxiv_data1/oa_pdf/1c/27/aair-7-312.PMC4446629.pdf
"2015 July;7(4):312-320. http://dx.doi.org/10.4168/aair.2015.7.4.312 AAIR 313 http://e-aair.orgPharmacological mechanisms for NSAID-induced  hypersensitivity reactions  The mechanism of action of NSAIDs was discovered in 1971  by Sir John Vane,7 who employed original bioassay, demonstrat - ed that these drugs share common pharmacologic activity,  namely inhibition of prostaglandin synthesis.",Non-OADS,/arxiv_data1/oa_pdf/1c/27/aair-7-312.PMC4446629.pdf
"2015 July;7(4):312-320. http://dx.doi.org/10.4168/aair.2015.7.4.312 Volume 7, Number 4, July 2015 314 http://e-aair.orgreactions have previously been called “pseudoallergic or idiosyn - cratic reactions, ” but these terms are not advised to be used any - more.",Non-OADS,/arxiv_data1/oa_pdf/1c/27/aair-7-312.PMC4446629.pdf
"2015 July;7(4):312-320. http://dx.doi.org/10.4168/aair.2015.7.4.312 AAIR 315 http://e-aair.orgNSAID-induced reactions are cysteinyl-leukotrienes (cysLTs),17  and pharmacological inhibition of cysLT type 1 receptors alle - viates NSAID-induced symptoms.18 Also polymorphisms of  cysteinyl leukotriene pathway were associated with develop - ment of NERD.19 NSAIDs exacerbate cutaneous disease (NECD)  This type of hypersensitivity manifesting with cutaneous symp - toms appears in patients with a history of chronic spontaneous  urticaria.",Non-OADS,/arxiv_data1/oa_pdf/1c/27/aair-7-312.PMC4446629.pdf
"2015 July;7(4):312-320. http://dx.doi.org/10.4168/aair.2015.7.4.312 Volume 7, Number 4, July 2015 316 http://e-aair.orginjection of metamizol).25 These subjects are usually otherwise  healthy individuals without any specific underlying chronic  diseases.",Non-OADS,/arxiv_data1/oa_pdf/1c/27/aair-7-312.PMC4446629.pdf
2015 July;7(4):312-320. http://dx.doi.org/10.4168/aair.2015.7.4.312 AAIR 317 http://e-aair.orgdiagnosis for some patients.,Non-OADS,/arxiv_data1/oa_pdf/1c/27/aair-7-312.PMC4446629.pdf
"2015 July;7(4):312-320. http://dx.doi.org/10.4168/aair.2015.7.4.312 Volume 7, Number 4, July 2015 318 http://e-aair.orgtivity.",Non-OADS,/arxiv_data1/oa_pdf/1c/27/aair-7-312.PMC4446629.pdf
2015 July;7(4):312-320. http://dx.doi.org/10.4168/aair.2015.7.4.312 AAIR 319 http://e-aair.org8.,Non-OADS,/arxiv_data1/oa_pdf/1c/27/aair-7-312.PMC4446629.pdf
"2015 July;7(4):312-320. http://dx.doi.org/10.4168/aair.2015.7.4.312 Volume 7, Number 4, July 2015 320 http://e-aair.orgmunol 2007;98:172-4.",Non-OADS,/arxiv_data1/oa_pdf/1c/27/aair-7-312.PMC4446629.pdf
"© Copyright The Korean Academy of Asthma, Allergy and Clinical Immunology • The Korean Academy of Pediatric Allergy and Respiratory Disease321 http://e-aair.orgINTRODUCTION  Immunoglobulin E (IgE) is a major contributing factor in mul - tiple airway diseases, including allergic rhinitis (AR) and chronic  rhinosinusitis with nasal polyposis (CRSwNP).",Non-OADS,/arxiv_data1/oa_pdf/06/5d/aair-7-321.PMC4446630.pdf
"Both SHM and CSR are initi -Local Immunoglobulin E in the Nasal Mucosa: Clinical Implications  Els De Schryver,1 Lien Devuyst,1 Lara Derycke,1 Melissa Dullaers,2 Thibaut Van Zele,1 Claus Bachert,1,3 Philippe Gevaert1*  1Upper Airways Research Laboratory, Department of Otorhinolaryngology, Ghent University Hospital, Ghent, Belgium 2Laboratory of Immunoregulation and Mucosal Immunology, Ghent University, Ghent, Belgium  3Division of ENT Diseases, Clintec, Karolinska Institutet, Stockholm, Sweden  This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits  unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/06/5d/aair-7-321.PMC4446630.pdf
2015 July;7(4):321-331. http://dx.doi.org/10.4168/aair.2015.7.4.321 pISSN 2092-7355 • eISSN 2092-7363,Non-OADS,/arxiv_data1/oa_pdf/06/5d/aair-7-321.PMC4446630.pdf
"2015 July;7(4):321-331. http://dx.doi.org/10.4168/aair.2015.7.4.321 Volume 7, Number 4, July 2015 322 http://e-aair.orgated by activation-induced cytidine deaminase (AID),6 and  thus this molecule can be used as a marker for these processes.",Non-OADS,/arxiv_data1/oa_pdf/06/5d/aair-7-321.PMC4446630.pdf
2015 July;7(4):321-331. http://dx.doi.org/10.4168/aair.2015.7.4.321 AAIR 323 http://e-aair.orgduced specific IgE.,Non-OADS,/arxiv_data1/oa_pdf/06/5d/aair-7-321.PMC4446630.pdf
"2015 July;7(4):321-331. http://dx.doi.org/10.4168/aair.2015.7.4.321 Volume 7, Number 4, July 2015 324 http://e-aair.orgclinical findings, for example, T-cell mediated delayed type hy - persensitivity and activation of mast cells by Ig free light chains  (FLCs).33,34  Evidence increases for the possibility that a T cell-mediated  inflammatory reaction to common antigens sustains asthma  and AR, especially when atopic dermatitis is identified in the  history.34 Here again, negative skin prick test (SPT) and RAST  can be expected.",Non-OADS,/arxiv_data1/oa_pdf/06/5d/aair-7-321.PMC4446630.pdf
"2015 July;7(4):321-331. http://dx.doi.org/10.4168/aair.2015.7.4.321 AAIR 325 http://e-aair.orgInflammation patterns  The definition ‘chronic sinusitis’ suggests a single clinical enti - ty, but in reality it represents multiple overlapping entities with  different inflammation patterns.",Non-OADS,/arxiv_data1/oa_pdf/06/5d/aair-7-321.PMC4446630.pdf
"2015 July;7(4):321-331. http://dx.doi.org/10.4168/aair.2015.7.4.321 Volume 7, Number 4, July 2015 326 http://e-aair.orgIL5, and IL13, namely innate lymphoid cells (ILC)49 (Fig.",Non-OADS,/arxiv_data1/oa_pdf/06/5d/aair-7-321.PMC4446630.pdf
"2015 July;7(4):321-331. http://dx.doi.org/10.4168/aair.2015.7.4.321 AAIR 327 http://e-aair.orgal.59 compared total IgE and HDM-specific IgE in nasal polyp  tissue from patients with strong or weak systemic hypersensi - tivity, and controls.",Non-OADS,/arxiv_data1/oa_pdf/06/5d/aair-7-321.PMC4446630.pdf
"2015 July;7(4):321-331. http://dx.doi.org/10.4168/aair.2015.7.4.321 Volume 7, Number 4, July 2015 328 http://e-aair.orggood choices, because they have an anti-inflammatory action  next to their antibiotic features.63 Macrolides like erythromycin,  clarithromycin, and roxithromycin affect neutrophils and eo - sinophils to reduce tissue damage by chronic bacterial coloni - zation.",Non-OADS,/arxiv_data1/oa_pdf/06/5d/aair-7-321.PMC4446630.pdf
2015 July;7(4):321-331. http://dx.doi.org/10.4168/aair.2015.7.4.321 AAIR 329 http://e-aair.orgREFERENCES  1.,Non-OADS,/arxiv_data1/oa_pdf/06/5d/aair-7-321.PMC4446630.pdf
"2015 July;7(4):321-331. http://dx.doi.org/10.4168/aair.2015.7.4.321 Volume 7, Number 4, July 2015 330 http://e-aair.org34.",Non-OADS,/arxiv_data1/oa_pdf/06/5d/aair-7-321.PMC4446630.pdf
2015 July;7(4):321-331. http://dx.doi.org/10.4168/aair.2015.7.4.321 AAIR 331 http://e-aair.org67.,Non-OADS,/arxiv_data1/oa_pdf/06/5d/aair-7-321.PMC4446630.pdf
"© Copyright The Korean Academy of Asthma, Allergy and Clinical Immunology • The Korean Academy of Pediatric Allergy and Respiratory Disease332 http://e-aair.orgINTRODUCTION Hen’s egg white (EW) and cow’s milk (CM) are the most com - mon causes of food allergy (FA) in infants and young children.1  The estimated prevalence of egg and CM allergies ranges be - tween 0.5 and 2.5%.2-5 Although the diagnosis of immediate- type egg and CM allergies is often based on a detailed clinical  history, physical examination, and the detection of specific IgE  (sIgE) to food allergens,6,7 oral food challenges (OFCs) are still  considered the gold standard test for diagnosis.",Non-OADS,/arxiv_data1/oa_pdf/d8/40/aair-7-332.PMC4446631.pdf
"To avoid unnecessary OFC for the diagnosis of food allergies,  the use of a predictive diagnostic decision point (DDP) of sIgE  levels has been proposed and is currently in wide use in clinical  settings.10-12 The quantification of sIgE antibodies in serum was  reported in some studies on an association with positive chal - lenge tests and clinical symptoms, while others found no corre - lation between the sIgE levels and clinical reactivity.11,13-15 More - over, the DDP  value of sIgE varies according to country and  race.16,17 For example, a recent study demonstrated that the sen - sitivity and specificity of the predictive DDP for EW-sIgE were  low in Korean children,17 while a Japanese study presented Diagnostic Decision Points of Specific IgE Concentrations in  Korean Children With Egg and Cow’s Milk Allergies  Jihyun Kim,1,2 Hye-young Kim,3 Mi-Ran Park,1,2 Jaehee Choi,1,2 Ji-Yeon Shim,2 Min-Ji Kim,4 Youngshin Han,2 Kangmo Ahn1,2* 1Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea  2Environmental Health Center for Atopic Diseases, Samsung Medical Center, Seoul, Korea 3Department of Pediatrics, Medical Research Institute of Pusan National University Hospital, Pusan National University School of Medicine, Busan, Korea 4Department of Biostatistics, Samsung Biomedical Research Institute, Seoul, Korea This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits  unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/d8/40/aair-7-332.PMC4446631.pdf
2015 July;7(4):332-338. http://dx.doi.org/10.4168/aair.2015.7.4.332 pISSN 2092-7355 • eISSN 2092-7363,Non-OADS,/arxiv_data1/oa_pdf/d8/40/aair-7-332.PMC4446631.pdf
"2015 July;7(4):332-338. http://dx.doi.org/10.4168/aair.2015.7.4.332 AAIR 333 http://e-aair.orgmuch higher levels of sIgE for the diagnosis of egg or CM aller - gy than the previous reports.16 Further studies to evaluate the  utility of sIgE levels in the diagnosis of egg and CM allergies are  needed, because there may be ethnic differences between Jap - anese and Korean people.",Non-OADS,/arxiv_data1/oa_pdf/d8/40/aair-7-332.PMC4446631.pdf
"2015 July;7(4):332-338. http://dx.doi.org/10.4168/aair.2015.7.4.332 Volume 7, Number 4, July 2015 334 http://e-aair.orgEW-sIgE levels between the egg allergy and nonallergy groups  was also found in subgroup analyses of the children <24  months (median 16.8 vs 0.53 kU/L, P<0.0001) and ≥24  months of age (median 16.7 vs 0.31 kU/L, P<0.0001) (Fig.",OADS,/arxiv_data1/oa_pdf/d8/40/aair-7-332.PMC4446631.pdf
2015 July;7(4):332-338. http://dx.doi.org/10.4168/aair.2015.7.4.332 AAIR 335 http://e-aair.orgapproximately 95% of the patients are predicted to have clinical  reactions when the sIgE concentrations exceed those diagnos - tic levels.,Non-OADS,/arxiv_data1/oa_pdf/d8/40/aair-7-332.PMC4446631.pdf
"2015 July;7(4):332-338. http://dx.doi.org/10.4168/aair.2015.7.4.332 Volume 7, Number 4, July 2015 336 http://e-aair.orgcal to use higher DDPs of EW- and CM-sIgE antibodies in Kore - an children for the diagnosis of egg and CM allergies in order to  avoid unnecessary restriction of diet.",Non-OADS,/arxiv_data1/oa_pdf/d8/40/aair-7-332.PMC4446631.pdf
2015 July;7(4):332-338. http://dx.doi.org/10.4168/aair.2015.7.4.332 AAIR 337 http://e-aair.orgFig.,Non-OADS,/arxiv_data1/oa_pdf/d8/40/aair-7-332.PMC4446631.pdf
"2015 July;7(4):332-338. http://dx.doi.org/10.4168/aair.2015.7.4.332 Volume 7, Number 4, July 2015 338 http://e-aair.orginstead of OFC, while OFC is required to confirm the diagnosis  in children with sIgE levels between the 2 DDPs.",Non-OADS,/arxiv_data1/oa_pdf/d8/40/aair-7-332.PMC4446631.pdf
"© Copyright The Korean Academy of Asthma, Allergy and Clinical Immunology • The Korean Academy of Pediatric Allergy and Respiratory Disease339 http://e-aair.orgINTRODUCTION Asthma has generally been defined as a chronic airway in - flammatory disorder characterized by bronchial hyperrespon - siveness (BHR) and recurrent airflow obstruction.",Non-OADS,/arxiv_data1/oa_pdf/9f/6c/aair-7-339.PMC4446632.pdf
"Clinical severity and lung function have been reported to be  similar in both AA and NAA children.5-7 In addition, no differ - ence was reported in the airway pathologic features of eosino -philic inflammation and remodeling in bronchial biopsies be - tween children with AA and NAA.8 However, the exhaled nitric  oxide (eNO) levels and BHR, especially to adenosine-5 ’-mono - phosphate (AMP), were found to be greater in AA.7,9 Moreover,  the proportion of eosinophils in induced sputum is higher in  children with AA.10,11  Bronchoprovocation challenge has been widely used for mea - suring BHR in patients with asthma, and stimuli used can be  categorized as direct stimuli, such as methacholine, or indirect  stimuli, such as AMP .12 BHR to methacholine is more closely as -The Association of Lung Function, Bronchial Hyperresponsiveness,  and Exhaled Nitric Oxide Differs Between Atopic and Non-atopic  Asthma in Children Eunhee Shim,1 Eun Lee,1 Song-I Yang,1 Young-Ho Jung,2 Geun Mi Park,3 Hyung Young Kim,4 Ju-Hee Seo,5 Jinho Yu1* Departments of 1Pediatrics and  3Pharmacy, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea 2Department of Pediatrics, Bundang CHA Medical Center, CHA University School of Medicine, Seongnam, Korea 4Department of Pediatrics, Pusan National University Yangsan Hospital, Yangsan, Korea  5Department of Pediatrics, Korea Cancer Center Hospital, Seoul, Korea This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits  unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/9f/6c/aair-7-339.PMC4446632.pdf
2015 July;7(4):339-345. http://dx.doi.org/10.4168/aair.2015.7.4.339 pISSN 2092-7355 • eISSN 2092-7363,Non-OADS,/arxiv_data1/oa_pdf/9f/6c/aair-7-339.PMC4446632.pdf
"2015 July;7(4):339-345. http://dx.doi.org/10.4168/aair.2015.7.4.339 Volume 7, Number 4, July 2015 340 http://e-aair.orgsociated with baseline forced expiratory volume in 1 sec  (FEV1), whereas BHR to AMP is a better marker of airway in - flammation in asthmatics.13,14 The eNO has been identified as a  non-invasive marker of airway inflammation15 and found to  have a significant correlation with BHR to AMP in adults with  asthma.16 However, no previous study has compared the rela - tionships between lung function, BHR to direct and indirect  stimuli, and eNO as a possible way to differentiate AA from  NAA in children.",Non-OADS,/arxiv_data1/oa_pdf/9f/6c/aair-7-339.PMC4446632.pdf
2015 July;7(4):339-345. http://dx.doi.org/10.4168/aair.2015.7.4.339 AAIR 341 http://e-aair.orgStatistical analysis Data are presented as the mean ±SD or as the geometric  mean with a range of 1 SD.,OADS,/arxiv_data1/oa_pdf/9f/6c/aair-7-339.PMC4446632.pdf
"2015 July;7(4):339-345. http://dx.doi.org/10.4168/aair.2015.7.4.339 Volume 7, Number 4, July 2015 342 http://e-aair.orgP<0.05), but not with FEV1 % pred (r =-0.108) or FEF 25%-75% %  pred (r =-0.150).",Non-OADS,/arxiv_data1/oa_pdf/9f/6c/aair-7-339.PMC4446632.pdf
2015 July;7(4):339-345. http://dx.doi.org/10.4168/aair.2015.7.4.339 AAIR 343 http://e-aair.orgels than the NAA children.,Non-OADS,/arxiv_data1/oa_pdf/9f/6c/aair-7-339.PMC4446632.pdf
"2015 July;7(4):339-345. http://dx.doi.org/10.4168/aair.2015.7.4.339 Volume 7, Number 4, July 2015 344 http://e-aair.orgsymptoms suggestive of airway obstruction.",Non-OADS,/arxiv_data1/oa_pdf/9f/6c/aair-7-339.PMC4446632.pdf
"2015 July;7(4):339-345. http://dx.doi.org/10.4168/aair.2015.7.4.339 AAIR 345 http://e-aair.orgLM, et al.",OADS,/arxiv_data1/oa_pdf/9f/6c/aair-7-339.PMC4446632.pdf
"© Copyright The Korean Academy of Asthma, Allergy and Clinical Immunology • The Korean Academy of Pediatric Allergy and Respiratory Disease346 http://e-aair.orgINTRODUCTION Chronic rhinosinusitis (CRS) is a common disease that affects  4%-10% of the global population, which is generally defined as  an inflammatory condition of paranasal sinuses and nasal pas - sages that persists for a minimum of 12 weeks.",Non-OADS,/arxiv_data1/oa_pdf/1a/5b/aair-7-346.PMC4446633.pdf
"Some authors proposed that atopy may be asso -Distinct Inflammatory Profiles in Atopic and Nonatopic Patients  With Chronic Rhinosinustis Accompanied by Nasal Polyps in  Western China Luo Ba,1,2,3 Jintao Du,1 Feng Liu,1 Fenglin Yang,2 Miaomiao Han,4 Sixi Liu,1 Ping Lin,3* Huabin Li4* 1Department of Otolaryngology, Head and Neck Surgery, West China Hospital, Sichuan University, Chengdu, China 2Department of Otolaryngology, People’s Hospital of the Tibet Autonomous Region, Lasha, China 3Department of Geriatrics, Center for Medical Stem Cell Biology, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China  4Department of Otolaryngology, Head and Neck Surgery, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits  unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/1a/5b/aair-7-346.PMC4446633.pdf
2015 July;7(4):346-358. http://dx.doi.org/10.4168/aair.2015.7.4.346 pISSN 2092-7355 • eISSN 2092-7363,Non-OADS,/arxiv_data1/oa_pdf/1a/5b/aair-7-346.PMC4446633.pdf
"2015 July;7(4):346-358. http://dx.doi.org/10.4168/aair.2015.7.4.346 AAIR 347 http://e-aair.orgciated with an enhanced Th2 response and tissue eosinophil - ia, which has been frequently observed in a Western popula - tion.4 However, recently a large subset of CRSwNP patients ob - served in some east Asian countries ( e.g., China, Japan, and  Korea) did not demonstrate significant eosinophilia.4,5 In these  CRSwNP patients, an enhanced Th1/Th17 response and neu - trophilia were commonly observed, which is likely to be asso - ciated with nonatopic factors.6-10 We previously reported that  only a minor part of polyp samples from western China were  IL-5+ and expressed Staphylococcus aureus  enterotoxin (SAE)- specific IgE, and showed differences in the colonization of pol - yps with either predominantly Gram-positive or Gram-nega - tive bacteria in IL-5- versus IL-5+ samples.11 We have also ob - served differences in inflammatory patterns between CRSwNP  patients in the coastal region and central China.12 To further  evaluate the effect of atopy on the pathogenesis of CRSwNP in  underdeveloped western China, we specially included a co - hort of atopic and nonatopic CRSwNP patients in Tibet and Si - chuan, and characterized their inflammatory profiles in this  study.",Non-OADS,/arxiv_data1/oa_pdf/1a/5b/aair-7-346.PMC4446633.pdf
"2015 July;7(4):346-358. http://dx.doi.org/10.4168/aair.2015.7.4.346 Volume 7, Number 4, July 2015 348 http://e-aair.orgAssessment of mRNA levels of transcription factors The mRNA levels of the transcription factors GATA-3, T-bet,  FOXP3, and RORc were determined by means of real-time  PCR as described elsewhere.11 Snap frozen tissue samples were  placed in liquid nitrogen and thoroughly ground with a mortar  and pestle and homogenized with Lysis Buffer (QIAGEN  GmbH, Hilden, Germany).",OADS,/arxiv_data1/oa_pdf/1a/5b/aair-7-346.PMC4446633.pdf
2015 July;7(4):346-358. http://dx.doi.org/10.4168/aair.2015.7.4.346 AAIR 349 http://e-aair.orgnasal polyps.,Non-OADS,/arxiv_data1/oa_pdf/1a/5b/aair-7-346.PMC4446633.pdf
"2015 July;7(4):346-358. http://dx.doi.org/10.4168/aair.2015.7.4.346 Volume 7, Number 4, July 2015 350 http://e-aair.orgobservers blinded to clinical data showed significantly more  eosinophils and mast cells in atopic CRSwNP than in nonatop - ic CRSwNP ( P<0.05), whereas neutrophils were significantly  increased in nonatopic CRSwNP than in atopic CRSwNP  (P<0.05).",Non-OADS,/arxiv_data1/oa_pdf/1a/5b/aair-7-346.PMC4446633.pdf
2015 July;7(4):346-358. http://dx.doi.org/10.4168/aair.2015.7.4.346 AAIR 351 http://e-aair.orgCD4 CD20 CD68 CD138Co NANP ANP A Fig.,Non-OADS,/arxiv_data1/oa_pdf/1a/5b/aair-7-346.PMC4446633.pdf
"2015 July;7(4):346-358. http://dx.doi.org/10.4168/aair.2015.7.4.346 Volume 7, Number 4, July 2015 352 http://e-aair.orgwere extensively distributed in the lamina propria of polyp tis - sues.",Non-OADS,/arxiv_data1/oa_pdf/1a/5b/aair-7-346.PMC4446633.pdf
"2015 July;7(4):346-358. http://dx.doi.org/10.4168/aair.2015.7.4.346 AAIR 353 http://e-aair.orgthe levels of IL-5, IFN- γ, IL-1 β, IL-6, IL-8, IL-2sR, and TNF- α  were significantly increased in polyp tissues compared to nor - mal controls, whereas the TGF- β1 level was significantly de - creased in polyp tissues compared to normal controls ( P<0.05).",Non-OADS,/arxiv_data1/oa_pdf/1a/5b/aair-7-346.PMC4446633.pdf
"2015 July;7(4):346-358. http://dx.doi.org/10.4168/aair.2015.7.4.346 Volume 7, Number 4, July 2015 354 http://e-aair.orgpolyp tissues ( P<0.05).",Non-OADS,/arxiv_data1/oa_pdf/1a/5b/aair-7-346.PMC4446633.pdf
2015 July;7(4):346-358. http://dx.doi.org/10.4168/aair.2015.7.4.346 AAIR 355 http://e-aair.orgFig.,Non-OADS,/arxiv_data1/oa_pdf/1a/5b/aair-7-346.PMC4446633.pdf
"2015 July;7(4):346-358. http://dx.doi.org/10.4168/aair.2015.7.4.346 Volume 7, Number 4, July 2015 356 http://e-aair.orgmatory mediators were compared between the stimulated  atopic and nonatopic subgroups, we found that the levels of IL- 5, IL-2, IL-10, IL-17A, and PGD2 were significantly increased in  atopic polyp tissues compared to nonatopic polyp tissues  (P<0.05).",Non-OADS,/arxiv_data1/oa_pdf/1a/5b/aair-7-346.PMC4446633.pdf
2015 July;7(4):346-358. http://dx.doi.org/10.4168/aair.2015.7.4.346 AAIR 357 http://e-aair.orgCRSwNP patients.,Non-OADS,/arxiv_data1/oa_pdf/1a/5b/aair-7-346.PMC4446633.pdf
"2015 July;7(4):346-358. http://dx.doi.org/10.4168/aair.2015.7.4.346 Volume 7, Number 4, July 2015 358 http://e-aair.orgof allergy.",Non-OADS,/arxiv_data1/oa_pdf/1a/5b/aair-7-346.PMC4446633.pdf
"© Copyright The Korean Academy of Asthma, Allergy and Clinical Immunology • The Korean Academy of Pediatric Allergy and Respiratory Disease359 http://e-aair.orgINTRODUCTION The prevalence of allergic disease has increased during the  past decade in Korea.",Non-OADS,/arxiv_data1/oa_pdf/6c/38/aair-7-359.PMC4446634.pdf
"Both epidemiologic and experimental studies have proposed  that exposure to TAP ( i.e., diesel exhaust from heavy traffic) can  increase the risks of airway or epidermal inflammation and al -Effect of Traffic-Related Air Pollution on Allergic Disease: Results  of the Children’s Health and Environmental Research Dal-Young Jung,1 Jong-Han Leem,1,2* Hwan-Cheol Kim,1,2 Jeong-Hee Kim,3 Seung-Sik Hwang,1 Ji-Young Lee,1   Byoung-Ju Kim,4 Yun-Chul Hong,5 Soo-Jong Hong,6 Ho-Jang Kwon7 1Department of Social and Preventive Medicine, Inha University School of Medicine, Incheon, Korea  2Department of Occupational and Environmental Medicine, Inha University hospital, Incheon, Korea  3Department of Pediatrics, Inha University School of Medicine, Incheon, Korea 4Department of Pediatrics, Inje University Haeundae Paik Hospital, Busan, Korea 5Department of Preventive Medicine, Seoul National University College of Medicine, Seoul, Korea  6 Department of Pediatrics, Childhood Asthma Atopy Center, Research Center for Standardization of Allergic Diseases, University of Ulsan College of Medicine,  Seoul, Korea 7Department of Preventive Medicine, Dankook University College of Medicine, Cheonan, Korea This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits  unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/6c/38/aair-7-359.PMC4446634.pdf
2015 July;7(4):359-366. http://dx.doi.org/10.4168/aair.2015.7.4.359 pISSN 2092-7355 • eISSN 2092-7363,Non-OADS,/arxiv_data1/oa_pdf/6c/38/aair-7-359.PMC4446634.pdf
"2015 July;7(4):359-366. http://dx.doi.org/10.4168/aair.2015.7.4.359 Volume 7, Number 4, July 2015 360 http://e-aair.orglergic sensitization, but the role of the exposure in the etiology  of asthma or allergic diseases is not completely understood.",Non-OADS,/arxiv_data1/oa_pdf/6c/38/aair-7-359.PMC4446634.pdf
2015 July;7(4):359-366. http://dx.doi.org/10.4168/aair.2015.7.4.359 AAIR 361 http://e-aair.orgfied into 4 categories.,Non-OADS,/arxiv_data1/oa_pdf/6c/38/aair-7-359.PMC4446634.pdf
"2015 July;7(4):359-366. http://dx.doi.org/10.4168/aair.2015.7.4.359 Volume 7, Number 4, July 2015 362 http://e-aair.orgfor trend =0.021) (Table 3).",Non-OADS,/arxiv_data1/oa_pdf/6c/38/aair-7-359.PMC4446634.pdf
"2015 July;7(4):359-366. http://dx.doi.org/10.4168/aair.2015.7.4.359 AAIR 363 http://e-aair.orgFor AHR, the highest adjusted PR for 75-150 m distance from  main road categories was significant (PR =1.30, 95% CIs: 1.02- 1.65), but no dose-response relationship was found ( P for trend =  0.099).",OADS,/arxiv_data1/oa_pdf/6c/38/aair-7-359.PMC4446634.pdf
"2015 July;7(4):359-366. http://dx.doi.org/10.4168/aair.2015.7.4.359 Volume 7, Number 4, July 2015 364 http://e-aair.orgDISCUSSION We found that the distance to main roads and the length of  main road are associated with the prevalence of allergic disease  in Korean schoolchildren.",Non-OADS,/arxiv_data1/oa_pdf/6c/38/aair-7-359.PMC4446634.pdf
"2015 July;7(4):359-366. http://dx.doi.org/10.4168/aair.2015.7.4.359 AAIR 365 http://e-aair.orgmethylation process affect differentiation of T helper cells) and  thereby possibly the risk of asthma and allergic sensitization.29 Although biological mechanisms by which TAP reduces lung  function in children are not fully understood, chronic airway  inflammation could decrease lung function measures like those  reported in our study.",Non-OADS,/arxiv_data1/oa_pdf/6c/38/aair-7-359.PMC4446634.pdf
"2015 July;7(4):359-366. http://dx.doi.org/10.4168/aair.2015.7.4.359 Volume 7, Number 4, July 2015 366 http://e-aair.orgtraffic-related air pollutants and allergic rhinitis prevalence in mid - dle-school children in Taiwan.",Non-OADS,/arxiv_data1/oa_pdf/6c/38/aair-7-359.PMC4446634.pdf
"© Copyright The Korean Academy of Asthma, Allergy and Clinical Immunology • The Korean Academy of Pediatric Allergy and Respiratory Disease367 http://e-aair.orgINTRODUCTION Patients with nasal polyps often suffer from progressive nasal  congestion, hyposmia, and rhinorrhea, which are frequently  confused with symptoms of allergic rhinitis and chronic sinus - itis.1-3 This is especially the case in a patient with chronic rhino - sinusitis with nasal polyps (CRSwNP), who suffers from pro - longed rhinorrhea even after adequate antimicrobial treatment.",Non-OADS,/arxiv_data1/oa_pdf/71/33/aair-7-367.PMC4446635.pdf
"CRSwNP is a disorder characterized by persistent eosinophil - ic Th2 inflammation and frequent sinonasal microbial coloni - zation.4 Studies of cytokines associated with chronic rhinosi - nusitis have showed that CRSwNP or CRS without nasal polyps  (CRSsNP) have a mixed Th1/Th2 cytokine profile, indicating  that cytokines play an important pathologic role in these condi - tions.4-11 A recent study investigating the expression of various cytokines in nasal epithelial cell cultures of CRSwNP or CRSs - NP patients and controls has demonstrated that IL-4 and IL-13  are increased in CRSwNP , whereas IL-4 is increased in CRSsNP ,  compared to controls.5 Ramanathan et al .4 created a model of  the Th2 inflammatory environment based on exposure of pri - mary human sinonasal epithelial cells (HSNECs) to the Th2 cy - tokines interleukin IL-4 or IL-13 for 36 hours  and demonstrat - ed that treatment of HSNECs with IL-4 or IL-13 significantly TMEM16A-Mediated Mucin Secretion in IL-13-Induced Nasal  Epithelial Cells From Chronic Rhinosinusitis Patients  Yu Zhang,1 Xiangdong Wang,1,2 Hong Wang,2 Jian Jiao,2 Ying Li,2 Erzhong Fan,2 Luo Zhang,1,2* Claus Bachert3 1Department of Otolaryngology, Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, China 2Key Laboratory of Otolaryngology, Head and Neck Surgery, Ministry of Education, Beijing Institute of Otolaryngology, Beijing, China 3Upper Airways Research Laboratory, Department of Oto-Rhino-Laryngology, Ghent University Hospital, Ghent, Belgium This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits  unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/71/33/aair-7-367.PMC4446635.pdf
2015 July;7(4):367-375. http://dx.doi.org/10.4168/aair.2015.7.4.367 pISSN 2092-7355 • eISSN 2092-7363,Non-OADS,/arxiv_data1/oa_pdf/71/33/aair-7-367.PMC4446635.pdf
"2015 July;7(4):367-375. http://dx.doi.org/10.4168/aair.2015.7.4.367 Volume 7, Number 4, July 2015 368 http://e-aair.orgdown-regulates the baseline expression of antimicrobial innate  immune genes and leads to microbial colonization and abnor - mal immune responses associated with CRSwNP .",Non-OADS,/arxiv_data1/oa_pdf/71/33/aair-7-367.PMC4446635.pdf
"2015 July;7(4):367-375. http://dx.doi.org/10.4168/aair.2015.7.4.367 AAIR 369 http://e-aair.organced salt solutions supplemented by penicillin (100 U/mL;  Gibco, Carlsbad, CA, USA), streptomycin (100 µg/mL; Gibco),  amphotericin B (2.5 µg/mL; Gibco) and  incubated in 0.5% pro - tease (type XIV; Sigma, St.Louis, MO, USA) in Dulbecco’s Modi - fied Eagle’s Medium (DMEM; Gibco) overnight at 4 ˚C.",Non-OADS,/arxiv_data1/oa_pdf/71/33/aair-7-367.PMC4446635.pdf
"2015 July;7(4):367-375. http://dx.doi.org/10.4168/aair.2015.7.4.367 Volume 7, Number 4, July 2015 370 http://e-aair.orgon ice, and the suspension was centrifuged at 3,000 rpm for 10  minutes at 4 ˚C.",Non-OADS,/arxiv_data1/oa_pdf/71/33/aair-7-367.PMC4446635.pdf
"2015 July;7(4):367-375. http://dx.doi.org/10.4168/aair.2015.7.4.367 AAIR 371 http://e-aair.orgC5AC further, we performed immunofluorescence combined  with confocal microscopy to assess the expressions of TME - M16A, MUC5AC, and acetylated-tubulin protein (a marker for  ciliated cells) in ALI-cultured HNPECs incubated with or with - out IL-13 (10 ng/mL) for 14 days.",Non-OADS,/arxiv_data1/oa_pdf/71/33/aair-7-367.PMC4446635.pdf
"2015 July;7(4):367-375. http://dx.doi.org/10.4168/aair.2015.7.4.367 Volume 7, Number 4, July 2015 372 http://e-aair.orgacetylated-tubulin proteins were not coexpressed within the  same cells in HNPECs incubated with or without IL-13, indicat - ing that TMEM16A was not expressed on ciliated cells (Fig.",Non-OADS,/arxiv_data1/oa_pdf/71/33/aair-7-367.PMC4446635.pdf
"2015 July;7(4):367-375. http://dx.doi.org/10.4168/aair.2015.7.4.367 AAIR 373 http://e-aair.orgof TMEM16A-positive cells was significantly decreased from  23.5%±3.4% to 6.1% ±1.6% of total cells, and the percentage of  MUC5AC-positive cells was decreased from 27.3% ±6.9% to  7.6%±2.1% of total cells in HNPECs incubated with IL-13 in the  presence of T16Ainh-A01 (n =6, both P<0.001); consequently,  the percentage of cell co-expressing TMEM16A and MUC5AC  was significantly decreased from 19.1% ±1.6% to 2.0% ±0.7% of  total cells (n =6, P<0.001).",Non-OADS,/arxiv_data1/oa_pdf/71/33/aair-7-367.PMC4446635.pdf
"2015 July;7(4):367-375. http://dx.doi.org/10.4168/aair.2015.7.4.367 Volume 7, Number 4, July 2015 374 http://e-aair.orgal epithelial cells, which may be derived from Clara cells.30 By  immunohistochemical analysis, we found that TMEM16A was  present not only in the apical cell membrane and on the cir - cumference of MUC5AC protein but also on the basolateral  side of nasal polyp epithelium.",OADS,/arxiv_data1/oa_pdf/71/33/aair-7-367.PMC4446635.pdf
"2015 July;7(4):367-375. http://dx.doi.org/10.4168/aair.2015.7.4.367 AAIR 375 http://e-aair.orgFund of Sanitation Elite Reconstruction of Beijing (2009-2-007),  Beijing Science and Technology Program (Z121107009212032), and  Beijing Health Bureau Program for high level talents (2011-3-043).",Non-OADS,/arxiv_data1/oa_pdf/71/33/aair-7-367.PMC4446635.pdf
"© Copyright The Korean Academy of Asthma, Allergy and Clinical Immunology • The Korean Academy of Pediatric Allergy and Respiratory Disease376 http://e-aair.orgINTRODUCTION Allergic disorders are one of the most common diseases, af - fecting approximately 20%-40% of the population in developed  countries.1 Recognized as an important cause of asthma in the  last 50 years, cockroach allergy is the second leading allergen in  Taiwan, next only to house dust mites.2-7  The most common domestic cockroaches associated with al - lergy are the German cockroach Blattella geranica  in the US  and Europe, and the American cockroach Periplaneta ameri - cana  in South America and Asian countries.8,9 Since the cloning  of Bla g 2,10 the major allergen of German cockroach, more and  more cockroach allergens have been identified.",Non-OADS,/arxiv_data1/oa_pdf/7d/20/aair-7-376.PMC4446636.pdf
"However, the po -IgE-Binding Epitope Mapping and Tissue Localization of the Major  American Cockroach Allergen Per a 2  Mey-Fann Lee,1,3 Chia-Wei Chang,4 Pei-Pong Song,1 Guang-Yuh Hwang,4 Shyh-Jye Lin,5 Yi-Hsing Chen2,4,6*  1Department of Medical Research, Taichung Veterans General Hospital, Taichung, Taiwan 2Division of Allergy, Immunology and Rheumatology, Taichung Veterans General Hospital, Taichung, Taiwan  3General Education Center, Tunghai University, Taichung, Taiwan  4Department of Life Science, Tunghai University, Taichung, Taiwan  5School of Medical Laboratory and Biotechnology, Chung Shan Medical University, Taichung, Taiwan  6Faculty of Medicine, National Yang-Ming University, Taipei, Taiwan  This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits  unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/7d/20/aair-7-376.PMC4446636.pdf
2015 July;7(4):376-383. http://dx.doi.org/10.4168/aair.2015.7.4.376 pISSN 2092-7355 • eISSN 2092-7363,Non-OADS,/arxiv_data1/oa_pdf/7d/20/aair-7-376.PMC4446636.pdf
2015 July;7(4):376-383. http://dx.doi.org/10.4168/aair.2015.7.4.376 AAIR 377 http://e-aair.orgtential for cross-reactivity among homologous allergens from  different species is expected.,Non-OADS,/arxiv_data1/oa_pdf/7d/20/aair-7-376.PMC4446636.pdf
"2015 July;7(4):376-383. http://dx.doi.org/10.4168/aair.2015.7.4.376 Volume 7, Number 4, July 2015 378 http://e-aair.orgBandPrep kit (Genepure, Taichung, Taiwan) and ligated into  pCR2.1 TA vector (Invitrogen, Carlsbad, CA, USA).",OADS,/arxiv_data1/oa_pdf/7d/20/aair-7-376.PMC4446636.pdf
2015 July;7(4):376-383. http://dx.doi.org/10.4168/aair.2015.7.4.376 AAIR 379 http://e-aair.orgcollected on glass slides coated with poly-L-lysine.,Non-OADS,/arxiv_data1/oa_pdf/7d/20/aair-7-376.PMC4446636.pdf
"RESULTS Identification of IgE-binding epitopes of Per a 2 using PCR- derived fragments First, 3 gene fragments of Per a 2 located at the amino-acid  residues 21-93, 87-211, and 200-351 were generated by PCR ac - cording to the prediction of domain linkers by amino acid com - position (http://armadillo.blueprint.org).",OADS,/arxiv_data1/oa_pdf/7d/20/aair-7-376.PMC4446636.pdf
"2015 July;7(4):376-383. http://dx.doi.org/10.4168/aair.2015.7.4.376 Volume 7, Number 4, July 2015 380 http://e-aair.orgbinding was detected in the non-allergic controls.",Non-OADS,/arxiv_data1/oa_pdf/7d/20/aair-7-376.PMC4446636.pdf
"2015 July;7(4):376-383. http://dx.doi.org/10.4168/aair.2015.7.4.376 AAIR 381 http://e-aair.orgindicated that human IgE-binding epitopes of Per a 2 were lo - cated at the amino acid sequences 57-86, 200-211, and 299-309.",Non-OADS,/arxiv_data1/oa_pdf/7d/20/aair-7-376.PMC4446636.pdf
"2015 July;7(4):376-383. http://dx.doi.org/10.4168/aair.2015.7.4.376 Volume 7, Number 4, July 2015 382 http://e-aair.orgACKNOWLEDGMENTS This study was supported by grants from Taichung Veterans  General Hospital (TCVGH-1007311C) and the National Science  Council of Taiwan (NSC97-2320-B075A-001-MY3).",Non-OADS,/arxiv_data1/oa_pdf/7d/20/aair-7-376.PMC4446636.pdf
2015 July;7(4):376-383. http://dx.doi.org/10.4168/aair.2015.7.4.376 AAIR 383 http://e-aair.orgallergenic components between German cockroach whole body  and fecal extracts.,Non-OADS,/arxiv_data1/oa_pdf/7d/20/aair-7-376.PMC4446636.pdf
"© Copyright The Korean Academy of Asthma, Allergy and Clinical Immunology • The Korean Academy of Pediatric Allergy and Respiratory Disease384 http://e-aair.orgINTRODUCTION Dog is a source of several important allergenic molecules.",Non-OADS,/arxiv_data1/oa_pdf/b4/e0/aair-7-384.PMC4446637.pdf
"For that purpose, IgE Reactivity of the Dog Lipocalin Allergen Can f 4 and the  Development of a Sandwich ELISA for Its Quantification Marja Rytkönen-Nissinen,1,2* Soili Saarelainen,1 Jukka Randell,3 Jukka Häyrinen,4 Nisse Kalkkinen,5 Tuomas Virtanen1 1Department of Clinical Microbiology, Institute of Clinical Medicine and Biocenter Kuopio, University of Eastern Finland, Kuopio Campus, Finland 2Institute of Dentistry, School of Medicine, University of Eastern Finland, Kuopio Campus, Finland 3Department of Pulmonary Diseases, Kuopio University Hospital, Kuopio, Finland 4Institute of Biomedicine, University of Eastern Finland, Kuopio Campus, Finland 5Institute of Biotechnology, Viikki Biocenter, University of Helsinki, Finland This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits  unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/b4/e0/aair-7-384.PMC4446637.pdf
2015 July;7(4):384-392. http://dx.doi.org/10.4168/aair.2015.7.4.384 pISSN 2092-7355 • eISSN 2092-7363,Non-OADS,/arxiv_data1/oa_pdf/b4/e0/aair-7-384.PMC4446637.pdf
2015 July;7(4):384-392. http://dx.doi.org/10.4168/aair.2015.7.4.384 AAIR 385 http://e-aair.orgwe purified natural Can f 4 from a dog dander extract and gen - erated a recombinant form of the allergen.,Non-OADS,/arxiv_data1/oa_pdf/b4/e0/aair-7-384.PMC4446637.pdf
"2015 July;7(4):384-392. http://dx.doi.org/10.4168/aair.2015.7.4.384 Volume 7, Number 4, July 2015 386 http://e-aair.orgInc., San Francisco, CA, USA) at a 1:10 w/w ratio of AH-BNHS  and mAb, according to the manufacturer’s instructions.",Non-OADS,/arxiv_data1/oa_pdf/b4/e0/aair-7-384.PMC4446637.pdf
The quantifica - tion of dot intensities was performed by using the public do - main ImageJ software (http://imagej.nih.gov/ij/)23 and the Mi - croArray Profile.jar algorithm (http://www.optinav.com/down - load/MicroArray_Profile.jar).,OADS,/arxiv_data1/oa_pdf/b4/e0/aair-7-384.PMC4446637.pdf
2015 July;7(4):384-392. http://dx.doi.org/10.4168/aair.2015.7.4.384 AAIR 387 http://e-aair.orgmolecular mass of 12-18 kDa7 was isolated by size exclusion  chromatography (SEC) from in-house dog dander extract and  used for immunizing mice.,Non-OADS,/arxiv_data1/oa_pdf/b4/e0/aair-7-384.PMC4446637.pdf
"2015 July;7(4):384-392. http://dx.doi.org/10.4168/aair.2015.7.4.384 Volume 7, Number 4, July 2015 388 http://e-aair.orgwas only fair ( κ=0.37, P<0.001).",Non-OADS,/arxiv_data1/oa_pdf/b4/e0/aair-7-384.PMC4446637.pdf
2015 July;7(4):384-392. http://dx.doi.org/10.4168/aair.2015.7.4.384 AAIR 389 http://e-aair.org48F were adopted for the ELISA.,Non-OADS,/arxiv_data1/oa_pdf/b4/e0/aair-7-384.PMC4446637.pdf
"2015 July;7(4):384-392. http://dx.doi.org/10.4168/aair.2015.7.4.384 Volume 7, Number 4, July 2015 390 http://e-aair.orgin immunoblotting (data not shown).",Non-OADS,/arxiv_data1/oa_pdf/b4/e0/aair-7-384.PMC4446637.pdf
2015 July;7(4):384-392. http://dx.doi.org/10.4168/aair.2015.7.4.384 AAIR 391 http://e-aair.orgduce divergent results on the prevalence of allergic sensitization.,Non-OADS,/arxiv_data1/oa_pdf/b4/e0/aair-7-384.PMC4446637.pdf
"2015 July;7(4):384-392. http://dx.doi.org/10.4168/aair.2015.7.4.384 Volume 7, Number 4, July 2015 392 http://e-aair.organtigenic and allergenic properties of three types of bovine epithe - lial material.",Non-OADS,/arxiv_data1/oa_pdf/b4/e0/aair-7-384.PMC4446637.pdf
"© Copyright The Korean Academy of Asthma, Allergy and Clinical Immunology • The Korean Academy of Pediatric Allergy and Respiratory Disease393 http://e-aair.orgINTRODUCTION Inhaled environmental allergens cause allergic symptoms in  millions of patients worldwide.",Non-OADS,/arxiv_data1/oa_pdf/8d/8b/aair-7-393.PMC4446638.pdf
"Structures  of MD2 and Der p2 exhibit homology, and Trompette et al .4  have reported that Der p2 can facilitate TLR4 signaling through Der p2 Internalization by Epithelium Synergistically Augments  Toll-like Receptor-Mediated Proinflammatory Signaling Sui-Chu Yin,1 En-Chih Liao,1,2,3 Chih-Liang Chiu,4 Ching-yun Chang,5 Jaw-Ji Tsai5,6,7* 1Center for Translational Medicine, Department of Medical Research, Taichung Veterans General Hospital, Taichung, Taiwan 2Department of Bioindustry Technology, Da-Yeh University, Changhua, Taiwan 3Department of Medical Technology, Jen-Teh Junior College of Medicine, Nursing and Management, Miaoli, Taiwan 4Instrumentation Center, Department of Medical Research, Taichung Veterans General Hospital, Taichung, Taiwan 5Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan 6Institute of Biomedical Sciences, National Chung-Hsing University, Taichung, Taiwan 7Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits  unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/8d/8b/aair-7-393.PMC4446638.pdf
2015 July;7(4):393-403. http://dx.doi.org/10.4168/aair.2015.7.4.393 pISSN 2092-7355 • eISSN 2092-7363,Non-OADS,/arxiv_data1/oa_pdf/8d/8b/aair-7-393.PMC4446638.pdf
"2015 July;7(4):393-403. http://dx.doi.org/10.4168/aair.2015.7.4.393 Volume 7, Number 4, July 2015 394 http://e-aair.orgdirect interactions with the TLR4 complex, reconstituting LPS- promoted TLR4 signaling in the absence of MD2 and facilitat - ing such signaling in the presence of MD2.",Non-OADS,/arxiv_data1/oa_pdf/8d/8b/aair-7-393.PMC4446638.pdf
"2015 July;7(4):393-403. http://dx.doi.org/10.4168/aair.2015.7.4.393 AAIR 395 http://e-aair.orgeach PCR reaction was obtained using an MJ Mini Personal  Thermal Cycler (Bio-Rad, Foster, CA, USA).",Non-OADS,/arxiv_data1/oa_pdf/8d/8b/aair-7-393.PMC4446638.pdf
"2015 July;7(4):393-403. http://dx.doi.org/10.4168/aair.2015.7.4.393 Volume 7, Number 4, July 2015 396 http://e-aair.orgby confocal microscopy.",Non-OADS,/arxiv_data1/oa_pdf/8d/8b/aair-7-393.PMC4446638.pdf
2015 July;7(4):393-403. http://dx.doi.org/10.4168/aair.2015.7.4.393 AAIR 397 http://e-aair.orgEffects of Der p2 on IL-6/IL-8 secretion by BEAS-2B cells and  effects of anti-MD2 antibody and MD2 overexpression on  IL-6/IL-8 secretion in rDer p2-treated cells BEAS-2B cells were cultured with rDer p2-EGFP with/without  additional LPS for 24 hours.,Non-OADS,/arxiv_data1/oa_pdf/8d/8b/aair-7-393.PMC4446638.pdf
"2015 July;7(4):393-403. http://dx.doi.org/10.4168/aair.2015.7.4.393 Volume 7, Number 4, July 2015 398 http://e-aair.organd 24.2% reductions, respectively, in the fold induction of IL-8  mRNA induced by rDer p2 in conjunction with LPS (Fig.",Non-OADS,/arxiv_data1/oa_pdf/8d/8b/aair-7-393.PMC4446638.pdf
"2015 July;7(4):393-403. http://dx.doi.org/10.4168/aair.2015.7.4.393 AAIR 399 http://e-aair.orgalone, at least in terms of the readouts we chose to study, it  markedly increased the secretion of both IL-6 and IL-8 by these  cells in response to rDer p2 in conjunction with LPS.",Non-OADS,/arxiv_data1/oa_pdf/8d/8b/aair-7-393.PMC4446638.pdf
"2015 July;7(4):393-403. http://dx.doi.org/10.4168/aair.2015.7.4.393 Volume 7, Number 4, July 2015 400 http://e-aair.orgMD2 and an anti-MD2 antibody significantly reduced the re - sponse of the cells to Der p2/LPS, while MD2 overexpression  greatly enhanced IL-6 secretion in response to this stimulus.",Non-OADS,/arxiv_data1/oa_pdf/8d/8b/aair-7-393.PMC4446638.pdf
2015 July;7(4):393-403. http://dx.doi.org/10.4168/aair.2015.7.4.393 AAIR 401 http://e-aair.orgD Fig.,Non-OADS,/arxiv_data1/oa_pdf/8d/8b/aair-7-393.PMC4446638.pdf
"2015 July;7(4):393-403. http://dx.doi.org/10.4168/aair.2015.7.4.393 Volume 7, Number 4, July 2015 402 http://e-aair.orgtion by fibroblasts isolated from nasal polyps.22 We observed  similar activity of calcitriol in this study.",Non-OADS,/arxiv_data1/oa_pdf/8d/8b/aair-7-393.PMC4446638.pdf
2015 July;7(4):393-403. http://dx.doi.org/10.4168/aair.2015.7.4.393 AAIR 403 http://e-aair.orgpoma derived xenograft model.,OADS,/arxiv_data1/oa_pdf/8d/8b/aair-7-393.PMC4446638.pdf
"© Copyright The Korean Academy of Asthma, Allergy and Clinical Immunology • The Korean Academy of Pediatric Allergy and Respiratory Disease404 http://e-aair.orgINTRODUCTION Since the discovery of nitric oxide in exhaled breath of humans  in 1991,1 evidence has been built up that its level is related to eo - sinophilic airway inflammation.2 The level of fractional exhaled  nitric oxide (FeNO) is recognized to be useful in diagnosing asth - ma, predicting steroid responsiveness and monitoring treatment  adherence.3,4 Being easy and noninvasive, FeNO measurement  can be of good use in daily practice.",Non-OADS,/arxiv_data1/oa_pdf/63/3a/aair-7-404.PMC4446639.pdf
"Fractional Exhaled Nitric Oxide: Comparison Between Portable  Devices and Correlation With Sputum Eosinophils Sehyo Yune,1 Jin-Young Lee,2 Dong-Chull Choi,1 Byung-Jae Lee1* 1Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea 2Center for Health Promotion, Samsung Medical Center, Seoul, Korea This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits  unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/63/3a/aair-7-404.PMC4446639.pdf
2015 July;7(4):404-408. http://dx.doi.org/10.4168/aair.2015.7.4.404 pISSN 2092-7355 • eISSN 2092-7363,Non-OADS,/arxiv_data1/oa_pdf/63/3a/aair-7-404.PMC4446639.pdf
2015 July;7(4):404-408. http://dx.doi.org/10.4168/aair.2015.7.4.404 AAIR 405 http://e-aair.orgMATERIALS AND METHODS Study subjects Data was prospectively collected in patients suspected to have  asthma by history and physical examination on their first visit  to the asthma clinic of a tertiary university center.,Non-OADS,/arxiv_data1/oa_pdf/63/3a/aair-7-404.PMC4446639.pdf
"2015 July;7(4):404-408. http://dx.doi.org/10.4168/aair.2015.7.4.404 Volume 7, Number 4, July 2015 406 http://e-aair.orgThe FeNO levels measured by NIOX-MINO® (FeNO NIOX-MINO )  and by NObreath® (FeNO NObreath ) were closely correlated with the intraclass correlation coefficient of 0.972 (95% CI, 0.948-0.985;  P<0.001).",OADS,/arxiv_data1/oa_pdf/63/3a/aair-7-404.PMC4446639.pdf
2015 July;7(4):404-408. http://dx.doi.org/10.4168/aair.2015.7.4.404 AAIR 407 http://e-aair.orgDISCUSSION Our study shows that the levels of FeNO measured by NIOX- MINO® and NObreath® agree with each other and that they are  strongly correlated to ISE.,OADS,/arxiv_data1/oa_pdf/63/3a/aair-7-404.PMC4446639.pdf
"2015 July;7(4):404-408. http://dx.doi.org/10.4168/aair.2015.7.4.404 Volume 7, Number 4, July 2015 408 http://e-aair.org4.",Non-OADS,/arxiv_data1/oa_pdf/63/3a/aair-7-404.PMC4446639.pdf
"© Copyright The Korean Academy of Asthma, Allergy and Clinical Immunology • The Korean Academy of Pediatric Allergy and Respiratory Disease409 http://e-aair.orgINTRODUCTION In the last decades, there was a significant increase in the prev - alence of allergic diseases in industrialized countries due to  multifactorial causes.1-3 In particular, allergic asthma is a com - plex and heterogeneous disease characterized by intermittent  reversible obstruction and chronic inflammation of the airways,  bronchial hyperactivity, and an infiltration of lymphocytes.",Non-OADS,/arxiv_data1/oa_pdf/2e/a6/aair-7-409.PMC4446640.pdf
"”8 Probiot - ics play a pivotal role in controlling intestinal microbiota ho - meostasis by checking pathogenic bacteria growth and in the development of tolerance against ingested food antigens.9 More - over, probiotics seem to be able to modulate mucosal immune  responses and reduce gastrointestinal inflammation in infants  and adults affected by allergic diseases,10 having additional im - munomodulatory action by exerting stimulatory effects on the  intestinal innate and adaptive immune system, enhancing mu - cosal barrier functions, inducing the production of anti-inflam - matory cytokines, and facilitating the maintenance of immune  tolerance.11-14 However, much evidence showed that each probi - otic effect is strictly strain-dependent: different strains belong - ing to the same species can have opposite effects when admin - istered in the same protocol study and under the same condi - tions.15 Also, the ability to influence the immune response by Immunomodulatory Effects of Lactobacillus salivarius  LS01 and  Bifidobacterium breve  BR03, Alone and in Combination, on  Peripheral Blood Mononuclear Cells of Allergic Asthmatics Lorenzo Drago,1,2* Elena De Vecchi,2 Arianna Gabrieli,2 Roberta De Grandi,1 Marco Toscano1 1Laboratory of Technical Sciences for Laboratory Medicine, Department of Biomedical Science for Health, University of Milan, Milan, Italy  2Laboratory of Clinical Chemistry and Microbiology, IRCCS Galeazzi Orthopaedic Institute, Milan, Italy This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits  unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/2e/a6/aair-7-409.PMC4446640.pdf
2015 July;7(4):409-413. http://dx.doi.org/10.4168/aair.2015.7.4.409 pISSN 2092-7355 • eISSN 2092-7363,Non-OADS,/arxiv_data1/oa_pdf/2e/a6/aair-7-409.PMC4446640.pdf
"2015 July;7(4):409-413. http://dx.doi.org/10.4168/aair.2015.7.4.409 Volume 7, Number 4, July 2015 410 http://e-aair.orgmodulating the release of pro- and anti-inflammatory cyto - kines varies among different strains.16 Probiotic microorgan - isms have been demonstrated to stimulate peripheral blood  monocytes cells (PBMCs), leading to a restriction of proinflam - matory cytokines and a significant activation of monocytes and  IL-10 production.14 The aim of this study was to analyze the ef - fect of 2 probiotic strains ( Lactobacillus salivarius  LS01 and Bifi- dobacterium breve  BR03), tested alone and in combination, on  the cytokine production by PBMCs from subjects affected by al - lergic asthma.",Non-OADS,/arxiv_data1/oa_pdf/2e/a6/aair-7-409.PMC4446640.pdf
2015 July;7(4):409-413. http://dx.doi.org/10.4168/aair.2015.7.4.409 AAIR 411 http://e-aair.orgof cytokine (pg) per milliliter in culture medium.,Non-OADS,/arxiv_data1/oa_pdf/2e/a6/aair-7-409.PMC4446640.pdf
"2015 July;7(4):409-413. http://dx.doi.org/10.4168/aair.2015.7.4.409 Volume 7, Number 4, July 2015 412 http://e-aair.orgour study, L. salivarius  LS01 and B. breve  BR03 did not show  growth incompatibility when mixed together in the same broth;  as a consequence the 2 tested strains can be used in the same  probiotic mixture without affecting their functionality each oth - er in the human gut.",Non-OADS,/arxiv_data1/oa_pdf/2e/a6/aair-7-409.PMC4446640.pdf
2015 July;7(4):409-413. http://dx.doi.org/10.4168/aair.2015.7.4.409 AAIR 413 http://e-aair.orgtion in Estonian infants.,Non-OADS,/arxiv_data1/oa_pdf/2e/a6/aair-7-409.PMC4446640.pdf
"© Copyright The Korean Academy of Asthma, Allergy and Clinical Immunology • The Korean Academy of Pediatric Allergy and Respiratory Disease414 http://e-aair.orgI recently read the article Threshold for Positivity and Optimal  Dipyrone Concentration in Flow Cytometry-Assisted Basophil  Activation Test  by Hagau et al .,1 in the August 2013 issue of AAIR,  where the authors assessed the usefulness of basophil activa - tion tests (BATs) in the diagnosis of allergy to dipyrone.",Non-OADS,/arxiv_data1/oa_pdf/53/c6/aair-7-414.PMC4446641.pdf
"This may prompt researchers to evaluate BAT as a  valuable tool to probe very low doses of dipyrone in allergy; This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits  unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/53/c6/aair-7-414.PMC4446641.pdf
2015 July;7(4):414-415. http://dx.doi.org/10.4168/aair.2015.7.4.414 pISSN 2092-7355 • eISSN 2092-7363,Non-OADS,/arxiv_data1/oa_pdf/53/c6/aair-7-414.PMC4446641.pdf
Basophil Activation Test in Dipyrone Allergy AAIR 415 http://e-aair.org Allergy Asthma Immunol Res.,Non-OADS,/arxiv_data1/oa_pdf/53/c6/aair-7-414.PMC4446641.pdf
"2015 July;7(4):414-415. http://dx.doi.org/10.4168/aair.2015.7.4.414however, the absence of a flow cytometry plot reported by the  authors1 makes it difficult to address this point and to elucidate  possible causes about the high sensitivity reported.",OADS,/arxiv_data1/oa_pdf/53/c6/aair-7-414.PMC4446641.pdf
"© Copyright The Korean Academy of Asthma, Allergy and Clinical Immunology • The Korean Academy of Pediatric Allergy and Respiratory Disease416 http://e-aair.orgWe have read the manuscript about codeine (3-methylmor - phine) anaphylaxis by Yoo et al .1 with great interest and would  like to take the opportunity to raise some issues and communi - cate our experience.",Non-OADS,/arxiv_data1/oa_pdf/c5/4f/aair-7-416.PMC4446642.pdf
"Vito Sabato is a Clini - cal Researcher of the Research Foundation Flanders (FWO:  1700614N).This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits  unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/c5/4f/aair-7-416.PMC4446642.pdf
2015 July;7(4):416-417. http://dx.doi.org/10.4168/aair.2015.7.4.416 pISSN 2092-7355 • eISSN 2092-7363,Non-OADS,/arxiv_data1/oa_pdf/c5/4f/aair-7-416.PMC4446642.pdf
The BAT in Opiate Allergy AAIR 417 http://e-aair.org Allergy Asthma Immunol Res.,Non-OADS,/arxiv_data1/oa_pdf/c5/4f/aair-7-416.PMC4446642.pdf
2015 July;7(4):416-417. http://dx.doi.org/10.4168/aair.2015.7.4.416REFERENCES 1.,Non-OADS,/arxiv_data1/oa_pdf/c5/4f/aair-7-416.PMC4446642.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/3.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/b3/03/main.PMC4446657.pdf
"The entire small bowel was healthy, with no http://dx.doi.org/10.1016/j.ijscr.2014.08.027 2210-2612/© 2015 Published by Elsevier Ltd. on behalf of Surgical Associates Ltd.",Non-OADS,/arxiv_data1/oa_pdf/b3/03/main.PMC4446657.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/ licenses/by-nc-nd/3.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/b3/03/main.PMC4446657.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/0b/30/main.PMC4446658.pdf
"In this case, we found that eight loose bodiesin the elderly subacromial space, which were hard, a maximum http://dx.doi.org/10.1016/j.ijscr.2015.02.004 2210-2612/© 2015 The Authors.",Non-OADS,/arxiv_data1/oa_pdf/0b/30/main.PMC4446658.pdf
This is an open access article under the CC BY-NC-ND lic ense (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/0b/30/main.PMC4446658.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/3.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/6a/2d/main.PMC4446660.pdf
http://dx.doi.org/10.1016/j.ijscr.2014.11.066 2210-2612/© 2014 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/6a/2d/main.PMC4446660.pdf
This is an open access article under the CC BY-NC-NDlicense ( http://creativecommons.org/licenses/by-nc-nd/3.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/6a/2d/main.PMC4446660.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/71/f6/main.PMC4446661.pdf
http://dx.doi.org/10.1016/j.ijscr.2014.06.006 2210-2612/© 2015 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/71/f6/main.PMC4446661.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/f2/cf/main.PMC4446662.pdf
http://dx.doi.org/10.1016/j.ijscr.2015.01.051 2210-2612/© 2015 Published by Elsevier Ltd. on behalf of Surgical Associates Ltd.,Non-OADS,/arxiv_data1/oa_pdf/f2/cf/main.PMC4446662.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/ licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/f2/cf/main.PMC4446662.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/05/d1/main.PMC4446663.pdf
http://dx.doi.org/10.1016/j.ijscr.2015.04.002 2210-2612/© 2015 The Author.,Non-OADS,/arxiv_data1/oa_pdf/05/d1/main.PMC4446663.pdf
This is an open access article under the CC BY-NC-ND lice nse (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/05/d1/main.PMC4446663.pdf
"Pract.2009 (2009) 3, http://dx.doi.org/10.1155/2009/483473, Article ID483473.",Non-OADS,/arxiv_data1/oa_pdf/05/d1/main.PMC4446663.pdf
"10 (April (2))(2014) 93–96, http://dx.doi.org/10.4103/0972-9941.129963.",Non-OADS,/arxiv_data1/oa_pdf/05/d1/main.PMC4446663.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/b1/03/main.PMC4446664.pdf
A right upper http://dx.doi.org/10.1016/j.ijscr.2015.03.057 2210-2612/© 2015 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/b1/03/main.PMC4446664.pdf
This is an open access article under the CC BY-NC-ND lic ense (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/b1/03/main.PMC4446664.pdf
This is an open access article under the CC BY-NC-SA license ( http://creativecommons.org/licenses/by-nc-sa/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/d7/20/main.PMC4446665.pdf
A single 4-0 Prolene pledgetedsuture was used to circumscribe the perforation site; the catheterwas withdrawn due to the inability of its advancement based on http://dx.doi.org/10.1016/j.ijscr.2015.03.025 2210-2612/© 2015 The Authors.,OADS,/arxiv_data1/oa_pdf/d7/20/main.PMC4446665.pdf
This is an open access article under the CC BY-NC-SA lic ense (http://creativecommons.org/licenses/by-nc-sa/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/d7/20/main.PMC4446665.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/90/b1/main.PMC4446666.pdf
"Speciﬁcally, http://dx.doi.org/10.1016/j.ijscr.2015.03.009 2210-2612/© 2015 The Authors.",Non-OADS,/arxiv_data1/oa_pdf/90/b1/main.PMC4446666.pdf
This is an open access article under the CC BY-NC-NDlicense ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/90/b1/main.PMC4446666.pdf
This is an open access article under the CC BY-NC-SA license ( http://creativecommons.org/licenses/by-nc-sa/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/e9/6f/main.PMC4446669.pdf
There was http://dx.doi.org/10.1016/j.ijscr.2015.03.010 2210-2612/© 2015 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/e9/6f/main.PMC4446669.pdf
This is an open access article under the CC BY-NC-SA lic ense (http://creativecommons.org/licenses/by-nc-sa/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/e9/6f/main.PMC4446669.pdf
"3 (4) (2014) 237–242,http://dx.doi.org/10.3978/j.issn.2227-684X.2014.11.01 .",Non-OADS,/arxiv_data1/oa_pdf/e9/6f/main.PMC4446669.pdf
<http://www.cancerresearchuk.org/cancer-info/cancerstats/types/breast/ incidence/uk-breast-cancer-incidence-statistics > (accessed 11.01.15).,Non-OADS,/arxiv_data1/oa_pdf/e9/6f/main.PMC4446669.pdf
http://www.ncbi.nlm.nih.gov/pubmed/25296018 [4] W.H.,Non-OADS,/arxiv_data1/oa_pdf/e9/6f/main.PMC4446669.pdf
"), 4th ed., IARC Press,Lyon, France, 2003 (accessed 11.01.15).http://www.iarc.fr/en/publications/pdfs-online/pat-gen/bb4/BB4.pdf [5] A. Sanguinetti, M. Ragusa, R. Lucchini, M. Monacelli, F. Calzolari, Primary breast lymphoma: case reports and review of the literature, G. Chir.",Non-OADS,/arxiv_data1/oa_pdf/e9/6f/main.PMC4446669.pdf
"20(12) (2009) 1993–1999, http://dx.doi.org/10.1093/annonc/mdp238 .",Non-OADS,/arxiv_data1/oa_pdf/e9/6f/main.PMC4446669.pdf
"Mariappan, A. McMillan, S. Horning, Non-Hodgkin lymphoma of the breast, Cancer 110 (1) (2007) 25–30,http://dx.doi.org/10.1002/cncr.22753 .",Non-OADS,/arxiv_data1/oa_pdf/e9/6f/main.PMC4446669.pdf
"[8] O. Julen, I. Dellacasa, M.-F. Pelte, et al., Primary breast lymphomas, Rare Tumors 1 (1) (2009) e14, http://dx.doi.org/10.4081/rt.2009 .",Non-OADS,/arxiv_data1/oa_pdf/e9/6f/main.PMC4446669.pdf
"93 (3) (2005)191–198, http://dx.doi.org/10.1007/s10549-005-5088-8 .",Non-OADS,/arxiv_data1/oa_pdf/e9/6f/main.PMC4446669.pdf
"214 (6) (1991) 724–726 (accessed 11.01.15).http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1358498&tool=pmcentrez&rendertype=abstract [11] E. Hinoshita, H. Tashiro, I. Takahashi, et al., Primary non-Hodgkin’s lymphoma of the breast: a report of two cases, Breast Cancer 5 (3) (1998) 309–312(accessed 11.01.15).",OADS,/arxiv_data1/oa_pdf/e9/6f/main.PMC4446669.pdf
"http://www.ncbi.nlm.nih.gov/pubmed/11091662 [12] N. Avenia, A. Sanguinetti, R. Cirocchi, et al., Primary breast lymphomas: a multicentric experience, World J. Surg.",Non-OADS,/arxiv_data1/oa_pdf/e9/6f/main.PMC4446669.pdf
"8 (53) (2010),http://dx.doi.org/10.1186/1477-7819-8-53 .",Non-OADS,/arxiv_data1/oa_pdf/e9/6f/main.PMC4446669.pdf
"[13] M. Uesato, Y. Miyazawa, Y. Gunji, T. Ochiai, Primary non-Hodgkin’s lymphoma of the breast: report of a case with special reference to 380 cases in theJapanese literature, Breast Cancer 12 (2) (2005) 154–158 (accessed 11.01.15).http://www.ncbi.nlm.nih.gov/pubmed/15858449 [14] B.",Non-OADS,/arxiv_data1/oa_pdf/e9/6f/main.PMC4446669.pdf
"40 (4)(2008) 345–351, http://dx.doi.org/10.1080/00313020801911520 .",Non-OADS,/arxiv_data1/oa_pdf/e9/6f/main.PMC4446669.pdf
17 (2)(1993) 193–197 (accessed 11.01.15).http://www.ncbi.nlm.nih.gov/pubmed/8422114 [16] M.A.,OADS,/arxiv_data1/oa_pdf/e9/6f/main.PMC4446669.pdf
"28 (12) (2004)1646–1651 (accessed 11.01.15).http://www.ncbi.nlm.nih.gov/pubmed/15577686 [17] T. Susini, S. Olivieri, C. Molino, F. Castiglione, K. Tavella, R. Viligiardi, Ovarian cancer initially presenting as intramammary metastases and mimicking aprimary breast carcinoma: a case report and literature review, J. WomensHealth (Larchmt) 19 (1) (2010) 169–174,http://dx.doi.org/10.1089/jwh.2009.1465 .",Non-OADS,/arxiv_data1/oa_pdf/e9/6f/main.PMC4446669.pdf
264 (3)(2000) 166–167 (accessed 11.01.15).http://www.ncbi.nlm.nih.gov/pubmed/11129521 [19] D.S.,OADS,/arxiv_data1/oa_pdf/e9/6f/main.PMC4446669.pdf
"37 (3) (1990) 432–436 (accessed 11.01.15).http://www.ncbi.nlm.nih.gov/pubmed/2190874 [20] A. Al Samaraee, N. Angamuthu, T. Fasih, Primary breast osteosarcoma: a case report and review of literature, Scott.",Non-OADS,/arxiv_data1/oa_pdf/e9/6f/main.PMC4446669.pdf
"59 (4) (2014) e1–e4,http://dx.doi.org/10.1177/0036933014551674 .",Non-OADS,/arxiv_data1/oa_pdf/e9/6f/main.PMC4446669.pdf
"29 (15) (2011) e428–e430,http://dx.doi.org/10.1200/JCO.2010.33.6719 .",Non-OADS,/arxiv_data1/oa_pdf/e9/6f/main.PMC4446669.pdf
"Cancer 91 (2) (2004) 237–241, http://dx.doi.org/10.1038/sj.bjc.6601920 .",Non-OADS,/arxiv_data1/oa_pdf/e9/6f/main.PMC4446669.pdf
"59 (2) (2009) 111–115,http://dx.doi.org/10.1111/j.1440-1827.2008.02338.x .",Non-OADS,/arxiv_data1/oa_pdf/e9/6f/main.PMC4446669.pdf
"1 (1) (2008) 80,http://dx.doi.org/10.1186/1757-1626-1-80 .",Non-OADS,/arxiv_data1/oa_pdf/e9/6f/main.PMC4446669.pdf
"131 (5) (2007)792–795, http://dx.doi.org/10.1043/1543-2165 .",Non-OADS,/arxiv_data1/oa_pdf/e9/6f/main.PMC4446669.pdf
"22 (8) (1998)925–933 (accessed 11.01.15).http://www.ncbi.nlm.nih.gov/pubmed/9706972 [27] D. Dragoumis, K. Bimpa, A. Assimaki, A. Tsiftsoglou, Primary osteogenic sarcoma of the breast, Sing.",Non-OADS,/arxiv_data1/oa_pdf/e9/6f/main.PMC4446669.pdf
"http://www.ncbi.nlm.nih.gov/pubmed/19037539 [28] S.A. Badge, M.P.",Non-OADS,/arxiv_data1/oa_pdf/e9/6f/main.PMC4446669.pdf
"91 (2) (2005) 173–178,http://dx.doi.org/10.1007/s10549-004-7260-y .",Non-OADS,/arxiv_data1/oa_pdf/e9/6f/main.PMC4446669.pdf
"59 (10)(2006) 1079–1083, http://dx.doi.org/10.1136/jcp.2005.030536 .",Non-OADS,/arxiv_data1/oa_pdf/e9/6f/main.PMC4446669.pdf
"16 (9) (2003) 893–901,http://dx.doi.org/10.1097/01 MP.85,027.75201.B5 .",Non-OADS,/arxiv_data1/oa_pdf/e9/6f/main.PMC4446669.pdf
http://www.ncbi.nlm.nih.gov/pubmed/10692021 [33] H.S.,Non-OADS,/arxiv_data1/oa_pdf/e9/6f/main.PMC4446669.pdf
"(2006) 1–13, http://dx.doi.org/10.1186/1746-1596-1-13 .",Non-OADS,/arxiv_data1/oa_pdf/e9/6f/main.PMC4446669.pdf
"23 (31) (2005) 7827–7835,http://dx.doi.org/10.1200/JCO.2004.00.9589 .",Non-OADS,/arxiv_data1/oa_pdf/e9/6f/main.PMC4446669.pdf
http://www.ncbi.nlm.nih.gov/pubmed/4348806 [36] E.R.,Non-OADS,/arxiv_data1/oa_pdf/e9/6f/main.PMC4446669.pdf
"6 (2008) 135,http://dx.doi.org/10.1186/1477-7819-6-135 .",Non-OADS,/arxiv_data1/oa_pdf/e9/6f/main.PMC4446669.pdf
"202(6) (2006) 465–469, http://dx.doi.org/10.1016/j.prp.2006.01.006 .",Non-OADS,/arxiv_data1/oa_pdf/e9/6f/main.PMC4446669.pdf
"29 (4) (2003) 386–389 (accessed 11.01.15).http://www.ncbi.nlm.nih.gov/pubmed/12711295 [39] W.R. Wrightson, M.J. Edwards, K.M.",Non-OADS,/arxiv_data1/oa_pdf/e9/6f/main.PMC4446669.pdf
65 (12)(1999) 1153–1155 (accessed 11.01.15).http://www.ncbi.nlm.nih.gov/pubmed/10597064 [40] T.B.,Non-OADS,/arxiv_data1/oa_pdf/e9/6f/main.PMC4446669.pdf
http://www.ncbi.nlm.nih.gov/pubmed/11450786 [41] Y.M.,Non-OADS,/arxiv_data1/oa_pdf/e9/6f/main.PMC4446669.pdf
"28(1) (2002) 91–93, http://dx.doi.org/10.1053/ejso.2001.1156 .",Non-OADS,/arxiv_data1/oa_pdf/e9/6f/main.PMC4446669.pdf
"34 (6) (1995) 619–623 (accessed 11.01.15).http://www.ncbi.nlm.nih.gov/pubmed/7661539 [44] R. Veeratterapillay, S. Veeratterapillay, E. Ward, H. Khout, T. Fasih, Adenoid cystic carcinoma of the breast: case report and review of literature, Ann.",Non-OADS,/arxiv_data1/oa_pdf/e9/6f/main.PMC4446669.pdf
"94 (4) (2012) e137–e138,http://dx.doi.org/10.1308/003588412x13171221499829 .",Non-OADS,/arxiv_data1/oa_pdf/e9/6f/main.PMC4446669.pdf
"12 (4) (2010),http://dx.doi.org/10.1186/bcr2613 .",Non-OADS,/arxiv_data1/oa_pdf/e9/6f/main.PMC4446669.pdf
"3 (2014) 433–436,http://dx.doi.org/10.4236/crcm.2014.37096 .",Non-OADS,/arxiv_data1/oa_pdf/e9/6f/main.PMC4446669.pdf
127 (2) (1992) 233–235 (accessed 11.01.15).http://www.ncbi.nlm.nih.gov/pubmed/1311551 [49] J.H.,Non-OADS,/arxiv_data1/oa_pdf/e9/6f/main.PMC4446669.pdf
"183 (6) (2002) 646–649, http://dx.doi.org/10.1016/S0002-9610(02)858-9 .",Non-OADS,/arxiv_data1/oa_pdf/e9/6f/main.PMC4446669.pdf
"Elledge, Adenoid cystic carcinoma of the breast: molecular markers, treatment, and clinical outcome,Cancer 94 (8) (2002) 2119–2127, http://dx.doi.org/10.1002/cncr.10455 .",Non-OADS,/arxiv_data1/oa_pdf/e9/6f/main.PMC4446669.pdf
"6 August) (2013) vi7–vi23,http://dx.doi.org/10.1093/annonc/mdt284 .",Non-OADS,/arxiv_data1/oa_pdf/e9/6f/main.PMC4446669.pdf
Most cases present with http://dx.doi.org/10.1016/j.ijscr.2015.04.005 2210-2612/© 2015 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/09/fc/main.PMC4446670.pdf
This is an open access article under the CC BY-NC-ND lic ense (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/09/fc/main.PMC4446670.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/71/84/main.PMC4446671.pdf
http://dx.doi.org/10.1016/j.ijscr.2015.03.045 2210-2612/© 2015 Published by Elsevier Ltd. on behalf of Surgical Associates Ltd.,Non-OADS,/arxiv_data1/oa_pdf/71/84/main.PMC4446671.pdf
This is an open access article under the CC BY-NC-NDlicense ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/71/84/main.PMC4446671.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/18/ac/main.PMC4446672.pdf
http://dx.doi.org/10.1016/j.ijscr.2015.02.009 2210-2612/Crown Copyright © 2015 Published by Elsevier Ltd. on behalf of Surgical Associates Ltd.,Non-OADS,/arxiv_data1/oa_pdf/18/ac/main.PMC4446672.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/18/ac/main.PMC4446672.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/40/b9/main.PMC4446673.pdf
http://dx.doi.org/10.1016/j.ijscr.2015.03.039 2210-2612/© 2015 Published by Elsevier Ltd. on behalf of Surgical Associates Ltd.,Non-OADS,/arxiv_data1/oa_pdf/40/b9/main.PMC4446673.pdf
This is an open access article under the CC BY-NC-ND license(http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/40/b9/main.PMC4446673.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/5c/71/main.PMC4446675.pdf
"An urgent MRI of theright thigh was performed, which showed a large 11.7 ×7.6×6.9- cm hematoma within the swollen vastus intermedius muscle with http://dx.doi.org/10.1016/j.ijscr.2015.04.003 2210-2612/© 2015 The Authors.",Non-OADS,/arxiv_data1/oa_pdf/5c/71/main.PMC4446675.pdf
This is an open access article under the CC BY-NC-ND lic ense (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/5c/71/main.PMC4446675.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/f3/78/main.PMC4446676.pdf
The supra-inguinal wound was closed in two layers of http://dx.doi.org/10.1016/j.ijscr.2015.03.060 2210-2612/© 2015 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/f3/78/main.PMC4446676.pdf
This is an open access article under the CC BY-NC-ND lic ense (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/f3/78/main.PMC4446676.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/d2/81/main.PMC4446677.pdf
The CT scan revealed an http://dx.doi.org/10.1016/j.ijscr.2015.04.025 2210-2612/© 2015 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/d2/81/main.PMC4446677.pdf
This is an open access article under the CC BY-NC-ND lic ense (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/d2/81/main.PMC4446677.pdf
"Schröder, Arthroscopic correction of extra-articular subspinal impingement in the hipjoint, Orthopade 42 (October (10)) (2013) 879–883,http://dx.doi.org/10.1007/s00132-013-2130-0 .",Non-OADS,/arxiv_data1/oa_pdf/d2/81/main.PMC4446677.pdf
"471 (8) (2013) 2497–2503, http://dx.doi.org/10.1007/s11999-013-2847-4 .",Non-OADS,/arxiv_data1/oa_pdf/d2/81/main.PMC4446677.pdf
"Kelly, J.C. Clohisy, Open vs. arthroscopic: which is better for treating extra-articular hip impingement, AAOS Now (2014)http://www.aaos.org/news/aaosnow/jul14/clinical6.asp[18] H. Pan, K. Kawanabe, H. Akiyama, K. Goto, E. Onishi, T. Nakamura, Operative treatment of hip impingement caused by hypertrophy of the anterior inferioriliac spine, J.",Non-OADS,/arxiv_data1/oa_pdf/d2/81/main.PMC4446677.pdf
"90 (5) (2008) 677–679,http://dx.doi.org/10.1302/0301-620X.90B5.20005 .",Non-OADS,/arxiv_data1/oa_pdf/d2/81/main.PMC4446677.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/a1/81/main.PMC4446678.pdf
The head and http://dx.doi.org/10.1016/j.ijscr.2015.04.022 2210-2612/© 2015 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/a1/81/main.PMC4446678.pdf
This is an open access article under the CC BY-NC-NDlicense ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/a1/81/main.PMC4446678.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/b5/a0/main.PMC4446679.pdf
Upon intra-oral http://dx.doi.org/10.1016/j.ijscr.2015.04.012 2210-2612/© 2015 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/b5/a0/main.PMC4446679.pdf
This is an open access article under the CC BY-NC-ND lic ense (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/b5/a0/main.PMC4446679.pdf
"[3] Meningioma of the Parapharyngeal Space: Case Report Yadranko Ducic, MD, FRCS(C), * and Greg Ward, MD, 2000, American Association of Oral andMaxillofacial Surgeons, 0278-2391/00/5808-0016$3.00/0http://dx.doi.org/10.1053/joms.2000.8220 [4] G.T.",Non-OADS,/arxiv_data1/oa_pdf/b5/a0/main.PMC4446679.pdf
"Case Rep. 2012 (December (12))(2012) 19, http://dx.doi.org/10.1093/jscr/rjs024 , pii: rjs024.",OADS,/arxiv_data1/oa_pdf/b5/a0/main.PMC4446679.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/cb/ad/main.PMC4446680.pdf
The CT scan conﬁrmed a 4.7 ×3.3 cm femoral hernia containing a loop http://dx.doi.org/10.1016/j.ijscr.2015.04.024 2210-2612/© 2015 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/cb/ad/main.PMC4446680.pdf
This is an open access article under the CC BY-NC-NDlicense ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/cb/ad/main.PMC4446680.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/8f/69/main.PMC4446681.pdf
These grafts can be used to prevent cere-brospinal leak or as a septal reinforcement graft in epistaxis cases http://dx.doi.org/10.1016/j.ijscr.2015.04.029 2210-2612/© 2015 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/8f/69/main.PMC4446681.pdf
This is an open access article under the CC BY-NC-ND lic ense (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/8f/69/main.PMC4446681.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/29/50/main.PMC4446682.pdf
She was right hand dominant and http://dx.doi.org/10.1016/j.ijscr.2015.04.015 2210-2612/© 2015 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/29/50/main.PMC4446682.pdf
This is an open access article under the CC BY-NC-ND lic ense (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/29/50/main.PMC4446682.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/d8/86/main.PMC4446683.pdf
http://dx.doi.org/10.1016/j.ijscr.2015.04.014 2210-2612/© 2015 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/d8/86/main.PMC4446683.pdf
This is an open access article under the CC BY-NC-ND lic ense (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/d8/86/main.PMC4446683.pdf
"13 (4) (2012)425–433, http://dx.doi.org/10.3348/kjr.2012.13.4.425 , pISSN 1229-6929, eISSN 2005-8330.",Non-OADS,/arxiv_data1/oa_pdf/d8/86/main.PMC4446683.pdf
"S9) (2009) S9–S12,http://dx.doi.org/10.4174/jkss.2009.77 .",Non-OADS,/arxiv_data1/oa_pdf/d8/86/main.PMC4446683.pdf
"Arjun Rao, Gastric glomus tumour, JSCR 6 (2014) 2, http://dx.doi.org/10.1093/jscr/rju049 .",Non-OADS,/arxiv_data1/oa_pdf/d8/86/main.PMC4446683.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/88/4d/main.PMC4446684.pdf
"The physical examination detected a mobile, palpable, ﬁrm http://dx.doi.org/10.1016/j.ijscr.2015.04.018 2210-2612/© 2015 The Authors.",Non-OADS,/arxiv_data1/oa_pdf/88/4d/main.PMC4446684.pdf
This is an open access article under the CC BY-NC-ND lic ense (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/88/4d/main.PMC4446684.pdf
"), National Cancer Institute, Bethesda, MD, 2013, based on November2012 SEER data submission, posted to the SEER web sitehttp://seer.cancer.gov/csr/1975 2010/ [2] C. DeSantis, R. Siegel, P. Bandi, A. Jemal, Breast cancer statistics, 2011, CA Cancer J. Clin.",Non-OADS,/arxiv_data1/oa_pdf/88/4d/main.PMC4446684.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/64/6d/main.PMC4446685.pdf
http://dx.doi.org/10.1016/j.ijscr.2015.04.017 2210-2612/© 2015 The Author.,Non-OADS,/arxiv_data1/oa_pdf/64/6d/main.PMC4446685.pdf
This is an open access article under the CC BY-NC-ND lice nse (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/64/6d/main.PMC4446685.pdf
"3 (2006) 33, http://dx.doi.org/10.1186/1477-7800-3-33 .",Non-OADS,/arxiv_data1/oa_pdf/64/6d/main.PMC4446685.pdf
"2012 (2012) 193787, http://dx.doi.org/10.1155/2012/193787 , Epub 2012 Oct 16.",Non-OADS,/arxiv_data1/oa_pdf/64/6d/main.PMC4446685.pdf
"68 (1998) 51–59,http://dx.doi.org/10.1002/(SICI)1096-9098(199,805)68:13.0.CO;2-U .",Non-OADS,/arxiv_data1/oa_pdf/64/6d/main.PMC4446685.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/b7/0d/main.PMC4446686.pdf
Surgery was http://dx.doi.org/10.1016/j.ijscr.2015.04.030 2210-2612/© 2015 The Authors.,OADS,/arxiv_data1/oa_pdf/b7/0d/main.PMC4446686.pdf
This is an open access article under the CC BY-NC-ND lic ense (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/b7/0d/main.PMC4446686.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/dc/ab/main.PMC4446687.pdf
The postoperative http://dx.doi.org/10.1016/j.ijscr.2015.04.027 2210-2612/© 2015 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/dc/ab/main.PMC4446687.pdf
This is an open access article under the CC BY-NC-NDlicense ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/dc/ab/main.PMC4446687.pdf
"53 (February (1)) (2012) 68–71,http://dx.doi.org/10.1016/j.pedneo.2011.11.014 , Epub 2012 January 24.",Non-OADS,/arxiv_data1/oa_pdf/dc/ab/main.PMC4446687.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/d0/cd/main.PMC4446688.pdf
http://dx.doi.org/10.1016/j.ijscr.2015.04.019 2210-2612/© 2015 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/d0/cd/main.PMC4446688.pdf
This is an open access article under the CC BY-NC-ND lic ense (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/d0/cd/main.PMC4446688.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/d5/e8/main.PMC4446689.pdf
"A pneumoperitoneum of 12 mm Hg was created, and4 additional ports (1 port with a diameter of 12 mm and 3 with adiameter of 5 mm) were inserted into the left upper, right lower,left lower, and right upper quadrants, under laparoscopic imaging.The tumor was located on the pancreatic tail; however, detailedlaparoscopic observation of the lesion site was difﬁcult due to the http://dx.doi.org/10.1016/j.ijscr.2015.04.016 2210-2612/© 2015 The Authors.",Non-OADS,/arxiv_data1/oa_pdf/d5/e8/main.PMC4446689.pdf
This is an open access article under the CC BY-NC-ND lic ense (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/d5/e8/main.PMC4446689.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/dd/5a/main.PMC4446690.pdf
Thesetechniques are based on the principle of having all working ports http://dx.doi.org/10.1016/j.ijscr.2015.04.034 2210-2612/© 2015 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/dd/5a/main.PMC4446690.pdf
This is an open access article under the CC BY-NC-NDlicense ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/dd/5a/main.PMC4446690.pdf
"A 21 (April (3)) (2011)203–208, http://dx.doi.org/10.1089/lap.2010.0455 , Epub 2011 Mar 5.",Non-OADS,/arxiv_data1/oa_pdf/dd/5a/main.PMC4446690.pdf
"35 (January (1)) (2011) 212–216, http://dx.doi.org/10.1007/s00268-010-0813-9 .",Non-OADS,/arxiv_data1/oa_pdf/dd/5a/main.PMC4446690.pdf
"Obstet.283 (January (1)) (2011) 91–95,http://dx.doi.org/10.1007/s00404-009-1333-4 , Epub 2009 December 29.",Non-OADS,/arxiv_data1/oa_pdf/dd/5a/main.PMC4446690.pdf
"176 (July (1)) (2012) 50–54,http://dx.doi.org/10.1016/j.jss.2011.07.031 , Epub 2011 Aug 12.",OADS,/arxiv_data1/oa_pdf/dd/5a/main.PMC4446690.pdf
"8 (July (3))(2012) 74–78, http://dx.doi.org/10.4103/0972-9941.97586 .",Non-OADS,/arxiv_data1/oa_pdf/dd/5a/main.PMC4446690.pdf
"A 23 (June (6)) (2013) 553–555,http://dx.doi.org/10.1089/lap.2013.0245 .",Non-OADS,/arxiv_data1/oa_pdf/dd/5a/main.PMC4446690.pdf
"A 23(October (10)) (2013) 815–831, http://dx.doi.org/10.1089/lap.2013.0040 .",Non-OADS,/arxiv_data1/oa_pdf/dd/5a/main.PMC4446690.pdf
"28 (June (6)) (2014) 1902–1907,http://dx.doi.org/10.1007/s00464-013-3411-8 , Epub 2014 Jan 18.",Non-OADS,/arxiv_data1/oa_pdf/dd/5a/main.PMC4446690.pdf
"86 (April (4)) (2014) 177–180,http://dx.doi.org/10.2478/pjs-2014-0032 .",Non-OADS,/arxiv_data1/oa_pdf/dd/5a/main.PMC4446690.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/54/dd/main.PMC4446691.pdf
Her surgical history prior to this was http://dx.doi.org/10.1016/j.ijscr.2015.04.036 2210-2612/© 2015 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/54/dd/main.PMC4446691.pdf
This is an open access article under the CC BY-NC-NDlicense ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/54/dd/main.PMC4446691.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/08/d3/main.PMC4446692.pdf
http://dx.doi.org/10.1016/j.ijscr.2015.04.031 2210-2612/© 2015 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/08/d3/main.PMC4446692.pdf
This is an open access article under the CC BY-NC-ND lic ense (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/08/d3/main.PMC4446692.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/51/b3/main.PMC4446693.pdf
The fetus was successfully http://dx.doi.org/10.1016/j.ijscr.2015.04.033 2210-2612/© 2015 Published by Elsevier Ltd. on behalf of Surgical Associates Ltd.,Non-OADS,/arxiv_data1/oa_pdf/51/b3/main.PMC4446693.pdf
This is an open access article under the CC BY-NC-NDlicense ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/51/b3/main.PMC4446693.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/c1/c4/main.PMC4446694.pdf
A midline for laparotomy was per-formed to identify an intra-abdominal hollow organ perforation http://dx.doi.org/10.1016/j.ijscr.2015.04.035 2210-2612/© 2015 Published by Elsevier Ltd. on behalf of Surgical Associates Ltd.,Non-OADS,/arxiv_data1/oa_pdf/c1/c4/main.PMC4446694.pdf
This is an open access article under the CC BY-NC-ND license(http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/c1/c4/main.PMC4446694.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/ licenses/by-nc/3.0/), which permits non-commercial reuse, distribution, and reproduction in any medium, provided the original work isproperly cited.",Non-OADS,/arxiv_data1/oa_pdf/76/8e/hcs208.PMC4446788.pdf
"In a randomized, double-blind, placebo-controlled trial, MacGregor Review Article http://dx.doi.org/10.4070/kcj.2015.45.3.175 Print ISSN 1738-5520  • On-line ISSN 1738-5555 Received:  November 10, 2014 Revision Received: December 17, 2014 Accepted: December 22, 2014 Correspondence: Moo-Yong Rhee, MD, Cardiovascular Center, Clinical  Trial Center, Dongguk University Ilsan Hospital, 27 Dongguk-ro,   Ilsandong-gu, Goyang 410-773, Korea Tel: 82-31-961-5775, Fax: 82-31-961-7786 E-mail: mooyong_rhee@dumc.or.kr • The author has no financial conflicts of interest.",Non-OADS,/arxiv_data1/oa_pdf/65/cb/kcj-45-175.PMC4446810.pdf
176  High Sodium Intake and Cardiovascular Events http://dx.doi.org/10.4070/kcj.2015.45.3.175 www.e-kcj.org et al.10) demonstrated that a reduction in dietary sodium intake from  162±9 mmol/day to 86±9 mmol/day can lower systolic BP by ap - proximately 7.1 mm Hg.,Non-OADS,/arxiv_data1/oa_pdf/65/cb/kcj-45-175.PMC4446810.pdf
"177 Moo-Yong Rhee http://dx.doi.org/10.4070/kcj.2015.45.3.175 www.e-kcj.org the Telmisartan Randomized Assessment Study in ACE Intolerant  Subjects with Cardiovascular Disease (TRANSCEND) and the Pro - spective Urban Rural Epidemiology (PURE) study showed a J-shaped  association between estimated urinary sodium excretion and car - diovascular events.6)7) According to the results of these studies, the  recommendation for sodium intake of less than 2000 mg/day may  be harmful because it has the possibility of increasing cardiovas - cular morbidity and mortality.",Non-OADS,/arxiv_data1/oa_pdf/65/cb/kcj-45-175.PMC4446810.pdf
178  High Sodium Intake and Cardiovascular Events http://dx.doi.org/10.4070/kcj.2015.45.3.175 www.e-kcj.org is expected that more than 50% of hypertensive subjects have so - dium sensitivity.26)27) Different BP responses to the same amount of  sodium intake may be an explanation for the inconsistent result  regarding the association between high sodium intake and cardio - vascular events.,Non-OADS,/arxiv_data1/oa_pdf/65/cb/kcj-45-175.PMC4446810.pdf
"179 Moo-Yong Rhee http://dx.doi.org/10.4070/kcj.2015.45.3.175 www.e-kcj.org variable content of sodium in manufactured or processed foods.43)44)  In addition, sodium loss during cooking (due to washing) or eating  (sodium in the soup left behind in the dishes or bowel) should be  considered, but it is extremely difficult to incorporate this sodium  loss into any type of survey method.",Non-OADS,/arxiv_data1/oa_pdf/65/cb/kcj-45-175.PMC4446810.pdf
180  High Sodium Intake and Cardiovascular Events http://dx.doi.org/10.4070/kcj.2015.45.3.175 www.e-kcj.org criteria for the creatinine-based determination method used.,Non-OADS,/arxiv_data1/oa_pdf/65/cb/kcj-45-175.PMC4446810.pdf
"181 Moo-Yong Rhee http://dx.doi.org/10.4070/kcj.2015.45.3.175 www.e-kcj.org estimation of sodium intake.83-85) All equations showed large limits  of agreement approximately more than 100 mmol.72)75)83)85) Further - more, the equations used for calculation of the 24-hour urinary  sodium excretion from spot urine have a tendency for under- or  over-estimation of the 24-hour urinary sodium excretion accord - ing to the level of an individual’s sodium intake (Fig.",Non-OADS,/arxiv_data1/oa_pdf/65/cb/kcj-45-175.PMC4446810.pdf
182  High Sodium Intake and Cardiovascular Events http://dx.doi.org/10.4070/kcj.2015.45.3.175 www.e-kcj.org 21.,Non-OADS,/arxiv_data1/oa_pdf/65/cb/kcj-45-175.PMC4446810.pdf
183 Moo-Yong Rhee http://dx.doi.org/10.4070/kcj.2015.45.3.175 www.e-kcj.org (Lond)  1983;64:629-35.,Non-OADS,/arxiv_data1/oa_pdf/65/cb/kcj-45-175.PMC4446810.pdf
http://dx.doi:10.31 09/10641963.2014.913601.,Non-OADS,/arxiv_data1/oa_pdf/65/cb/kcj-45-175.PMC4446810.pdf
"The intact SAN is a  heterogeneous structure  that includes multiple different cell types Review Article http://dx.doi.org/10.4070/kcj.2015.45.3.184 Print ISSN 1738-5520  • On-line ISSN 1738-5555 Function and Dysfunction of Human Sinoatrial Node Boyoung Joung, MD, PhD1 and Peng-Sheng Chen, MD2  1Division of Cardiology, Department of Medicine, Yonsei University College of Medicine, Seoul, Korea   2The Krannert Institute of Cardiology and the Division of Cardiology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA Sinoatrial node (SAN) a utomaticity is jointly regulated by a voltage (cyclic activation and deactivation of membrane ion channels) and  Ca2+ clocks (rhythmic spontaneous sarcoplasmic reticulum Ca2+ release).",OADS,/arxiv_data1/oa_pdf/67/d2/kcj-45-184.PMC4446811.pdf
"http://dx.doi.org/10.4070/kcj.2015.45.3.184 www.e-kcj.org interacting with each other.4-6) The Ca2+ clock in the superior SAN is  primarily responsible for rate acceleration during sympathetic  stimulation.7-11) However, t he relative importance of the voltage  and Ca2+ clocks for pacemaking in different regions of the SAN,  and in response to neurohumeral stimuli such as β-agonists, may  be different.",Non-OADS,/arxiv_data1/oa_pdf/67/d2/kcj-45-184.PMC4446811.pdf
"186  Sinoatrial Node Dysfunction in Humans http://dx.doi.org/10.4070/kcj.2015.45.3.184 www.e-kcj.org with sick sinus syndrome.27)28) The SAN dysfunction may be revers - ible after successful catheter ablation of AF.29) In dogs, persistent  (>2 weeks) rapid atrial pacing and chronic AF resulted in SAN dys - function, as evidenced by prolongation of the SAN recovery time  and decreases in the intrinsic heart rates.30) Unresponsiveness of  the Ca2+ clock in the superior SAN to sympathetic stimulation is a  characteristic finding in dogs with AF and heart failure.31)32) Consis - tent with that found in a canine model,31) the patient with AF with  SAN dysfunction had impaired heart rate acceleration and absence  of upward shift of the EAS during isoproterenol stimulation (Fig.",Non-OADS,/arxiv_data1/oa_pdf/67/d2/kcj-45-184.PMC4446811.pdf
http://dx.doi.org/10.4070/kcj.2015.45.3.184 www.e-kcj.org patients and is associated with an increased risk of pacemaker in - sertion.38) Our study also showed that amiodarone induced SAN  dysfunction in one-fourth of patients without SAN dysfunction at  baseline.39) Amiodarone caused impaired heart rate acceleration  and impaired cranial shift of EAS after sympathetic stimulation  (Fig.,Non-OADS,/arxiv_data1/oa_pdf/67/d2/kcj-45-184.PMC4446811.pdf
188  Sinoatrial Node Dysfunction in Humans http://dx.doi.org/10.4070/kcj.2015.45.3.184 www.e-kcj.org and time consuming tests.,Non-OADS,/arxiv_data1/oa_pdf/67/d2/kcj-45-184.PMC4446811.pdf
http://dx.doi.org/10.4070/kcj.2015.45.3.184 www.e-kcj.org Conclusion The voltage and Ca2+ clocks jointly regulate SAN automaticity.,OADS,/arxiv_data1/oa_pdf/67/d2/kcj-45-184.PMC4446811.pdf
190  Sinoatrial Node Dysfunction in Humans http://dx.doi.org/10.4070/kcj.2015.45.3.184 www.e-kcj.org the heart beat.,Non-OADS,/arxiv_data1/oa_pdf/67/d2/kcj-45-184.PMC4446811.pdf
http://dx.doi.org/10.4070/kcj.2015.45.3.184 www.e-kcj.org cal characteristics of the pulmonary vein and the Sinoatrial Node.,Non-OADS,/arxiv_data1/oa_pdf/67/d2/kcj-45-184.PMC4446811.pdf
"During  these 30 years, mortality rates for total heart disease, rheumatic Editorial http://dx.doi.org/10.4070/kcj.2015.45.3.192 Print ISSN 1738-5520  • On-line ISSN 1738-5555 Mortality Trends of Cardiovascular Disease in Korea; Big Challenges in  Ischemic Heart Disease Hyun Kuk Kim, MD and Youngkeun Ahn, MD Department of Cardiology, Cardiovascular Center, Chonnam National University Hospital, Gwangju, Korea Received:  May 1, 2015 Revision Received: May 15, 2015 Accepted: May 19, 2015 Correspondence: Youngkeun Ahn, MD, Department of Cardiology,  Cardiovascular Center, Chonnam National University Hospital, 671 Jebong-ro,  Dong-gu, Gwangju 501-757, Korea  Tel: 82-62-220-4764, Fax: 82-62-224-4764  E-mail: cecilyk@hanmail.net • The authors have no financial conflicts of interest.",Non-OADS,/arxiv_data1/oa_pdf/81/6c/kcj-45-192.PMC4446812.pdf
http://dx.doi.org/10.4070/kcj.2015.45.3.192 www.e-kcj.org of in-hospital death due to IHD might be helpful in developing a  strategy to improve the prognosis and to analyze the data more  accurately.,Non-OADS,/arxiv_data1/oa_pdf/81/6c/kcj-45-192.PMC4446812.pdf
"Previous studies Original Article http://dx.doi.org/10.4070/kcj.2015.45.3.194 Print ISSN 1738-5520  • On-line ISSN 1738-5555 Usefulness of Hyperemic Microvascular Resistance Index as a  Predictor of Clinical Outcomes in Patients with ST-Segment Elevation  Myocardial Infarction XiongJie Jin, MD, Myeong-Ho Yoon, MD, Kyoung-Woo Seo, MD, Seung-Jea Tahk, MD, Hong-Seok Lim, MD,   Hyoung-Mo Yang, MD, Byoung-Joo Choi, MD, So-Yeon Choi, MD, Gyo-Seung Hwang, MD, Joon-Han Shin, MD,   and Jin-Sun Park, MD Department of Cardiology, Ajou University School of Medicine, Suwon, Korea Background and Objectives:  Microvascular function is a useful predictor of left ventricular functional changes in patients with ST-seg - ment elevation myocardial infarction (STEMI).",Non-OADS,/arxiv_data1/oa_pdf/00/80/kcj-45-194.PMC4446813.pdf
"http://dx.doi.org/10.4070/kcj.2015.45.3.194 www.e-kcj.org have shown that the IMR and hMVRI measured during optimal  hyperemia are not affected by coronary hemodynamic statuses  such as heart rate, preload, and afterload.5)8) Thus, these indices have good reproducibility compared to CFR  or another indice.11) However, the effect of hMVRI on long-term  clinical outcomes in patients with STEMI has not been evaluated.",Non-OADS,/arxiv_data1/oa_pdf/00/80/kcj-45-194.PMC4446813.pdf
"196  Hyperemic Microvascular Resistance Index in STEMI http://dx.doi.org/10.4070/kcj.2015.45.3.194 www.e-kcj.org deviation, and the discrete variables were expressed as counts and  percentages.",OADS,/arxiv_data1/oa_pdf/00/80/kcj-45-194.PMC4446813.pdf
"http://dx.doi.org/10.4070/kcj.2015.45.3.194 www.e-kcj.org (88% vs. 72%, p=0.035), had lower EF (43 ±10 vs. 51±9, p<0.001)  and higher WMSI (1.71 ±0.35 vs. 1.49 ±0.28, p=0.001) at baseline, a  decreased CFR (1.51 ±0.57 vs. 1.93 ±0.69, p=0.006) and an increased  hMVRI (4.37 ±1.54 vs. 2.65 ±1.12, p<0.001) compared to the pa - tients without MACEs (Fig.",Non-OADS,/arxiv_data1/oa_pdf/00/80/kcj-45-194.PMC4446813.pdf
"198  Hyperemic Microvascular Resistance Index in STEMI http://dx.doi.org/10.4070/kcj.2015.45.3.194 www.e-kcj.org ratio: 1.741; 95% confidence interval: 1.348-2.264, p<0.001) and EF  (hazard ratio: 0.910; 95% confidence interval: 0.862-0.961, p=0.001)  as independent risk factors for any future cardiovascular events  (Table 3).",Non-OADS,/arxiv_data1/oa_pdf/00/80/kcj-45-194.PMC4446813.pdf
http://dx.doi.org/10.4070/kcj.2015.45.3.194 www.e-kcj.org the patients with hMVRI ≤2.82 mm Hg∙cm-1∙sec.,Non-OADS,/arxiv_data1/oa_pdf/00/80/kcj-45-194.PMC4446813.pdf
"200  Hyperemic Microvascular Resistance Index in STEMI http://dx.doi.org/10.4070/kcj.2015.45.3.194 www.e-kcj.org as compared with in patients with higher hMVRI, and the micro - vascular indices were measured by an intracoronary Doppler wire  immediately after primary PCI.",Non-OADS,/arxiv_data1/oa_pdf/00/80/kcj-45-194.PMC4446813.pdf
http://dx.doi.org/10.4070/kcj.2015.45.3.194 www.e-kcj.org References   1.,Non-OADS,/arxiv_data1/oa_pdf/00/80/kcj-45-194.PMC4446813.pdf
"Thus, we examined the  changing pattern of cardiovascular disease mortality in Korea dur - ing a 30-year period using Cause of Death statistics from Statistics  Korea.4)Original Article http://dx.doi.org/10.4070/kcj.2015.45.3.202 Print ISSN 1738-5520  • On-line ISSN 1738-5555 Thirty-Year Trends in Mortality from Cardiovascular Diseases in Korea Seung Won Lee, MPH1,2, Hyeon Chang Kim, MD2,3, Hye Sun Lee, MS4, and Il Suh, MD3 1Department of Public Health, Yonsei University Graduate School, Seoul,   2Cardiovascular and Metabolic Diseases Etiology Research Center, 3Department of Preventive Medicine, 4Department of Biostatistics, Yonsei University College of  Medicine, Seoul, Korea Background and Objectives:  An understanding of cardiovascular diseases (CVD) mortality is important for the development of strate - gies aimed at reducing the burden of CVD.",Non-OADS,/arxiv_data1/oa_pdf/89/96/kcj-45-202.PMC4446814.pdf
http://dx.doi.org/10.4070/kcj.2015.45.3.202 www.e-kcj.org Materials and Methods Annual mortality data were obtained from Korean Statistical In - formation Service managed by Statistics Korea (formerly known as  Korea National Statistical Office).,OADS,/arxiv_data1/oa_pdf/89/96/kcj-45-202.PMC4446814.pdf
"204  Cardiovascular Diseases Mortality in Korea http://dx.doi.org/10.4070/kcj.2015.45.3.202 www.e-kcj.org mortality rate for men was higher than for women, but this gender  gap gradually decreased, and post-1992 the mortality rate has  been higher for women.",Non-OADS,/arxiv_data1/oa_pdf/89/96/kcj-45-202.PMC4446814.pdf
http://dx.doi.org/10.4070/kcj.2015.45.3.202 www.e-kcj.org Fig.,Non-OADS,/arxiv_data1/oa_pdf/89/96/kcj-45-202.PMC4446814.pdf
206  Cardiovascular Diseases Mortality in Korea http://dx.doi.org/10.4070/kcj.2015.45.3.202 www.e-kcj.org (2012) (Fig.,Non-OADS,/arxiv_data1/oa_pdf/89/96/kcj-45-202.PMC4446814.pdf
"http://dx.doi.org/10.4070/kcj.2015.45.3.202 www.e-kcj.org population is expected to face an increasing disease burden from  IHD, even though the IHD mortality in Korea is still lower than  those of people in Western countries.8)9)  Fortunately, age-standardized mortality from IHD showed a de - crease during the last 10 years in our study.",Non-OADS,/arxiv_data1/oa_pdf/89/96/kcj-45-202.PMC4446814.pdf
"208  Cardiovascular Diseases Mortality in Korea http://dx.doi.org/10.4070/kcj.2015.45.3.202 www.e-kcj.org deaths were classified as unknown causes, although deaths of un - known cause are decreasing.",Non-OADS,/arxiv_data1/oa_pdf/89/96/kcj-45-202.PMC4446814.pdf
Supplementary Materials The online-only Data Supplement is available with this article at  http://dx.doi.org/10.4070/kcj.2015.45.3.202.,Non-OADS,/arxiv_data1/oa_pdf/89/96/kcj-45-202.PMC4446814.pdf
Available at: http://kosis.kr.,Non-OADS,/arxiv_data1/oa_pdf/89/96/kcj-45-202.PMC4446814.pdf
http://dx.doi.org/10.4070/kcj.2015.45.3.202 www.e-kcj.org study of 14 786 middle-aged men and women in Finland.,Non-OADS,/arxiv_data1/oa_pdf/89/96/kcj-45-202.PMC4446814.pdf
"210 Copyright © 2015 The Korean Society of CardiologyKorean Circulation JournalIntroduction Subclinical hypothyroidism (SH) is defined as an elevated thyroid  stimulating hormone (TSH) level with normal free thyroxine (fT4)  and free triiodothyronine (fT3) concentrations,1) and SH occurs in 4%  to 20% of the adult population.2) Hypothyroidism is considered to Original Article http://dx.doi.org/10.4070/kcj.2015.45.3.210 Print ISSN 1738-5520  • On-line ISSN 1738-5555 The Association between Subclinical Hypothyroidism and   Epicardial Adipose Tissue Thickness Erdal Belen, MD1, Aleks De g˘irmencio g˘lu, MD2, Ertu g˘rul Zencirci, MD3, Fatih Fahri Tipi, MD1, Özgür Altun, MD1,   Gültekin Karaku s¸, MD3, Ays¸en Helvacı, MD1, Aycan Esen Zencirci, MD4, and Ezgi Kalaycıo g˘lu, MD5 1Istanbul Okmeydanı Training and Research Hospital, Istanbul,   2Acibadem University School of Medicine, Istanbul,   3Acibadem Maslak Hospital, Istanbul,   4Dr.",Non-OADS,/arxiv_data1/oa_pdf/8d/04/kcj-45-210.PMC4446815.pdf
http://dx.doi.org/10.4070/kcj.2015.45.3.210 www.e-kcj.org Subjects and Methods Patients Fifty-one patients with SH and 51 healthy age-matched euthy - roid subjects were enrolled in this study between June 2013 and  February 2014 after obtaining their written informed consent.,Non-OADS,/arxiv_data1/oa_pdf/8d/04/kcj-45-210.PMC4446815.pdf
212  Hypothyroidism and Epicardial Adiposity http://dx.doi.org/10.4070/kcj.2015.45.3.210 www.e-kcj.org Logistic regression analysis was performed in patients with SH  (Table 2).,Non-OADS,/arxiv_data1/oa_pdf/8d/04/kcj-45-210.PMC4446815.pdf
"http://dx.doi.org/10.4070/kcj.2015.45.3.210 www.e-kcj.org These risk factors are associated with insulin resistance, and this  led to the identification of the unique disease entity, which is  called MS. MS is a combination of risk factors for CVD.7) Although  multiple risk factors, such as obesity, insulin resistance, physical in - activity, advanced age, and hormonal imbalance, appear to predis - pose people to the MS,7) VAT plays a major role in the development  of MS.8) It is well accepted that hypothyroidism is associated with  CVD,4) and increasing evidence also suggests an association be - tween SH and CVD.5)16)17) One such potential mechanism for this  association is MS.",Non-OADS,/arxiv_data1/oa_pdf/8d/04/kcj-45-210.PMC4446815.pdf
"214  Hypothyroidism and Epicardial Adiposity http://dx.doi.org/10.4070/kcj.2015.45.3.210 www.e-kcj.org Although some recent studies suggested an association between  SH and EAT,28)29) there are some conflicting results.30) Our study re - vealed an independent relationship between EAT thickness and SH  in the multivariate analysis.",Non-OADS,/arxiv_data1/oa_pdf/8d/04/kcj-45-210.PMC4446815.pdf
"http://dx.doi.org/10.4070/kcj.2015.45.3.210 www.e-kcj.org stiffness: echocardiographic epicardial fat thickness reflects, better  than waist circumference, carotid arterial stiffness in a large popula - tion of hypertensives.",Non-OADS,/arxiv_data1/oa_pdf/8d/04/kcj-45-210.PMC4446815.pdf
"For ex - ample, balloon assisted (BA) method and methods using pulmo - nary vein (PV) have improved the success rates and overcame the  anatomical disadvantages, but those methods still have limitations  with varying success rates.3)4)6) To find the risk factors for the complicated conventional method  of the transcatheter device closure, we investigated the echocar - diographic parameters for the anatomy of ASD and for the size of  the left atrium (LA).Original Article http://dx.doi.org/10.4070/kcj.2015.45.3.216 Print ISSN 1738-5520  • On-line ISSN 1738-5555 Small Left Atrial Size Complicating Percutaneous Transcatheter Device  Closure of Secundum Atrial Septal Defect with Conventional Approach Hong Ki Ko, MD1, So Yeon Kang, MD2, Jeong Jin Yu, MD2, Jae-Kon, Ko, MD2, and Young-Hwue Kim, MD2 1Department of Pediatrics, Ajou University Hospital, Ajou University School of Medicine, Suwon,   2Division of Pediatric Cardiology, Department of Pediatrics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea Background and Objectives:  Transcatheter device closure becomes the first option for treating secundum atrial septal defect (ASD), but  the conventional method is sometimes unsuccessful even when the defect size indicates the closure to be feasible.",Non-OADS,/arxiv_data1/oa_pdf/c6/40/kcj-45-216.PMC4446816.pdf
"http://dx.doi.org/10.4070/kcj.2015.45.3.216 www.e-kcj.org Subjects and Methods Patient selection and collecting data This study analyzed 92 consecutive patients who had undergone  percutaneous transcatheter closure of the secundum ASD at the  congenital heart diseases center at the Asan Medical Center, Seoul,  Korea between October 2010 and December 2012.",Non-OADS,/arxiv_data1/oa_pdf/c6/40/kcj-45-216.PMC4446816.pdf
"218  Small LA Size Complicating ASD Device Closure http://dx.doi.org/10.4070/kcj.2015.45.3.216 www.e-kcj.org cava rim from a subcostal view, posterosuperior (PS) and mitral valve  rim from an apical four-chamber (A4C) view, and posteroinferior and  retroaortic (RAo) rim from a parasternal short axis view (Fig.",Non-OADS,/arxiv_data1/oa_pdf/c6/40/kcj-45-216.PMC4446816.pdf
"http://dx.doi.org/10.4070/kcj.2015.45.3.216 www.e-kcj.org closure with the Amplatzer septal occluder (AGA Medical Corpora - tion, Golden Valley, MN, USA) and device implantation was initially  tried by the conventional method that had already been extensive - ly described.3)4) Devices measuring1-2 mm larger than the defect  sizes were measured by an intraoperative TEE and were employed  in the transcatheter closure.",Non-OADS,/arxiv_data1/oa_pdf/c6/40/kcj-45-216.PMC4446816.pdf
220  Small LA Size Complicating ASD Device Closure http://dx.doi.org/10.4070/kcj.2015.45.3.216 www.e-kcj.org significantly different.,Non-OADS,/arxiv_data1/oa_pdf/c6/40/kcj-45-216.PMC4446816.pdf
"http://dx.doi.org/10.4070/kcj.2015.45.3.216 www.e-kcj.org AP diameter/device size were the most important parameter based  on the result of the logistic regression test (odds ratio 0.059, 95%  confidence interval 0.008-0.448, p=0.006).",OADS,/arxiv_data1/oa_pdf/c6/40/kcj-45-216.PMC4446816.pdf
"222  Small LA Size Complicating ASD Device Closure http://dx.doi.org/10.4070/kcj.2015.45.3.216 www.e-kcj.org complication, such as aortic erosion or thrombosis, (within the first  6 months) after the hospital discharge was observed in any of the  patients during the outpatient follow-up period.",Non-OADS,/arxiv_data1/oa_pdf/c6/40/kcj-45-216.PMC4446816.pdf
http://dx.doi.org/10.4070/kcj.2015.45.3.216 www.e-kcj.org population.,OADS,/arxiv_data1/oa_pdf/c6/40/kcj-45-216.PMC4446816.pdf
224  Small LA Size Complicating ASD Device Closure http://dx.doi.org/10.4070/kcj.2015.45.3.216 www.e-kcj.org teristics and relating factors to the need of technical modification in  transcatheter closure of large atrial septal defect (>/=25 mm).,Non-OADS,/arxiv_data1/oa_pdf/c6/40/kcj-45-216.PMC4446816.pdf
"225 Copyright © 2015 The Korean Society of CardiologyKorean Circulation JournalOriginal Article http://dx.doi.org/10.4070/kcj.2015.45.3.225 Print ISSN 1738-5520 • On-line ISSN 1738-5555 Additive Beneficial Effects of Valsartan Combined with Rosuvastatin in the Treatment of Hypercholesterolemic Hypertensive Patients Ji-Yong Jang, MD1*, Sang-Hak Lee, MD1*, Byung Soo Kim, MD2, Hong Seog Seo, MD3, Woo-Shik Kim, MD4,   Youngkeun Ahn, MD5 , Nae-Hee Lee, MD6, Kwang Kon Koh, MD7, Tae-Soo Kang, MD8, Sang-Ho Jo, MD9, Bum-Kee Hong, MD10,  Jang-Ho Bae, MD11, Hyoung-Mo Yang, MD12, Kwang Soo Cha, MD13, Bum Soo Kim, MD14, Choong Hwan Kwak, MD15,  Deok-Kyu Cho, MD16, Ung Kim, MD17, Joo-Hee Zo, MD18, Duk-Hyun Kang, MD19, Wook Bum Pyun, MD20,   Kook Jin Chun, MD21, June Namgung, MD22, Tae-Joon Cha, MD23, Jae-Hyeon Juhn24, YeiLi Jung24, and Yangsoo Jang, MD1 1Division of Cardiology and Cardiovascular Research Institute, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, 2Division of Cardiology, Department of Internal Medicine, Daedong Hospital, Busan, 3Division of Cardiology, Cardiovascular Center, Korea University Guro Hospital, Korea  University College of Medicine, Seoul, 4Division of Cardiology, Department of Internal Medicine, Kyung Hee University Medical Center, Seoul, 5Department of Cardiology,  Heart Research Center of Chonnam National University Hospital, Gwangju, 6Department of Cardiology, Soon Chun Hyang University Bucheon Hospital, Bucheon, 7Department of Cardiology, Gachon University Gil Medical Center, Incheon, 8Division of Cardiology, Dankook University College of Medicine, Cheonan, 9Division of Cardiology, Department of Internal Medicine, Hallym University Sacred Heart Hospital, Anyang, 10Division of Cardiology, Department of Internal Medicine,  Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, 11Division of Cardiology, Department of Internal Medicine, Konyang University Hospital,  Daejeon, 12Department of Cardiology, Ajou University Medical Center, Suwon, 13Division of Cardiology, Pusan National University Hospital, Busan, 14Division of Cardiology,  Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, 15Division of Cardiology, Department of Internal  Medicine, Gyeongsang National University Hospital and Gyeongsang National University School of Medicine, Jinju, 16Department of Cardiology, Myongji Hospital  Cardiovascular Center, Goyang, 17Division of Cardiology, Department of Internal Medicine, Yeungnam University Hospital, Daegu, 18Division of Cardiology, Department of  Internal Medicine, SMG-SNU Boramae Medical Center, Seoul National University College of Medicine, Seoul, 19Division of Cardiology, Asan Medical Center, University of  Ulsan College of Medicine, Seoul,  20Division of Cardiology, Department of Internal Medicine, Ewha Womans University Mokdong Hospital, Seoul,  21Department of  Cardiology, Pusan National University Yangsan Hospital, Yangsan,  22Division of Cardiology, Department of Internal Medicine, Inje University Ilsan Paik Hospital, Goyang,   23Division of Cardiology, Department of Internal Medicine, Kosin University Gospel Hospital, Busan,  24Clinical Development Department, LG Life Sciences Ltd., Seoul, Korea Background and Objectives:  We compared the efficacy and safety of valsartan and rosuvastatin combination therapy with each treat - ment alone in hypercholesterolemic hypertensive patients.",Non-OADS,/arxiv_data1/oa_pdf/c8/a3/kcj-45-225.PMC4446817.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/  by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/c8/a3/kcj-45-225.PMC4446817.pdf
226  Synergistic Effects of Valsartan and Rosuvastatin http://dx.doi.org/10.4070/kcj.2015.45.3.225 www.e-kcj.org Introduction Hypertension and hyperlipidemia are well known cardiovascular  risk factors that commonly coexist in a single patient.1) Patients  with multiple risk factors have higher cardiovascular risk than pa - tients with single factor.2) Thus it is critical to comprehensively  control multiple factors for reducing future cardiovascular events.,Non-OADS,/arxiv_data1/oa_pdf/c8/a3/kcj-45-225.PMC4446817.pdf
http://dx.doi.org/10.4070/kcj.2015.45.3.225 www.e-kcj.org period to maintain double blindness.,Non-OADS,/arxiv_data1/oa_pdf/c8/a3/kcj-45-225.PMC4446817.pdf
"228  Synergistic Effects of Valsartan and Rosuvastatin http://dx.doi.org/10.4070/kcj.2015.45.3.225 www.e-kcj.org subjects, 101 completed the study: 35 in the combination group,  36 in the valsartan group, and 30 in the rosuvastatin group.",Non-OADS,/arxiv_data1/oa_pdf/c8/a3/kcj-45-225.PMC4446817.pdf
http://dx.doi.org/10.4070/kcj.2015.45.3.225 www.e-kcj.org 4 and 8 were presented in Fig.,OADS,/arxiv_data1/oa_pdf/c8/a3/kcj-45-225.PMC4446817.pdf
"230  Synergistic Effects of Valsartan and Rosuvastatin http://dx.doi.org/10.4070/kcj.2015.45.3.225 www.e-kcj.org diet, cholestyramine, gemfibrozil, or simvastatin.",Non-OADS,/arxiv_data1/oa_pdf/c8/a3/kcj-45-225.PMC4446817.pdf
http://dx.doi.org/10.4070/kcj.2015.45.3.225 www.e-kcj.org The mechanism by which statins affect blood pressure is not  clearly understood.,Non-OADS,/arxiv_data1/oa_pdf/c8/a3/kcj-45-225.PMC4446817.pdf
232  Synergistic Effects of Valsartan and Rosuvastatin http://dx.doi.org/10.4070/kcj.2015.45.3.225 www.e-kcj.org this study had a relatively small sample size and was conducted  over a short period of time.,Non-OADS,/arxiv_data1/oa_pdf/c8/a3/kcj-45-225.PMC4446817.pdf
Supplementary Materials The online-only Data Supplement is available with this article at  http://dx.doi.org/10.4070/kcj.2015.45.3.225.,Non-OADS,/arxiv_data1/oa_pdf/c8/a3/kcj-45-225.PMC4446817.pdf
http://dx.doi.org/10.4070/kcj.2015.45.3.225 www.e-kcj.org 18.,Non-OADS,/arxiv_data1/oa_pdf/c8/a3/kcj-45-225.PMC4446817.pdf
"This solution is a simple, low-cost, and widely  practical therapy and has demonstrated favorable effects for rapid  and complete resolution of ST segment shifts, fewer arrhythmias,  smaller infarct sizes, and reduced circulating free fatty acids.6-8) A  GIK solution may reduce mortality through several mechanisms.6)  High-dose glucose improves myocardial energy production effi - ciency during acute ischemia by becoming the preferred fuel for  the heart.6,9) Because intracellular potassium levels are depleted Original Article http://dx.doi.org/10.4070/kcj.2015.45.3.234 Print ISSN 1738-5520  • On-line ISSN 1738-5555 Glucose-Insulin-Potassium Solution Protects Ventricular Myocytes   of Neonatal Rat in an In Vitro  Coverslip Ischemia/Reperfusion Model Woo-Jung Chun, MD1, Deuk-Young Nah, MD2, Jun-Ho Bae, MD2, Jin-Wook Chung, MD2, HyunSook Lee, PhD3, and  Il Soo Moon, PhD3 1Division of Cardiology, Department of Internal Medicine, Samsung Changwon Hospital, Sungkyunkwan University, College of Medicine, Changwon,   2Division of Cardiology, Department of Internal Medicine, 3Department of Anatomy, Dongguk Medical Institute, College of Medicine, Dongguk University, Gyeongju, Korea Background and Objectives:  The benefit of high glucose-insulin-potassium (GIK) solution in clinical applications is controversial.",Non-OADS,/arxiv_data1/oa_pdf/bd/0a/kcj-45-234.PMC4446818.pdf
"http://dx.doi.org/10.4070/kcj.2015.45.3.234 www.e-kcj.org during ischemia, providing exogenous potassium increases its con - centration within myocytes, thereby raising the threshold for ven - tricular arrhythmia.8)10) Exogenous insulin suppresses circulating  levels and myocardial uptake of free fatty acids, which are toxic to  ischemic myocardium.7-11) Evidence indicates that insulin reduces  ischemic damage by suppressing reactive oxygen species (ROS)  and consequent increased lipid peroxidation during myocardial  ischemia/reperfusion (I/R) injury.12) The effects of the GIK solution  in clinical applications remain controversial.",Non-OADS,/arxiv_data1/oa_pdf/bd/0a/kcj-45-234.PMC4446818.pdf
236  GIK Protects NRVM  In Vitro http://dx.doi.org/10.4070/kcj.2015.45.3.234 www.e-kcj.org Annexin V (AV) (Invitrogen) and 100 µg/mL propidium iodide (PI;  Sigma) for 15 min at room temperature.,Non-OADS,/arxiv_data1/oa_pdf/bd/0a/kcj-45-234.PMC4446818.pdf
http://dx.doi.org/10.4070/kcj.2015.45.3.234 www.e-kcj.org and expressed as % of total (mean±standard deviation).,OADS,/arxiv_data1/oa_pdf/bd/0a/kcj-45-234.PMC4446818.pdf
238  GIK Protects NRVM  In Vitro http://dx.doi.org/10.4070/kcj.2015.45.3.234 www.e-kcj.org staining.,Non-OADS,/arxiv_data1/oa_pdf/bd/0a/kcj-45-234.PMC4446818.pdf
http://dx.doi.org/10.4070/kcj.2015.45.3.234 www.e-kcj.org medium with the same glucose (1.0 or 2.0 g/L) concentrations {Fig.,Non-OADS,/arxiv_data1/oa_pdf/bd/0a/kcj-45-234.PMC4446818.pdf
240  GIK Protects NRVM  In Vitro http://dx.doi.org/10.4070/kcj.2015.45.3.234 www.e-kcj.org significantly upregulated O-GlcNAc (Fig.,Non-OADS,/arxiv_data1/oa_pdf/bd/0a/kcj-45-234.PMC4446818.pdf
http://dx.doi.org/10.4070/kcj.2015.45.3.234 www.e-kcj.org References   1.,Non-OADS,/arxiv_data1/oa_pdf/bd/0a/kcj-45-234.PMC4446818.pdf
"Because Case Report http://dx.doi.org/10.4070/kcj.2015.45.3.242 Print ISSN 1738-5520  • On-line ISSN 1738-5555 The Relationship between Spontaneous Multi-Vessel Coronary   Artery Dissection and Celiac Disease Nermin Bayar, MD, Göksel C¸ag˘ırcı, MD, C¸ag˘ın Mustafa Üreyen, MD, Görkem Ku s¸, MD,   Selc¸uk Kü c¸ükseymen, MD, and S¸akir Arslan, MD Department of Cardiology, Antalya Education and Research Hospital, Antalya, Turkey Celiac disease (CD) is an immune-mediated enteropathy involving the small intestines.",Non-OADS,/arxiv_data1/oa_pdf/7c/d5/kcj-45-242.PMC4446819.pdf
"http://dx.doi.org/10.4070/kcj.2015.45.3.242 www.e-kcj.org the diffuse dissections involved many vessels, coronary artery by - pass grafting (CABG) was selected as the best treatment.",Non-OADS,/arxiv_data1/oa_pdf/7c/d5/kcj-45-242.PMC4446819.pdf
244  Celiac Disease and Coronary Artery Dissection http://dx.doi.org/10.4070/kcj.2015.45.3.242 www.e-kcj.org De Marchi et al.13) showed a relationship with increased carotid in - tima-media thickness (CIMT) and decreased flow-mediated dilata - tion (FMD) in addition to elevated CRP and homocysteine levels in  recently diagnosed young CD patients.,OADS,/arxiv_data1/oa_pdf/7c/d5/kcj-45-242.PMC4446819.pdf
"CAAs are uncommon lesions, noted in 0.2% to 4.9% of patients  undergoing coronary angiography.3)4) “Giant” CAAs, which are Case Report http://dx.doi.org/10.4070/kcj.2015.45.3.245 Print ISSN 1738-5520  • On-line ISSN 1738-5555 Coronary Artery Fistula with Giant Aneurysm and Coronary Stenosis  Treated by Transcatheter Embolization and Stent Zhe Hao Piao, MD, Myung Ho Jeong, MD, Hae Chang Jeong, MD, Keun Ho Park, MD,   Doo Sun Sim, MD, Young Joon Hong, MD, Ju Han Kim, MD, and Youngkeun Ahn, MD Department of Cardiovascular Medicine, Cardiovascular Center, Chonnam National University Hospital, Gwangju, Korea   Coronary artery fistula (CAF) with giant aneurysm and accompanied by coronary artery stenosis is a very rare disease.",Non-OADS,/arxiv_data1/oa_pdf/2a/b1/kcj-45-245.PMC4446820.pdf
"246  Coronary Aneurysm Treated by Percutaneous Intervention http://dx.doi.org/10.4070/kcj.2015.45.3.245 www.e-kcj.org Therefore, she was diagnosed with a non-ST-segment elevation  myocardial infarction and an early coronary angiogram was per - formed.",Non-OADS,/arxiv_data1/oa_pdf/2a/b1/kcj-45-245.PMC4446820.pdf
http://dx.doi.org/10.4070/kcj.2015.45.3.245 www.e-kcj.org Discussion Coronary artery fistula is accompanied with CAA in approximately  20% of patients.7)8) The mechanism by which an aneurysm forms in  the CAF is unclear.,Non-OADS,/arxiv_data1/oa_pdf/2a/b1/kcj-45-245.PMC4446820.pdf
"When AMI occurs  in the large coronary artery without stenosis, reperfusion therapy Case Report http://dx.doi.org/10.4070/kcj.2015.45.3.248 Print ISSN 1738-5520  • On-line ISSN 1738-5555 Mechanical Extraction of a Massive Intracoronary Thrombus   from the Super-Dominant Right Coronary Artery in Thrombogenic   Lung Cancer Patient Dong-Kie Kim, MD1, Sung-Hyun Ko, MD1, Guang-Won Seo, MD1, Pil-Sang Song, MD1, Ki-Hun Kim, MD1,   Sang-Hoon Seol, MD1, Jong-Woon Song, MD2, and Doo-Il Kim, MD1 1Division of Cardiology and 2 Department of Radiology, Inje University Haeundae Paik Hospital, Inje University College of Medicine, Busan, Korea The congenital absence of the left circumflex artery and a compensatory super-dominant right coronary artery (RCA) is a very rare benign  coronary anomaly in the clinic.",Non-OADS,/arxiv_data1/oa_pdf/c3/14/kcj-45-248.PMC4446821.pdf
"http://dx.doi.org/10.4070/kcj.2015.45.3.248 www.e-kcj.org The patient received 300 mg oral aspirin and 600 mg clopidogrel  in addition to intravenous unfractionated heparin (bolus 5000 IU,  infusion 80 IU/hr).",Non-OADS,/arxiv_data1/oa_pdf/c3/14/kcj-45-248.PMC4446821.pdf
"250  Massive Intracoronary Thrombosuction Using a Guiding Catheter http://dx.doi.org/10.4070/kcj.2015.45.3.248 www.e-kcj.org catheter (Heartrail, Terumo, Tokyo, Japan) and a coronary thrombo - suction device.",Non-OADS,/arxiv_data1/oa_pdf/c3/14/kcj-45-248.PMC4446821.pdf
http://dx.doi.org/10.4070/kcj.2015.45.3.248 www.e-kcj.org usually considered benign.,Non-OADS,/arxiv_data1/oa_pdf/c3/14/kcj-45-248.PMC4446821.pdf
252  Massive Intracoronary Thrombosuction Using a Guiding Catheter http://dx.doi.org/10.4070/kcj.2015.45.3.248 www.e-kcj.org tector-row CT. Eur Radiol  2004;14:2163-71.,Non-OADS,/arxiv_data1/oa_pdf/c3/14/kcj-45-248.PMC4446821.pdf
"They were successfully ablated at the left posterior in - teratrial septum at the time of targeting 2 preceding beats of APCs Case Report http://dx.doi.org/10.4070/kcj.2015.45.3.253 Print ISSN 1738-5520  • On-line ISSN 1738-5555 Swallowing-Induced Atrial Tachyarrhythmias Successfully Ablated   at the Left Posterior Interatrial Septum in Patient with   Wolff-Parkinson-White Syndrome Ji-Eun Ban, MD, Sang-Weon Park, MD, Hyun-Soo Lee, MPH, Jong-Il Choi, MD, and Young-Hoon Kim, MD Division of Cardiology, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea We reported a case of a 55-year-old patient who presented with palpitation after swallowing.",Non-OADS,/arxiv_data1/oa_pdf/77/44/kcj-45-253.PMC4446822.pdf
"254  Swallowing-Induced Atrial Tachyarrhythmias http://dx.doi.org/10.4070/kcj.2015.45.3.253 www.e-kcj.org catheter (St. Jude Medical, St. Paul, MN, USA) was placed in the  coronary sinus (CS) via the right femoral vein, and 2 quadripolar  catheters were placed in the His bundle region and right ventricu - lar apex via the left femoral vein.",Non-OADS,/arxiv_data1/oa_pdf/77/44/kcj-45-253.PMC4446822.pdf
http://dx.doi.org/10.4070/kcj.2015.45.3.253 www.e-kcj.org Discussion Swallowing-induced tachyarrhythmia is rare and the prevalence  is reported as 0.6% among patients who underwent RFCA for atrial  arrhythmias.1) APCs and/or AT are the most common presenting ar - rhythmias.,Non-OADS,/arxiv_data1/oa_pdf/77/44/kcj-45-253.PMC4446822.pdf
256  Swallowing-Induced Atrial Tachyarrhythmias http://dx.doi.org/10.4070/kcj.2015.45.3.253 www.e-kcj.org Fig.,Non-OADS,/arxiv_data1/oa_pdf/77/44/kcj-45-253.PMC4446822.pdf
"http://dx.doi.org/10.4070/kcj.2015.45.3.253 www.e-kcj.org swallowing-induced multifocal AT originating from the right PV,  which was abolished by extensive isolation of ipsilateral right-sided  PVs.9) There are only a few case reports regarding ablation therapy in  this situation.1)8-11) We performed mapping of atrial arrhythmia dur - ing swallowing or drinking water, in the present case.",Non-OADS,/arxiv_data1/oa_pdf/77/44/kcj-45-253.PMC4446822.pdf
258  Swallowing-Induced Atrial Tachyarrhythmias http://dx.doi.org/10.4070/kcj.2015.45.3.253 www.e-kcj.org dia: report of two cases.,Non-OADS,/arxiv_data1/oa_pdf/77/44/kcj-45-253.PMC4446822.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/0c/3f/rmhp-8-091.PMC4446901.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pRisk Management and Healthcare Policy 2015:8 91–97Risk Management and Healthcare Policy Dove press submit your manuscript | www.dovepress.co m Dove press  91ORiginal ReseaRcHopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/RMHP .S7175 0The impact of age and severity of comorbid  illness on outcomes after isolated aortic valve  replacement for aortic stenosis Mark J Russo1,2 alexander iribarne3 emily chen2 ashwin Karanam2 chris Pettit2 Fabio Barili4 atman P shah5 craig R saunders1,2 1Barnabas Health Hospital, newark/ livingston, nJ, Usa; 2Barnabas Health  cardiovascular clinical Research  center, newark, nJ, Usa; 3Duke  University, Durham, nc, Usa;   4Department of cardiovascular  surgery, s croce Hospital, cuneo,   italy; 5University of chicago, chicago,   il, Usa correspondence: Mark J Russo   newark Beth israel Medical center,  Barnabas Health Heart Hospitals,   201 lyons avenue, suite g5, newark,   nJ 07112, Usa   Tel +1 973 926 6938   Fax +1 973 322 2411   email mr2143@gmail.co mObjectives:  This study examines outcomes in a national sample of patients undergoing iso - lated aortic valve replacement (A VR) for aortic stenosis, with particular focus on advanced-age  patients and those with extreme severity of comorbid illness (SOI).",Non-OADS,/arxiv_data1/oa_pdf/0c/3f/rmhp-8-091.PMC4446901.pdf
Available  at: https://www.hcup-us.ahrq.gov/db/nation/nis/APR- DRGsV20Metho dologyOverviewandBibliography .pdf.,Non-OADS,/arxiv_data1/oa_pdf/0c/3f/rmhp-8-091.PMC4446901.pdf
"Risk Management and Healthcare Policy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/risk-management-and-healthcare-policy-journa lRisk Management and Healthcare Policy is an international, peer- reviewed, open access journal focusing on all aspects of public health,  policy, and preventative measures to promote good health and improve  morbidity and mortality in the population.",Non-OADS,/arxiv_data1/oa_pdf/0c/3f/rmhp-8-091.PMC4446901.pdf
Visit http://www.dovepress.com/   testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/0c/3f/rmhp-8-091.PMC4446901.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/0d/b4/ppa-9-685.PMC4446999.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pPatient Preference and Adherence 2015:9 685–693Patient Preference and Adherence Dove press submit your manuscript | www.dovepress.co m Dove press  685Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/PPA.S5735 4Patient experience and practice trends in multiple  sclerosis – clinical utility of fingolimod Correspondence: May H Han Department of Neurology and  Neurological Sciences, Stanford  University School of Medicine, Stanford  University, 1201 Welch Road, Stanford,  CA 94305, USA email mayhan@stanford.ed uJong-Mi Lee1 May H Han1,2 1Stanford Healthcare, Multiple  Sclerosis Center, 2Department  of Neurology and Neurological  Sciences, Stanford University School  of Medicine, Stanford University,   Stanford, CA, USAAbstract:  Targeting sphingosine-1-phosphate pathway with orally available immune-modulatory  fingolimod (Gilenya™) therapy ameliorates relapsing–remitting multiple sclerosis (RRMS) by  decreasing relapse rate as shown in FREEDOMS and TRANSFORMS.",Non-OADS,/arxiv_data1/oa_pdf/0d/b4/ppa-9-685.PMC4446999.pdf
"Keywords:  sphingosine-1-phosphate, RRMS, FREEDOMS, TRANSFORMS, side effects,  IFNβ Introduction Fingolimod (Gilenya™) is the first US Food and Drug Administration (FDA)- approved oral therapy for treatment of multiple sclerosis (MS) based on two Phase  III pivotal trials, FREEDOMS and TRANSFORMS.1–4 Fingolimod targets the  sphingosine-1-phosphate (S1P) pathway by regulation of lymphocyte trafficking from  secondary lymphoid organs into the systemic circulation (Table 1).5–8 Interaction  of the sphingolipid ligand, S1P, in the blood or lymph with the G protein-coupled  receptor S1P receptor 1 (S1PR1) on lymphocytes is necessary for lymphocyte egress  from lymph nodes into blood and lymph.9–11 The critical role played by S1P–S1PR1  interaction in immune trafficking is perturbed by fingolimod, a functional antagonist  of S1PR.12,13 Fingolimod sequesters lymphocytes in the spleen and lymph nodes by  inducing receptor internalization and degradation, causing lymphopenia and sparing  the central nervous system from immune attack by myelin-reactive lymphocytes.11  Fingolimod has been shown to effectively decrease relapse rate up to 50% and is  superior to interferon-beta (IFN β) therapy.14–17 However, since fingolimod signals  via most of the S1PRs (S1PR1 and 3–5), untoward effects in systems express - ing these receptors, including cardiovascular and visual systems (such as cardiac  rhythm abnormalities and macular edema), have been observed in patients treated  with fingolimod.18–21 Furthermore, due to fingolimod’s action on lymphopenia, side  effects related to serious infections and cancer risk, possibly by interfering immune  surveillance function of lymphocytes, are also observed.18 In the post-market experi - ence, rebound disease activity (most likely due to reversing fingolimod’s effect on  lymphocyte egress) is observed upon discontinuation of the therapy.22–25 Thus, care - ful patient selection with rigorous and frequent monitoring and pre-consideration  of optimal treatment sequencing are required for patients undergoing fingolimod Journal name: Patient Preference and Adherence Article Designation: Review Y ear: 2015 Volume: 9 Running head verso: Lee and Han Running head recto: Clinical utility of fingolimod DOI: http://dx.doi.org/10.2147/PPA.S57354",Non-OADS,/arxiv_data1/oa_pdf/0d/b4/ppa-9-685.PMC4446999.pdf
"Available from: http://www.pharma.us.novartis.com/product/pi/pdf/ gilenya.pd f. Accessed December 8, 2014.",Non-OADS,/arxiv_data1/oa_pdf/0d/b4/ppa-9-685.PMC4446999.pdf
Available from: http://www.ema.europa.,Non-OADS,/arxiv_data1/oa_pdf/0d/b4/ppa-9-685.PMC4446999.pdf
"Available from: http://www.fda.gov/Drugs/DrugSafety/ ucm303192.ht m. Accessed December 8, 2014.",Non-OADS,/arxiv_data1/oa_pdf/0d/b4/ppa-9-685.PMC4446999.pdf
"Available from: http://www.fda.gov/ Drugs/DrugSafety/ucm284240.ht m. Accessed December 8, 2014.",Non-OADS,/arxiv_data1/oa_pdf/0d/b4/ppa-9-685.PMC4446999.pdf
Available from: http://www.fda.gov/Drugs/DrugSafety/ucm366529.,Non-OADS,/arxiv_data1/oa_pdf/0d/b4/ppa-9-685.PMC4446999.pdf
"Patient Preference and Adherence Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/patient-preference-and-adherence-journa lPatient Preference and Adherence is an international, peer-reviewed,  open access journal that focuses on the growing importance of patient   preference  and adherence throughout the therapeutic continuum.",Non-OADS,/arxiv_data1/oa_pdf/0d/b4/ppa-9-685.PMC4446999.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/94/ed/prom-6-145.PMC4447000.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pPatient Related Outcome Measures 2015:6 145–155Patient Related Outcome Measures Dove press submit your manuscript | www.dovepress.co m Dove press  145ORiginal ReseaRchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/PROM.S8212 1Development of the Oxford Participation and  activities Questionnaire: constructing an item  pool laura Kelly crispin Jenkinson sarah Dummett Jill Dawson Ray Fitzpatrick David Morley health services Research Unit,   nuffield Department of Population  health, University of Oxford,    Oxford, UK correspondence: laura Kelly   Health Services Research Unit, Nuffield  Department of Population health,  University of Oxford, new Richards  Building, Old Road campus, headington,   Oxford OX3 7lF, UK   Tel +44 1865 289 425   email laura.kelly@dph.ox.ac.u kPurpose:  The Oxford Participation and Activities Questionnaire is a patient-reported outcome  measure in development that is grounded on the World Health Organization International Clas - sification of Functioning, Disability, and Health (ICF).",Non-OADS,/arxiv_data1/oa_pdf/94/ed/prom-6-145.PMC4447000.pdf
Further details of the  development process can be found at http://www.dph.ox.ac.,Non-OADS,/arxiv_data1/oa_pdf/94/ed/prom-6-145.PMC4447000.pdf
"Patient Related Outcome Measures Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/patient-related-outcome-measures-journa lPatient Related Outcome Measures is an international, peer-reviewed,  open access journal focusing on treatment outcomes specifically  relevant to patients.",Non-OADS,/arxiv_data1/oa_pdf/94/ed/prom-6-145.PMC4447000.pdf
Visit http://www.dovepress.,Non-OADS,/arxiv_data1/oa_pdf/94/ed/prom-6-145.PMC4447000.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/51/3f/prom-6-139.PMC4447001.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pPatient Related Outcome Measures 2015:6 139–144Patient Related Outcome Measures Dove press submit your manuscript | www.dovepress.co m Dove press  139ORIGINAL RESEARCHopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/PROM.S8147 3User preference for a por table syringe pump   for iloprost infusion Antonella Laria1 Alfredo Maria Lurati1 Katia Angela Re1 Maria Grazia Marrazza1 Daniela Mazzocchi1 Alberto Farina2 Magda Scarpellini1 1Department of Rheumatology,   Fornaroli Hospital, Magenta, Milan,   Italy; 2Medical Affairs Department,   Italfarmaco S.p.A., Cinisello Balsamo,   Milan, Italy Correspondence: Alfredo Maria Lurati   Department of Rheumatology, Fornaroli  Hospital, Via Al Donatore di Sangue,   50 – 20013, Magenta, Milan, Italy   Email alfredomaria.lurati@ao-legnano.i tPurpose:  Administration of intravenous iloprost – a first-line European League Against Rheu - matism (EULAR)-recommended choice for the treatment of scleroderma (SSc)-related digital  vasculopathy – requires repeated treatment cycles of 6  hours per day in a hospital setting.",Non-OADS,/arxiv_data1/oa_pdf/51/3f/prom-6-139.PMC4447001.pdf
"Patient Related Outcome Measures Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/patient-related-outcome-measures-journa lPatient Related Outcome Measures is an international, peer-reviewed,  open access journal focusing on treatment outcomes specifically  relevant to patients.",Non-OADS,/arxiv_data1/oa_pdf/51/3f/prom-6-139.PMC4447001.pdf
Visit http://www.dovepress.,Non-OADS,/arxiv_data1/oa_pdf/51/3f/prom-6-139.PMC4447001.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/25/5c/ijn-10-3641.PMC4447003.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pInternational Journal of Nanomedicine 2015:10 3641–3649International Journal of Nanomedicine Dove press submit your manuscript | www.dovepress.co m Dove press  3641OrIg INal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/IJN.S8030 2external beam radiotherapy synergizes   188re-liposome against human esophageal  cancer xenograft and modulates 188re-liposome  pharmacokinetics correspondence: Yu-Jen chen Department of radiation Oncology,  MacKay Memorial hospital, No 92,  section 2, Zhongshan North road,  Zhongshan District, Taipei 10449, Taiwan email chenmdphd@gmail.co m chih-hsien chang1,2 shin-Yi liu3 chih-Wen chi3 hsiang-lin Yu1 Tsui-Jung chang1 T ung-hu Tsai4 T e-Wei lee1 Yu-Jen chen3–5 1Isotope application Division, Institute  of Nuclear energy research, Taoyuan,   Taiwan; 2Department of Biomedical  Imaging and radiological sciences,   National Yang-Ming University,   3Department of Medical research  MacKay Memorial hospital, 4Institute  of Traditional Medicine, National  Yang-Ming University, 5Department of  radiation Oncology, MacKay Memorial  hospital, Taipei, TaiwanAbstract:  External beam radiotherapy (EBRT) treats gross tumors and local microscopic  diseases.",Non-OADS,/arxiv_data1/oa_pdf/25/5c/ijn-10-3641.PMC4447003.pdf
EBRT can deliver high-energy radiation beams to cover both Journal name: International Journal of Nanomedicine Article Designation: Original Research Y ear: 2015 Volume: 10 Running head verso: Chang et al Running head recto: Combination of EBRT and 188Re-liposome against esophageal cancer DOI: http://dx.doi.org/10.2147/IJN.S80302,OADS,/arxiv_data1/oa_pdf/25/5c/ijn-10-3641.PMC4447003.pdf
"International Journal of Nanomedicine Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-nanomedicine-journa lThe International Journal of Nanomedicine is an international, peer- reviewed journal focusing on the application of nanotechnology   in diagnostics, therapeutics, and drug delivery systems throughout   the biomedical field.",Non-OADS,/arxiv_data1/oa_pdf/25/5c/ijn-10-3641.PMC4447003.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/25/5c/ijn-10-3641.PMC4447003.pdf
"Non-native invasive species andnovel ecosystems Daniel Simberloff Address: Department ofEcology andEvolutionary Biology, University ofTennessee, Knoxville, TN37996, USA Email: dsimberloff@utk.edu F1000Prime Reports 2015, 7:47(doi:10.12703/P7-47) AllF1000Prime Reports articles aredistributed under theterms oftheCreative Commons Attribution-Non Commercial License (http://creativecommons.org/licenses/by-nc/3.0/legalcode), which permits non-commercial use, distribution, andreproduction inanymedium, provided theoriginal work isproperly cited.",Non-OADS,/arxiv_data1/oa_pdf/fd/4c/biolrep-07-47.PMC4447029.pdf
The electronic version ofthisarticle isthecomplete one andcanbefound at:http://f1000.com/prime/reports/b/7/47 Abstract Invasions bynon-native species have caused many extinctions andgreatly modified many ecosystems and areamong themajor anthropogenic global changes transforming theearth.,Non-OADS,/arxiv_data1/oa_pdf/fd/4c/biolrep-07-47.PMC4447029.pdf
"Criticism 3 is an assertion, generally leveled as part of a social Page 2 of 7 (page number not for citation purposes)F1000Prime Reports 2015, 7:47 http://f1000.com/prime/reports/b/7/47",Non-OADS,/arxiv_data1/oa_pdf/fd/4c/biolrep-07-47.PMC4447029.pdf
"For instance, sterile males have beenused in many maintenance management and even eradication programs for insects, especially flies [57,58], Page 3 of 7 (page number not for citation purposes)F1000Prime Reports 2015, 7:47 http://f1000.com/prime/reports/b/7/47",Non-OADS,/arxiv_data1/oa_pdf/fd/4c/biolrep-07-47.PMC4447029.pdf
"Page 4 of 7 (page number not for citation purposes)F1000Prime Reports 2015, 7:47 http://f1000.com/prime/reports/b/7/47",Non-OADS,/arxiv_data1/oa_pdf/fd/4c/biolrep-07-47.PMC4447029.pdf
"Page 5of7 (page number notforcitation purposes)F1000Prime Reports 2015, 7:47 http://f1000.com/prime/reports/b/7/47",Non-OADS,/arxiv_data1/oa_pdf/fd/4c/biolrep-07-47.PMC4447029.pdf
"[http://e360.yale.edu/feature/ true_nature_revising_ideas_on_what_is_pristine_and_wild/2649/] Page 6of7 (page number notforcitation purposes)F1000Prime Reports 2015, 7:47 http://f1000.com/prime/reports/b/7/47",Non-OADS,/arxiv_data1/oa_pdf/fd/4c/biolrep-07-47.PMC4447029.pdf
[http://e360.yale.edu/feature/ on_a_remote_island_lessons__in_how_ecosystems_function/2683/] 76.,Non-OADS,/arxiv_data1/oa_pdf/fd/4c/biolrep-07-47.PMC4447029.pdf
"Page 7of7 (page number notforcitation purposes)F1000Prime Reports 2015, 7:47 http://f1000.com/prime/reports/b/7/47",Non-OADS,/arxiv_data1/oa_pdf/fd/4c/biolrep-07-47.PMC4447029.pdf
"From Darwin ’sOrigin ofSpecies toward atheory ofnatural history Ferdinando Boero Addresses: DiSTeBA, University ofSalento, 73100 Lecce (LE), Italy; CNR-ISMAR, viaDeMarini 6,16149 Genova (GE), Italy Email: boero@unisalento.it F1000Prime Reports 2015, 7:49(doi:10.12703/P7-49) AllF1000Prime Reports articles aredistributed under theterms oftheCreative Commons Attribution-Non Commercial License (http://creativecommons.org/licenses/by-nc/3.0/legalcode), which permits non-commercial use, distribution, andreproduction inanymedium, provided theoriginal work isproperly cited.",Non-OADS,/arxiv_data1/oa_pdf/85/93/biolrep-07-49.PMC4447030.pdf
"The electronic version ofthisarticle isthecomplete oneandcanbefound at:http://f1000.com/prime/reports/b/7/49 Abstract Darwin isthefather ofevolutionary theory because heidentified evolutionary patterns and, with Natural Selection, heascertained theexquisitely ecological ultimate processes thatlead toevolution.",Non-OADS,/arxiv_data1/oa_pdf/85/93/biolrep-07-49.PMC4447030.pdf
"Paginations vary in different files of the same text; hence, the exact pages of the original printed version(s) are not reported: the readers can find the citationssimply by searching any electronic version of the firstedition of the Origin , such as http://www.gutenberg.org/ files/1228/1228-h/1228-h.htm.",Non-OADS,/arxiv_data1/oa_pdf/85/93/biolrep-07-49.PMC4447030.pdf
"Thus, at thebeginning of the last century, biology became reductio-nistic, started to divorce from natural history, and budded off many branches (from genetics and embryology to Page 2 of 13 (page number not for citation purposes)F1000Prime Reports 2015, 7:49 http://f1000.com/prime/reports/b/7/49",Non-OADS,/arxiv_data1/oa_pdf/85/93/biolrep-07-49.PMC4447030.pdf
"Page 3 of 13 (page number not for citation purposes)F1000Prime Reports 2015, 7:49 http://f1000.com/prime/reports/b/7/49",Non-OADS,/arxiv_data1/oa_pdf/85/93/biolrep-07-49.PMC4447030.pdf
"Everything started withfisheries, when the zoologist Umberto D ‘Ancona gave his data to the mathematician Vito Volterra, who elaborated Page 4 of 13 (page number not for citation purposes)F1000Prime Reports 2015, 7:49 http://f1000.com/prime/reports/b/7/49",Non-OADS,/arxiv_data1/oa_pdf/85/93/biolrep-07-49.PMC4447030.pdf
"Chaos theory provides a Page 5 of 13 (page number not for citation purposes)F1000Prime Reports 2015, 7:49 http://f1000.com/prime/reports/b/7/49",Non-OADS,/arxiv_data1/oa_pdf/85/93/biolrep-07-49.PMC4447030.pdf
"Page 6 of 13 (page number not for citation purposes)F1000Prime Reports 2015, 7:49 http://f1000.com/prime/reports/b/7/49",Non-OADS,/arxiv_data1/oa_pdf/85/93/biolrep-07-49.PMC4447030.pdf
"Page 7 of 13 (page number not for citation purposes)F1000Prime Reports 2015, 7:49 http://f1000.com/prime/reports/b/7/49",Non-OADS,/arxiv_data1/oa_pdf/85/93/biolrep-07-49.PMC4447030.pdf
"Darwin even makes predictions about possible outcomes of intricate species interactions: “Perhaps Paraguay offers the most curious instance of this; for here neither cattle nor horses nor dogs have ever run wild,though they swarm southward and northward in a feral state;and Azara and Rengger have shown that this is caused by the greater number in Paraguay of a certain fly, which lays its eggs Page 8 of 13 (page number not for citation purposes)F1000Prime Reports 2015, 7:49 http://f1000.com/prime/reports/b/7/49",Non-OADS,/arxiv_data1/oa_pdf/85/93/biolrep-07-49.PMC4447030.pdf
"Theresources areinonebigcompartment, butthewayto usethem differs inthevarious species and allows for Page 9of13 (page number notforcitation purposes)F1000Prime Reports 2015, 7:49 http://f1000.com/prime/reports/b/7/49",Non-OADS,/arxiv_data1/oa_pdf/85/93/biolrep-07-49.PMC4447030.pdf
"Page 10 of 13 (page number not for citation purposes)F1000Prime Reports 2015, 7:49 http://f1000.com/prime/reports/b/7/49",Non-OADS,/arxiv_data1/oa_pdf/85/93/biolrep-07-49.PMC4447030.pdf
"Page 11of13 (page number notforcitation purposes)F1000Prime Reports 2015, 7:49 http://f1000.com/prime/reports/b/7/49",Non-OADS,/arxiv_data1/oa_pdf/85/93/biolrep-07-49.PMC4447030.pdf
"David Reznick and an Page 12 of 13 (page number not for citation purposes)F1000Prime Reports 2015, 7:49 http://f1000.com/prime/reports/b/7/49",Non-OADS,/arxiv_data1/oa_pdf/85/93/biolrep-07-49.PMC4447030.pdf
"Page 13 of 13 (page number not for citation purposes)F1000Prime Reports 2015, 7:49 http://f1000.com/prime/reports/b/7/49",Non-OADS,/arxiv_data1/oa_pdf/85/93/biolrep-07-49.PMC4447030.pdf
"Recent advances inunderstanding andmanaging leiomyosarcomas Florence Duffaud1*,Isabelle Ray-Coquard2,Sébastien Salas1 andPatricia Pautier3 Addresses:1AixMarseille Université (AMU), Service d’Oncologie médicale, CHU laTimone Boulevard JMoulin 13005 Marseille, France; 2Université Claude Bernard Lyon I,Oncologie Médicale, Centre Leon Bérard, 28rueLaennec, 69008 Lyon, France;3Gustave Roussy Cancer Campus, 114 RueEVaillant, 94805 Villejuif, France *Corresponding author: Florence Duffaud (fduffaud@mail.ap-hm.fr) F1000Prime Reports 2015, 7:55(doi:10.12703/P7-55) AllF1000Prime Reports articles aredistributed under theterms oftheCreative Commons Attribution-Non Commercial License (http://creativecommons.org/licenses/by-nc/3.0/legalcode), which permits non-commercial use, distribution, andreproduction inanymedium, provided theoriginal work isproperly cited.",Non-OADS,/arxiv_data1/oa_pdf/58/ab/medrep-07-55.PMC4447031.pdf
The electronic version ofthisarticle isthecomplete oneandcanbefound at:http://f1000.com/prime/reports/m/7/55 Abstract Leiomyosarcomas aremalignant mesenchymal tumours that derive from thesmooth muscle lineage.,Non-OADS,/arxiv_data1/oa_pdf/58/ab/medrep-07-55.PMC4447031.pdf
"Following appropriate Page 2 of 8 (page number not for citation purposes)F1000Prime Reports 2015, 7:55 http://f1000.com/prime/reports/m/7/55",Non-OADS,/arxiv_data1/oa_pdf/58/ab/medrep-07-55.PMC4447031.pdf
"Radiotherapy demonstrated an increased local control Page 3 of 8 (page number not for citation purposes)F1000Prime Reports 2015, 7:55 http://f1000.com/prime/reports/m/7/55",Non-OADS,/arxiv_data1/oa_pdf/58/ab/medrep-07-55.PMC4447031.pdf
"Another gemcitabine-based combination has shown benefit in soft tissue sarcomas, and interesting activity Page 4 of 8 (page number not for citation purposes)F1000Prime Reports 2015, 7:55 http://f1000.com/prime/reports/m/7/55",Non-OADS,/arxiv_data1/oa_pdf/58/ab/medrep-07-55.PMC4447031.pdf
[http://seer.cancer.gov/csr/1975_2010/] 4.,Non-OADS,/arxiv_data1/oa_pdf/58/ab/medrep-07-55.PMC4447031.pdf
"Ylisaukko-oja SK, Kiuru M, Lehtonen HJ, Lehtonen R, Pukkala E, Arola J, Launonen V, Aaltonen LA: Analysis of fumarate hydratase Page 5 of 8 (page number not for citation purposes)F1000Prime Reports 2015, 7:55 http://f1000.com/prime/reports/m/7/55",OADS,/arxiv_data1/oa_pdf/58/ab/medrep-07-55.PMC4447031.pdf
"Zagars GK, Ballo MT, Pisters, Peter WT, Pollock RE, Patel SR, Benjamin RS,Evans HL:Prognostic factors forpatients with localized soft-tissue sarcoma treated with conservation Page 6of8 (page number notforcitation purposes)F1000Prime Reports 2015, 7:55 http://f1000.com/prime/reports/m/7/55",Non-OADS,/arxiv_data1/oa_pdf/58/ab/medrep-07-55.PMC4447031.pdf
"Pautier P, Floquet A, Penel N, Piperno-Neumann S, Isambert N, Rey A, Bompas E, Cioffi A, Delcambre C, Cupissol D, Collin F, Blay J, Page 7 of 8 (page number not for citation purposes)F1000Prime Reports 2015, 7:55 http://f1000.com/prime/reports/m/7/55",Non-OADS,/arxiv_data1/oa_pdf/58/ab/medrep-07-55.PMC4447031.pdf
"Page 8 of 8 (page number not for citation purposes)F1000Prime Reports 2015, 7:55 http://f1000.com/prime/reports/m/7/55",Non-OADS,/arxiv_data1/oa_pdf/58/ab/medrep-07-55.PMC4447031.pdf
"Mitochondria and apoptosis: emerging concepts Mark Xiang Li1,2and Grant Dewson1,2* Addresses:1Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, Melbourne, Victoria 3052, Australia; 2Department of Medical Biology, University of Melbourne, Parkville, Victoria 3050, Australia * Corresponding author: Grant Dewson (dewson@wehi.edu.au) F1000Prime Reports 2015, 7:42 (doi:10.12703/P7-42) All F1000Prime Reports articles are distributed under the terms of the Creative Commons Attribution-Non Commercial License (http://creativecommons.org/licenses/by-nc/3.0/legalcode), which permits non-commercial use, distribution, and reproduction in any medium , provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/d1/ba/biolrep-07-42.PMC4447032.pdf
"The electronic version of this article is the complete one and can be found at: http://f1000.com/prime/reports/b/7/42 Abstract As mitochondria are the powerhouses of the cell, their damage during the cell suicide process of apoptosis is essentially responsible for cellular demise in most cells.",Non-OADS,/arxiv_data1/oa_pdf/d1/ba/biolrep-07-42.PMC4447032.pdf
"Another breakthrough has been the realiza-tion that a membrane environment, and specifically thatof the mitochondrial outer membrane, is critical forinteractions between the BCL-2 family proteins [25].Together, these studies have led to the appreciation that these interactions are not a series of static, dead-end Page 2 of 9 (page number not for citation purposes)F1000Prime Reports 2015, 7:42 http://f1000.com/prime/reports/b/7/42",Non-OADS,/arxiv_data1/oa_pdf/d1/ba/biolrep-07-42.PMC4447032.pdf
"Page 3 of 9 (page number not for citation purposes)F1000Prime Reports 2015, 7:42 http://f1000.com/prime/reports/b/7/42",Non-OADS,/arxiv_data1/oa_pdf/d1/ba/biolrep-07-42.PMC4447032.pdf
"Do BAX and BAK form ordered proteinaceous pores or more heterogeneous pores Page 4 of 9 (page number not for citation purposes)F1000Prime Reports 2015, 7:42 http://f1000.com/prime/reports/b/7/42",Non-OADS,/arxiv_data1/oa_pdf/d1/ba/biolrep-07-42.PMC4447032.pdf
"Pro-survival BCL-2 proteins were observed to Page 5 of 9 (page number not for citation purposes)F1000Prime Reports 2015, 7:42 http://f1000.com/prime/reports/b/7/42",OADS,/arxiv_data1/oa_pdf/d1/ba/biolrep-07-42.PMC4447032.pdf
"Page 6 of 9 (page number not for citation purposes)F1000Prime Reports 2015, 7:42 http://f1000.com/prime/reports/b/7/42",Non-OADS,/arxiv_data1/oa_pdf/d1/ba/biolrep-07-42.PMC4447032.pdf
"Page 7 of 9 (page number not for citation purposes)F1000Prime Reports 2015, 7:42 http://f1000.com/prime/reports/b/7/42",Non-OADS,/arxiv_data1/oa_pdf/d1/ba/biolrep-07-42.PMC4447032.pdf
"Chipuk JE, McStay GP, Bharti A, Kuwana T, Clarke CJ, Siskind LJ, Obeid LM, Green DR: Sphingolipid metabolism cooperates Page 8 of 9 (page number not for citation purposes)F1000Prime Reports 2015, 7:42 http://f1000.com/prime/reports/b/7/42",Non-OADS,/arxiv_data1/oa_pdf/d1/ba/biolrep-07-42.PMC4447032.pdf
"Page 9 of 9 (page number not for citation purposes)F1000Prime Reports 2015, 7:42 http://f1000.com/prime/reports/b/7/42",Non-OADS,/arxiv_data1/oa_pdf/d1/ba/biolrep-07-42.PMC4447032.pdf
"Advancing ourknowledge ofthecomplexity andmanagement ofintimate partner violence andco-occurring mental health and substance abuse problems inwomen Robin Mason* andJanice DuMont Address: Women ’sCollege Research Institute, Women ’sCollege Hospital, 790 BayStreet, 7thfloor, Toronto, ONM5G 1N8, Canada *Corresponding author: Robin Mason (Robin.Mason@wchospital.ca) F1000Prime Reports 2015, 7:65(doi:10.12703/P7-65) AllF1000Prime Reports articles aredistributed under theterms oftheCreative Commons Attribution-Non Commercial License (http://creativecommons.org/licenses/by-nc/3.0/legalcode), which permits non-commercial use, distribution, andreproduction inanymedium, provided theoriginal work isproperly cited.",Non-OADS,/arxiv_data1/oa_pdf/9c/f8/medrep-07-65.PMC4447033.pdf
"The electronic version ofthisarticle isthecomplete one andcanbefound at:http://f1000.com/prime/reports/m/7/65 Abstract Globally, intimate partner violence (IPV) isapervasive andinsidious human rights problem with significant adverse physical health outcomes forwomen.",Non-OADS,/arxiv_data1/oa_pdf/9c/f8/medrep-07-65.PMC4447033.pdf
"Gilbert and colleagues [22] attempted to Page 2 of 6 (page number not for citation purposes)F1000Prime Reports 2015, 7:65 http://f1000.com/prime/reports/m/7/65",Non-OADS,/arxiv_data1/oa_pdf/9c/f8/medrep-07-65.PMC4447033.pdf
"The challenges of integrating IPV into substance abuse treatment settings (and vice versa ) may derive from the sectors ’different philosophical orientations, ideologies, Page 3 of 6 (page number not for citation purposes)F1000Prime Reports 2015, 7:65 http://f1000.com/prime/reports/m/7/65",Non-OADS,/arxiv_data1/oa_pdf/9c/f8/medrep-07-65.PMC4447033.pdf
"World Health Organization Page 4 of 6 (page number not for citation purposes)F1000Prime Reports 2015, 7:65 http://f1000.com/prime/reports/m/7/65",Non-OADS,/arxiv_data1/oa_pdf/9c/f8/medrep-07-65.PMC4447033.pdf
[http://www.who.int/mediacentre/news/releases/2013/ violence_against_women_20130620/en/] 4.,Non-OADS,/arxiv_data1/oa_pdf/9c/f8/medrep-07-65.PMC4447033.pdf
[http://apps.who.in t/iris/bitstream/10665/85239/1/ 9789241564625_eng.pdf] 6.,Non-OADS,/arxiv_data1/oa_pdf/9c/f8/medrep-07-65.PMC4447033.pdf
"Page 5 of 6 (page number not for citation purposes)F1000Prime Reports 2015, 7:65 http://f1000.com/prime/reports/m/7/65",Non-OADS,/arxiv_data1/oa_pdf/9c/f8/medrep-07-65.PMC4447033.pdf
[http://www.ncbi.nlm.nih.gov/books/NBK64437/pdf/TOC.pdf] 35.,Non-OADS,/arxiv_data1/oa_pdf/9c/f8/medrep-07-65.PMC4447033.pdf
"Page 6 of 6 (page number not for citation purposes)F1000Prime Reports 2015, 7:65 http://f1000.com/prime/reports/m/7/65",Non-OADS,/arxiv_data1/oa_pdf/9c/f8/medrep-07-65.PMC4447033.pdf
"Liver Xreceptors andcholesterol metabolism: role inventral midbrain development andneurodegeneration Spyridon Theofilopoulos andErnest Arenas* Address: Laboratory ofMolecular Neurobiology, Department ofMedical Biochemistry andBiophysics, Karolinska Institutet, Stockholm SE-17177, Sweden *Corresponding author: Ernest Arenas (ernest.arenas@ki.se) F1000Prime Reports 2015, 7:37(doi:10.12703/P7-37) AllF1000Prime Reports articles aredistributed under theterms oftheCreative Commons Attribution-Non Commercial License (http://creativecommons.org/licenses/by-nc/3.0/legalcode), which permits non-commercial use, distribution, andreproduction inanymedium, provided theoriginal work isproperly cited.",Non-OADS,/arxiv_data1/oa_pdf/b5/cc/biolrep-07-37.PMC4447034.pdf
"The electronic version ofthisarticle isthecomplete oneandcanbefound at:http://f1000.com/prime/reports/b/7/37 Abstract Thedevelopment oftheventral midbrain isorchestrated byanumber ofcell-extrinsic and-intrinsic factors thatcontrol critical processes, such asthepatterning oftheneural tube along themain body axis and thespecification ofdiverse neuronal celltypes indistinct positions oftheneural tube.",Non-OADS,/arxiv_data1/oa_pdf/b5/cc/biolrep-07-37.PMC4447034.pdf
"Page 2 of 8 (page number not for citation purposes)F1000Prime Reports 2015, 7:37 http://f1000.com/prime/reports/b/7/37",Non-OADS,/arxiv_data1/oa_pdf/b5/cc/biolrep-07-37.PMC4447034.pdf
"Page 3of8 (page number notforcitation purposes)F1000Prime Reports 2015, 7:37 http://f1000.com/prime/reports/b/7/37",Non-OADS,/arxiv_data1/oa_pdf/b5/cc/biolrep-07-37.PMC4447034.pdf
"Moreover, Dai and colleagues[86] have shown that Lxrb −/−mice are more vulnerable to MPTP-induced DA neuron loss and that GW3965 prevents the loss of substantia nigra DA neurons and of Page 4 of 8 (page number not for citation purposes)F1000Prime Reports 2015, 7:37 http://f1000.com/prime/reports/b/7/37",OADS,/arxiv_data1/oa_pdf/b5/cc/biolrep-07-37.PMC4447034.pdf
"Repa JJ, Liang G, Ou J, Bashmakov Y, Lobaccaro JM, Shimomura I, Shan B, Brown MS, Goldstein JL, Mangelsdorf DJ: Regulation of Page 5 of 8 (page number not for citation purposes)F1000Prime Reports 2015, 7:37 http://f1000.com/prime/reports/b/7/37",Non-OADS,/arxiv_data1/oa_pdf/b5/cc/biolrep-07-37.PMC4447034.pdf
"Page 6 of 8 (page number not for citation purposes)F1000Prime Reports 2015, 7:37 http://f1000.com/prime/reports/b/7/37",Non-OADS,/arxiv_data1/oa_pdf/b5/cc/biolrep-07-37.PMC4447034.pdf
"Terwel D, Steffensen KR, Verghese PB, Kummer MP, Gustafsson JÅ, Holtzman DM, Heneka MT: Critical role of astroglial Page 7 of 8 (page number not for citation purposes)F1000Prime Reports 2015, 7:37 http://f1000.com/prime/reports/b/7/37",Non-OADS,/arxiv_data1/oa_pdf/b5/cc/biolrep-07-37.PMC4447034.pdf
"Page 8 of 8 (page number not for citation purposes)F1000Prime Reports 2015, 7:37 http://f1000.com/prime/reports/b/7/37",Non-OADS,/arxiv_data1/oa_pdf/b5/cc/biolrep-07-37.PMC4447034.pdf
"Hematopoietic transcription factor mutations andinherited platelet dysfunction Natthapol Songdej andA.Koneti Rao Address: Hematology-Oncology Section, Department ofMedicine andtheSolSherry, Thrombosis Research Center, Temple University School of Medicine, Philadelphia, PA,USA *Corresponding author: A.Koneti Rao, M.D., (koneti@temple.edu) F1000Prime Reports 2015, 7:66(doi:10.12703/P7-66) AllF1000Prime Reports articles aredistributed under theterms oftheCreative Commons Attribution-Non Commercial License (http://creativecommons.org/licenses/by-nc/3.0/legalcode), which permits non-commercial use, distribution, andreproduction inanymedium, provided theoriginal work isproperly cited.",Non-OADS,/arxiv_data1/oa_pdf/f7/9b/medrep-07-66.PMC4447035.pdf
The electronic version ofthisarticle isthecomplete oneandcanbefound at:http://f1000.com/prime/reports/m/7/66 Abstract Themolecular andgenetic mechanisms inmost patients with inherited platelet dysfunction areunknown.,Non-OADS,/arxiv_data1/oa_pdf/f7/9b/medrep-07-66.PMC4447035.pdf
"These features have important implications fortreatment, as previously described pedigrees have docu- mented recurrence of leukemia following hematopoietic Page 2 of 6 (page number not for citation purposes)F1000Prime Reports 2015, 7:66 http://f1000.com/prime/reports/m/7/66",Non-OADS,/arxiv_data1/oa_pdf/f7/9b/medrep-07-66.PMC4447035.pdf
"Alpha-granule defi-ciency due to mutations in the gene encoding the VPS33Bprotein (a member of the Sec1/Munc18 protein family)and the VPS16B gene in the arthrogryposis multiplex congenita, renal dysfunction, and cholestasis (ARC) Page 3 of 6 (page number not for citation purposes)F1000Prime Reports 2015, 7:66 http://f1000.com/prime/reports/m/7/66",Non-OADS,/arxiv_data1/oa_pdf/f7/9b/medrep-07-66.PMC4447035.pdf
"Page 4 of 6 (page number not for citation purposes)F1000Prime Reports 2015, 7:66 http://f1000.com/prime/reports/m/7/66",Non-OADS,/arxiv_data1/oa_pdf/f7/9b/medrep-07-66.PMC4447035.pdf
"Kahr, Walter HA, Hinckley J, Li L, Schwertz H, Christensen H, Rowley JW, Pluthero FG, Urban D, Fabbro S, Nixon B, Gadzinski R, Storck M, Wang K, Ryu G, Jobe SM, Schutte BC, Moseley J, Page 5 of 6 (page number not for citation purposes)F1000Prime Reports 2015, 7:66 http://f1000.com/prime/reports/m/7/66",Non-OADS,/arxiv_data1/oa_pdf/f7/9b/medrep-07-66.PMC4447035.pdf
"Page 6 of 6 (page number not for citation purposes)F1000Prime Reports 2015, 7:66 http://f1000.com/prime/reports/m/7/66",Non-OADS,/arxiv_data1/oa_pdf/f7/9b/medrep-07-66.PMC4447035.pdf
"Cochlear implantation: abiomechanical prosthesis forhearing loss Robert Yawn, Jacob B.Hunter, Alex D.Sweeney, andMarc L.Bennett* Address: TheOtology Group, Department ofOtolaryngology-Head andNeck Surgery, TheBillWilkerson Center forOtolaryngology & Communication Sciences 7209 Medical Center East, South Tower 1215 21st Avenue South, Nashville, TN37232, USA *Corresponding author: Marc L.Bennett (marc.bennett@vanderbilt.edu) F1000Prime Reports 2015, 7:45(doi:10.12703/P7-45) AllF1000Prime Reports articles aredistributed under theterms oftheCreative Commons Attribution-Non Commercial License (http://creativecommons.org/licenses/by-nc/3.0/legalcode), which permits non-commercial use, distribution, andreproduction inanymedium, provided theoriginal work isproperly cited.",Non-OADS,/arxiv_data1/oa_pdf/92/27/medrep-07-45.PMC4447036.pdf
"The electronic version ofthisarticle isthecomplete oneandcanbefound at:http://f1000.com/prime/reports/m/7/45 Abstract Cochlear implants areamedical prosthesis used totreat sensorineural deafness, andoneofthegreatest advances inmodern medicine.",Non-OADS,/arxiv_data1/oa_pdf/92/27/medrep-07-45.PMC4447036.pdf
"Currently the FDA recommends routine pneumococcal Page 2 of 6 (page number not for citation purposes)F1000Prime Reports 2015, 7:45 http://f1000.com/prime/reports/m/7/45",Non-OADS,/arxiv_data1/oa_pdf/92/27/medrep-07-45.PMC4447036.pdf
"A recent study of 100 patients demonstrated that the best hearing Page 3 of 6 (page number not for citation purposes)F1000Prime Reports 2015, 7:45 http://f1000.com/prime/reports/m/7/45",Non-OADS,/arxiv_data1/oa_pdf/92/27/medrep-07-45.PMC4447036.pdf
"Page 4 of 6 (page number not for citation purposes)F1000Prime Reports 2015, 7:45 http://f1000.com/prime/reports/m/7/45",Non-OADS,/arxiv_data1/oa_pdf/92/27/medrep-07-45.PMC4447036.pdf
[http://www.nidcd.nih.gov/health/hearing/pages/coch.aspx].,Non-OADS,/arxiv_data1/oa_pdf/92/27/medrep-07-45.PMC4447036.pdf
"Page 5of6 (page number notforcitation purposes)F1000Prime Reports 2015, 7:45 http://f1000.com/prime/reports/m/7/45",Non-OADS,/arxiv_data1/oa_pdf/92/27/medrep-07-45.PMC4447036.pdf
"Page 6 of 6 (page number not for citation purposes)F1000Prime Reports 2015, 7:45 http://f1000.com/prime/reports/m/7/45",Non-OADS,/arxiv_data1/oa_pdf/92/27/medrep-07-45.PMC4447036.pdf
"Recent advances in the management of peritoneal dialysis patients Anjali B. Saxena, MD Addresses: Department of Medicine, Division of Nephrology, Santa Clara Valley Medical Center, 751 S. Bascom Ave, San Jose, CA 95128, USA; Department of Medicine, Division of Nephrology, Stanford University, Stanford, CA, 94304, USA Email: anjali.saxena@hhs.sccgov.org F1000Prime Reports 2015, 7:57 (doi:10.12703/P7-57) All F1000Prime Reports articles are distributed under the terms of the Creative Commons Attribution-Non Commercial License (http://creativecommons.org/licenses/by-nc/3.0/legalcode), which permits non-commercial use, distribution, and reproduction in any medium , provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/cf/be/medrep-07-57.PMC4447037.pdf
The electronic version of this article is the complete one and can be found at: http://f1000.com/prime/reports/m/7/57 Abstract Peritoneal dialysis is a form of kidney dialysis that is used to remove accumulated metabolic waste products and water in patients with end stage kidney disease.,Non-OADS,/arxiv_data1/oa_pdf/cf/be/medrep-07-57.PMC4447037.pdf
"Some glucose-degradation products (GDPs) found in peritoneal dialysis fluid (PDF) GDP found in PDF Acetaldehyde Formaldehyde2-furaldehydeGlyoxal5-hydroxymethylfuraldehydeMethylglyoxal Valeraldehyde 3-deoxyglucosone3,4-dideoxyglucosone-3-ene Page 2 of 6 (page number not for citation purposes)F1000Prime Reports 2015, 7:57 http://f1000.com/prime/reports/m/7/57",Non-OADS,/arxiv_data1/oa_pdf/cf/be/medrep-07-57.PMC4447037.pdf
"Page 3 of 6 (page number not for citation purposes)F1000Prime Reports 2015, 7:57 http://f1000.com/prime/reports/m/7/57",Non-OADS,/arxiv_data1/oa_pdf/cf/be/medrep-07-57.PMC4447037.pdf
"Page 4 of 6 (page number not for citation purposes)F1000Prime Reports 2015, 7:57 http://f1000.com/prime/reports/m/7/57",Non-OADS,/arxiv_data1/oa_pdf/cf/be/medrep-07-57.PMC4447037.pdf
"Overview of the IMPENDIA and EDEN trial study design [23] IMPENDIA EDEN Multi-site in 10 countries Multi-site in Colombia only n = 180 n = 71Study regimen: 1 icodextrin bag 1 amino acid bag 2 bicarbonate-based dextrose bagsStudy regimen: 1 icodextrin bag 1 amino acid bag 2 lactate-based dextrose bags Controls: 4 lactate-dextrose bagsControls: 4 lactate-dextrose bags Page 5 of 6 (page number not for citation purposes)F1000Prime Reports 2015, 7:57 http://f1000.com/prime/reports/m/7/57",Non-OADS,/arxiv_data1/oa_pdf/cf/be/medrep-07-57.PMC4447037.pdf
"Page 6 of 6 (page number not for citation purposes)F1000Prime Reports 2015, 7:57 http://f1000.com/prime/reports/m/7/57",Non-OADS,/arxiv_data1/oa_pdf/cf/be/medrep-07-57.PMC4447037.pdf
"Steffen Husby1*andJoseph Murray2 Addresses:1Hans Christian Andersen Children ‘sHospital, Odense University Hospital, 29Sdr.Boulevard, DK-5000 Odense C,Denmark; 2Division ofGastroenterology andHepatology, Mayo Clinic, 2001stStSW,Rochester, MN55905, USA *Corresponding author: Steffen Husby (Steffen.Husby@rsyd.dk) F1000Prime Reports 2015, 7:54(doi:10.12703/P7-54) AllF1000Prime Reports articles aredistributed under theterms oftheCreative Commons Attribution-Non Commercial License (http://creativecommons.org/licenses/by-nc/3.0/legalcode), which permits non-commercial use, distribution, andreproduction inanymedium, provided theoriginal work isproperly cited.",Non-OADS,/arxiv_data1/oa_pdf/f3/b4/medrep-07-54.PMC4447038.pdf
The electronic version ofthisarticle isthecomplete oneandcanbefound at:http://f1000.com/prime/reports/m/7/54 Abstract Non-celiac gluten sensitivity (NCGS) hasbeen introduced recently asapotentially common disease onthebasis ofstudies ofpatients with claimed reactivity togluten butwithout thecharacteristics of celiac disease (CD).,Non-OADS,/arxiv_data1/oa_pdf/f3/b4/medrep-07-54.PMC4447038.pdf
"Page 2 of 4 (page number not for citation purposes)F1000Prime Reports 2015, 7:54 http://f1000.com/prime/reports/m/7/54",Non-OADS,/arxiv_data1/oa_pdf/f3/b4/medrep-07-54.PMC4447038.pdf
"Page 3 of 4 (page number not for citation purposes)F1000Prime Reports 2015, 7:54 http://f1000.com/prime/reports/m/7/54",Non-OADS,/arxiv_data1/oa_pdf/f3/b4/medrep-07-54.PMC4447038.pdf
"Page 4 of 4 (page number not for citation purposes)F1000Prime Reports 2015, 7:54 http://f1000.com/prime/reports/m/7/54",Non-OADS,/arxiv_data1/oa_pdf/f3/b4/medrep-07-54.PMC4447038.pdf
"Memory CD8 T cell transcriptional plasticity Ben Youngblood*1,2, J. Scott Hale1,3and Rafi Ahmed*1,3 Addresses:1Department of Microbiology and Immunology, Emory University, 1510 Clifton Road, Atlanta, GA 30322, USA;2Department of Immunology, St Jude Children ’s Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105-3678, USA;3Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA 30329 * Corresponding author: Ben Youngblood (benjamin.youngblood@stjude.org) or Rafi Ahmed (rahmed@emory.edu) F1000Prime Reports 2015, 7:38 (doi:10.12703/P7-38) All F1000Prime Reports articles are distributed under the terms of the Creative Commons Attribution-Non Commercial License (http://creativecommons.org/licenses/by-nc/3.0/legalcode), which permits non-commercial use, distribution, and reproduction in any medium , provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/a2/dc/biolrep-07-38.PMC4447039.pdf
"The electronic version of this article is the complete one and can be found at: http://f1000.com/prime/reports/b/7/38 Abstract Memory CD8 T cells generated after acute viral infections or live vaccines can persist for extended periods, in some instances for life, and play an important role in protective immunity.",Non-OADS,/arxiv_data1/oa_pdf/a2/dc/biolrep-07-38.PMC4447039.pdf
"Page 2 of 10 (page number not for citation purposes)F1000Prime Reports 2015, 7:38 http://f1000.com/prime/reports/b/7/38",Non-OADS,/arxiv_data1/oa_pdf/a2/dc/biolrep-07-38.PMC4447039.pdf
"Page 3 of 10 (page number not for citation purposes)F1000Prime Reports 2015, 7:38 http://f1000.com/prime/reports/b/7/38",Non-OADS,/arxiv_data1/oa_pdf/a2/dc/biolrep-07-38.PMC4447039.pdf
"Their analysis revealed thatbrain Trm cells acquired distinct gene expression programs of several transcription factors previously Page 4 of 10 (page number not for citation purposes)F1000Prime Reports 2015, 7:38 http://f1000.com/prime/reports/b/7/38",OADS,/arxiv_data1/oa_pdf/a2/dc/biolrep-07-38.PMC4447039.pdf
"Page 5 of 10 (page number not for citation purposes)F1000Prime Reports 2015, 7:38 http://f1000.com/prime/reports/b/7/38",Non-OADS,/arxiv_data1/oa_pdf/a2/dc/biolrep-07-38.PMC4447039.pdf
"Page 6 of 10 (page number not for citation purposes)F1000Prime Reports 2015, 7:38 http://f1000.com/prime/reports/b/7/38",Non-OADS,/arxiv_data1/oa_pdf/a2/dc/biolrep-07-38.PMC4447039.pdf
"Page 7 of 10 (page number not for citation purposes)F1000Prime Reports 2015, 7:38 http://f1000.com/prime/reports/b/7/38",Non-OADS,/arxiv_data1/oa_pdf/a2/dc/biolrep-07-38.PMC4447039.pdf
"Proceedings Page 8 of 10 (page number not for citation purposes)F1000Prime Reports 2015, 7:38 http://f1000.com/prime/reports/b/7/38",Non-OADS,/arxiv_data1/oa_pdf/a2/dc/biolrep-07-38.PMC4447039.pdf
"Page 9 of 10 (page number not for citation purposes)F1000Prime Reports 2015, 7:38 http://f1000.com/prime/reports/b/7/38",Non-OADS,/arxiv_data1/oa_pdf/a2/dc/biolrep-07-38.PMC4447039.pdf
"Page 10 of 10 (page number not for citation purposes)F1000Prime Reports 2015, 7:38 http://f1000.com/prime/reports/b/7/38",Non-OADS,/arxiv_data1/oa_pdf/a2/dc/biolrep-07-38.PMC4447039.pdf
"Alton Address: Department ofGene Therapy andtheUKCystic Fibrosis Gene Therapy Consortium, Imperial College, London SW3 6LR, UK *Corresponding author: UtaGriesenbach (u.griesenbach@imperial.ac.uk) F1000Prime Reports 2015, 7:64(doi:10.12703/P7-64) AllF1000Prime Reports articles aredistributed under theterms oftheCreative Commons Attribution-Non Commercial License (http://creativecommons.org/licenses/by-nc/3.0/legalcode), which permits non-commercial use, distribution, andreproduction inanymedium, provided theoriginal work isproperly cited.",Non-OADS,/arxiv_data1/oa_pdf/ce/0d/medrep-07-64.PMC4447040.pdf
The electronic version ofthisarticle isthecomplete oneandcanbefound at:http://f1000.com/prime/reports/m/7/64 Abstract Cystic fibrosis isthemost common autosomal recessive genetic disease inCaucasians andhasbeen extensively studied formany decades.,Non-OADS,/arxiv_data1/oa_pdf/ce/0d/medrep-07-64.PMC4447040.pdf
"TheCystic Fibrosis Mutation Database (CFTR1) currently lists1,991 CFTR mutations (http://www.genet.sickkids.on.ca/cftr) and understand - ingtheconsequences ofaparticular mutation onprotein function iscentral tothedevelopment ofmutation- specific treatments.",Non-OADS,/arxiv_data1/oa_pdf/ce/0d/medrep-07-64.PMC4447040.pdf
"Page 2 of 8 (page number not for citation purposes)F1000Prime Reports 2015, 7:64 http://f1000.com/prime/reports/m/7/64",Non-OADS,/arxiv_data1/oa_pdf/ce/0d/medrep-07-64.PMC4447040.pdf
"Page 3 of 8 (page number not for citation purposes)F1000Prime Reports 2015, 7:64 http://f1000.com/prime/reports/m/7/64",Non-OADS,/arxiv_data1/oa_pdf/ce/0d/medrep-07-64.PMC4447040.pdf
"Page 4 of 8 (page number not for citation purposes)F1000Prime Reports 2015, 7:64 http://f1000.com/prime/reports/m/7/64",Non-OADS,/arxiv_data1/oa_pdf/ce/0d/medrep-07-64.PMC4447040.pdf
"We are,forexample, currently developing alentiviral vector Page 5of8 (page number notforcitation purposes)F1000Prime Reports 2015, 7:64 http://f1000.com/prime/reports/m/7/64",Non-OADS,/arxiv_data1/oa_pdf/ce/0d/medrep-07-64.PMC4447040.pdf
"Chen J, Stoltz DA, Karp PH, Ernst SE, Pezzulo AA, Moninger TO, Rector MV, Reznikov LR, Launspach JL, Chaloner K, Zabner J, Welsh MJ: Loss of anion transport without increased sodium Page 6 of 8 (page number not for citation purposes)F1000Prime Reports 2015, 7:64 http://f1000.com/prime/reports/m/7/64",Non-OADS,/arxiv_data1/oa_pdf/ce/0d/medrep-07-64.PMC4447040.pdf
"Lim, MTC, Wallis C, Price JF, Carr SB, Chavasse RJ, Shankar A, Seddon P, Balfour-Lynn IM: Diagnosis of cystic fibrosis in London and South East England before and after the introduction of Page 7 of 8 (page number not for citation purposes)F1000Prime Reports 2015, 7:64 http://f1000.com/prime/reports/m/7/64",Non-OADS,/arxiv_data1/oa_pdf/ce/0d/medrep-07-64.PMC4447040.pdf
"Page 8 of 8 (page number not for citation purposes)F1000Prime Reports 2015, 7:64 http://f1000.com/prime/reports/m/7/64",Non-OADS,/arxiv_data1/oa_pdf/ce/0d/medrep-07-64.PMC4447040.pdf
"Philadelphia, PA19104, USA;3Department ofPharmacology, Drexel University College ofMedicine, N.15thSt.,Philadelphia, PA19102, USA *Corresponding author: Rita J.Valentino (rjv@mail.med.upenn.edu orvalentino@email.chop.edu) F1000Prime Reports 2015, 7:58(doi:10.12703/P7-58) AllF1000Prime Reports articles aredistributed under theterms oftheCreative Commons Attribution-Non Commercial License (http://creativecommons.org/licenses/by-nc/3.0/legalcode), which permits non-commercial use, distribution, andreproduction inanymedium, provided theoriginal work isproperly cited.",Non-OADS,/arxiv_data1/oa_pdf/2c/6c/biolrep-07-58.PMC4447041.pdf
The electronic version ofthisarticle isthecomplete oneandcanbefound at:http://f1000.com/prime/reports/b/7/58 Abstract The stress response ischaracterized bythecoordinated engagement ofcentral andperipheral neural systems inresponse tolife-threatening challenges.,Non-OADS,/arxiv_data1/oa_pdf/2c/6c/biolrep-07-58.PMC4447041.pdf
"A specific exampleof this is seen with brain locus coeruleus (LC)- norepinephrine (NE) neurons, which are targeted by Page 2 of 7 (page number not for citation purposes)F1000Prime Reports 2015, 7:58 http://f1000.com/prime/reports/b/7/58",Non-OADS,/arxiv_data1/oa_pdf/2c/6c/biolrep-07-58.PMC4447041.pdf
"Page 3 of 7 (page number not for citation purposes)F1000Prime Reports 2015, 7:58 http://f1000.com/prime/reports/b/7/58",Non-OADS,/arxiv_data1/oa_pdf/2c/6c/biolrep-07-58.PMC4447041.pdf
"Page 4 of 7 (page number not for citation purposes)F1000Prime Reports 2015, 7:58 http://f1000.com/prime/reports/b/7/58",Non-OADS,/arxiv_data1/oa_pdf/2c/6c/biolrep-07-58.PMC4447041.pdf
"Page 5 of 7 (page number not for citation purposes)F1000Prime Reports 2015, 7:58 http://f1000.com/prime/reports/b/7/58",Non-OADS,/arxiv_data1/oa_pdf/2c/6c/biolrep-07-58.PMC4447041.pdf
"Page 6 of 7 (page number not for citation purposes)F1000Prime Reports 2015, 7:58 http://f1000.com/prime/reports/b/7/58",Non-OADS,/arxiv_data1/oa_pdf/2c/6c/biolrep-07-58.PMC4447041.pdf
"Page 7 of 7 (page number not for citation purposes)F1000Prime Reports 2015, 7:58 http://f1000.com/prime/reports/b/7/58",Non-OADS,/arxiv_data1/oa_pdf/2c/6c/biolrep-07-58.PMC4447041.pdf
"*Corresponding author: Olivier Thaunat (olivier.thaunat@chu-lyon.fr) F1000Prime Reports 2015, 7:51(doi:10.12703/P7-51) AllF1000Prime Reports articles aredistributed under theterms oftheCreative Commons Attribution-Non Commercial License (http://creativecommons.org/licenses/by-nc/3.0/legalcode), which permits non-commercial use, distribution, andreproduction inanymedium, provided theoriginal work isproperly cited.",Non-OADS,/arxiv_data1/oa_pdf/3f/6b/medrep-07-51.PMC4447042.pdf
"The electronic version ofthisarticle isthecomplete oneandcanbefound at:http://f1000.com/prime/reports/m/7/51 Abstract Overlooked fordecades, antibodies have taken center stage inrenal transplantation andarenow widely recognized asthefirstcause ofallograft failure.",Non-OADS,/arxiv_data1/oa_pdf/3f/6b/medrep-07-51.PMC4447042.pdf
"The firstevidence supporting this concept came from Colvin and colleagues, who transplanted RAG KO immunodeficient Page 2 of 10 (page number not for citation purposes)F1000Prime Reports 2015, 7:51 http://f1000.com/prime/reports/m/7/51",Non-OADS,/arxiv_data1/oa_pdf/3f/6b/medrep-07-51.PMC4447042.pdf
"Page 3 of 10 (page number not for citation purposes)F1000Prime Reports 2015, 7:51 http://f1000.com/prime/reports/m/7/51",Non-OADS,/arxiv_data1/oa_pdf/3f/6b/medrep-07-51.PMC4447042.pdf
"These limitations explained the Page 4 of 10 (page number not for citation purposes)F1000Prime Reports 2015, 7:51 http://f1000.com/prime/reports/m/7/51",Non-OADS,/arxiv_data1/oa_pdf/3f/6b/medrep-07-51.PMC4447042.pdf
"In an attempt to provide a sustained therapeutic effect, anti-CD20 monoclonal depleting antibody (rituximab), a widely established treatment of B cell lymphoma, has Page 5 of 10 (page number not for citation purposes)F1000Prime Reports 2015, 7:51 http://f1000.com/prime/reports/m/7/51",Non-OADS,/arxiv_data1/oa_pdf/3f/6b/medrep-07-51.PMC4447042.pdf
"In fact, the only multicenter randomizedstudy —Impact of Treatment With Rituximab on the Progression of Humoral Acute Rejection After Renal Transplantation (RITUX-ERAH) (ClinicalTrials.gov Iden-tifier: NCT01350882 http://clinicaltrials.gov/ct2/show/NCT01350882) —performed to investigate the effect of rituximab on AMR, found no difference at 12 months ongraft loss, epidermal growth factor receptor (eGFR),proteinuria, and glomerulitis score between placebo andrituximab groups [73].",Non-OADS,/arxiv_data1/oa_pdf/3f/6b/medrep-07-51.PMC4447042.pdf
"Clinical experience with this drug in the context of AMR is still limited [83], but, based on these promising prelimin- ary results, prospective studies have been launched to evaluate bortezomib efficiency and tolerance profile in this indication (ClinicalTrials.gov Identifier: NCT02201576http://clinicaltri als.gov/ct2/show/NCT02201576, Clinical- Trials.gov Identifier: NCT01873157 http://clinicaltrials.gov/ct2/show/NCT01873157).",Non-OADS,/arxiv_data1/oa_pdf/3f/6b/medrep-07-51.PMC4447042.pdf
"Abbreviations ADCC, antibody-dependent cell-mediated cytotoxicity;AMR, antibody-mediated rejection; ATG, antithymocyteglobulin; CDC, complement-dependent cytotoxicity;DSA, donor-specific antibody; Fc, fragment crystallizable; FCXM, flow cytometry cross-match; Ig, immunoglobulin; Page 6 of 10 (page number not for citation purposes)F1000Prime Reports 2015, 7:51 http://f1000.com/prime/reports/m/7/51",Non-OADS,/arxiv_data1/oa_pdf/3f/6b/medrep-07-51.PMC4447042.pdf
"Page 7 of 10 (page number not for citation purposes)F1000Prime Reports 2015, 7:51 http://f1000.com/prime/reports/m/7/51",Non-OADS,/arxiv_data1/oa_pdf/3f/6b/medrep-07-51.PMC4447042.pdf
"Sis B, Jhangri GS, Bunnag S, Allanach K, Kaplan B, Halloran PF: Endothelial gene expression in kidney transplants with alloantibody indicates antibody-mediated damage despite Page 8 of 10 (page number not for citation purposes)F1000Prime Reports 2015, 7:51 http://f1000.com/prime/reports/m/7/51",Non-OADS,/arxiv_data1/oa_pdf/3f/6b/medrep-07-51.PMC4447042.pdf
"Page 9 of 10 (page number not for citation purposes)F1000Prime Reports 2015, 7:51 http://f1000.com/prime/reports/m/7/51",Non-OADS,/arxiv_data1/oa_pdf/3f/6b/medrep-07-51.PMC4447042.pdf
"Page 10 of 10 (page number not for citation purposes)F1000Prime Reports 2015, 7:51 http://f1000.com/prime/reports/m/7/51",Non-OADS,/arxiv_data1/oa_pdf/3f/6b/medrep-07-51.PMC4447042.pdf
"Recent advances intheentirely subcutaneous ICD System Markus Bettin*, Florian Reinke, Benjamin Rath, Julia Köbe andLars Eckardt Address: Division ofClinical andExperimental Electrophysiology, Department ofCardiology andAngiology, University Hospital Münster, Albert- Schweitzer-Campus 1,Gebäude A1,48149 Münster, Germany *Corresponding author: Markus Bettin (markus.bettin@ukmuenster.de) F1000Prime Reports 2015, 7:46(doi:10.12703/P7-46) AllF1000Prime Reports articles aredistributed under theterms oftheCreative Commons Attribution-Non Commercial License (http://creativecommons.org/licenses/by-nc/3.0/legalcode), which permits non-commercial use, distribution, andreproduction inanymedium, provided theoriginal work isproperly cited.",Non-OADS,/arxiv_data1/oa_pdf/13/c6/medrep-07-46.PMC4447043.pdf
The electronic version ofthisarticle isthecomplete oneandcanbefound at:http://f1000.com/prime/reports/m/7/46 Abstract The entirely subcutaneous implantable cardioverter defibrillator (S-ICD®)isemerging asawidely accepted therapeutic alternative toaconventional implantable cardioverter defibrillator (ICD) for prevention ofsudden cardiac death.,Non-OADS,/arxiv_data1/oa_pdf/13/c6/medrep-07-46.PMC4447043.pdf
"Page 2 of 10 (page number not for citation purposes)F1000Prime Reports 2015, 7:46 http://f1000.com/prime/reports/m/7/46",Non-OADS,/arxiv_data1/oa_pdf/13/c6/medrep-07-46.PMC4447043.pdf
"Page 3 of 10 (page number not for citation purposes)F1000Prime Reports 2015, 7:46 http://f1000.com/prime/reports/m/7/46",Non-OADS,/arxiv_data1/oa_pdf/13/c6/medrep-07-46.PMC4447043.pdf
"Page 4 of 10 (page number not for citation purposes)F1000Prime Reports 2015, 7:46 http://f1000.com/prime/reports/m/7/46",Non-OADS,/arxiv_data1/oa_pdf/13/c6/medrep-07-46.PMC4447043.pdf
"[14] (2014)472 49 282/167 166 43 236 18 93 (33 patients) 73 (7%) Page 5 of 10 (page number not for citation purposes)F1000Prime Reports 2015, 7:46 http://f1000.com/prime/reports/m/7/46",Non-OADS,/arxiv_data1/oa_pdf/13/c6/medrep-07-46.PMC4447043.pdf
"Especially in these patients, an Page 6 of 10 (page number not for citation purposes)F1000Prime Reports 2015, 7:46 http://f1000.com/prime/reports/m/7/46",Non-OADS,/arxiv_data1/oa_pdf/13/c6/medrep-07-46.PMC4447043.pdf
"Page 7 of 10 (page number not for citation purposes)F1000Prime Reports 2015, 7:46 http://f1000.com/prime/reports/m/7/46",Non-OADS,/arxiv_data1/oa_pdf/13/c6/medrep-07-46.PMC4447043.pdf
"Page 8 of 10 (page number not for citation purposes)F1000Prime Reports 2015, 7:46 http://f1000.com/prime/reports/m/7/46",Non-OADS,/arxiv_data1/oa_pdf/13/c6/medrep-07-46.PMC4447043.pdf
"Bardy GH, Smith WM, Hood MA, Crozier IG, Melton IC, Jordaens L, Theuns D, Park RE, Wright DJ, Connelly DT, Fynn SP, Murgatroyd FD, Sperzel J, Neuzner J, Spitzer SG, Ardashev AV, Oduro A, Boersma L, Maass AH, Van Gelder , Isabelle C, Wilde AA, Page 9 of 10 (page number not for citation purposes)F1000Prime Reports 2015, 7:46 http://f1000.com/prime/reports/m/7/46",Non-OADS,/arxiv_data1/oa_pdf/13/c6/medrep-07-46.PMC4447043.pdf
"Page 10 of 10 (page number not for citation purposes)F1000Prime Reports 2015, 7:46 http://f1000.com/prime/reports/m/7/46",Non-OADS,/arxiv_data1/oa_pdf/13/c6/medrep-07-46.PMC4447043.pdf
"Pathogenesis ofCrohn ’sdisease RayBoyapati1,2,Jack Satsangi1,2andGwo-Tzer Ho*1,2 Addresses:1Centre forInflammation Research, Queens Medical Research Institute, University ofEdinburgh, Edinburgh, EH16 4TJ,UK; 2Gastrointestinal Unit, Institute ofGenetics andMolecular Medicine, Western General Hospital, Edinburgh, EH4 2XU, UK *Corresponding author: Gwo-Tzer Ho(gho@ed.ac.uk) F1000Prime Reports 2015, 7:44(doi:10.12703/P7-44) AllF1000Prime Reports articles aredistributed under theterms oftheCreative Commons Attribution-Non Commercial License (http://creativecommons.org/licenses/by-nc/3.0/legalcode), which permits non-commercial use, distribution, andreproduction inanymedium, provided theoriginal work isproperly cited.",Non-OADS,/arxiv_data1/oa_pdf/37/8f/biolrep-07-44.PMC4447044.pdf
"The electronic version ofthisarticle isthecomplete oneandcanbefound at:http://f1000.com/prime/reports/b/7/44 Abstract Significant progress inourunderstanding ofCrohn ’sdisease (CD), anarchetypal common, complex disease, hasnow been achieved.",Non-OADS,/arxiv_data1/oa_pdf/37/8f/biolrep-07-44.PMC4447044.pdf
"Page 2 of 18 (page number not for citation purposes)F1000Prime Reports 2015, 7:44 http://f1000.com/prime/reports/b/7/44",Non-OADS,/arxiv_data1/oa_pdf/37/8f/biolrep-07-44.PMC4447044.pdf
"In mice, NOD2 deficiency does not result in colitis but in defective Page 3 of 18 (page number not for citation purposes)F1000Prime Reports 2015, 7:44 http://f1000.com/prime/reports/b/7/44",Non-OADS,/arxiv_data1/oa_pdf/37/8f/biolrep-07-44.PMC4447044.pdf
"Page 4 of 18 (page number not for citation purposes)F1000Prime Reports 2015, 7:44 http://f1000.com/prime/reports/b/7/44",Non-OADS,/arxiv_data1/oa_pdf/37/8f/biolrep-07-44.PMC4447044.pdf
"NOD2 interactome and functional networks Activation ○Muramyl dipeptide entry into cells (bacterial secretion systems and direct transportation into cytosol) ○Ligand-NOD2 interaction ○Cellular localization (for example, recruitment to the plasma membrane) Signaling (for example, RIPK2 interaction and nuclear factor- kappa-B signaling) Regulation (for example, cytoskeleton regulation, epistatic interactions, autoinhibition, and degradation) Effects ○Innate inflamma tory responses ○Adaptive immune responses ○Antimicrobial functions ○Facilitating autophagy and xenophagy ○Gut homeostasis (barrier function, microbiota, and gut epithelial restitution) NOD2, nucleotide-binding oligomerization domain containing 2; RIPK2, Receptor-interacting serine/threonine-protein kinase 2 Page 5 of 18 (page number not for citation purposes)F1000Prime Reports 2015, 7:44 http://f1000.com/prime/reports/b/7/44",Non-OADS,/arxiv_data1/oa_pdf/37/8f/biolrep-07-44.PMC4447044.pdf
"Impairment in either of these processes inIECs results in each other ’s compensatory engagement and in severe spontaneous CD-like transmural ileitis if Page 6 of 18 (page number not for citation purposes)F1000Prime Reports 2015, 7:44 http://f1000.com/prime/reports/b/7/44",Non-OADS,/arxiv_data1/oa_pdf/37/8f/biolrep-07-44.PMC4447044.pdf
"Page 7 of 18 (page number not for citation purposes)F1000Prime Reports 2015, 7:44 http://f1000.com/prime/reports/b/7/44",Non-OADS,/arxiv_data1/oa_pdf/37/8f/biolrep-07-44.PMC4447044.pdf
"Ileal microbiome signatures were Page 8 of 18 (page number not for citation purposes)F1000Prime Reports 2015, 7:44 http://f1000.com/prime/reports/b/7/44",OADS,/arxiv_data1/oa_pdf/37/8f/biolrep-07-44.PMC4447044.pdf
"Page 9 of 18 (page number not for citation purposes)F1000Prime Reports 2015, 7:44 http://f1000.com/prime/reports/b/7/44",Non-OADS,/arxiv_data1/oa_pdf/37/8f/biolrep-07-44.PMC4447044.pdf
"Conclusions In the next 10 years, we envisage major progress in(1) stratifying and addressing disease heterogeneity inCD on the basis of dominant molecular mechanism(s);(2) re-design of clinical trials that will follow from (1),where the ‘one size fits all ’approach to new therapeutics requires major re-thinking [193]; and (3) a shift of focusto the causative factors to prevent disease onset andmaintain long-term remission in addition to inhibiting Page 10 of 18 (page number not for citation purposes)F1000Prime Reports 2015, 7:44 http://f1000.com/prime/reports/b/7/44",Non-OADS,/arxiv_data1/oa_pdf/37/8f/biolrep-07-44.PMC4447044.pdf
"Cuthbert AP, Fisher SA, Mirza MM, King K, Hampe J, Croucher, Peter JP, Mascheretti S, Sanderson J, Forbes A, Mansfield J, Schreiber S, Page 11 of 18 (page number not for citation purposes)F1000Prime Reports 2015, 7:44 http://f1000.com/prime/reports/b/7/44",Non-OADS,/arxiv_data1/oa_pdf/37/8f/biolrep-07-44.PMC4447044.pdf
"Petnicki-Ocwieja T, Hrncir T, Liu Y, Biswas A, Hudcovic T, Tlaskalova- Hogenova H, Kobayashi KS: Nod2 is required for the regulation Page 12 of 18 (page number not for citation purposes)F1000Prime Reports 2015, 7:44 http://f1000.com/prime/reports/b/7/44",Non-OADS,/arxiv_data1/oa_pdf/37/8f/biolrep-07-44.PMC4447044.pdf
"Page 13 of 18 (page number not for citation purposes)F1000Prime Reports 2015, 7:44 http://f1000.com/prime/reports/b/7/44",Non-OADS,/arxiv_data1/oa_pdf/37/8f/biolrep-07-44.PMC4447044.pdf
"Page 14 of 18 (page number not for citation purposes)F1000Prime Reports 2015, 7:44 http://f1000.com/prime/reports/b/7/44",Non-OADS,/arxiv_data1/oa_pdf/37/8f/biolrep-07-44.PMC4447044.pdf
"Page 15of18 (page number notforcitation purposes)F1000Prime Reports 2015, 7:44 http://f1000.com/prime/reports/b/7/44",Non-OADS,/arxiv_data1/oa_pdf/37/8f/biolrep-07-44.PMC4447044.pdf
"Page 16 of 18 (page number not for citation purposes)F1000Prime Reports 2015, 7:44 http://f1000.com/prime/reports/b/7/44",Non-OADS,/arxiv_data1/oa_pdf/37/8f/biolrep-07-44.PMC4447044.pdf
"Page 17 of 18 (page number not for citation purposes)F1000Prime Reports 2015, 7:44 http://f1000.com/prime/reports/b/7/44",Non-OADS,/arxiv_data1/oa_pdf/37/8f/biolrep-07-44.PMC4447044.pdf
"Page 18 of 18 (page number not for citation purposes)F1000Prime Reports 2015, 7:44 http://f1000.com/prime/reports/b/7/44",Non-OADS,/arxiv_data1/oa_pdf/37/8f/biolrep-07-44.PMC4447044.pdf
"New insights into nucleolar structure andfunction Yun Wah Lam1andLaura Trinkle-Mulcahy2* Addresses:1Department ofBiology andChemistry, City University ofHong Kong, TatChee Avenue, Kowloon, Hong Kong;2Department of Cellular &Molecular Medicine andOttawa Institute ofSystems Biology, University ofOttawa, 451Smyth Road, Ottawa, ON, K1H 8M5, Canada *Corresponding author: Laura Trinkle-Mulcahy (ltrinkle@uottawa.ca) F1000Prime Reports 2015, 7:48(doi:10.12703/P7-48) AllF1000Prime Reports articles aredistributed under theterms oftheCreative Commons Attribution-Non Commercial License (http://creativecommons.org/licenses/by-nc/3.0/legalcode), which permits non-commercial use, distribution, andreproduction inanymedium, provided theoriginal work isproperly cited.",Non-OADS,/arxiv_data1/oa_pdf/73/17/biolrep-07-48.PMC4447046.pdf
The electronic version ofthisarticle isthecomplete oneandcanbefound at:http://f1000.com/prime/reports/b/7/48 Abstract The nucleolus isanon-membrane-bound nuclear organelle found inalleukaryotes.,Non-OADS,/arxiv_data1/oa_pdf/73/17/biolrep-07-48.PMC4447046.pdf
"Importantly, phase transitions have also Page 2 of 9 (page number not for citation purposes)F1000Prime Reports 2015, 7:48 http://f1000.com/prime/reports/b/7/48",Non-OADS,/arxiv_data1/oa_pdf/73/17/biolrep-07-48.PMC4447046.pdf
"Interestingly, the Pederson group [44] has nowdemonstrated nucleolar retention of specific mRNAs,including a spliced IGF2 mRNA that contains target sites for all five of the miRNAs that they have localized to the Page 3 of 9 (page number not for citation purposes)F1000Prime Reports 2015, 7:48 http://f1000.com/prime/reports/b/7/48",Non-OADS,/arxiv_data1/oa_pdf/73/17/biolrep-07-48.PMC4447046.pdf
"Page 4 of 9 (page number not for citation purposes)F1000Prime Reports 2015, 7:48 http://f1000.com/prime/reports/b/7/48",Non-OADS,/arxiv_data1/oa_pdf/73/17/biolrep-07-48.PMC4447046.pdf
"They went on to identify a structure- dependent interaction between these transcripts and Page 5 of 9 (page number not for citation purposes)F1000Prime Reports 2015, 7:48 http://f1000.com/prime/reports/b/7/48",OADS,/arxiv_data1/oa_pdf/73/17/biolrep-07-48.PMC4447046.pdf
"Page 6 of 9 (page number not for citation purposes)F1000Prime Reports 2015, 7:48 http://f1000.com/prime/reports/b/7/48",Non-OADS,/arxiv_data1/oa_pdf/73/17/biolrep-07-48.PMC4447046.pdf
"Page 7 of 9 (page number not for citation purposes)F1000Prime Reports 2015, 7:48 http://f1000.com/prime/reports/b/7/48",Non-OADS,/arxiv_data1/oa_pdf/73/17/biolrep-07-48.PMC4447046.pdf
"Peltonen K, Colis L, Liu H, Jäämaa S, Moore HM, Enbäck J, Laakkonen P, Vaahtokari A, Jones RJ, af Hällström TM, Laiho M: Identification of novel p53 pathway activating small-molecule Page 8 of 9 (page number not for citation purposes)F1000Prime Reports 2015, 7:48 http://f1000.com/prime/reports/b/7/48",OADS,/arxiv_data1/oa_pdf/73/17/biolrep-07-48.PMC4447046.pdf
"Page 9of9 (page number notforcitation purposes)F1000Prime Reports 2015, 7:48 http://f1000.com/prime/reports/b/7/48",Non-OADS,/arxiv_data1/oa_pdf/73/17/biolrep-07-48.PMC4447046.pdf
"Recent advances intheprevention andmanagement of preterm birth Min YiTanandMeekai To* Address: Harris Birthright Unit, 3rdFloor, Golden Jubilee Wing, Denmark Hill, London SE59RS, UK *Corresponding author: Meekai To(meekaito@nhs.net) F1000Prime Reports 2015, 7:40(doi:10.12703/P7-40) AllF1000Prime Reports articles aredistributed under theterms oftheCreative Commons Attribution-Non Commercial License (http://creativecommons.org/licenses/by-nc/3.0/legalcode), which permits non-commercial use, distribution, andreproduction inanymedium, provided theoriginal work isproperly cited.",Non-OADS,/arxiv_data1/oa_pdf/5b/11/medrep-07-40.PMC4447047.pdf
"The electronic version ofthisarticle isthecomplete one andcanbefound at:http://f1000.com/prime/reports/m/7/40 Abstract The management ofpreterm birth hasseen major transformations inthelastfew decades with increasing interest worldwide, due totheimpact ofpreterm birth onneonatal morbidity and mortality.",Non-OADS,/arxiv_data1/oa_pdf/5b/11/medrep-07-40.PMC4447047.pdf
"A recently publishedindividual participant data meta-analysis (13 trials;3768 women/7536 infants) confirmed the lack ofbenefit in preventing prete rm birth at <34 weeks when progestogens were used in unselected twin pregnancies Page 2 of 7 (page number not for citation purposes)F1000Prime Reports 2015, 7:40 http://f1000.com/prime/reports/m/7/40",Non-OADS,/arxiv_data1/oa_pdf/5b/11/medrep-07-40.PMC4447047.pdf
"At earlychildhood follow-up, the primary outcomes (mortality,survival free of disability, serious outcome) and second- ary growth assessments did not reveal any significant Page 3 of 7 (page number not for citation purposes)F1000Prime Reports 2015, 7:40 http://f1000.com/prime/reports/m/7/40",Non-OADS,/arxiv_data1/oa_pdf/5b/11/medrep-07-40.PMC4447047.pdf
"Page 4 of 7 (page number not for citation purposes)F1000Prime Reports 2015, 7:40 http://f1000.com/prime/reports/m/7/40",Non-OADS,/arxiv_data1/oa_pdf/5b/11/medrep-07-40.PMC4447047.pdf
"Geneva, 2012. http://apps.who.int/iris/bitstream/10665/44864/1/ 9789241503433_eng.pdf?ua=1 3.",Non-OADS,/arxiv_data1/oa_pdf/5b/11/medrep-07-40.PMC4447047.pdf
"Dodd JM,Jones L,Flenady V,Cincotta R,Crowther CA:Prenatal administration ofprogesterone forpreventing preterm birth Page 5of7 (page number notforcitation purposes)F1000Prime Reports 2015, 7:40 http://f1000.com/prime/reports/m/7/40",Non-OADS,/arxiv_data1/oa_pdf/5b/11/medrep-07-40.PMC4447047.pdf
"Crowther CA, McKinlay CJ, Middleton P, Harding JE: Repeat doses of prenatal corticosteroids for women at risk of preterm Page 6 of 7 (page number not for citation purposes)F1000Prime Reports 2015, 7:40 http://f1000.com/prime/reports/m/7/40",Non-OADS,/arxiv_data1/oa_pdf/5b/11/medrep-07-40.PMC4447047.pdf
[http://www.adelaide.edu.au/ arch] 56.,Non-OADS,/arxiv_data1/oa_pdf/5b/11/medrep-07-40.PMC4447047.pdf
"Page 7of7 (page number notforcitation purposes)F1000Prime Reports 2015, 7:40 http://f1000.com/prime/reports/m/7/40",Non-OADS,/arxiv_data1/oa_pdf/5b/11/medrep-07-40.PMC4447047.pdf
"Chicken ortheegg:Warburg effect andmitochondrial dysfunction Deniz Senyilmaz andAurelio A.Teleman* Address: German Cancer Research Center (DKFZ), Heidelberg, Germany *Corresponding author: Aurelio A.Teleman (a.teleman@dkfz.de) F1000Prime Reports 2015, 7:41(doi:10.12703/P7-41) AllF1000Prime Reports articles aredistributed under theterms oftheCreative Commons Attribution-Non Commercial License (http://creativecommons.org/licenses/by-nc/3.0/legalcode), which permits non-commercial use, distribution, andreproduction inanymedium, provided theoriginal work isproperly cited.",Non-OADS,/arxiv_data1/oa_pdf/84/b1/biolrep-07-41.PMC4447048.pdf
"The electronic version ofthisarticle isthecomplete oneandcanbefound at:http://f1000.com/prime/reports/b/7/41 Abstract Compared with normal cells, cancer cells show alterations inmany cellular processes, including energy metabolism.",Non-OADS,/arxiv_data1/oa_pdf/84/b1/biolrep-07-41.PMC4447048.pdf
"PFKB has four Page 2 of 13 (page number not for citation purposes)F1000Prime Reports 2015, 7:41 http://f1000.com/prime/reports/b/7/41",Non-OADS,/arxiv_data1/oa_pdf/84/b1/biolrep-07-41.PMC4447048.pdf
"Page 3 of 13 (page number not for citation purposes)F1000Prime Reports 2015, 7:41 http://f1000.com/prime/reports/b/7/41",Non-OADS,/arxiv_data1/oa_pdf/84/b1/biolrep-07-41.PMC4447048.pdf
"Page 4 of 13 (page number not for citation purposes)F1000Prime Reports 2015, 7:41 http://f1000.com/prime/reports/b/7/41",Non-OADS,/arxiv_data1/oa_pdf/84/b1/biolrep-07-41.PMC4447048.pdf
"Page 5 of 13 (page number not for citation purposes)F1000Prime Reports 2015, 7:41 http://f1000.com/prime/reports/b/7/41",Non-OADS,/arxiv_data1/oa_pdf/84/b1/biolrep-07-41.PMC4447048.pdf
"Page 6 of 13 (page number not for citation purposes)F1000Prime Reports 2015, 7:41 http://f1000.com/prime/reports/b/7/41",Non-OADS,/arxiv_data1/oa_pdf/84/b1/biolrep-07-41.PMC4447048.pdf
"Page 7 of 13 (page number not for citation purposes)F1000Prime Reports 2015, 7:41 http://f1000.com/prime/reports/b/7/41",Non-OADS,/arxiv_data1/oa_pdf/84/b1/biolrep-07-41.PMC4447048.pdf
"Page 8 of 13 (page number not for citation purposes)F1000Prime Reports 2015, 7:41 http://f1000.com/prime/reports/b/7/41",Non-OADS,/arxiv_data1/oa_pdf/84/b1/biolrep-07-41.PMC4447048.pdf
"Azoulay-Zohar H, Israelson A, Abu-Hamad S, Shoshan-Barmatz V: In self-defence: hexokinase promotes voltage-dependent anion Page 9 of 13 (page number not for citation purposes)F1000Prime Reports 2015, 7:41 http://f1000.com/prime/reports/b/7/41",Non-OADS,/arxiv_data1/oa_pdf/84/b1/biolrep-07-41.PMC4447048.pdf
"Israelsen WJ, Dayton TL, Davidson SM, Fiske BP, Hosios AM, Bellinger G, Li J, Yu Y, Sasaki M, Horner JW, Burga LN, Xie J, Jurczak MJ, DePinho RA, Clish CB, Jacks T, Kibbey RG, Wulf GM, Di Vizio D, Mills GB, Cantley LC, Vander Heiden MG: PKM2 isoform-specific deletion reveals a Page 10 of 13 (page number not for citation purposes)F1000Prime Reports 2015, 7:41 http://f1000.com/prime/reports/b/7/41",Non-OADS,/arxiv_data1/oa_pdf/84/b1/biolrep-07-41.PMC4447048.pdf
"Page 11 of 13 (page number not for citation purposes)F1000Prime Reports 2015, 7:41 http://f1000.com/prime/reports/b/7/41",Non-OADS,/arxiv_data1/oa_pdf/84/b1/biolrep-07-41.PMC4447048.pdf
"Page 12 of 13 (page number not for citation purposes)F1000Prime Reports 2015, 7:41 http://f1000.com/prime/reports/b/7/41",Non-OADS,/arxiv_data1/oa_pdf/84/b1/biolrep-07-41.PMC4447048.pdf
"Page 13 of 13 (page number not for citation purposes)F1000Prime Reports 2015, 7:41 http://f1000.com/prime/reports/b/7/41",Non-OADS,/arxiv_data1/oa_pdf/84/b1/biolrep-07-41.PMC4447048.pdf
"The search fornovel analgesics: targets andmechanisms Tony L.Yaksh*, Sarah A.Woller, Roshni Ramachandran, andLinda S.Sorkin Address: University ofCalifornia, SanDiego, Department ofAnesthesiology 0818, 9500 Gilman, Dr.(CTF C-312), LaJolla, CA92093, USA *Corresponding author: Tony L.Yaksh (tyaksh@ucsd.edu) F1000Prime Reports 2015, 7:56(doi:10.12703/P7-56) AllF1000Prime Reports articles aredistributed under theterms oftheCreative Commons Attribution-Non Commercial License (http://creativecommons.org/licenses/by-nc/3.0/legalcode), which permits non-commercial use, distribution, andreproduction inanymedium, provided theoriginal work isproperly cited.",Non-OADS,/arxiv_data1/oa_pdf/68/a0/medrep-07-56.PMC4447049.pdf
The electronic version ofthisarticle isthecomplete oneandcanbefound at:http://f1000.com/prime/reports/m/7/56 Abstract The management ofthepain state isofgreat therapeutic relevance tovirtually every medical specialty.,Non-OADS,/arxiv_data1/oa_pdf/68/a0/medrep-07-56.PMC4447049.pdf
"It isrecognized that the assertion that a particular staterepresents a pain experience, and that conversely the actions of an agent targeting those mechanisms are “analgesic ”, Page 2 of 27 (page number not for citation purposes)F1000Prime Reports 2015, 7:56 http://f1000.com/prime/reports/m/7/56",Non-OADS,/arxiv_data1/oa_pdf/68/a0/medrep-07-56.PMC4447049.pdf
"Summary of preclinical models Stimulus environment Model Time course Reference Acute Heat/cold/mechanical withdrawal Acute [409 –411] Acute Afferent evoked hyperalgesiaIntraplantar formalin Intraplantar capsaicinMin-hours [412,413] Inflammation - Acute Carrageenan: thermal (heat and cold )/mechanical withdrawal Min-hours [320,414] Inflammation - Chronic Freunds adjuvant (systemic): allodynia Days-weeks [415] KBxN serum transfer (joint): allodynia Days-months [46]CAIA antibody transfer (joint): allodynia Days-months [47] Osteoarthritis Anterior cruciate ligament section: weight bearing, activity, mechanical thresholdsDays-months [76,416,417] Iodoacetate model: weight bearing, activity, and mechanical thresholdsDays-weeks [418] Skin Incision Plantar incision: tactile allodynia Hours-days [419] Paw Burn Plantar burn: thermal and mechanical allodynia Hours-days [420]Visceral Colonic distention/inflammation: pseudoaffective response, tactile sensitivityDays-weeks [421,422] Pancreatitis Evoked inflammation: affective behavior and hypersensitivity Days-weeks [423] Bladder (Cystitis) Evoked inflammation: abdominal hypersensitivity Days-weeks [424]Mononeuropathy Nerve compression: allodynia Nerve ligation: allodyniaNeedle stick: allodyniaDays-months [425 –427] [428] [433] Polyneuropathy Diabetic model (Streptozotocin): allodynia Days-weeks [429] Chemotherapy: tactile allodynia Days-months [430] Spinal Injury Compression/section: tactile allodynia Days-months [207]Bone Cancer Femoral osteosarcoma: pressure/allodynia Days-weeks [431,432] Page 3 of 27 (page number not for citation purposes)F1000Prime Reports 2015, 7:56 http://f1000.com/prime/reports/m/7/56",Non-OADS,/arxiv_data1/oa_pdf/68/a0/medrep-07-56.PMC4447049.pdf
"Page 4 of 27 (page number not for citation purposes)F1000Prime Reports 2015, 7:56 http://f1000.com/prime/reports/m/7/56",Non-OADS,/arxiv_data1/oa_pdf/68/a0/medrep-07-56.PMC4447049.pdf
"Page 5 of 27 (page number not for citation purposes)F1000Prime Reports 2015, 7:56 http://f1000.com/prime/reports/m/7/56",Non-OADS,/arxiv_data1/oa_pdf/68/a0/medrep-07-56.PMC4447049.pdf
"The originof this ongoing activity reflects changes in channelexpression where local nerve injury and persistentinflammation can lead to the following: (a) an upregula-tion of sodium channels in the C-fiber afferent axon [133 –135] and a downregulation of potassium channels Page 6 of 27 (page number not for citation purposes)F1000Prime Reports 2015, 7:56 http://f1000.com/prime/reports/m/7/56",Non-OADS,/arxiv_data1/oa_pdf/68/a0/medrep-07-56.PMC4447049.pdf
"In either case, these changes alter the result of chloride ionophore Page 7 of 27 (page number not for citation purposes)F1000Prime Reports 2015, 7:56 http://f1000.com/prime/reports/m/7/56",OADS,/arxiv_data1/oa_pdf/68/a0/medrep-07-56.PMC4447049.pdf
"Page 8 of 27 (page number not for citation purposes)F1000Prime Reports 2015, 7:56 http://f1000.com/prime/reports/m/7/56",Non-OADS,/arxiv_data1/oa_pdf/68/a0/medrep-07-56.PMC4447049.pdf
"Page 9 of 27 (page number not for citation purposes)F1000Prime Reports 2015, 7:56 http://f1000.com/prime/reports/m/7/56",Non-OADS,/arxiv_data1/oa_pdf/68/a0/medrep-07-56.PMC4447049.pdf
"Recent work has suggested activation can be achieved independently of ß arrestin signaling and these “G protein biased ”ligands yield Page 10 of 27 (page number not for citation purposes)F1000Prime Reports 2015, 7:56 http://f1000.com/prime/reports/m/7/56",Non-OADS,/arxiv_data1/oa_pdf/68/a0/medrep-07-56.PMC4447049.pdf
"Page 11 of 27 (page number not for citation purposes)F1000Prime Reports 2015, 7:56 http://f1000.com/prime/reports/m/7/56",Non-OADS,/arxiv_data1/oa_pdf/68/a0/medrep-07-56.PMC4447049.pdf
"Delivery systems can involve sprays, wafers and Page 12 of 27 (page number not for citation purposes)F1000Prime Reports 2015, 7:56 http://f1000.com/prime/reports/m/7/56",Non-OADS,/arxiv_data1/oa_pdf/68/a0/medrep-07-56.PMC4447049.pdf
"Original work with novel targeted sodium channelblockers was negative [375], but more recent work hasborn positive fruit in models of postherpetic neuralgia and primary erythromelalgia [376] (https://clinicaltrials.gov/ ct2/results?term=Xen+402&Search=Search).",Non-OADS,/arxiv_data1/oa_pdf/68/a0/medrep-07-56.PMC4447049.pdf
"In Phase II clinical trials, an AT2 antagonist was found to be tolerated and it met its Page 13 of 27 (page number not for citation purposes)F1000Prime Reports 2015, 7:56 http://f1000.com/prime/reports/m/7/56",Non-OADS,/arxiv_data1/oa_pdf/68/a0/medrep-07-56.PMC4447049.pdf
"IncreasingIL-10 release by delivery of intrathecal transfection Page 14 of 27 (page number not for citation purposes)F1000Prime Reports 2015, 7:56 http://f1000.com/prime/reports/m/7/56",Non-OADS,/arxiv_data1/oa_pdf/68/a0/medrep-07-56.PMC4447049.pdf
methodologies is reported to have salutary effects in canine models of persistent pain and development of a caninetherapeutic would be important (http://xaludthera.com/products/).,Non-OADS,/arxiv_data1/oa_pdf/68/a0/medrep-07-56.PMC4447049.pdf
Pathways for drug development for veterinary use resemble those required for humanapproval and are in the tract of development that would beemployed for human application (see: http://www.fda.gov/AnimalVeterinary).,Non-OADS,/arxiv_data1/oa_pdf/68/a0/medrep-07-56.PMC4447049.pdf
"Page 15 of 27 (page number not for citation purposes)F1000Prime Reports 2015, 7:56 http://f1000.com/prime/reports/m/7/56",Non-OADS,/arxiv_data1/oa_pdf/68/a0/medrep-07-56.PMC4447049.pdf
"Page 16 of 27 (page number not for citation purposes)F1000Prime Reports 2015, 7:56 http://f1000.com/prime/reports/m/7/56",Non-OADS,/arxiv_data1/oa_pdf/68/a0/medrep-07-56.PMC4447049.pdf
"Page 17 of 27 (page number not for citation purposes)F1000Prime Reports 2015, 7:56 http://f1000.com/prime/reports/m/7/56",Non-OADS,/arxiv_data1/oa_pdf/68/a0/medrep-07-56.PMC4447049.pdf
"Page 18 of 27 (page number not for citation purposes)F1000Prime Reports 2015, 7:56 http://f1000.com/prime/reports/m/7/56",Non-OADS,/arxiv_data1/oa_pdf/68/a0/medrep-07-56.PMC4447049.pdf
"Page 19 of 27 (page number not for citation purposes)F1000Prime Reports 2015, 7:56 http://f1000.com/prime/reports/m/7/56",Non-OADS,/arxiv_data1/oa_pdf/68/a0/medrep-07-56.PMC4447049.pdf
"Svensson C, Lucas KK, Hua XY, Powell HC, Dennis EA, Yaksh TL: Spinal phospholipase A2 in inflammatory hyperalgesia: role Page 20 of 27 (page number not for citation purposes)F1000Prime Reports 2015, 7:56 http://f1000.com/prime/reports/m/7/56",Non-OADS,/arxiv_data1/oa_pdf/68/a0/medrep-07-56.PMC4447049.pdf
"Page 21 of 27 (page number not for citation purposes)F1000Prime Reports 2015, 7:56 http://f1000.com/prime/reports/m/7/56",Non-OADS,/arxiv_data1/oa_pdf/68/a0/medrep-07-56.PMC4447049.pdf
"Page 22 of 27 (page number not for citation purposes)F1000Prime Reports 2015, 7:56 http://f1000.com/prime/reports/m/7/56",Non-OADS,/arxiv_data1/oa_pdf/68/a0/medrep-07-56.PMC4447049.pdf
"Page 23 of 27 (page number not for citation purposes)F1000Prime Reports 2015, 7:56 http://f1000.com/prime/reports/m/7/56",Non-OADS,/arxiv_data1/oa_pdf/68/a0/medrep-07-56.PMC4447049.pdf
"Page 24 of 27 (page number not for citation purposes)F1000Prime Reports 2015, 7:56 http://f1000.com/prime/reports/m/7/56",Non-OADS,/arxiv_data1/oa_pdf/68/a0/medrep-07-56.PMC4447049.pdf
"Page 25 of 27 (page number not for citation purposes)F1000Prime Reports 2015, 7:56 http://f1000.com/prime/reports/m/7/56",Non-OADS,/arxiv_data1/oa_pdf/68/a0/medrep-07-56.PMC4447049.pdf
"Page 26 of 27 (page number not for citation purposes)F1000Prime Reports 2015, 7:56 http://f1000.com/prime/reports/m/7/56",Non-OADS,/arxiv_data1/oa_pdf/68/a0/medrep-07-56.PMC4447049.pdf
"Page 27 of 27 (page number not for citation purposes)F1000Prime Reports 2015, 7:56 http://f1000.com/prime/reports/m/7/56",Non-OADS,/arxiv_data1/oa_pdf/68/a0/medrep-07-56.PMC4447049.pdf
"The problem ofdropout from “gold standard ”PTSD therapies Lisa M.Najavits1,2 Addresses:1Veterans Affairs Boston Healthcare System, 150South Huntington Ave., Boston, MA02130, USA;2Department ofPsychiatry, Boston University School ofMedicine, 715Albany St.,M-8thFloor, Boston, MA02118, USA Email: Lisa.Najavits@va.gov F1000Prime Reports 2015, 7:43(doi:10.12703/P7-43) AllF1000Prime Reports articles aredistributed under theterms oftheCreative Commons Attribution-Non Commercial License (http://creativecommons.org/licenses/by-nc/3.0/legalcode), which permits non-commercial use, distribution, andreproduction inanymedium, provided theoriginal work isproperly cited.",Non-OADS,/arxiv_data1/oa_pdf/8e/a1/medrep-07-43.PMC4447050.pdf
The electronic version ofthisarticle isthecomplete oneandcanbefound at:http://f1000.com/prime/reports/m/7/43 Abstract Understanding ofposttraumatic stress disorder (PTSD) hasincreased substantially inthepast several decades.,Non-OADS,/arxiv_data1/oa_pdf/8e/a1/medrep-07-43.PMC4447050.pdf
"Both PE and CPT were designed and tested as short- term treatments: 12 sessions for CPT and typically Page 2 of 8 (page number not for citation purposes)F1000Prime Reports 2015, 7:43 http://f1000.com/prime/reports/m/7/43",Non-OADS,/arxiv_data1/oa_pdf/8e/a1/medrep-07-43.PMC4447050.pdf
"It can also be noted that several studies that purport to research drop-out from PE and CPT in “ real-world ” Page 3 of 8 (page number not for citation purposes)F1000Prime Reports 2015, 7:43 http://f1000.com/prime/reports/m/7/43",Non-OADS,/arxiv_data1/oa_pdf/8e/a1/medrep-07-43.PMC4447050.pdf
"Thus, it is important to Page 4 of 8 (page number not for citation purposes)F1000Prime Reports 2015, 7:43 http://f1000.com/prime/reports/m/7/43",Non-OADS,/arxiv_data1/oa_pdf/8e/a1/medrep-07-43.PMC4447050.pdf
"[12] found that 11.4% received CPT or PE, and note that their slightly higher rate (albeit still very low) is due Page 5 of 8 (page number not for citation purposes)F1000Prime Reports 2015, 7:43 http://f1000.com/prime/reports/m/7/43",Non-OADS,/arxiv_data1/oa_pdf/8e/a1/medrep-07-43.PMC4447050.pdf
"Page 6 of 8 (page number not for citation purposes)F1000Prime Reports 2015, 7:43 http://f1000.com/prime/reports/m/7/43",Non-OADS,/arxiv_data1/oa_pdf/8e/a1/medrep-07-43.PMC4447050.pdf
[http://opinionator.blogs.nytimes.com/ 2015/01/17/after-ptsd-more-trauma/] 7.,Non-OADS,/arxiv_data1/oa_pdf/8e/a1/medrep-07-43.PMC4447050.pdf
[http://www.alrest.org/pdf/CPT_Manual_- _Modified_for_PRRP%282%29.pdf] 9.,Non-OADS,/arxiv_data1/oa_pdf/8e/a1/medrep-07-43.PMC4447050.pdf
[http://www.seattleimplementation.org/wp- content/uploads/2011/11/Ruzek-PE_Initiative_SIRC_2011_final.pdf] 26.,Non-OADS,/arxiv_data1/oa_pdf/8e/a1/medrep-07-43.PMC4447050.pdf
"Cook JM,O’Donnell C,Dinnen S,Bernardy N,Rosenheck R,Hoff R: A formative evaluation of two evidence-based Page 7of8 (page number notforcitation purposes)F1000Prime Reports 2015, 7:43 http://f1000.com/prime/reports/m/7/43",Non-OADS,/arxiv_data1/oa_pdf/8e/a1/medrep-07-43.PMC4447050.pdf
"Page 8 of 8 (page number not for citation purposes)F1000Prime Reports 2015, 7:43 http://f1000.com/prime/reports/m/7/43",Non-OADS,/arxiv_data1/oa_pdf/8e/a1/medrep-07-43.PMC4447050.pdf
"Recent advances inunderstanding andmanaging rhabdomyosarcoma Susan M.Hiniker andSarah S.Donaldson* Address: Stanford University Medical Center, Stanford, CA94305 *Corresponding author: Sarah S.Donaldson (sarah2@stanford.edu) F1000Prime Reports 2015, 7:59(doi:10.12703/P7-59) AllF1000Prime Reports articles aredistributed under theterms oftheCreative Commons Attribution-Non Commercial License (http://creativecommons.org/licenses/by-nc/3.0/legalcode), which permits non-commercial use, distribution, andreproduction inanymedium, provided theoriginal work isproperly cited.",Non-OADS,/arxiv_data1/oa_pdf/61/37/medrep-07-59.PMC4447051.pdf
The electronic version ofthisarticle isthecomplete oneandcanbefound at:http://f1000.com/prime/reports/m/7/59 Abstract Rhabdomyosarcoma isthemost common childhood softtissue sarcoma andthefourth most common pediatric solid tumor.,Non-OADS,/arxiv_data1/oa_pdf/61/37/medrep-07-59.PMC4447051.pdf
"Recent preclinical Page 2 of 7 (page number not for citation purposes)F1000Prime Reports 2015, 7:59 http://f1000.com/prime/reports/m/7/59",Non-OADS,/arxiv_data1/oa_pdf/61/37/medrep-07-59.PMC4447051.pdf
"Page 3 of 7 (page number not for citation purposes)F1000Prime Reports 2015, 7:59 http://f1000.com/prime/reports/m/7/59",Non-OADS,/arxiv_data1/oa_pdf/61/37/medrep-07-59.PMC4447051.pdf
"The current open ARST 0531 and ARST 08P1 Page 4 of 7 (page number not for citation purposes)F1000Prime Reports 2015, 7:59 http://f1000.com/prime/reports/m/7/59",Non-OADS,/arxiv_data1/oa_pdf/61/37/medrep-07-59.PMC4447051.pdf
"Page 5 of 7 (page number not for citation purposes)F1000Prime Reports 2015, 7:59 http://f1000.com/prime/reports/m/7/59",Non-OADS,/arxiv_data1/oa_pdf/61/37/medrep-07-59.PMC4447051.pdf
"Page 6 of 7 (page number not for citation purposes)F1000Prime Reports 2015, 7:59 http://f1000.com/prime/reports/m/7/59",Non-OADS,/arxiv_data1/oa_pdf/61/37/medrep-07-59.PMC4447051.pdf
"Page 7 of 7 (page number not for citation purposes)F1000Prime Reports 2015, 7:59 http://f1000.com/prime/reports/m/7/59",Non-OADS,/arxiv_data1/oa_pdf/61/37/medrep-07-59.PMC4447051.pdf
"Advances intheunderstanding andmanagement ofheart transplantation Dhssraj Singh and David O.Taylor* Address: Department ofCardiovascular Medicine, Heart andVascular Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, Ohio 44195, USA *Corresponding author: David O.Taylor (taylord2@ccf.org) F1000Prime Reports 2015, 7:52(doi:10.12703/P7-52) AllF1000Prime Reports articles aredistributed under theterms oftheCreative Commons Attribution-Non Commercial License (http://creativecommons.org/licenses/by-nc/3.0/legalcode), which permits non-commercial use, distribution, andreproduction inanymedium, provided theoriginal work isproperly cited.",Non-OADS,/arxiv_data1/oa_pdf/88/1c/medrep-07-52.PMC4447052.pdf
The electronic version ofthisarticle isthecomplete oneandcanbefound at:http://f1000.com/prime/reports/m/7/52 Abstract Cardiac transplantation represents one ofthegreat triumphs inmodern medicine andremains the cornerstone inthetreatment ofadvanced heart failure.,Non-OADS,/arxiv_data1/oa_pdf/88/1c/medrep-07-52.PMC4447052.pdf
"While its uptake isnot uniform among transplant centers, it remains anoption in patients at otherwise low risk of rejection inwhom endomyocardial biopsy is especially problematic.Preliminary reports have shown that the use of AlloMAP may be comparable to endomyocardial biopsy within Page 2 of 6 (page number not for citation purposes)F1000Prime Reports 2015, 7:52 http://f1000.com/prime/reports/m/7/52",Non-OADS,/arxiv_data1/oa_pdf/88/1c/medrep-07-52.PMC4447052.pdf
"Trends from the International Society for Heart and Lung Transplantation Page 3 of 6 (page number not for citation purposes)F1000Prime Reports 2015, 7:52 http://f1000.com/prime/reports/m/7/52",Non-OADS,/arxiv_data1/oa_pdf/88/1c/medrep-07-52.PMC4447052.pdf
"Page 4 of 6 (page number not for citation purposes)F1000Prime Reports 2015, 7:52 http://f1000.com/prime/reports/m/7/52",Non-OADS,/arxiv_data1/oa_pdf/88/1c/medrep-07-52.PMC4447052.pdf
"Page 5 of 6 (page number not for citation purposes)F1000Prime Reports 2015, 7:52 http://f1000.com/prime/reports/m/7/52",Non-OADS,/arxiv_data1/oa_pdf/88/1c/medrep-07-52.PMC4447052.pdf
"Page 6 of 6 (page number not for citation purposes)F1000Prime Reports 2015, 7:52 http://f1000.com/prime/reports/m/7/52",Non-OADS,/arxiv_data1/oa_pdf/88/1c/medrep-07-52.PMC4447052.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/77/75/euu329.PMC4447053.pdf
"Advances inunderstanding Giardia :determinants andmechanisms ofchronic sequelae Luther A.Bartelt1*andR.Balfour Sartor2 Addresses:1Division ofInfectious Diseases andInternational Health, University ofVirginia, Box801340, Charlottesville, VA22908, USA; 2Division ofGastroenterology, Center forGastrointestinal Biology andDisease, University ofNorth Carolina atChapel Hill, Campus Box7032, Chapel Hill, NC27599-7032, USA *Corresponding author: Luther A.Bartelt (lab2za@virginia.edu) F1000Prime Reports 2015, 7:62(doi:10.12703/P7-62) AllF1000Prime Reports articles aredistributed under theterms oftheCreative Commons Attribution-Non Commercial License (http://creativecommons.org/licenses/by-nc/3.0/legalcode), which permits non-commercial use, distribution, andreproduction inanymedium, provided theoriginal work isproperly cited.",Non-OADS,/arxiv_data1/oa_pdf/e3/8f/biolrep-07-62.PMC4447054.pdf
The electronic version ofthisarticle isthecomplete oneandcanbefound at:http://f1000.com/prime/reports/b/7/62 Abstract Giardia lamblia isaflagellated protozoan thatisthemost common cause ofintestinal parasitic infection in children living inresource-limited settings.,Non-OADS,/arxiv_data1/oa_pdf/e3/8f/biolrep-07-62.PMC4447054.pdf
"Page 2 of 14 (page number not for citation purposes)F1000Prime Reports 2015, 7:62 http://f1000.com/prime/reports/b/7/62",Non-OADS,/arxiv_data1/oa_pdf/e3/8f/biolrep-07-62.PMC4447054.pdf
"Thetype of diarrhea experienced in giardiasis is classicallygreasy and foul-smelling (steatorrhea) with findings ofmalabsorption of vitamins A and B12, d-xylose, iron, and zinc [3,67 –69] as well as lactase deficiency in 20-40% of Page 3 of 14 (page number not for citation purposes)F1000Prime Reports 2015, 7:62 http://f1000.com/prime/reports/b/7/62",Non-OADS,/arxiv_data1/oa_pdf/e3/8f/biolrep-07-62.PMC4447054.pdf
"Page 4 of 14 (page number not for citation purposes)F1000Prime Reports 2015, 7:62 http://f1000.com/prime/reports/b/7/62",Non-OADS,/arxiv_data1/oa_pdf/e3/8f/biolrep-07-62.PMC4447054.pdf
"Arginine utilizationrepresents an example of how shunting of key nutrients may provide an advantage to the parasite at a detriment to Page 5 of 14 (page number not for citation purposes)F1000Prime Reports 2015, 7:62 http://f1000.com/prime/reports/b/7/62",Non-OADS,/arxiv_data1/oa_pdf/e3/8f/biolrep-07-62.PMC4447054.pdf
"The down-regulatory effect of Giardia lysate on dendritic cell responses to TLR4 agonists has been shown to be dependent on phosphoinositide 3-kinase Page 6 of 14 (page number not for citation purposes)F1000Prime Reports 2015, 7:62 http://f1000.com/prime/reports/b/7/62",Non-OADS,/arxiv_data1/oa_pdf/e3/8f/biolrep-07-62.PMC4447054.pdf
"Such chronic and repeated Giardia exposures are common in children in low-income settings who alsohave a high prevalence of malnutrition and an increas-ingly recognized gut dysfunction with chronic intestinal inflammation, increased gut permeability, and reduced Page 7 of 14 (page number not for citation purposes)F1000Prime Reports 2015, 7:62 http://f1000.com/prime/reports/b/7/62",Non-OADS,/arxiv_data1/oa_pdf/e3/8f/biolrep-07-62.PMC4447054.pdf
"Page 8 of 14 (page number not for citation purposes)F1000Prime Reports 2015, 7:62 http://f1000.com/prime/reports/b/7/62",Non-OADS,/arxiv_data1/oa_pdf/e3/8f/biolrep-07-62.PMC4447054.pdf
"Page 9 of 14 (page number not for citation purposes)F1000Prime Reports 2015, 7:62 http://f1000.com/prime/reports/b/7/62",Non-OADS,/arxiv_data1/oa_pdf/e3/8f/biolrep-07-62.PMC4447054.pdf
"Page 10 of 14 (page number not for citation purposes)F1000Prime Reports 2015, 7:62 http://f1000.com/prime/reports/b/7/62",Non-OADS,/arxiv_data1/oa_pdf/e3/8f/biolrep-07-62.PMC4447054.pdf
"Cotton JA, Motta JP, Schenck LP, Hirota SA, Beck PL, Buret AG: Giardia duodenalis infection reduces granulocyte infiltration in an in vivo model of bacterial toxin-Induced colitis and Page 11 of 14 (page number not for citation purposes)F1000Prime Reports 2015, 7:62 http://f1000.com/prime/reports/b/7/62",Non-OADS,/arxiv_data1/oa_pdf/e3/8f/biolrep-07-62.PMC4447054.pdf
"Naess H, Nyland M, Hausken T, Follestad I, Nyland HI: Chronic fatigue syndrome after Giardia enteritis: clinical characteristics, Page 12 of 14 (page number not for citation purposes)F1000Prime Reports 2015, 7:62 http://f1000.com/prime/reports/b/7/62",Non-OADS,/arxiv_data1/oa_pdf/e3/8f/biolrep-07-62.PMC4447054.pdf
"Page 13 of 14 (page number not for citation purposes)F1000Prime Reports 2015, 7:62 http://f1000.com/prime/reports/b/7/62",Non-OADS,/arxiv_data1/oa_pdf/e3/8f/biolrep-07-62.PMC4447054.pdf
"Page 14 of 14 (page number not for citation purposes)F1000Prime Reports 2015, 7:62 http://f1000.com/prime/reports/b/7/62",Non-OADS,/arxiv_data1/oa_pdf/e3/8f/biolrep-07-62.PMC4447054.pdf
"Advances inthemanagement ofbasal cellcarcinoma Jesse M.Lewin* andJohn A.Carucci Address: 240East 38thStreet, 12thFloor, New York, NY10016; USA *Corresponding author: Jesse M.Lewin (Lewin.jesse@gmail.com) F1000Prime Reports 2015, 7:53(doi:10.12703/P7-53) AllF1000Prime Reports articles aredistributed under theterms oftheCreative Commons Attribution-Non Commercial License (http://creativecommons.org/licenses/by-nc/3.0/legalcode), which permits non-commercial use, distribution, andreproduction inanymedium, provided theoriginal work isproperly cited.",Non-OADS,/arxiv_data1/oa_pdf/f4/7f/medrep-07-53.PMC4447055.pdf
"The electronic version ofthisarticle isthecomplete oneandcanbefound at:http://f1000.com/prime/reports/m/7/53 Abstract Basal cellcarcinoma (BCC), amalignant neoplasm derived from non-keratinizing cells thatoriginate in thebasal layer oftheepidermis, isthemost common cancer inhumans.",Non-OADS,/arxiv_data1/oa_pdf/f4/7f/medrep-07-53.PMC4447055.pdf
"Page 2 of 8 (page number not for citation purposes)F1000Prime Reports 2015, 7:53 http://f1000.com/prime/reports/m/7/53",Non-OADS,/arxiv_data1/oa_pdf/f4/7f/medrep-07-53.PMC4447055.pdf
"The procedure involves Page 3 of 8 (page number not for citation purposes)F1000Prime Reports 2015, 7:53 http://f1000.com/prime/reports/m/7/53",Non-OADS,/arxiv_data1/oa_pdf/f4/7f/medrep-07-53.PMC4447055.pdf
"It is important to Page 4 of 8 (page number not for citation purposes)F1000Prime Reports 2015, 7:53 http://f1000.com/prime/reports/m/7/53",Non-OADS,/arxiv_data1/oa_pdf/f4/7f/medrep-07-53.PMC4447055.pdf
"In one study of Page 5 of 8 (page number not for citation purposes)F1000Prime Reports 2015, 7:53 http://f1000.com/prime/reports/m/7/53",Non-OADS,/arxiv_data1/oa_pdf/f4/7f/medrep-07-53.PMC4447055.pdf
"13. van Dam RM, Huang Z, Rimm EB, Weinstock MA, Spiegelman D, Colditz GA, Willett WC, Giovannucci E: Risk factors for basal cell Page 6 of 8 (page number not for citation purposes)F1000Prime Reports 2015, 7:53 http://f1000.com/prime/reports/m/7/53",Non-OADS,/arxiv_data1/oa_pdf/f4/7f/medrep-07-53.PMC4447055.pdf
[https://www.aad.org/education/ appropriate-use-criteria/mohs-auc-app].,Non-OADS,/arxiv_data1/oa_pdf/f4/7f/medrep-07-53.PMC4447055.pdf
"Geisse JK, Rich P, Pandya A, Gross K, Andres K, Ginkel A, Owens M: Imiquimod 5% cream for the treatment of superficial basal Page 7 of 8 (page number not for citation purposes)F1000Prime Reports 2015, 7:53 http://f1000.com/prime/reports/m/7/53",Non-OADS,/arxiv_data1/oa_pdf/f4/7f/medrep-07-53.PMC4447055.pdf
[http://www.wsj.com/ articles/new-drugs-treat-advanced-stages-of-a-common-skin- cancer-1416869882?KEYWORDS=basal+cell+carcinoma .,Non-OADS,/arxiv_data1/oa_pdf/f4/7f/medrep-07-53.PMC4447055.pdf
"Page 8of8 (page number notforcitation purposes)F1000Prime Reports 2015, 7:53 http://f1000.com/prime/reports/m/7/53",Non-OADS,/arxiv_data1/oa_pdf/f4/7f/medrep-07-53.PMC4447055.pdf
"Recent treatment advances and novel therapeutic approaches in epilepsy Enrique Serrano and Andres M. Kanner* Address: Department of Neurology, University of Miami, Miller School of Medicine, 1120 NW 14th Street, Miami, FL 33136, USA * Corresponding author: Andres M. Kanner (a.kanner@med.miami.edu) F1000Prime Reports 2015, 7:61 (doi:10.12703/P7-61) All F1000Prime Reports articles are distributed under the terms of the Creative Commons Attribution-Non Commercial License (http://creativecommons.org/licenses/by-nc/3.0/legalcode), which permits non-commercial use, distribution, and reproduction in any medium , provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/bd/49/medrep-07-61.PMC4447056.pdf
The electronic version of this article is the complete one and can be found at: http://f1000.com/prime/reports/m/7/61 Abstract The purpose of this article is to review recent advances in the treatment of epilepsy.,Non-OADS,/arxiv_data1/oa_pdf/bd/49/medrep-07-61.PMC4447056.pdf
"Furthermore, ESL acetate was developed to overcome the unnecessary production of enantiomers, Page 2 of 9 (page number not for citation purposes)F1000Prime Reports 2015, 7:61 http://f1000.com/prime/reports/m/7/61",Non-OADS,/arxiv_data1/oa_pdf/bd/49/medrep-07-61.PMC4447056.pdf
"Page 3 of 9 (page number not for citation purposes)F1000Prime Reports 2015, 7:61 http://f1000.com/prime/reports/m/7/61",Non-OADS,/arxiv_data1/oa_pdf/bd/49/medrep-07-61.PMC4447056.pdf
"Page 4 of 9 (page number not for citation purposes)F1000Prime Reports 2015, 7:61 http://f1000.com/prime/reports/m/7/61",Non-OADS,/arxiv_data1/oa_pdf/bd/49/medrep-07-61.PMC4447056.pdf
"There is evidence of increased levels of IL-1 band IL-1R1 and increased ICE/ caspase-1 activation in surgically resected epileptogenictissue from patients with treatment-resistant TLE [62].As an inflammatory enzyme, caspase-1 is involved in the Page 5 of 9 (page number not for citation purposes)F1000Prime Reports 2015, 7:61 http://f1000.com/prime/reports/m/7/61",Non-OADS,/arxiv_data1/oa_pdf/bd/49/medrep-07-61.PMC4447056.pdf
"New drugs in the pipeline for epilepsy The following are new drugs in the pipeline for epilepsy:BGG492 (Novartis), a competitive AMPA/kainate receptorantagonist; Brivaracetam (UCB), a novel high-affinitySV2A ligand; CPP-115 (Catalyst), a GABA transaminaseinhibitor (vigabatrin derived); ICA-105665 (Pfizer), ahighly selective opener of neuronal Kv7 (KCNQ) potas-sium channels; T2000 (Taro), a non-sedating barbiturate;Tonabersat (Upsher-Smith), which utilizes a novel mechanism of uncoupling of neuronal gap junctions; UCB0942 (UCB), a new pre- and post-synaptic inhibitor;VX-765 (Vertex), a selective inhibitor of interleukin-converting enzyme; YKP3089 (SK Life), which features anovel mechanism of action; 2-Deoxy-D-glucose (Neuro-GenomeX), a glucose analog and glycolytic inhibitor;Ganaxolone (Marinus), a synthetic neurosteroid andGABA-A receptor modulator; Imepitoin, a low-affinity partial agonist at the benzodiazepine site of the GABA-A Page 6 of 9 (page number not for citation purposes)F1000Prime Reports 2015, 7:61 http://f1000.com/prime/reports/m/7/61",Non-OADS,/arxiv_data1/oa_pdf/bd/49/medrep-07-61.PMC4447056.pdf
[http://www.who.int/mediacentre/ factsheets/fs999/en/index.html] 4.,Non-OADS,/arxiv_data1/oa_pdf/bd/49/medrep-07-61.PMC4447056.pdf
[http://www.fda.gov/drugs/drugsafety/ucm349538.htm] 16.,Non-OADS,/arxiv_data1/oa_pdf/bd/49/medrep-07-61.PMC4447056.pdf
"Page 7 of 9 (page number not for citation purposes)F1000Prime Reports 2015, 7:61 http://f1000.com/prime/reports/m/7/61",Non-OADS,/arxiv_data1/oa_pdf/bd/49/medrep-07-61.PMC4447056.pdf
[http://news.emory.edu/stories/ 2013/12/better_memory_with_laser_epilepsy_surgery/index.html] 25.,Non-OADS,/arxiv_data1/oa_pdf/bd/49/medrep-07-61.PMC4447056.pdf
[http://www.medscape.com/viewarticle/817498] 26.,Non-OADS,/arxiv_data1/oa_pdf/bd/49/medrep-07-61.PMC4447056.pdf
[http://www.fda.gov/newsevents/newsroom/pressannoun cements/ucm375041.htm] 27.,Non-OADS,/arxiv_data1/oa_pdf/bd/49/medrep-07-61.PMC4447056.pdf
"Vezzani A, Balosso S, Maroso M, Zardoni D, Noé F, Ravizza T: ICE/ caspase 1 inhibitors and IL-1 beta receptor antagonists as Page 8 of 9 (page number not for citation purposes)F1000Prime Reports 2015, 7:61 http://f1000.com/prime/reports/m/7/61",Non-OADS,/arxiv_data1/oa_pdf/bd/49/medrep-07-61.PMC4447056.pdf
"Page 9 of 9 (page number not for citation purposes)F1000Prime Reports 2015, 7:61 http://f1000.com/prime/reports/m/7/61",Non-OADS,/arxiv_data1/oa_pdf/bd/49/medrep-07-61.PMC4447056.pdf
"Advances intheprevention ofAlzheimer ’sDisease Shireen Sindi1,2*,Francesca Mangialasche1,2andMiia Kivipelto1,2,3 Addresses:1Karolinska Institutet Center forAlzheimer Research, Novum, 5thfloor, 14186Huddinge, Sweden;2Aging Research Center, Karolinska Institutet andStockholm University, Gävelagatan 16,8thfloor, 11330Stockholm, Sweden;3Department ofNeurology, University ofEastern Finland, Yliopistonranta 1B,70211 Kuopio, Finland *Corresponding author: Shireen Sindi (shireen.sindi@ki.se) F1000Prime Reports 2015, 7:50(doi:10.12703/P7-50) AllF1000Prime Reports articles aredistributed under theterms oftheCreative Commons Attribution-Non Commercial License (http://creativecommons.org/licenses/by-nc/3.0/legalcode), which permits non-commercial use, distribution, andreproduction inanymedium, provided theoriginal work isproperly cited.",Non-OADS,/arxiv_data1/oa_pdf/fc/4d/medrep-07-50.PMC4447057.pdf
"The electronic version ofthisarticle isthecomplete oneandcanbefound at:http://f1000.com/prime/reports/m/7/50 Abstract Alzheimer ’sdisease (AD), theleading cause ofdementia, hasreached epidemic proportions, with major social, medical andeconomical burdens.",Non-OADS,/arxiv_data1/oa_pdf/fc/4d/medrep-07-50.PMC4447057.pdf
"Risk factors for dementia and Alzheimer ’s disease across the lifespan (Figure modified from [51]) Page 2 of 12 (page number not for citation purposes)F1000Prime Reports 2015, 7:50 http://f1000.com/prime/reports/m/7/50",Non-OADS,/arxiv_data1/oa_pdf/fc/4d/medrep-07-50.PMC4447057.pdf
"Page 3of12 (page number notforcitation purposes)F1000Prime Reports 2015, 7:50 http://f1000.com/prime/reports/m/7/50",Non-OADS,/arxiv_data1/oa_pdf/fc/4d/medrep-07-50.PMC4447057.pdf
"Currently, there are three ongoing large multidomain Page 4 of 12 (page number not for citation purposes)F1000Prime Reports 2015, 7:50 http://f1000.com/prime/reports/m/7/50",Non-OADS,/arxiv_data1/oa_pdf/fc/4d/medrep-07-50.PMC4447057.pdf
"Page 5 of 12 (page number not for citation purposes)F1000Prime Reports 2015, 7:50 http://f1000.com/prime/reports/m/7/50",Non-OADS,/arxiv_data1/oa_pdf/fc/4d/medrep-07-50.PMC4447057.pdf
"The APItrialisalsoduetolaunch another preventive study in Page 6of12 (page number notforcitation purposes)F1000Prime Reports 2015, 7:50 http://f1000.com/prime/reports/m/7/50",Non-OADS,/arxiv_data1/oa_pdf/fc/4d/medrep-07-50.PMC4447057.pdf
"Page 7of12 (page number notforcitation purposes)F1000Prime Reports 2015, 7:50 http://f1000.com/prime/reports/m/7/50",Non-OADS,/arxiv_data1/oa_pdf/fc/4d/medrep-07-50.PMC4447057.pdf
"Page 8 of 12 (page number not for citation purposes)F1000Prime Reports 2015, 7:50 http://f1000.com/prime/reports/m/7/50",Non-OADS,/arxiv_data1/oa_pdf/fc/4d/medrep-07-50.PMC4447057.pdf
[http://www.who.int/mental_health/publications/ dementia_report_2012/en/].,Non-OADS,/arxiv_data1/oa_pdf/fc/4d/medrep-07-50.PMC4447057.pdf
[https://www.gov.uk/government/uploads/system/ uploads/attachment_data/file/265869/2901668_G8_DementiaSummit Declaration_acc.pdf].,Non-OADS,/arxiv_data1/oa_pdf/fc/4d/medrep-07-50.PMC4447057.pdf
"Page 9 of 12 (page number not for citation purposes)F1000Prime Reports 2015, 7:50 http://f1000.com/prime/reports/m/7/50",Non-OADS,/arxiv_data1/oa_pdf/fc/4d/medrep-07-50.PMC4447057.pdf
CAIDE Dementia Risk App : [http://www.memantine.com/en/ patients_and_caregivers/everyday_life_management/caide_risk_factor_ app/caide_risk_factor_app.php].,Non-OADS,/arxiv_data1/oa_pdf/fc/4d/medrep-07-50.PMC4447057.pdf
": Trends in Page 10 of 12 (page number not for citation purposes)F1000Prime Reports 2015, 7:50 http://f1000.com/prime/reports/m/7/50",Non-OADS,/arxiv_data1/oa_pdf/fc/4d/medrep-07-50.PMC4447057.pdf
"EMA/ CHMP/SAWP/893622/2011; 2012, [http://www.ema.europa.eu/ docs/en_GB/document_library/Regulatory_and_procedural_guideline/ 2012/04/WC500125019.pdf].",Non-OADS,/arxiv_data1/oa_pdf/fc/4d/medrep-07-50.PMC4447057.pdf
"Page 11 of 12 (page number not for citation purposes)F1000Prime Reports 2015, 7:50 http://f1000.com/prime/reports/m/7/50",Non-OADS,/arxiv_data1/oa_pdf/fc/4d/medrep-07-50.PMC4447057.pdf
[http://www.edpi.org/].,Non-OADS,/arxiv_data1/oa_pdf/fc/4d/medrep-07-50.PMC4447057.pdf
[http://www.hatice.eu/].,Non-OADS,/arxiv_data1/oa_pdf/fc/4d/medrep-07-50.PMC4447057.pdf
[http://banneralz.org/research- plus-discovery/alzheimers-prevention-initiative.aspx].85.,Non-OADS,/arxiv_data1/oa_pdf/fc/4d/medrep-07-50.PMC4447057.pdf
[http://www.dian-info.org/].,Non-OADS,/arxiv_data1/oa_pdf/fc/4d/medrep-07-50.PMC4447057.pdf
[http://www.adcs.org/Studies/A4.aspx].,Non-OADS,/arxiv_data1/oa_pdf/fc/4d/medrep-07-50.PMC4447057.pdf
[http://www.douglas.qc.ca/ page/prevent-alzheimer-program].,Non-OADS,/arxiv_data1/oa_pdf/fc/4d/medrep-07-50.PMC4447057.pdf
[http://www.idf.org/diabetesatlas/update-2014].,Non-OADS,/arxiv_data1/oa_pdf/fc/4d/medrep-07-50.PMC4447057.pdf
[http://www.imi.europa.eu].,Non-OADS,/arxiv_data1/oa_pdf/fc/4d/medrep-07-50.PMC4447057.pdf
"Page 12 of 12 (page number not for citation purposes)F1000Prime Reports 2015, 7:50 http://f1000.com/prime/reports/m/7/50",Non-OADS,/arxiv_data1/oa_pdf/fc/4d/medrep-07-50.PMC4447057.pdf
"Management oftachycardia Rakesh Gopinathannair, MD, MA1*andBrian Olshansky, MD2 Addresses:1Division ofCardiovascular Medicine, University ofLouisville School ofMedicine, ACB/A3L41, 550So.Jackson St.,Louisville, KY,USA; 2University ofIowa Hospitals andClinics, 200Hawkins Dr,Iowa City, IA,USA *Corresponding author: Rakesh Gopinathannair (rakesh.gopinathannair@louisville.edu) F1000Prime Reports 2015, 7:60(doi:10.12703/P7-60) AllF1000Prime Reports articles aredistributed under theterms oftheCreative Commons Attribution-Non Commercial License (http://creativecommons.org/licenses/by-nc/3.0/legalcode), which permits non-commercial use, distribution, andreproduction inanymedium, provided theoriginal work isproperly cited.",Non-OADS,/arxiv_data1/oa_pdf/98/68/medrep-07-60.PMC4447058.pdf
"The electronic version ofthisarticle isthecomplete oneandcanbefound at:http://f1000.com/prime/reports/m/7/60 Abstract Tachycardia, conventionally, butarbitrarily, defined asanatrial and/or ventricular rate of>100 beats perminute, isencountered commonly andcanbephysiological orpathological inorigin.",Non-OADS,/arxiv_data1/oa_pdf/98/68/medrep-07-60.PMC4447058.pdf
"Arrhythmias responsible for tachycardia-mediated cardiomyopathy Supraventricular Atrial fibrillationAtrial flutterAtrial tachycardiaAV nodal reentrant tachycardiaAV reentrant tachycardia Permanent junctional reciprocating tachycardia (PJRT) Ventricular Idiopathic ventricular tachycardiaFascicular tachycardia (left septal ventricular tachycardia) Ectopy Frequent premature ventricular contractionsFrequent premature atrial contractions Pacing High-rate atrial pacingPersistent rapid ventricular pacing Page 2 of 5 (page number not for citation purposes)F1000Prime Reports 2015, 7:60 http://f1000.com/prime/reports/m/7/60",Non-OADS,/arxiv_data1/oa_pdf/98/68/medrep-07-60.PMC4447058.pdf
"Page 3 of 5 (page number not for citation purposes)F1000Prime Reports 2015, 7:60 http://f1000.com/prime/reports/m/7/60",Non-OADS,/arxiv_data1/oa_pdf/98/68/medrep-07-60.PMC4447058.pdf
"Hsu L, Jaïs P, Sanders P, Garrigue S, Hocini M, Sacher F, Takahashi Y, Rotter M, Pasquié J, Scavée C, Bordachar P, Clémenty J, Page 4 of 5 (page number not for citation purposes)F1000Prime Reports 2015, 7:60 http://f1000.com/prime/reports/m/7/60",Non-OADS,/arxiv_data1/oa_pdf/98/68/medrep-07-60.PMC4447058.pdf
"Page 5 of 5 (page number not for citation purposes)F1000Prime Reports 2015, 7:60 http://f1000.com/prime/reports/m/7/60",Non-OADS,/arxiv_data1/oa_pdf/98/68/medrep-07-60.PMC4447058.pdf
"Insomnia andsleep apnea inmidlife women: prevalence and consequences tohealth andfunctioning Martica H.Hall*1,Christopher E.Kline1,andSara Nowakowski2 Addresses:1Department ofPsychiatry, University ofPittsburgh School ofMedicine, 3811 O’Hara Street, Pittsburgh, PA15213, USA; 2Department ofObstetrics andGynecology, University ofTexas Medical Branch, 301University Boulevard, Galveston, TX77555-0587, USA *Corresponding author: Martica H.Hall (hallmh@upmc.edu) F1000Prime Reports 2015, 7:63(doi:10.12703/P7-63) AllF1000Prime Reports articles aredistributed under theterms oftheCreative Commons Attribution-Non Commercial License (http://creativecommons.org/licenses/by-nc/3.0/legalcode), which permits non-commercial use,distribution, andreproduction inanymedium, provided theoriginal work isproperly cited.",Non-OADS,/arxiv_data1/oa_pdf/78/12/medrep-07-63.PMC4447062.pdf
"Theelectronic version ofthisarticle isthecomplete oneandcanbefound at:http://f1000.com/prime/reports/m/63 Abstract Sleep disturbance iscommon during themenopausal transition, with numerous downstream consequences tohealth andfunctioning, including reduced quality oflife,impaired mental health, and increased physical health morbidity.",Non-OADS,/arxiv_data1/oa_pdf/78/12/medrep-07-63.PMC4447062.pdf
"Risk for Page 2 of 11 (page number not for citation purposes)F1000Prime Reports 2015, 7:63 http://f1000.com/prime/reports/m/63",Non-OADS,/arxiv_data1/oa_pdf/78/12/medrep-07-63.PMC4447062.pdf
"Page 3 of 11 (page number not for citation purposes)F1000Prime Reports 2015, 7:63 http://f1000.com/prime/reports/m/63",Non-OADS,/arxiv_data1/oa_pdf/78/12/medrep-07-63.PMC4447062.pdf
"Across multiple races and ethnicities and without regard to age and obesity status, recent estimates indicate thatapproximately 20% of women have at least mild OSA(AHI of at least 5) and that 6% have moderate to severe Page 4 of 11 (page number not for citation purposes)F1000Prime Reports 2015, 7:63 http://f1000.com/prime/reports/m/63",Non-OADS,/arxiv_data1/oa_pdf/78/12/medrep-07-63.PMC4447062.pdf
"Similarly, only a handful of studies have Page 5 of 11 (page number not for citation purposes)F1000Prime Reports 2015, 7:63 http://f1000.com/prime/reports/m/63",Non-OADS,/arxiv_data1/oa_pdf/78/12/medrep-07-63.PMC4447062.pdf
"Page 6 of 11 (page number not for citation purposes)F1000Prime Reports 2015, 7:63 http://f1000.com/prime/reports/m/63",Non-OADS,/arxiv_data1/oa_pdf/78/12/medrep-07-63.PMC4447062.pdf
"Page 7 of 11 (page number not for citation purposes)F1000Prime Reports 2015, 7:63 http://f1000.com/prime/reports/m/63",Non-OADS,/arxiv_data1/oa_pdf/78/12/medrep-07-63.PMC4447062.pdf
"Sands-Lincoln M, Loucks EB, Lu B, Carskadon MA, Sharkey K, Stefanick ML, Ockene J, Shah N, Hairston KG, Robinson JG, Page 8 of 11 (page number not for citation purposes)2015, 7:63 http://f1000.com/prime/reports/m/63",Non-OADS,/arxiv_data1/oa_pdf/78/12/medrep-07-63.PMC4447062.pdf
"Young T, Shahar E, Nieto FJ, Redline S, Newman AB, Gottlieb DJ, Walsleben JA, Finn L, Enright P, Samet JM: Predictors of sleep- disordered breathing in community-dwelling adults: the Page 9 of 11 (page number not for citation purposes)2015, 7:63 http://f1000.com/prime/reports/m/63",Non-OADS,/arxiv_data1/oa_pdf/78/12/medrep-07-63.PMC4447062.pdf
"Page 10 of 11 (page number not for citation purposes)2015, 7:63 http://f1000.com/prime/reports/m/63",Non-OADS,/arxiv_data1/oa_pdf/78/12/medrep-07-63.PMC4447062.pdf
"Page 11 of 11 (page number not for citation purposes)2015, 7:63 http://f1000.com/prime/reports/m/63",Non-OADS,/arxiv_data1/oa_pdf/78/12/medrep-07-63.PMC4447062.pdf
"Ancient Transposable Elements Transformed the Uterine  Regulatory Landscape and Transcriptome during the Evolution  of Mammalian Pregnancy Vincent J. Lynch1,*, Mauris C. Nnamani2, Aurélie Kapusta3, Kathryn Brayer2,10, Silvia L.  Plaza2, Erik C. Mazur8, Deena Emera2,11, Shehzad Z. Sheikh4, Frank Grützner5, Stefan  Bauersachs6,12, Alexander Graf6, Steven L. Young7, Jason D. Lieb1, Francesco J.  DeMayo8,9, Cédric Feschotte3, and Günter P. Wagner2 1Department of Human Genetics, The University of Chicago, 920 East 58th Street, CLSC 319C,  Chicago, IL 60637, USA 2Yale Systems Biology Institute and Department of Ecology and Evolutionary Biology, Yale  University, New Haven, CT 06511, USA 3Department of Human Genetics, University of Utah School of Medicine, Salt Lake City, UT  84112, USA 4Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill, Chapel  Hill, NC 27599, USA 5The Robinson Institute, School of Molecular and Biomedical Sciences, University of Adelaide,  Adelaide, SA 5005, Australia 6Laboratory for Functional Genome Analysis (LAFUGA), Gene Center, LMU Munich, Feodor  Lynen Strasse 25, 81377 Munich, Germany 7Department of Obstetrics and Gynecology, University of North Carolina at Chapel Hill, Chapel  Hill, NC 27705, USA 8Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030,  USA ©2015 The Authors This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/3.0/ ).",Non-OADS,/arxiv_data1/oa_pdf/b7/36/nihms689152.PMC4447085.pdf
"SUPPLEMENTAL INFORMATION Supplemental Information includes Supplemental Experimental Procedures, two figures, eight tables, and one data file and can be  found with this article online at http://dx.doi.org/10.1016/j.celrep.2014.12.052 .",OADS,/arxiv_data1/oa_pdf/b7/36/nihms689152.PMC4447085.pdf
"First we used CisFinder  webserver ( http://lgsun.grc.nia.nih.gov/CisFinder/ ) to identify overrepresented short DNA  motifs in TE-derived regulatory elements, the top 10 scoring motifs from CisFinder were  annotated using the STAMP webserver ( http://www.benoslab.pitt.edu/stamp/ ) with  TRANSFAC (families labeled) motifs.",OADS,/arxiv_data1/oa_pdf/b7/36/nihms689152.PMC4447085.pdf
March 2010. http://www.who.int/malaria/news/ WHO policy recommendation IPTi 032010.pdf (06/11/ 2012):1–3.,Non-OADS,/arxiv_data1/oa_pdf/d1/e3/CD010767.PMC4447115.pdf
World Malaria Report 2012. http://www.who.int/ malaria/publications/world malaria report 2012/report/en/ index.html (30/07/2013):1–195.,Non-OADS,/arxiv_data1/oa_pdf/d1/e3/CD010767.PMC4447115.pdf
http://www.who.int/malaria/publications/atoz/ smcpolicy recommendation en032012.pdf (01/02/ 2013):1–4.,Non-OADS,/arxiv_data1/oa_pdf/d1/e3/CD010767.PMC4447115.pdf
August 2013. http://www.who.int/malaria/publications/ atoz/9789241504737/en/ (13/09/2013):1–56.,Non-OADS,/arxiv_data1/oa_pdf/d1/e3/CD010767.PMC4447115.pdf
"This Open Access article is distributed under the terms of the Creative Commons Attribution Noncommercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits any non-commercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.THYROID Volume 25, Number 5, 2015DOI: 10.1089/thy.2014.0353 538",Non-OADS,/arxiv_data1/oa_pdf/a3/bb/thy.2014.0353.PMC4447137.pdf
"This open-access article is distributed under the terms of the Creative Commons Attribution Non-Commercial License (CC BY-NC) (http://creativecommons.org/licenses/by-nc/4.0/), which permits reuse, distribution and reproduction of the article, provided that the original work is properly cited and the reuse is restricted to noncommercial purposes.",Non-OADS,/arxiv_data1/oa_pdf/5d/56/prm-20-118.PMC4447152.pdf
"This open-access article is distributed under the terms of the Creative Commons Attribution Non-Commercial License (CC BY-NC) (http://creativecommons.org/licenses/by-nc/4.0/), which permits reuse, distribution and reproduction of the article, provided that the original work is properly cited and the reuse is restricted to noncommercial purposes.",Non-OADS,/arxiv_data1/oa_pdf/9d/23/prm-20-123.PMC4447153.pdf
"Collen M. P AIN <http://painexhibit.org/> (Accessed August 5, 2014).",Non-OADS,/arxiv_data1/oa_pdf/9d/23/prm-20-123.PMC4447153.pdf
"This open-access article is distributed under the terms of the Creative Commons Attribution Non-Commercial License (CC BY-NC) (http://creativecommons.org/licenses/by-nc/4.0/), which permits reuse, distribution and reproduction of the article, provided that the original work is properly cited and the reuse is restricted to noncommercial purposes.",Non-OADS,/arxiv_data1/oa_pdf/28/05/prm-20-129.PMC4447154.pdf
"This open-access article is distributed under the terms of the Creative Commons Attribution Non-Commercial License (CC BY-NC) (http://creativecommons.org/licenses/by-nc/4.0/), which permits reuse, distribution and reproduction of the article, provided that the original work is properly cited and the reuse is restricted to noncommercial purposes.",Non-OADS,/arxiv_data1/oa_pdf/75/82/prm-20-133.PMC4447155.pdf
"This open-access article is distributed under the terms of the Creative Commons Attribution Non-Commercial License (CC BY-NC) (http://creativecommons.org/licenses/by-nc/4.0/), which permits reuse, distribution and reproduction of the article, provided that the original work is properly cited and the reuse is restricted to noncommercial purposes.",Non-OADS,/arxiv_data1/oa_pdf/2c/2f/prm-20-137.PMC4447156.pdf
"This open-access article is distributed under the terms of the Creative Commons Attribution Non-Commercial License (CC BY-NC) (http://creativecommons.org/licenses/by-nc/4.0/), which permits reuse, distribution and reproduction of the article, provided that the original work is properly cited and the reuse is restricted to noncommercial purposes.",Non-OADS,/arxiv_data1/oa_pdf/01/bc/prm-20-141.PMC4447157.pdf
"This open-access article is distributed under the terms of the Creative Commons Attribution Non-Commercial License (CC BY-NC) (http://creativecommons.org/licenses/by-nc/4.0/), which permits reuse, distribution and reproduction of the article, provided that the original work is properly cited and the reuse is restricted to noncommercial purposes.",Non-OADS,/arxiv_data1/oa_pdf/c0/b8/prm-20-145.PMC4447158.pdf
"<http://accforum.org/forums/index.php?/topic/13972-new-zealand-acute-low-back-pain-guide/> (Accessed June 27, 2014).",Non-OADS,/arxiv_data1/oa_pdf/c0/b8/prm-20-145.PMC4447158.pdf
"<https://r-forge.r-project.org/scm/viewvc.php/pkg/DESCRIPTION?view=markup&revision=109&root=bbmle> (Accessed June 27, 2014).",OADS,/arxiv_data1/oa_pdf/c0/b8/prm-20-145.PMC4447158.pdf
"This open-access article is distributed under the terms of the Creative Commons Attribution Non-Commercial License (CC BY-NC) (http://creativecommons.org/licenses/by-nc/4.0/), which permits reuse, distribution and reproduction of the article, provided that the original work is properly cited and the reuse is restricted to noncommercial purposes.",Non-OADS,/arxiv_data1/oa_pdf/33/e8/prm-20-153.PMC4447159.pdf
"This open-access article is distributed under the terms of the Creative Commons Attribution Non-Commercial License (CC BY-NC) (http://creativecommons.org/licenses/by-nc/4.0/), which permits reuse, distribution and reproduction of the article, provided that the original work is properly cited and the reuse is restricted to noncommercial purposes.",Non-OADS,/arxiv_data1/oa_pdf/ce/3f/prm-20-159.PMC4447160.pdf
t he  c anadian Pain Society website provides scheduling information:   https://canadianpainsociety.site-ym.com/?2015Program c onvention registrants will receive a complete program on site.,Non-OADS,/arxiv_data1/oa_pdf/37/24/prm-20-164.PMC4447161.pdf
"Available from:   http://neuroimage.usc.edu/brainstorm P58 Trans Border T raffic K ing of P rescri PT ion o P ioids  in c anada and  T he  u ni T ed sTaT es  stevan g  s evertson1, Jl green, n d asgupta, M s  e llis, TJ c icero,   rc   d art 1rocky Mountain Poison and drug center, denver h ealth and  h ospital  a uthority,  d enver,  c olorado,  usa POSTER  AIM: This study uses surveillance data to examine cross-border  trafficking of prescription opioids manufactured in Canada and the United  States (US).METHODS: Reports from two surveillance programs were analyzed: the StreetRx Program, a website that uses crowdsourcing to assess the street price of prescription and illicit drugs, and the Researchers and Participants Interacting Directly (RAPID) Program, a survey administered to a sample of treatment-seeking individuals in the US who are dependent on opioids.",Non-OADS,/arxiv_data1/oa_pdf/3b/35/prm-20-e28.PMC4447163.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/1a/d2/jpr-8-239.PMC4447165.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pJournal of Pain Research Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/journal-of-pain-research-journa lThe Journal of Pain Research is an international, peer-reviewed, open  access, online journal that welcomes laboratory and clinical findings  in the fields of pain research and the prevention and management  of pain.",Non-OADS,/arxiv_data1/oa_pdf/1a/d2/jpr-8-239.PMC4447165.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/1a/d2/jpr-8-239.PMC4447165.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/b5/89/ceor-7-267.PMC4447166.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pClinicoEconomics and Outcomes Research 2015:7 267–272ClinicoEconomics and Outcomes Research Dove press submit your manuscript | www.dovepress.co m Dove press  267ORiginal REsEaRChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/CEOR.S8551 4Modeling the budget impact of long-acting  injectable paliperidone palmitate in the treatment  of schizophrenia in Japan Jörg Mahlich1,2 Masamichi nishi3 Y oshimichi saito1 1health Economics, Janssen  Pharmaceutical KK, T okyo, Japan;   2Düsseldorf institute for Competition  Economics, University of Düsseldorf,   Düsseldorf, germany; 3Pricing, Janssen  Pharmaceutical KK, T okyo, Japan Correspondence: Jörg Mahlich   Janssen Pharmaceutical KK,   3-5-2, nishi-kanda, Chiyoda-ku,   Tokyo 101-0065, Japan   Email jmahlich@its.jnj.co mBackground:  The cost of schizophrenia in Japan is high and new long-acting injec table  (LAI)  antipsychotics might be able to reduce costs by causing a reduction of hospital stays.",Non-OADS,/arxiv_data1/oa_pdf/b5/89/ceor-7-267.PMC4447166.pdf
"ClinicoEconomics and Outcomes Research Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinicoeconomics-and-outcomes-research-journa lClinicoEconomics & Outcomes Research is an international, peer- reviewed open-access journal focusing on Health Technology Assess - ment, Pharmacoeconomics and Outcomes Research in the areas of  diagnosis, medical devices, and clinical, surgical and pharmacological  intervention.",Non-OADS,/arxiv_data1/oa_pdf/b5/89/ceor-7-267.PMC4447166.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/b5/89/ceor-7-267.PMC4447166.pdf
"Available  from: http://www.stat.go.jp/english/data/jinsui/2013np/index.ht m.  Accessed December 15, 2014.",OADS,/arxiv_data1/oa_pdf/b5/89/ceor-7-267.PMC4447166.pdf
"Available from: http://www.mhlw.go.jp/toukei/saikin/hw/ kanja/11/index.htm l. Accessed December 15, 2014.",OADS,/arxiv_data1/oa_pdf/b5/89/ceor-7-267.PMC4447166.pdf
"Available  from: http://www.stat.go.jp/data/cpi/index.ht m. Accessed December 15,  2014.",OADS,/arxiv_data1/oa_pdf/b5/89/ceor-7-267.PMC4447166.pdf
Available from: http://www.mhlw.go.jp/bunya/shou - gaihoken/cyousajigyou/dl/seikabutsu30-2.pdf#search =’%E7%B2%B E%E7%A5%9E%E7%96%BE%E6%82%A3%E3%81%AE%E7%A 4%BE%E4%BC%9A%E7%9A%84%E3%82%B3%E3%82%B9%E 3%83%8 8’.,Non-OADS,/arxiv_data1/oa_pdf/b5/89/ceor-7-267.PMC4447166.pdf
"Available from:  http://www.mof.go.jp/english/jgbs/reference/interest_rate/index.ht m.  Accessed December 15, 2014.",Non-OADS,/arxiv_data1/oa_pdf/b5/89/ceor-7-267.PMC4447166.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/34/f5/opth-9-907.PMC4447167.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpClinical Ophthalmology 2015:9 907–919Clinical Ophthalmology Dove press submit your manuscript | www.dovepress.co m Dove press  907Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/OPTH.S7757 0Management of exfoliative glaucoma: challenges  and solutions Gábor Holló1 Andreas Katsanos2 Anastasios GP Konstas3 1Department of Ophthalmology,   Semmelweis University, Budapest,   Hungary; 2Department of  Ophthalmology, University of  ioannina, ioannina, 3First and Third  Departments of Ophthalmology,   Aristotle University of Thessaloniki,   Thessaloniki, GreeceAbstract:  Exfoliative glaucoma is the most common type of secondary open-angle glaucoma  worldwide.",Non-OADS,/arxiv_data1/oa_pdf/34/f5/opth-9-907.PMC4447167.pdf
"However, even in apparently unilateral cases, the presence of exfoliation material can  be ultrastructurally detected in both eyes as well as in other organ systems.2,3 In 38%  of unilateral cases, XFS becomes clinically detectable in the clinically uninvolved Correspondence: Gábor Holló Department of Ophthalmology,  Semmelweis University, Mária u 39,  1085 Budapest, Hungary Tel +36 20 825 8461 email hollo.gabor@med.semmelweis- univ.h u Journal name: Clinical Ophthalmology Article Designation: Review Y ear: 2015 Volume: 9 Running head verso: Holló et al Running head recto: Management of exfoliative glaucoma DOI: http://dx.doi.org/10.2147/OPTH.S77570",Non-OADS,/arxiv_data1/oa_pdf/34/f5/opth-9-907.PMC4447167.pdf
"Clinical Ophthalmology Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-ophthalmology-journa lClinical Ophthalmology is an international, peer-reviewed journal  covering all subspecialties within ophthalmology.",Non-OADS,/arxiv_data1/oa_pdf/34/f5/opth-9-907.PMC4447167.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/34/f5/opth-9-907.PMC4447167.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/28/15/tcrm-11-857.PMC4447168.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pTherapeutics and Clinical Risk Management 2015:11 857–862Therapeutics and Clinical Risk Management Dove press submit your manuscript | www.dovepress.co m Dove press  857Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/TCRM.S6455 3New developments in the management of severe  skin and deep skin structure infections – focus   on tedizolid Michael J Durkin1 G Ralph Corey2,3 1Department of Medicine, Division  of infectious Diseases, Duke  University, Durham, NC, USA;   2Department of Medicine, Duke  Clinical Research institute, Durham,   NC, USA; 3Duke Global Health  institute, Durham, NC,  USAAbstract:  Tedizolid, a novel oxazolidinone, is approved for treatment of acute bacterial skin  and skin structure infections (ABSSSIs).",Non-OADS,/arxiv_data1/oa_pdf/28/15/tcrm-11-857.PMC4447168.pdf
"Correspondence: Michael J Durkin Division of infectious Diseases, Duke  University, Hanes House Room 181,   315 Trent Drive, Durham,  NC 27710, USA Tel +1 919 684 5722 Fax +1 919 681 7494 email durkin.m.j@gmail.co m Journal name: Therapeutics and Clinical Risk Management Article Designation: Review Y ear: 2015 Volume: 11 Running head verso: Durkin and Corey Running head recto: Tedizolid for acute bacterial skin and skin structure infections DOI: http://dx.doi.org/10.2147/TCRM.S64553",Non-OADS,/arxiv_data1/oa_pdf/28/15/tcrm-11-857.PMC4447168.pdf
"Available from: http://content.stockpr.com/duratatherapeutics/db/ Publications/2134/file/3-13c_SHM_HCUP_Poster.pd f. Accessed  December 10, 2014.",Non-OADS,/arxiv_data1/oa_pdf/28/15/tcrm-11-857.PMC4447168.pdf
Available from: http://www.costco.com/Pharmacy/drug-directory-main?,Non-OADS,/arxiv_data1/oa_pdf/28/15/tcrm-11-857.PMC4447168.pdf
"Available from:  http://i.walmart.com/i/if/hmp/fusion/genericdruglist.pd f. Accessed  February 3, 2015.",OADS,/arxiv_data1/oa_pdf/28/15/tcrm-11-857.PMC4447168.pdf
"Therapeutics and Clinical Risk Management Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/therapeutics-and-clinical-risk-management-journa lTherapeutics and Clinical Risk Management is an international, peer- reviewed journal of clinical therapeutics and risk management, focusing  on concise rapid reporting of clinical studies in all therapeutic areas,  outcomes, safety, and programs for the effective, safe, and sustained  use of medicines.",Non-OADS,/arxiv_data1/oa_pdf/28/15/tcrm-11-857.PMC4447168.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/28/15/tcrm-11-857.PMC4447168.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/3a/44/nss-7-051.PMC4447169.pdf
"Information on how to request permission may be found at: http://www.dovepress.com/permissions.ph pNature and Science of Sleep 2015:7 51–61Nature and Science of Sleep Dove press submit your manuscript | www.dovepress.co m Dove press  51Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/NSS.S5607 7Unmet needs of patients with narcolepsy:  perspectives on emerging treatment options Dariusz R wozniak Timothy G Quinnell Respiratory Support and Sleep  Centre, Papworth Hospital,   Cambridge, UKAbstract:  The treatment options currently available for narcolepsy are often unsatisfactory due  to suboptimal efficacy, troublesome side effects, development of drug tolerance, and inconve - nience.",Non-OADS,/arxiv_data1/oa_pdf/3a/44/nss-7-051.PMC4447169.pdf
"Available  from: http://www.wakeupnarcolepsy.org/press- releasenarcolepsy -patient- community-prepares-share-life-impacts-treatment-perspectives-fda- regulator s. Accessed March 20, 2015.",Non-OADS,/arxiv_data1/oa_pdf/3a/44/nss-7-051.PMC4447169.pdf
"Nature and Science of Sleep Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/nature-and-science-of-sleep-journa lNature and Science of Sleep is an international, peer-reviewed, open  access journal covering all aspects of sleep science and sleep medicine,  including the neurophysiology and functions of sleep, the genetics of  sleep, sleep and society, biological rhythms, dreaming, sleep disorders and  therapy, and strategies to optimize healthy sleep.",Non-OADS,/arxiv_data1/oa_pdf/3a/44/nss-7-051.PMC4447169.pdf
Visit http://www.dovepress.com/   testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/3a/44/nss-7-051.PMC4447169.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/85/4b/ijn-10-3719.PMC4447170.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pInternational Journal of Nanomedicine 2015:10 3719–3736International Journal of Nanomedicine Dove press submit your manuscript | www.dovepress.co m Dove press  3719OrIg INal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/IJN.S8216 2Upconversion nanoparticle-mediated photodynamic  therapy induces ThP-1 macrophage apoptosis via  rOs bursts and activation of the mitochondrial  caspase pathway Xing Zhu,1,* hao Wang,2,*  longbin Zheng,1 Zhaoyu  Zhong,1 Xuesong li,1 Jing  Zhao,3 Jiayuan Kou,1 Yueqing  Jiang,1 Xiufeng Zheng,1  Zhongni liu,1 hongxia li,1  Wenwu cao,4,5 Ye Tian,1,6  Y ou Wang,2 liming Yang1 1Department of Pathophysiology, harbin  Medical University, harbin, People’s  republic of china; 2Materials Physics  and chemistry Department, harbin  Institute of Technology, harbin, People’s  republic of china; 3Blood Transfusion  Department, Jining No 1 People’s hospital,   Jining, People’s republic of china;   4laboratory of sono- and Photo- theranostic T echnologies, harbin Institute  of Technology, harbin, People’s republic  of china; 5Materials research Institute, The  Pennsylvania state University, University  Park, P a, Usa; 6Division of cardiology, The  First affiliated hospital, harbin Medical  University, harbin, People’s republic  of china *These authors contributed equally to this  workAbstract:  Atherosclerosis (AS) is the most vital cardiovascular disease, which poses a great  threat to human health.",Non-OADS,/arxiv_data1/oa_pdf/85/4b/ijn-10-3719.PMC4447170.pdf
"92 Xidazhi street Nangang District,  harbin 150001, People’s republic of china Tel +86 451 8640 3109 Fax +86 451 8641 2516 email wangyouhit@163.co m Journal name: International Journal of Nanomedicine Article Designation: Original Research Y ear: 2015 Volume: 10 Running head verso: Zhu et al Running head recto: Upconversion nanoparticle-mediated PDT induces THP-1 macrophage apoptosis DOI: http://dx.doi.org/10.2147/IJN.S82162",Non-OADS,/arxiv_data1/oa_pdf/85/4b/ijn-10-3719.PMC4447170.pdf
"International Journal of Nanomedicine Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-nanomedicine-journa lThe International Journal of Nanomedicine is an international, peer- reviewed journal focusing on the application of nanotechnology   in diagnostics, therapeutics, and drug delivery systems throughout   the biomedical field.",Non-OADS,/arxiv_data1/oa_pdf/85/4b/ijn-10-3719.PMC4447170.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/85/4b/ijn-10-3719.PMC4447170.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/5f/9c/opth-9-921.PMC4447171.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pClinical Ophthalmology 2015:9 921–928Clinical Ophthalmology Dove press submit your manuscript | www.dovepress.co m Dove press  921Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/OPTH.S8355 2Cataract surgery and methods of wound closure:  a review Correspondence: Richard Potvin Science in vision, 6197 Dye Road,  Akron, NY 14001, USA Tel +1 407 697 6008 Fax +1 716 442 5110 email rick@scienceinvision.co mCynthia Matossian1 Sarah Makari2 Richard Potvin2 1Matossian eye Associates, Pennington,   NJ, 2Science in vision, Akron, NY,  USAAbstract:  Clear corneal incisions are routinely used in cataract surgery, but watertight wound  closure may not always be achieved, which can increase the risk for anterior chamber fluid  egress or ocular surface fluid ingress.",Non-OADS,/arxiv_data1/oa_pdf/5f/9c/opth-9-921.PMC4447171.pdf
"Current evidence suggests that anterior chamber content egress is not uncommon.2–4  One study found that in 100 cases, almost one-third of the incisions leaked.2 Another  case report demonstrated fluid egress in a seemingly watertight 1.4 mm CCI.3 There  is also a documented case of iris prolapse through the CCI, 2 weeks after cataract  surgery, due to postoperative (PO) vomiting.4 During the early PO period, intraocular pressure (IOP) fluctuation may be common  since patients may inadvertently rub their eye, dab instilled eye medications from their  eye, or squeeze their eyelids; lid squeezing has been demonstrated to produce IOP spikes  up to 110 mmHg.5–7 Even if nominal or no pressure is applied to the eye, wound leaks may  still occur.8 In a recent multicenter study comprising 487 patients receiving single-plane  incisions, fluid egress was observed in 97.6% of patients when #1.0 ounce force (0.278  Newtons) was applied and in 48.8% of patients prior to pressure application.8 The concern  is that a wound that is not watertight may potentially signify a pathway for pathogen  entry into the anterior chamber with each blink or eyelid squeeze.9 A leaking CCI on the  first PO day was associated with a 44-fold increased risk of endophthalmitis.10 Of particular concern is the potential for hypotony, which can create a relative  vacuum and possibly result in poor wound stability1,7 with an increased risk of infec - tion or toric intraocular lens (IOL) rotation.11 Eyes with an IOP less than 5 mmHg are  especially susceptible to wound gapes.7 Even an IOP less than 10 mmHg (observed  in 11% or 7/64 patients in one study)12 could cause wound separation.7 Hypotony  can be present during the first 24 PO hours in the presence of a seemingly watertight  sutureless incision.13Journal name: Clinical Ophthalmology Article Designation: Review Y ear: 2015 Volume: 9 Running head verso: Matossian et al Running head recto: Cataract surgery and methods of wound closure DOI: http://dx.doi.org/10.2147/OPTH.S83552 Point your SmartPhone at the code above.",Non-OADS,/arxiv_data1/oa_pdf/5f/9c/opth-9-921.PMC4447171.pdf
Or use: http://youtu.be/EAJGV69kDU Evideo abstract,Non-OADS,/arxiv_data1/oa_pdf/5f/9c/opth-9-921.PMC4447171.pdf
"Clinical Ophthalmology Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-ophthalmology-journa lClinical Ophthalmology is an international, peer-reviewed journal  covering all subspecialties within ophthalmology.",Non-OADS,/arxiv_data1/oa_pdf/5f/9c/opth-9-921.PMC4447171.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/5f/9c/opth-9-921.PMC4447171.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/04/fb/ott-8-1175.PMC4447172.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pOncoTargets and Therapy 2015:8 1175–1183OncoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  1175Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/OTT .S8031 1Association of the CYP24A1-rs2296241  polymorphism of the vitamin D catabolism  enzyme with hormone-related cancer risk:  a meta-analysis Ping wang1,* Hemei Zhang1,* Zengli Zhang2 Liqiang Qin3 Bingyan Li1 1Medical College of Soochow  University, Suzhou, 2Department  of Labor Hygiene and environmental  Health, 3Department of Nutrition  and Food Hygiene, School of Public  Health, Soochow University, Suzhou,   People’s Republic of China *These authors contributed equally  to this workBackground:  The evidence for vitamin D reducing cancer risk is inconsistent, and it is not clear  whether this reduction is related to variation in cytochrome P450 (CYP)24A1, the only enzyme  known to degrade active vitamin D. We focused on evaluating the association of CYP24A1- rs2296241 polymorphism with hormone-related cancer risk by conducting a meta-analysis.",Non-OADS,/arxiv_data1/oa_pdf/04/fb/ott-8-1175.PMC4447172.pdf
"Vitamin D   is hydroxylated by 27-hydroxylase (cytochrome P450 [CYP]27A1 to 25(OH)D in  the liver, followed by further metabolism by 1 α-hydroxylase [CYP]27B1) to 1 α,25- dihydroxyvitamin D3 (1,25(OH)2D3).1 The level of the main circulating form of vitamin D,   25(OH)D, is a widely accepted biomarker of vitamin D status, and 1,25(OH)2D3 is  the activity of one that influence metabolic pathway, cell functions, and expression  of target genes.2 The final step in vitamin D metabolism is degradation of 25(OH)D  and 1,25(OH)2D3 to 24,25(OH)D3 and 1,24,25(OH)2D3, respectively, which occurs  via 25-hydroxyvitamin D 24-hydrolase (encoded by the CYP24A1  gene).3 CYP24A1  has been clearly established as the main enzyme responsible for the degradation of Correspondence: Bingyan Li Medical College of Soochow University,  199 Ren’ai Road, Suzhou industrial  Park, Suzhou 215123, People’s Republic  of China Tel +86 512 6588 2636 Fax +86 512 6588 0070 email bingyanli@suda.edu.c n Journal name: OncoTargets and Therapy Article Designation: Review Y ear: 2015 Volume: 8 Running head verso: Wang et al Running head recto: rs2296241 variation and cancer risk DOI: http://dx.doi.org/10.2147/OTT.S80311",Non-OADS,/arxiv_data1/oa_pdf/04/fb/ott-8-1175.PMC4447172.pdf
"OncoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncotargets-and-therapy-journa lOncoTargets and Therapy is an international, peer-reviewed, open  access journal focusing on the pathological basis of all cancers, potential  targets for therapy and treatment protocols employed to improve the  management of cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/04/fb/ott-8-1175.PMC4447172.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/04/fb/ott-8-1175.PMC4447172.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/95/13/ijn-10-3737.PMC4447173.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pInternational Journal of Nanomedicine 2015:10 3737–3750International Journal of Nanomedicine Dove press submit your manuscript | www.dovepress.co m Dove press  3737OrIg INal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/IJN.S8029 7Delivery of baicalein and paclitaxel using self- assembled nanoparticles: synergistic antitumor  effect in vitro and in vivo Wei Wang1,* Mei Xi2,* Xuezhong Duan1 Y ong Wang3 Fansheng Kong4 1Department of chinese Medicine  Integrated Traditional chinese  Medicine and Western Medicine,   general hospital of Ji’nan command,   People’s liberation army, 2emergency  Department, The Fourth People’s  hospital of Ji’nan, Medical school, Tai  shan Medical college, 3Department  of rehabilitation and Physiotherapy,   general hospital of Ji’nan  command, People’s liberation army,   4Department of hematology, general  hospital of Ji’nan command, People’s  liberation army, Ji’nan, People’s  republic of china *These authors contributed equally to  this workPurpose:  Combination anticancer therapy is promising to generate synergistic anticancer effects  to maximize the treatment effect and overcome multidrug resistance.",Non-OADS,/arxiv_data1/oa_pdf/95/13/ijn-10-3737.PMC4447173.pdf
"Keywords:  combination chemotherapy, prodrug-based nano-drug delivery system, multidrug  resistance, self-assembled nanoparticles Introduction Combination chemotherapy for anticancer treatment is a promising strategy to generate  synergistic anticancer effects, reduce individual drug-related toxicity, suppress multi - drug resistance (MDR) through different mechanisms of action, and reduce the dose  of each agent required.1,2 It refers to the simultaneous administration of two or more  active agents to modulate different signaling pathways in tumor cells, to induce cell  cycle arrest in a different phase of the cell cycle, to maximize the treatment effect, and  to overcome MDR.3 Recently, there have been several reviews concerning nano-sized  carriers designed for combination drug delivery in cancer chemotherapy.4–7 Most of  them focused only on conventional nanocarriers, such as micelles,8,9 liposomes,10 and  polymeric nanoparticles (NPs).11 Prodrug-based nano-drug delivery systems (P-N- DDSs) in the field of combination chemotherapy are still an advanced and pioneering correspondence: Fansheng Kong Department of hematology, general  hospital of Ji’nan command, Pla,  25 shifan road, Ji’nan, 250031,  People’s republic of china email kongfanshengphd@yahoo.com.c n Journal name: International Journal of Nanomedicine Article Designation: Original Research Y ear: 2015 Volume: 10 Running head verso: Wang et al Running head recto: Self-assembled nanoparticles for delivery of baicalein and paclitaxel DOI: http://dx.doi.org/10.2147/IJN.S80297",Non-OADS,/arxiv_data1/oa_pdf/95/13/ijn-10-3737.PMC4447173.pdf
"International Journal of Nanomedicine Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-nanomedicine-journa lThe International Journal of Nanomedicine is an international, peer- reviewed journal focusing on the application of nanotechnology   in diagnostics, therapeutics, and drug delivery systems throughout   the biomedical field.",Non-OADS,/arxiv_data1/oa_pdf/95/13/ijn-10-3737.PMC4447173.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/95/13/ijn-10-3737.PMC4447173.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/d6/57/oajsm-6-173.PMC4447174.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pOpen Access Journal of Sports Medicine 2015:6 173–179Open Access Journal of Sports Medicine Dove press submit your manuscript | www.dovepress.co m Dove press  173OriginAl reSeArchopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/OAJSM.S8230 5Overuse injuries in youth basketball and floorball Mari leppänen1 Kati Pasanen1 Urho M Kujala2 Jari Parkkari1 1Tampere research center of Sports  Medicine, UKK institute for health  Promotion research, Tampere,  2Department of health Sciences,  University of Jyväskylä, Jyväskylä,  Finland correspondence: Mari leppänen   Tampere research center of Sports  Medicine, UKK institute for health  Promotion research, PO Box 30,   33501 Tampere, Finland   Tel +358 3 282 9111   Fax +358 3 282 9200   email mari.h.leppanen@jyu.fiBackground:  The popularity of team sports is growing among young people.",Non-OADS,/arxiv_data1/oa_pdf/d6/57/oajsm-6-173.PMC4447174.pdf
"Open Access Journal of Sports Medicine Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/open-access-journal-of-sports-medicine-journa lOpen Access Journal of Sports Medicine is an international,  peer-reviewed, open access journal publishing original research,  reports, reviews and commentaries on all areas of sports  medicine.",Non-OADS,/arxiv_data1/oa_pdf/d6/57/oajsm-6-173.PMC4447174.pdf
Visit http://www.dovepress.com/testimonials.ph p to read real quotes  from published authors.,Non-OADS,/arxiv_data1/oa_pdf/d6/57/oajsm-6-173.PMC4447174.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/00/4d/tcrm-11-863.PMC4447175.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpTherapeutics and Clinical Risk Management 2015:11 863–871Therapeutics and Clinical Risk Management Dove press submit your manuscript | www.dovepress.co m Dove press  863ORiginal ReseaRChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/TCRM.S8377 6The incidence and risk factors of peripherally  inserted central catheter-related infection among  cancer patients Yufang gao1,* Yuxiu liu2,* Xiaoyan Ma3 lili Wei4 Weifen Chen2 lei song2 1President’s Office, 2Oncology  Department, the affiliated hospital  of Qingdao University, Qingdao,   3intensive Care Unit, shanghai  east hospital, shanghai, 4nursing  Department, the affiliated hospital of  Qingdao University, Qingdao, People’s  Republic of China *These authors contributed equally  to this workBackground:  As the use of peripherally inserted central catheters (PICCs) increased in  chemotherapy, the identification of complications and risk factors became essential to prevent  patient harm.",Non-OADS,/arxiv_data1/oa_pdf/00/4d/tcrm-11-863.PMC4447175.pdf
"Moreover, PICCs facilitate transitions from hospital to home for intermittent  intravenous therapy.2 Therefore, PICCs have been demonstrated to be an outstanding  tool for providing chemotherapy access in oncology patients.3 Despite the benefits of PICCs in chemotherapy, PICCs are frequently associated  with severe complications including thrombophlebitis, catheter-related thrombosis, Correspondence: Yufang gao President’s Office, the Affiliated Hospital  of Qingdao University, no 16 Jiangsu  Road, shinan District, Qingdao 266001,  People’s Republic of China Tel +86 186 6360 8162 email gaoyufang0612@163.co m Journal name: Therapeutics and Clinical Risk Management Article Designation: Original Research Y ear: 2015 Volume: 11 Running head verso: Gao et al Running head recto: PICC-related infection in cancer patients DOI: http://dx.doi.org/10.2147/TCRM.S83776",Non-OADS,/arxiv_data1/oa_pdf/00/4d/tcrm-11-863.PMC4447175.pdf
"Therapeutics and Clinical Risk Management Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/therapeutics-and-clinical-risk-management-journa lTherapeutics and Clinical Risk Management is an international, peer- reviewed journal of clinical therapeutics and risk management, focusing  on concise rapid reporting of clinical studies in all therapeutic areas,  outcomes, safety, and programs for the effective, safe, and sustained  use of medicines.",Non-OADS,/arxiv_data1/oa_pdf/00/4d/tcrm-11-863.PMC4447175.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/00/4d/tcrm-11-863.PMC4447175.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/b5/9c/jpr-8-241.PMC4447176.pdf
Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pJournal of Pain Research 2015:8 241–245Journal of Pain Research Dove press submit your manuscript | www.dovepress.co m Dove press  241Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/JPR.S8270 8is chronic post-herniorrhaphy pain always chronic?,Non-OADS,/arxiv_data1/oa_pdf/b5/9c/jpr-8-241.PMC4447176.pdf
"Journal of Pain Research Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/journal-of-pain-research-journa lThe Journal of Pain Research is an international, peer-reviewed, open  access, online journal that welcomes laboratory and clinical findings  in the fields of pain research and the prevention and management  of pain.",Non-OADS,/arxiv_data1/oa_pdf/b5/9c/jpr-8-241.PMC4447176.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/b5/9c/jpr-8-241.PMC4447176.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/08/28/ott-8-1157.PMC4447177.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pOncoTargets and Therapy 2015:8 1157–1164OncoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  1157Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OTT .S8165 9The prognostic significance of fibroblast growth  factor receptor 4 in non-small-cell lung cancer Hong-ping Huang hui Feng Hong-bo Qiao Ze-xiang Ren Ge-dong Zhu Department of General Medicine,   Linyi Hospital Affiliated to  Shandong  University, Linyi City,   People’s Republic of ChinaBackground:  Fibroblast growth factor receptor 4 (FGFR4) has been proved to be correlated  with progression and prognosis in many cancers.",Non-OADS,/arxiv_data1/oa_pdf/08/28/ott-8-1157.PMC4447177.pdf
"Consequently, the 5-year  survival rate of NSCLC is as low as approximately 11%.9 Fibroblast growth factor receptors (FGFRs) consist of a family of four members,  FGFR1, 2, 3, and 4, which have been demonstrated to be involved in the progression Correspondence: Hong-ping Huang  Department of General Medicine,  Linyi Hospital Affiliated to Shandong  University, 233#, East of Phoenix Street,  Hedong District, Linyi City, 276034  Shandong Province, People’s Republic  of China Tel +86 187 5313 0114 Fax +86 539 822 2186 email easonlinyi@163.co mJournal name: OncoTargets and Therapy Article Designation: Original Research Y ear: 2015 Volume: 8 Running head verso: Huang et al Running head recto: FGFR4 as prognostic marker in NSCLC DOI: http://dx.doi.org/10.2147/OTT.S81659",Non-OADS,/arxiv_data1/oa_pdf/08/28/ott-8-1157.PMC4447177.pdf
"OncoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncotargets-and-therapy-journa lOncoTargets and Therapy is an international, peer-reviewed, open  access journal focusing on the pathological basis of all cancers, potential  targets for therapy and treatment protocols employed to improve the  management of cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/08/28/ott-8-1157.PMC4447177.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/08/28/ott-8-1157.PMC4447177.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/c2/0d/ott-8-1149.PMC4447178.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pOncoTargets and Therapy 2015:8 1149–1156OncoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  1149REVIEWopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/OTT .S8262 4Tracking the 2015 Gastrointestinal Cancers  Symposium: bridging cancer biology to clinical  gastrointestinal oncology Giuseppe Aprile1 Francesco Leone2,3 Riccardo Giampieri4 Mariaelena Casagrande1 Donatella Marino2,3 Luca Faloppi4 Stefano Cascinu4 Gianpiero Fasola1 Mario Scartozzi5,6 1Department of Oncology, University  and General Hospital, Udine, Italy;   2Medical Oncology Department,   University of T urin, 3Institute for  Cancer Research and Treatment,   Candiolo, T urin, Italy; 4Medical  Oncology Unit, Azienda Ospedaliero- Universitaria Ospedali Riuniti,   Universita Politecnica delle Marche,   Ancona, Italy; 5Medical Oncology  Department, University of Cagliari,   6General Hospital, Cagliari, ItalyAbstract:  The 2015 Gastrointestinal Cancers Symposium (San Francisco, CA, USA; January  15–17) is the world-class conference co-sponsored by the American Society of Clinical Oncol - ogy, the American Society for Radiation Oncology, the American Gastroenterological Asso - ciation Institute, and the Society of Surgical Oncology, in which the most innovative research  results in digestive tract oncology are presented and discussed.",Non-OADS,/arxiv_data1/oa_pdf/c2/0d/ott-8-1149.PMC4447178.pdf
"In the final section focused on colorectal cancers (CRCs),  we will face the most recent advances in molecular selection for targeted therapies  and understand that CRC has many underlying drivers, as well as the opportunity to  identify targets responsible for drug resistance and the possibility of reshaping the Correspondence: Giuseppe Aprile Department of Oncology, University  and General Hospital, Piazzale S Maria  della Misericordia 15, 33100 Udine, Italy   Tel +39 0432 55 9308 Fax +39 0432 55 9305 Email aprile.giuseppe@aoud.sanita.fvg.i t Journal name: OncoTargets and Therapy Article Designation: REVIEW Y ear: 2015 Volume: 8 Running head verso: Aprile et al Running head recto: Cancer biology and clinical gastrointestinal oncology: symposium notes DOI: http://dx.doi.org/10.2147/OTT.S82624",Non-OADS,/arxiv_data1/oa_pdf/c2/0d/ott-8-1149.PMC4447178.pdf
Available from: http://www.roche.com/media/store/releases/med-cor- 2014-03-03.ht m. Accessed on February 8th 2015.,Non-OADS,/arxiv_data1/oa_pdf/c2/0d/ott-8-1149.PMC4447178.pdf
Available from: http://www.prnewswire.com/news-releases/amgen- announces-termination-of-all-amgen-sponsored-clinical-studies-of- rilotumumab-in-advanced-gastric-cancer-300000103.htm l. Accessed  on February 8th 2015.,Non-OADS,/arxiv_data1/oa_pdf/c2/0d/ott-8-1149.PMC4447178.pdf
"OncoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncotargets-and-therapy-journa lOncoTargets and Therapy is an international, peer-reviewed, open  access journal focusing on the pathological basis of all cancers, potential  targets for therapy and treatment protocols employed to improve the  management of cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/c2/0d/ott-8-1149.PMC4447178.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/c2/0d/ott-8-1149.PMC4447178.pdf
http://dx.doi.org/10.1038/nrmicro3235 .,OADS,/arxiv_data1/oa_pdf/b8/ac/mBio.00500-15.PMC4447244.pdf
http://dx.doi.org/10.1371/ journal.ppat.0010045 .,Non-OADS,/arxiv_data1/oa_pdf/b8/ac/mBio.00500-15.PMC4447244.pdf
BMC Genomics 13:545. http://dx.doi.org/10.1186/1471-2164-13 -545 .,OADS,/arxiv_data1/oa_pdf/b8/ac/mBio.00500-15.PMC4447244.pdf
http://dx.doi.org/10.1053/ jinf.2001.0933 .,Non-OADS,/arxiv_data1/oa_pdf/b8/ac/mBio.00500-15.PMC4447244.pdf
Vaccine 30:6957– 6959. http://dx.doi.org/10.1016/j.vaccine.2012.09.084 .,Non-OADS,/arxiv_data1/oa_pdf/b8/ac/mBio.00500-15.PMC4447244.pdf
BMC PublicHealth 11:694. http://dx.doi.org/10.1186/1471-2458-11-694 .,Non-OADS,/arxiv_data1/oa_pdf/b8/ac/mBio.00500-15.PMC4447244.pdf
Korean J Pediatr 53:629 – 633. http://dx.doi.org/10.3345/kjp.2010.53.5.629 .,Non-OADS,/arxiv_data1/oa_pdf/b8/ac/mBio.00500-15.PMC4447244.pdf
http://dx.doi.org/10.1111/j.1365-2958.1992.tb01443.x .,Non-OADS,/arxiv_data1/oa_pdf/b8/ac/mBio.00500-15.PMC4447244.pdf
http://dx.doi.org/10.1016/ S0378-1119(00)00360-7 .,OADS,/arxiv_data1/oa_pdf/b8/ac/mBio.00500-15.PMC4447244.pdf
http://dx.doi.org/ 10.1111/j.1365-2958.1988.tb00061.x .,Non-OADS,/arxiv_data1/oa_pdf/b8/ac/mBio.00500-15.PMC4447244.pdf
http://dx.doi.org/10.1128/ IAI.68.4.2024-2033.2000 .,Non-OADS,/arxiv_data1/oa_pdf/b8/ac/mBio.00500-15.PMC4447244.pdf
http://dx.doi.org/ 10.1128/IAI.73.6.3618-3626.2005 .,Non-OADS,/arxiv_data1/oa_pdf/b8/ac/mBio.00500-15.PMC4447244.pdf
http://dx.doi.org/10.1128/IAI.00148-12 .,Non-OADS,/arxiv_data1/oa_pdf/b8/ac/mBio.00500-15.PMC4447244.pdf
http://dx.doi.org/10.1111/j.1365-2958.2009.06623.x .,Non-OADS,/arxiv_data1/oa_pdf/b8/ac/mBio.00500-15.PMC4447244.pdf
http://dx.doi.org/10.1111/mmi.12394 .,Non-OADS,/arxiv_data1/oa_pdf/b8/ac/mBio.00500-15.PMC4447244.pdf
Infect Immun 80:4317– 4332. http://dx.doi.org/10.1128/ IAI.00808-12 .,Non-OADS,/arxiv_data1/oa_pdf/b8/ac/mBio.00500-15.PMC4447244.pdf
Epithelial anion transporter pendrin contributes to inﬂam- matory lung pathology in mouse models of Bordetella pertussis infection.Infect Immun 82:4212– 4221. http://dx.doi.org/10.1128/IAI.02222-14 .,Non-OADS,/arxiv_data1/oa_pdf/b8/ac/mBio.00500-15.PMC4447244.pdf
http://dx.doi.org/10.4049/ jimmunol.0803045 .,Non-OADS,/arxiv_data1/oa_pdf/b8/ac/mBio.00500-15.PMC4447244.pdf
http://dx.doi.org/10.1016/S0882-4010(03)00087-1 .,OADS,/arxiv_data1/oa_pdf/b8/ac/mBio.00500-15.PMC4447244.pdf
http://dx.doi.org/10.1542/peds.2012-1928 .,Non-OADS,/arxiv_data1/oa_pdf/b8/ac/mBio.00500-15.PMC4447244.pdf
Appl Environ Microbiol 75:6496 – 6503. http://dx.doi.org/ 10.1128/AEM.01669-09 .,OADS,/arxiv_data1/oa_pdf/b8/ac/mBio.00500-15.PMC4447244.pdf
http://dx.doi.org/10.1046/j.1365-2958.1998.00850.x .,OADS,/arxiv_data1/oa_pdf/b8/ac/mBio.00500-15.PMC4447244.pdf
http://dx.doi.org/10.1146/ annurev.micro.112408.134054 .,Non-OADS,/arxiv_data1/oa_pdf/f4/ba/mBio.00616-15.PMC4447245.pdf
http://dx.doi.org/10.1146/ annurev.biochem.69.1.183 .,OADS,/arxiv_data1/oa_pdf/f4/ba/mBio.00616-15.PMC4447245.pdf
http://dx.doi.org/10.1073/ pnas.86.13.5054 .,Non-OADS,/arxiv_data1/oa_pdf/f4/ba/mBio.00616-15.PMC4447245.pdf
Cell 122:461– 472. http://dx.doi.org/10.1016/ j.cell.2005.05.030 .,OADS,/arxiv_data1/oa_pdf/f4/ba/mBio.00616-15.PMC4447245.pdf
http://dx.doi.org/10.1016/ j.molcel.2007.03.008 .,OADS,/arxiv_data1/oa_pdf/f4/ba/mBio.00616-15.PMC4447245.pdf
http://dx.doi.org/10.1016/S0092-8674(00)81003-X .,OADS,/arxiv_data1/oa_pdf/f4/ba/mBio.00616-15.PMC4447245.pdf
Mol Microbiol 34:633– 640. http://dx.doi.org/10.1046/ j.1365-2958.1999.01646.x .,OADS,/arxiv_data1/oa_pdf/f4/ba/mBio.00616-15.PMC4447245.pdf
Proteomics 1:597– 607. http://dx.doi.org/10.1002/ 1615-9861(200104)1:4 /H11021597::AID-PROT597 /H110223.0.CO;2-P .,OADS,/arxiv_data1/oa_pdf/f4/ba/mBio.00616-15.PMC4447245.pdf
http://dx.doi.org/10.1046/j.1365-2958.2003.03675.x .,Non-OADS,/arxiv_data1/oa_pdf/f4/ba/mBio.00616-15.PMC4447245.pdf
http://dx.doi.org/10.1126/science.2646710 .,Non-OADS,/arxiv_data1/oa_pdf/f4/ba/mBio.00616-15.PMC4447245.pdf
http://dx.doi.org/ 10.1126/science.276.5310.250 .,Non-OADS,/arxiv_data1/oa_pdf/f4/ba/mBio.00616-15.PMC4447245.pdf
http://dx.doi.org/10.1128/JB.185.1.89 -97.2003 .,Non-OADS,/arxiv_data1/oa_pdf/f4/ba/mBio.00616-15.PMC4447245.pdf
http://dx.doi.org/10.1111/j.1574-6968.1999.tb13650.x .,Non-OADS,/arxiv_data1/oa_pdf/f4/ba/mBio.00616-15.PMC4447245.pdf
http://dx.doi.org/10.1021/bi980607g .,Non-OADS,/arxiv_data1/oa_pdf/f4/ba/mBio.00616-15.PMC4447245.pdf
http://dx.doi.org/10.1046/j.1365 -2958.1999.01562.x .,Non-OADS,/arxiv_data1/oa_pdf/f4/ba/mBio.00616-15.PMC4447245.pdf
http://dx.doi.org/10.1016/j.jmb.2010.02.031 .,OADS,/arxiv_data1/oa_pdf/f4/ba/mBio.00616-15.PMC4447245.pdf
J Bacteriol 190: 6676 – 6685. http://dx.doi.org/10.1128/ JB.00750-08 .,Non-OADS,/arxiv_data1/oa_pdf/f4/ba/mBio.00616-15.PMC4447245.pdf
http://dx.doi.org/10.1016/j.cell.2006.06.058 .,OADS,/arxiv_data1/oa_pdf/f4/ba/mBio.00616-15.PMC4447245.pdf
Structure of concat- enated HAMP domains provides a mechanism for signal transduction.Structure 18:436 – 448. http://dx.doi.org/10.1016/j.str.2010.01.013 .,OADS,/arxiv_data1/oa_pdf/f4/ba/mBio.00616-15.PMC4447245.pdf
Mol Mi-crobiol 80:596 – 611. http://dx.doi.org/10.1111/j.1365 -2958.2011.07577.x .,OADS,/arxiv_data1/oa_pdf/f4/ba/mBio.00616-15.PMC4447245.pdf
Mol Microbiol 73:801– 814. http://dx.doi.org/10.1111/ j.1365-2958.2009.06819.x .,OADS,/arxiv_data1/oa_pdf/f4/ba/mBio.00616-15.PMC4447245.pdf
http://dx.doi.org/10.1038/nprot.2010.5 .,Non-OADS,/arxiv_data1/oa_pdf/f4/ba/mBio.00616-15.PMC4447245.pdf
BMC Bioinformatics 9:40.http://dx.doi.org/10.1186/1471-2105-9-40 .,OADS,/arxiv_data1/oa_pdf/f4/ba/mBio.00616-15.PMC4447245.pdf
http://dx.doi.org/ 10.1016/S0076-6879(07)23002-2 .,OADS,/arxiv_data1/oa_pdf/f4/ba/mBio.00616-15.PMC4447245.pdf
http://dx.doi.org/10.1016/S0006-3495(92)81806-4 .,OADS,/arxiv_data1/oa_pdf/f4/ba/mBio.00616-15.PMC4447245.pdf
http://dx.doi.org/10.1128/ JB.185.6.1935-1941.2003 .,Non-OADS,/arxiv_data1/oa_pdf/f4/ba/mBio.00616-15.PMC4447245.pdf
http://dx.doi.org/10.1074/jbc.M701342200 .,Non-OADS,/arxiv_data1/oa_pdf/f4/ba/mBio.00616-15.PMC4447245.pdf
http://dx.doi.org/10.1016/j.jmb.2014.08.003 .,OADS,/arxiv_data1/oa_pdf/f4/ba/mBio.00616-15.PMC4447245.pdf
Structure 20:56 – 66. http://dx.doi.org/10.1016/ j.str.2011.11.014 .,OADS,/arxiv_data1/oa_pdf/f4/ba/mBio.00616-15.PMC4447245.pdf
http://dx.doi.org/10.1016/j.str.2011.01.006 .,OADS,/arxiv_data1/oa_pdf/f4/ba/mBio.00616-15.PMC4447245.pdf
http://dx.doi.org/10.1111/j.1365-2958.2010.07231.x .,Non-OADS,/arxiv_data1/oa_pdf/f4/ba/mBio.00616-15.PMC4447245.pdf
http://dx.doi.org/10.1128/ JB.00578-08 .,Non-OADS,/arxiv_data1/oa_pdf/f4/ba/mBio.00616-15.PMC4447245.pdf
http://dx.doi.org/10.1371/ journal.pbio.1001776 .,Non-OADS,/arxiv_data1/oa_pdf/f4/ba/mBio.00616-15.PMC4447245.pdf
http://dx.doi.org/10.1111/j.1365-2958.2008.06303.x .,Non-OADS,/arxiv_data1/oa_pdf/f4/ba/mBio.00616-15.PMC4447245.pdf
http://dx.doi.org/ 10.1021/bi980343y .,Non-OADS,/arxiv_data1/oa_pdf/f4/ba/mBio.00616-15.PMC4447245.pdf
http://dx.doi.org/ 10.1371/journal.pone.0066917 .,Non-OADS,/arxiv_data1/oa_pdf/f4/ba/mBio.00616-15.PMC4447245.pdf
http://dx.doi.org/10.1371/journal.pbio.1001493 .,Non-OADS,/arxiv_data1/oa_pdf/f4/ba/mBio.00616-15.PMC4447245.pdf
http://dx.doi.org/10.1021/bi701832b .,Non-OADS,/arxiv_data1/oa_pdf/f4/ba/mBio.00616-15.PMC4447245.pdf
http://dx.doi.org/10.1128/ JB.01858-07 .,Non-OADS,/arxiv_data1/oa_pdf/f4/ba/mBio.00616-15.PMC4447245.pdf
J Bac-teriol 193:4095– 4103. http://dx.doi.org/10.1128/JB.01069-10 .,Non-OADS,/arxiv_data1/oa_pdf/f4/ba/mBio.00616-15.PMC4447245.pdf
"http://dx.doi.org/10.1128/JB.186.21.7440-7449.2004 .56.Anantharaman V, Balaji S, Aravind L .",OADS,/arxiv_data1/oa_pdf/f4/ba/mBio.00616-15.PMC4447245.pdf
Biol Direct 1:25. http://dx.doi.org/10.1186/1745-6150-1-25 .,Non-OADS,/arxiv_data1/oa_pdf/f4/ba/mBio.00616-15.PMC4447245.pdf
http://dx.doi.org/10.1128/ JB.00172-09 .,Non-OADS,/arxiv_data1/oa_pdf/f4/ba/mBio.00616-15.PMC4447245.pdf
Bio-chemistry 37:5335. http://dx.doi.org/10.1021/bi9750293 .Matamouros et al.,OADS,/arxiv_data1/oa_pdf/f4/ba/mBio.00616-15.PMC4447245.pdf
http://dx.doi.org/10.1016/j.molmed.2006.03.006 .,OADS,/arxiv_data1/oa_pdf/48/54/mBio.00565-15.PMC4447246.pdf
http://dx.doi.org/10.1038/ nature07082 .,Non-OADS,/arxiv_data1/oa_pdf/48/54/mBio.00565-15.PMC4447246.pdf
J Virol 76:6841– 6844. http://dx.doi.org/10.1128/ JVI.76.13.6841-6844.2002 .,Non-OADS,/arxiv_data1/oa_pdf/48/54/mBio.00565-15.PMC4447246.pdf
http://dx.doi.org/10.1099/0022-1317-76-2-393 .,Non-OADS,/arxiv_data1/oa_pdf/48/54/mBio.00565-15.PMC4447246.pdf
Proc NatlAcad Sc iUSA 108: 8426 – 8431. http://dx.doi.org/10.1073/ pnas.1019030108 .,OADS,/arxiv_data1/oa_pdf/48/54/mBio.00565-15.PMC4447246.pdf
http://dx.doi.org/10.1371/journal.ppat.1001121 .,Non-OADS,/arxiv_data1/oa_pdf/48/54/mBio.00565-15.PMC4447246.pdf
http://dx.doi.org/10.1371/journal.ppat.1001110 .,Non-OADS,/arxiv_data1/oa_pdf/48/54/mBio.00565-15.PMC4447246.pdf
http://dx.doi.org/10.1038/nature10348 .,Non-OADS,/arxiv_data1/oa_pdf/48/54/mBio.00565-15.PMC4447246.pdf
http://dx.doi.org/10.1038/nature10380 .,Non-OADS,/arxiv_data1/oa_pdf/48/54/mBio.00565-15.PMC4447246.pdf
http://dx.doi.org/10.3390/v4112471 .,Non-OADS,/arxiv_data1/oa_pdf/48/54/mBio.00565-15.PMC4447246.pdf
http://dx.doi.org/10.1038/ emboj.2012.53 .,Non-OADS,/arxiv_data1/oa_pdf/48/54/mBio.00565-15.PMC4447246.pdf
http://dx.doi.org/ 10.1074/jbc.M002184200 .,Non-OADS,/arxiv_data1/oa_pdf/48/54/mBio.00565-15.PMC4447246.pdf
J Biol Chem 275: 4013– 4021. http://dx.doi.org/10.1074/ jbc.275.6.4013 .,OADS,/arxiv_data1/oa_pdf/48/54/mBio.00565-15.PMC4447246.pdf
http://dx.doi.org/10.1073/ pnas.0807328105 .,Non-OADS,/arxiv_data1/oa_pdf/48/54/mBio.00565-15.PMC4447246.pdf
http://dx.doi.org/10.1126/science.277.5323.228 .,Non-OADS,/arxiv_data1/oa_pdf/48/54/mBio.00565-15.PMC4447246.pdf
http://dx.doi.org/ 10.1126/science.290.5500.2298 .,Non-OADS,/arxiv_data1/oa_pdf/48/54/mBio.00565-15.PMC4447246.pdf
J Biol Chem 278: 4168 – 4175. http://dx.doi.org/10.1074/ jbc.M205406200 .,OADS,/arxiv_data1/oa_pdf/48/54/mBio.00565-15.PMC4447246.pdf
Mol Biol Cell 12:601– 614. http://dx.doi.org/ 10.1091/mbc.12.3.601 .,Non-OADS,/arxiv_data1/oa_pdf/48/54/mBio.00565-15.PMC4447246.pdf
Lipids 44:477– 487. http://dx.doi.org/10.1007/s11745-009-3305-7 .,Non-OADS,/arxiv_data1/oa_pdf/48/54/mBio.00565-15.PMC4447246.pdf
http://dx.doi.org/10.1074/jbc.M000875200 .,Non-OADS,/arxiv_data1/oa_pdf/48/54/mBio.00565-15.PMC4447246.pdf
http://dx.doi.org/10.1016/0005 -2760(90)90284-5 .,OADS,/arxiv_data1/oa_pdf/48/54/mBio.00565-15.PMC4447246.pdf
http://dx.doi.org/10.1073/ pnas.0308456101 .,Non-OADS,/arxiv_data1/oa_pdf/48/54/mBio.00565-15.PMC4447246.pdf
http://dx.doi.org/10.1371/journal.pone.0006951 .,Non-OADS,/arxiv_data1/oa_pdf/48/54/mBio.00565-15.PMC4447246.pdf
http://dx.doi.org/10.1073/ pnas.0810895106 .,Non-OADS,/arxiv_data1/oa_pdf/48/54/mBio.00565-15.PMC4447246.pdf
http://dx.doi.org/10.1002/ hep.21285 .,Non-OADS,/arxiv_data1/oa_pdf/48/54/mBio.00565-15.PMC4447246.pdf
http://dx.doi.org/10.1016/ j.ejphar.2010.04.005 .,OADS,/arxiv_data1/oa_pdf/48/54/mBio.00565-15.PMC4447246.pdf
http://dx.doi.org/10.1371/journal.pone.0011943 .,Non-OADS,/arxiv_data1/oa_pdf/48/54/mBio.00565-15.PMC4447246.pdf
http://dx.doi.org/10.1124/ jpet.106.103143 .,Non-OADS,/arxiv_data1/oa_pdf/48/54/mBio.00565-15.PMC4447246.pdf
Biol Pharm Bull 30:835– 838. http://dx.doi.org/10.1248/bpb.30.835 .,Non-OADS,/arxiv_data1/oa_pdf/48/54/mBio.00565-15.PMC4447246.pdf
Exp Eye Res37:33– 43. http://dx.doi.org/10.1016/0014-4835(83)90147-1 .,OADS,/arxiv_data1/oa_pdf/48/54/mBio.00565-15.PMC4447246.pdf
http://dx.doi.org/10.1038/ emboj.2012.53 .,Non-OADS,/arxiv_data1/oa_pdf/48/54/mBio.00565-15.PMC4447246.pdf
http://dx.doi.org/10.1016/j.virol.2012.05.018 .,OADS,/arxiv_data1/oa_pdf/48/54/mBio.00565-15.PMC4447246.pdf
http://dx.doi.org/10.1038/ 329289a0 .,Non-OADS,/arxiv_data1/oa_pdf/48/54/mBio.00565-15.PMC4447246.pdf
Biochim Biophys Acta 1685: 48 – 62. http://dx.doi.org/10.1016/j.bbalip.2004.08.011 .,OADS,/arxiv_data1/oa_pdf/48/54/mBio.00565-15.PMC4447246.pdf
http://dx.doi.org/10.1126/ science.1110656 .,Non-OADS,/arxiv_data1/oa_pdf/48/54/mBio.00565-15.PMC4447246.pdf
http://dx.doi.org/10.1038/ nrmicro2764 .,OADS,/arxiv_data1/oa_pdf/48/54/mBio.00565-15.PMC4447246.pdf
http://dx.doi.org/10.1371/ journal.pone.0027287 .,Non-OADS,/arxiv_data1/oa_pdf/48/54/mBio.00565-15.PMC4447246.pdf
http://dx.doi.org/10.1128/ JVI.00136-12 .,Non-OADS,/arxiv_data1/oa_pdf/48/54/mBio.00565-15.PMC4447246.pdf
http://dx.doi.org/10.1074/jbc.M601796200 .50.,Non-OADS,/arxiv_data1/oa_pdf/48/54/mBio.00565-15.PMC4447246.pdf
http://dx.doi.org/10.1371/ journal.pone.0056265 .,Non-OADS,/arxiv_data1/oa_pdf/48/54/mBio.00565-15.PMC4447246.pdf
http://dx.doi.org/10.1126/scitranslmed.3005471 .,Non-OADS,/arxiv_data1/oa_pdf/48/54/mBio.00565-15.PMC4447246.pdf
http://dx.doi.org/10.1371/journal.pone.0000851 .,Non-OADS,/arxiv_data1/oa_pdf/48/54/mBio.00565-15.PMC4447246.pdf
http://dx.doi.org/10.1074/jbc.274.14.9627 .,OADS,/arxiv_data1/oa_pdf/48/54/mBio.00565-15.PMC4447246.pdf
J Infect Dis 178:651– 661. http://dx.doi.org/10.1086/515386 .,OADS,/arxiv_data1/oa_pdf/48/54/mBio.00565-15.PMC4447246.pdf
http://dx.doi.org/ 10.1073/pnas.94.26.14764 .,Non-OADS,/arxiv_data1/oa_pdf/48/54/mBio.00565-15.PMC4447246.pdf
J Comp Neurol480:415– 426. http://dx.doi.org/10.1002/cne.20355 .,OADS,/arxiv_data1/oa_pdf/48/54/mBio.00565-15.PMC4447246.pdf
"Using the SignalP 4.1 server ( http://www.cbs .dtu.dk/services/SignalP/ ), we found a potential cleavage site at position 30 after the ATT codon (EbpA-1143) (see Fig.",OADS,/arxiv_data1/oa_pdf/26/73/mBio.00467-15.PMC4447247.pdf
http://dx.doi.org/10.1086/668770 .,Non-OADS,/arxiv_data1/oa_pdf/26/73/mBio.00467-15.PMC4447247.pdf
http://dx.doi.org/ 10.1038/nrmicro2761 .,OADS,/arxiv_data1/oa_pdf/26/73/mBio.00467-15.PMC4447247.pdf
http://dx.doi.org/10.1086/517524 .,OADS,/arxiv_data1/oa_pdf/26/73/mBio.00467-15.PMC4447247.pdf
http://dx.doi.org/10.1128/mBio.00177 -12.,Non-OADS,/arxiv_data1/oa_pdf/26/73/mBio.00467-15.PMC4447247.pdf
http://dx.doi.org/ 10.1172/JCI29021 .,Non-OADS,/arxiv_data1/oa_pdf/26/73/mBio.00467-15.PMC4447247.pdf
http://dx.doi.org/10.1128/IAI.00038-11 .,Non-OADS,/arxiv_data1/oa_pdf/26/73/mBio.00467-15.PMC4447247.pdf
http://dx.doi.org/10.1086/588143 .,OADS,/arxiv_data1/oa_pdf/26/73/mBio.00467-15.PMC4447247.pdf
Res Microbiol 163: 645– 658. http://dx.doi.org/10.1016/ j.resmic.2012.10.012 .,OADS,/arxiv_data1/oa_pdf/26/73/mBio.00467-15.PMC4447247.pdf
http://dx.doi.org/ 10.1128/JB.00725-10 .,Non-OADS,/arxiv_data1/oa_pdf/26/73/mBio.00467-15.PMC4447247.pdf
BMC Microbiol 10:17.http://dx.doi.org/ 10.1186/1471-2180-10-17 .,OADS,/arxiv_data1/oa_pdf/26/73/mBio.00467-15.PMC4447247.pdf
http://dx.doi.org/10.1126/scitranslmed.3009384 .,Non-OADS,/arxiv_data1/oa_pdf/26/73/mBio.00467-15.PMC4447247.pdf
http://dx.doi.org/10.1128/IAI.01403-13 .,Non-OADS,/arxiv_data1/oa_pdf/26/73/mBio.00467-15.PMC4447247.pdf
http://dx.doi.org/10.1128/MMBR.69.1.101-123.2005 .,Non-OADS,/arxiv_data1/oa_pdf/26/73/mBio.00467-15.PMC4447247.pdf
http://dx.doi.org/10.1046/j.1365-2958.2002.02945.x .,Non-OADS,/arxiv_data1/oa_pdf/26/73/mBio.00467-15.PMC4447247.pdf
http://dx.doi.org/ 10.1046/j.1365-2958.1996.6361359.x .,Non-OADS,/arxiv_data1/oa_pdf/26/73/mBio.00467-15.PMC4447247.pdf
http://dx.doi.org/10.1016/ j.sbi.2009.04.010 .,OADS,/arxiv_data1/oa_pdf/26/73/mBio.00467-15.PMC4447247.pdf
http://dx.doi.org/10.1371/journal.ppat.1000422 .,Non-OADS,/arxiv_data1/oa_pdf/26/73/mBio.00467-15.PMC4447247.pdf
http://dx.doi.org/10.1016/j.str.2009.10.019 .,OADS,/arxiv_data1/oa_pdf/26/73/mBio.00467-15.PMC4447247.pdf
http://dx.doi.org/10.1371/ journal.ppat.1003860 .,Non-OADS,/arxiv_data1/oa_pdf/26/73/mBio.00467-15.PMC4447247.pdf
http://dx.doi.org/10.4161/viru.1.4.11966 .,Non-OADS,/arxiv_data1/oa_pdf/26/73/mBio.00467-15.PMC4447247.pdf
http://dx.doi.org/10.1016/ j.plasmid.2006.08.003 .,OADS,/arxiv_data1/oa_pdf/26/73/mBio.00467-15.PMC4447247.pdf
BMC Mi- crobiol 11:20.http://dx.doi.org/10.1186/1471-2180-11-20 .,OADS,/arxiv_data1/oa_pdf/26/73/mBio.00467-15.PMC4447247.pdf
http://dx.doi.org/10.1371/ journal.pgen.1002666 .,Non-OADS,/arxiv_data1/oa_pdf/26/73/mBio.00467-15.PMC4447247.pdf
Mol Microbiol 82:634 – 647. http://dx.doi.org/10.1111/j.1365 -2958.2011.07843.x .,OADS,/arxiv_data1/oa_pdf/26/73/mBio.00467-15.PMC4447247.pdf
http://dx.doi.org/10.1128/IAI.72.6.3658-3663.2004 .,Non-OADS,/arxiv_data1/oa_pdf/26/73/mBio.00467-15.PMC4447247.pdf
http://dx.doi.org/10.1007/s004380050315 .EbpA Pilin Regulation by an ATT Initiation Codon May/June 2015 Volume 6 Issue 3 e00467-15®mbio.asm.org 9,Non-OADS,/arxiv_data1/oa_pdf/26/73/mBio.00467-15.PMC4447247.pdf
http://dx.doi.org/10.1046/j.1365 -2958.2000.02036.x .,OADS,/arxiv_data1/oa_pdf/f6/59/mBio.00308-15.PMC4447248.pdf
http://dx.doi.org/10.1111/j.1751-7915.2008.00071.x .,Non-OADS,/arxiv_data1/oa_pdf/f6/59/mBio.00308-15.PMC4447248.pdf
http://dx.doi.org/10.1128/mBio.00277-11 .,Non-OADS,/arxiv_data1/oa_pdf/f6/59/mBio.00308-15.PMC4447248.pdf
http://dx.doi.org/10.1128/AEM.01862-08 .,Non-OADS,/arxiv_data1/oa_pdf/f6/59/mBio.00308-15.PMC4447248.pdf
http://dx.doi.org/10.1128/ JB.02418-14 .,Non-OADS,/arxiv_data1/oa_pdf/f6/59/mBio.00308-15.PMC4447248.pdf
http://dx.doi.org/10.1128/JB.00418-06 .,Non-OADS,/arxiv_data1/oa_pdf/f6/59/mBio.00308-15.PMC4447248.pdf
http://dx.doi.org/ 10.1093/bfgp/elt006 .,Non-OADS,/arxiv_data1/oa_pdf/f6/59/mBio.00308-15.PMC4447248.pdf
http://dx.doi.org/10.1128/JCM.44.5.1875-1876.2006 .,Non-OADS,/arxiv_data1/oa_pdf/f6/59/mBio.00308-15.PMC4447248.pdf
http://dx.doi.org/10.1038/305709a0 .,Non-OADS,/arxiv_data1/oa_pdf/f6/59/mBio.00308-15.PMC4447248.pdf
http://dx.doi.org/10.1093/nar/gkn884 .,Non-OADS,/arxiv_data1/oa_pdf/f6/59/mBio.00308-15.PMC4447248.pdf
http://dx.doi.org/ 10.1093/nar/gks891 .,Non-OADS,/arxiv_data1/oa_pdf/f6/59/mBio.00308-15.PMC4447248.pdf
http://dx.doi.org/10.1093/nar/gkt535 .,Non-OADS,/arxiv_data1/oa_pdf/f6/59/mBio.00308-15.PMC4447248.pdf
http://dx.doi.org/10.1128/AEM.00314-08 .,Non-OADS,/arxiv_data1/oa_pdf/f6/59/mBio.00308-15.PMC4447248.pdf
Adv Biochem Eng Biotechnol 86:47– 82. http://dx.doi.org/10.1007/b12440 .,OADS,/arxiv_data1/oa_pdf/f6/59/mBio.00308-15.PMC4447248.pdf
Front Cell Infect Microbiol 2:48.http://dx.doi.org/10.3389/ fcimb.2012.00048 .,OADS,/arxiv_data1/oa_pdf/f6/59/mBio.00308-15.PMC4447248.pdf
http://dx.doi.org/10.1111/apm.12230 .,Non-OADS,/arxiv_data1/oa_pdf/f6/59/mBio.00308-15.PMC4447248.pdf
BMC Microbiol 8:134. http://dx.doi.org/10.1186/1471-2180-8-134 .,OADS,/arxiv_data1/oa_pdf/f6/59/mBio.00308-15.PMC4447248.pdf
Nat Commun 5:5055. http://dx.doi.org/ 10.1038/ncomms6055 .,OADS,/arxiv_data1/oa_pdf/f6/59/mBio.00308-15.PMC4447248.pdf
http://dx.doi.org/ 10.1093/nar/gkt1201 .,Non-OADS,/arxiv_data1/oa_pdf/f6/59/mBio.00308-15.PMC4447248.pdf
http://dx.doi.org/10.1038/nbt.2432 .,Non-OADS,/arxiv_data1/oa_pdf/f6/59/mBio.00308-15.PMC4447248.pdf
http://dx.doi.org/10.1016/0092-8674(76)90134-3 .,OADS,/arxiv_data1/oa_pdf/f6/59/mBio.00308-15.PMC4447248.pdf
Front Immunol 5:109. http://dx.doi.org/10.3389/ﬁmmu.2014.00109 .,Non-OADS,/arxiv_data1/oa_pdf/f6/59/mBio.00308-15.PMC4447248.pdf
http://dx.doi.org/10.1016/0378 -1097(90)90283-V .,OADS,/arxiv_data1/oa_pdf/f6/59/mBio.00308-15.PMC4447248.pdf
Nat Methods 6:447– 450. http://dx.doi.org/10.1038/ nmeth.1326 .,OADS,/arxiv_data1/oa_pdf/f6/59/mBio.00308-15.PMC4447248.pdf
http://dx.doi.org/ 10.1093/nar/gkp1193 .34.,Non-OADS,/arxiv_data1/oa_pdf/f6/59/mBio.00308-15.PMC4447248.pdf
http://dx.doi.org/10.1101/ gr.092759.109 .,Non-OADS,/arxiv_data1/oa_pdf/f6/59/mBio.00308-15.PMC4447248.pdf
http://dx.doi.org/10.1016/S0140 -6736(00)04403-2 .,OADS,/arxiv_data1/oa_pdf/f6/59/mBio.00308-15.PMC4447248.pdf
BMC Microbiol 11:215. http://dx.doi.org/10.1186/ 1471-2180-11-215 .,OADS,/arxiv_data1/oa_pdf/f6/59/mBio.00308-15.PMC4447248.pdf
http://dx.doi.org/10.1128/ JB.184.19.5457-5467.2002 .,OADS,/arxiv_data1/oa_pdf/f6/59/mBio.00308-15.PMC4447248.pdf
http://dx.doi.org/ 10.1128/JB.01000-07 .,Non-OADS,/arxiv_data1/oa_pdf/f6/59/mBio.00308-15.PMC4447248.pdf
http://dx.doi.org/10.1128/JB.00951-10 .,Non-OADS,/arxiv_data1/oa_pdf/f6/59/mBio.00308-15.PMC4447248.pdf
http://dx.doi.org/ 10.1099/00221287-10-1-174 .,Non-OADS,/arxiv_data1/oa_pdf/f6/59/mBio.00308-15.PMC4447248.pdf
http://dx.doi.org/10.1099/mic.0.052548-0 .,Non-OADS,/arxiv_data1/oa_pdf/f6/59/mBio.00308-15.PMC4447248.pdf
http://dx.doi.org/10.1099/00221287-144-11-3097 .,Non-OADS,/arxiv_data1/oa_pdf/f6/59/mBio.00308-15.PMC4447248.pdf
http://dx.doi.org/10.1007/978-3-540-75418-3_10 .,Non-OADS,/arxiv_data1/oa_pdf/04/60/mBio.00413-15.PMC4447249.pdf
Nat Rev Microbiol 12:49 – 62. http://dx.doi.org/10.1038/ nrmicro3161 .Herman-Bausier et al.,OADS,/arxiv_data1/oa_pdf/04/60/mBio.00413-15.PMC4447249.pdf
Nat Rev Microbiol 7:629 – 641. http://dx.doi.org/ 10.1038/nrmicro2200 .,OADS,/arxiv_data1/oa_pdf/04/60/mBio.00413-15.PMC4447249.pdf
http://dx.doi.org/10.1016/S0140-6736(09)61999-1 .,OADS,/arxiv_data1/oa_pdf/04/60/mBio.00413-15.PMC4447249.pdf
Front Cell Infect Microbiol 4:171. http://dx.doi.org/10.3389/fcimb.2014.00171 .,Non-OADS,/arxiv_data1/oa_pdf/04/60/mBio.00413-15.PMC4447249.pdf
http://dx.doi.org/10.1128/JB.00167-08 .,Non-OADS,/arxiv_data1/oa_pdf/04/60/mBio.00413-15.PMC4447249.pdf
http://dx.doi.org/10.1128/JB.02128-12 .,Non-OADS,/arxiv_data1/oa_pdf/04/60/mBio.00413-15.PMC4447249.pdf
http://dx.doi.org/10.1111/1574 -6968.12424 .,Non-OADS,/arxiv_data1/oa_pdf/04/60/mBio.00413-15.PMC4447249.pdf
http://dx.doi.org/10.1016/S0092-8674(03)00809-2 .,OADS,/arxiv_data1/oa_pdf/04/60/mBio.00413-15.PMC4447249.pdf
http://dx.doi.org/10.1111/j.1365 -2958.2006.05552.x .,Non-OADS,/arxiv_data1/oa_pdf/04/60/mBio.00413-15.PMC4447249.pdf
http://dx.doi.org/ 10.1074/jbc.M113.543546 .,Non-OADS,/arxiv_data1/oa_pdf/04/60/mBio.00413-15.PMC4447249.pdf
http://dx.doi.org/ 10.1128/AEM.00948-08 .,Non-OADS,/arxiv_data1/oa_pdf/04/60/mBio.00413-15.PMC4447249.pdf
http://dx.doi.org/10.1021/la100549u .,Non-OADS,/arxiv_data1/oa_pdf/04/60/mBio.00413-15.PMC4447249.pdf
J Biol Chem 287:6693– 6701. http://dx.doi.org/10.1074/ jbc.M111.285692 .,OADS,/arxiv_data1/oa_pdf/04/60/mBio.00413-15.PMC4447249.pdf
http://dx.doi.org/10.1021/la061984u .,Non-OADS,/arxiv_data1/oa_pdf/04/60/mBio.00413-15.PMC4447249.pdf
Langmuir 30:4019 – 4025. http://dx.doi.org/10.1021/la404673q .,Non-OADS,/arxiv_data1/oa_pdf/04/60/mBio.00413-15.PMC4447249.pdf
http://dx.doi.org/10.1371/journal.ppat.1003516 .21.Dufrêne YF .,OADS,/arxiv_data1/oa_pdf/04/60/mBio.00413-15.PMC4447249.pdf
http://dx.doi.org/10.1128/mBio.01363-14 .,Non-OADS,/arxiv_data1/oa_pdf/04/60/mBio.00413-15.PMC4447249.pdf
http://dx.doi.org/10.1016/j.bpj.2013.03.046 .,OADS,/arxiv_data1/oa_pdf/04/60/mBio.00413-15.PMC4447249.pdf
http://dx.doi.org/10.1038/nprot.2014.066 .,Non-OADS,/arxiv_data1/oa_pdf/04/60/mBio.00413-15.PMC4447249.pdf
Mol Microbiol 89:649 – 659. http://dx.doi.org/10.1111/mmi.12301 .,OADS,/arxiv_data1/oa_pdf/04/60/mBio.00413-15.PMC4447249.pdf
http://dx.doi.org/ 10.1073/pnas.95.21.12283 .,Non-OADS,/arxiv_data1/oa_pdf/04/60/mBio.00413-15.PMC4447249.pdf
http://dx.doi.org/ 10.1099/mic.0.047639-0 .,Non-OADS,/arxiv_data1/oa_pdf/04/60/mBio.00413-15.PMC4447249.pdf
http://dx.doi.org/10.1126/science.288.5463.143 .,Non-OADS,/arxiv_data1/oa_pdf/04/60/mBio.00413-15.PMC4447249.pdf
http://dx.doi.org/ 10.1111/mmi.12663 .,Non-OADS,/arxiv_data1/oa_pdf/04/60/mBio.00413-15.PMC4447249.pdf
http://dx.doi.org/10.1021/la403237f .,Non-OADS,/arxiv_data1/oa_pdf/04/60/mBio.00413-15.PMC4447249.pdf
http://dx.doi.org/10.1128/JB.01116 -08.,Non-OADS,/arxiv_data1/oa_pdf/04/60/mBio.00413-15.PMC4447249.pdf
J Bacteriol 189:8801– 8806. http://dx.doi.org/10.1128/JB.01299-07 .,Non-OADS,/arxiv_data1/oa_pdf/04/60/mBio.00413-15.PMC4447249.pdf
http://dx.doi.org/10.1111/mmi.12750 .,Non-OADS,/arxiv_data1/oa_pdf/04/60/mBio.00413-15.PMC4447249.pdf
http://dx.doi.org/10.1111/1574-6976.12088 .,Non-OADS,/arxiv_data1/oa_pdf/04/60/mBio.00413-15.PMC4447249.pdf
http://dx.doi.org/ 10.1128/JB.00628-10 .,Non-OADS,/arxiv_data1/oa_pdf/04/60/mBio.00413-15.PMC4447249.pdf
http://dx.doi.org/10.1073/ pnas.1208134110 .,Non-OADS,/arxiv_data1/oa_pdf/04/60/mBio.00413-15.PMC4447249.pdf
"http://dx.doi.org/ 10.2144/06404RR02 .45.Rice KC, Mann EE, Endres JL, Weiss EC, Cassat JE, Smeltzer MS, Bayles KW .",OADS,/arxiv_data1/oa_pdf/04/60/mBio.00413-15.PMC4447249.pdf
Proc Natl Acad Sc iUSA 104: 8113– 8118. http://dx.doi.org/10.1073/ pnas.0610226104 .,Non-OADS,/arxiv_data1/oa_pdf/04/60/mBio.00413-15.PMC4447249.pdf
http://dx.doi.org/10.1046/j.1432-1033.2002.02900.x .,Non-OADS,/arxiv_data1/oa_pdf/04/60/mBio.00413-15.PMC4447249.pdf
http://dx.doi.org/10.1016/j.chom.2013.05.003 .,OADS,/arxiv_data1/oa_pdf/04/60/mBio.00413-15.PMC4447249.pdf
http://dx.doi.org/10.1021/la050162e .Herman-Bausier et al.,OADS,/arxiv_data1/oa_pdf/04/60/mBio.00413-15.PMC4447249.pdf
http://dx.doi.org/10.1016/j.gde.2005.02.007 .,OADS,/arxiv_data1/oa_pdf/21/74/mBio.00686-15.PMC4447250.pdf
Nat Rev Genet 15:453– 468. http://dx.doi.org/10.1038/nrg3684 .,Non-OADS,/arxiv_data1/oa_pdf/21/74/mBio.00686-15.PMC4447250.pdf
Nat Rev Microbiol 2:57– 65. http://dx.doi.org/10.1038/ nrmicro787 .,OADS,/arxiv_data1/oa_pdf/21/74/mBio.00686-15.PMC4447250.pdf
http://dx.doi.org/ 10.1146/annurev.micro.091208.073214 .,Non-OADS,/arxiv_data1/oa_pdf/21/74/mBio.00686-15.PMC4447250.pdf
http://dx.doi.org/10.1016/j.mib.2009.12.009 .,OADS,/arxiv_data1/oa_pdf/21/74/mBio.00686-15.PMC4447250.pdf
http://dx.doi.org/10.1146/ annurev-micro-092611-150039 .,Non-OADS,/arxiv_data1/oa_pdf/21/74/mBio.00686-15.PMC4447250.pdf
http://dx.doi.org/ 10.1016/j.mib.2010.01.014 .,OADS,/arxiv_data1/oa_pdf/21/74/mBio.00686-15.PMC4447250.pdf
http://dx.doi.org/10.1038/ emboj.2011.271 .,OADS,/arxiv_data1/oa_pdf/21/74/mBio.00686-15.PMC4447250.pdf
http://dx.doi.org/10.1371/ journal.pone.0047314 .,Non-OADS,/arxiv_data1/oa_pdf/21/74/mBio.00686-15.PMC4447250.pdf
http://dx.doi.org/10.1093/nar/ gkl365 .,Non-OADS,/arxiv_data1/oa_pdf/21/74/mBio.00686-15.PMC4447250.pdf
http://dx.doi.org/10.1002/ pmic.200500238 .,Non-OADS,/arxiv_data1/oa_pdf/21/74/mBio.00686-15.PMC4447250.pdf
http://dx.doi.org/10.1371/ journal.pone.0050682 .,Non-OADS,/arxiv_data1/oa_pdf/21/74/mBio.00686-15.PMC4447250.pdf
Appl Environ Microbiol 78:6762– 6768. http://dx.doi.org/10.1128/ AEM.01015-12 .,OADS,/arxiv_data1/oa_pdf/21/74/mBio.00686-15.PMC4447250.pdf
http://dx.doi.org/10.1016/S0969 -2126(02)00761-X .,OADS,/arxiv_data1/oa_pdf/21/74/mBio.00686-15.PMC4447250.pdf
http://dx.doi.org/10.1146/annurev-biochem-060408-091030 .,Non-OADS,/arxiv_data1/oa_pdf/21/74/mBio.00686-15.PMC4447250.pdf
J Mol Biol 188:415– 431. http://dx.doi.org/10.1016/0022-2836(86)90165-8 .,OADS,/arxiv_data1/oa_pdf/21/74/mBio.00686-15.PMC4447250.pdf
http://dx.doi.org/ 10.1038/nmeth1008 .,Non-OADS,/arxiv_data1/oa_pdf/21/74/mBio.00686-15.PMC4447250.pdf
http://dx.doi.org/10.1002/bies.20769 .,Non-OADS,/arxiv_data1/oa_pdf/21/74/mBio.00686-15.PMC4447250.pdf
http://dx.doi.org/10.1371/journal.pcbi.1002265 .,Non-OADS,/arxiv_data1/oa_pdf/21/74/mBio.00686-15.PMC4447250.pdf
http://dx.doi.org/10.1007/s00438-004-1030-8 .,Non-OADS,/arxiv_data1/oa_pdf/21/74/mBio.00686-15.PMC4447250.pdf
http://dx.doi.org/10.1016/j.mib.2014.12.003 .,OADS,/arxiv_data1/oa_pdf/21/74/mBio.00686-15.PMC4447250.pdf
http://dx.doi.org/ 10.1038/nbt.2205 .,Non-OADS,/arxiv_data1/oa_pdf/21/74/mBio.00686-15.PMC4447250.pdf
http://dx.doi.org/10.1038/ng.2729 .,Non-OADS,/arxiv_data1/oa_pdf/21/74/mBio.00686-15.PMC4447250.pdf
Mol Microbiol 84:463– 485. http://dx.doi.org/10.1111/j.1365-2958.2012.08036.x .,OADS,/arxiv_data1/oa_pdf/21/74/mBio.00686-15.PMC4447250.pdf
http://dx.doi.org/10.1128/ mBio.01485-14 .,Non-OADS,/arxiv_data1/oa_pdf/21/74/mBio.00686-15.PMC4447250.pdf
http://dx.doi.org/10.1371/journal.pgen.1003927 .,Non-OADS,/arxiv_data1/oa_pdf/21/74/mBio.00686-15.PMC4447250.pdf
http://dx.doi.org/10.1128/JB.187.4.1357-1368.2005 .,Non-OADS,/arxiv_data1/oa_pdf/21/74/mBio.00686-15.PMC4447250.pdf
http://dx.doi.org/10.1128/JB.01684-06 .,Non-OADS,/arxiv_data1/oa_pdf/21/74/mBio.00686-15.PMC4447250.pdf
http://dx.doi.org/10.1101/ gad.1890410 .,Non-OADS,/arxiv_data1/oa_pdf/21/74/mBio.00686-15.PMC4447250.pdf
http://dx.doi.org/ 10.1038/nature06867 .,Non-OADS,/arxiv_data1/oa_pdf/21/74/mBio.00686-15.PMC4447250.pdf
http://dx.doi.org/ 10.1371/journal.pbio.1001252 .,Non-OADS,/arxiv_data1/oa_pdf/21/74/mBio.00686-15.PMC4447250.pdf
http://dx.doi.org/10.1126/science.1058758 .,Non-OADS,/arxiv_data1/oa_pdf/21/74/mBio.00686-15.PMC4447250.pdf
Nat Genet 36:486 – 491. http://dx.doi.org/10.1038/ ng1348 .,OADS,/arxiv_data1/oa_pdf/21/74/mBio.00686-15.PMC4447250.pdf
http://dx.doi.org/ 10.1038/nbt.1499 .,Non-OADS,/arxiv_data1/oa_pdf/21/74/mBio.00686-15.PMC4447250.pdf
http://dx.doi.org/10.1371/journal.pbio.0000028 .,Non-OADS,/arxiv_data1/oa_pdf/21/74/mBio.00686-15.PMC4447250.pdf
J Bacteriol 183:6384 – 6393. http://dx.doi.org/10.1128/ JB.183.21.6384-6393.2001 .,Non-OADS,/arxiv_data1/oa_pdf/21/74/mBio.00686-15.PMC4447250.pdf
BMC Bioinformatics 13:124. http://dx.doi.org/10.1186/1471-2105-13-124 .,OADS,/arxiv_data1/oa_pdf/21/74/mBio.00686-15.PMC4447250.pdf
http://dx.doi.org/10.1056/NEJMoa030747 .,OADS,/arxiv_data1/oa_pdf/8a/2d/mBio.00638-15.PMC4447251.pdf
http://dx.doi.org/10.1056/ NEJMoa1211721 .,Non-OADS,/arxiv_data1/oa_pdf/8a/2d/mBio.00638-15.PMC4447251.pdf
J VetDiagn Invest 25:649 – 654. http://dx.doi.org/10.1177/1040638713501675 .,Non-OADS,/arxiv_data1/oa_pdf/8a/2d/mBio.00638-15.PMC4447251.pdf
http://www.who.int/csr/sars/country/ table2004_04_21/en/ .,OADS,/arxiv_data1/oa_pdf/8a/2d/mBio.00638-15.PMC4447251.pdf
http://dx.doi.org/10.1128/mBio.00598-13 .,Non-OADS,/arxiv_data1/oa_pdf/8a/2d/mBio.00638-15.PMC4447251.pdf
Int J Infect Dis 20:42– 46. http://dx.doi.org/10.1016/j.ijid.2013.12.003 .,OADS,/arxiv_data1/oa_pdf/8a/2d/mBio.00638-15.PMC4447251.pdf
http://dx.doi.org/10.1371/ journal.pmed.0030343 .,Non-OADS,/arxiv_data1/oa_pdf/8a/2d/mBio.00638-15.PMC4447251.pdf
Sci Rep 3:1686. http://dx.doi.org/10.1038/ srep01686 .,OADS,/arxiv_data1/oa_pdf/8a/2d/mBio.00638-15.PMC4447251.pdf
http://dx.doi.org/10.1038/nature12711 .11.,Non-OADS,/arxiv_data1/oa_pdf/8a/2d/mBio.00638-15.PMC4447251.pdf
http://dx.doi.org/10.1128/JVI.06048-11 .,Non-OADS,/arxiv_data1/oa_pdf/8a/2d/mBio.00638-15.PMC4447251.pdf
http://dx.doi.org/10.1371/journal.pmed.0030525 .,Non-OADS,/arxiv_data1/oa_pdf/8a/2d/mBio.00638-15.PMC4447251.pdf
Lancet Infect Dis14:57– 69. http://dx.doi.org/10.1016/S1473-3099(13)70286-X .,Non-OADS,/arxiv_data1/oa_pdf/8a/2d/mBio.00638-15.PMC4447251.pdf
http://dx.doi.org/10.1309/ C0EDU0RAQBTXBHCE .,OADS,/arxiv_data1/oa_pdf/8a/2d/mBio.00638-15.PMC4447251.pdf
http://dx.doi.org/10.1016/j.jaci.2013.06.006 .,OADS,/arxiv_data1/oa_pdf/8a/2d/mBio.00638-15.PMC4447251.pdf
http://dx.doi.org/10.1371/journal.ppat.0020053 .,Non-OADS,/arxiv_data1/oa_pdf/8a/2d/mBio.00638-15.PMC4447251.pdf
http://dx.doi.org/10.4049/ jimmunol.176.3.1937 .,Non-OADS,/arxiv_data1/oa_pdf/8a/2d/mBio.00638-15.PMC4447251.pdf
http://dx.doi.org/10.1371/ journal.ppat.1002070 .,Non-OADS,/arxiv_data1/oa_pdf/8a/2d/mBio.00638-15.PMC4447251.pdf
http://dx.doi.org/10.1074/ jbc.M410592200 .,Non-OADS,/arxiv_data1/oa_pdf/8a/2d/mBio.00638-15.PMC4447251.pdf
http://dx.doi.org/10.1038/35099560 .,Non-OADS,/arxiv_data1/oa_pdf/8a/2d/mBio.00638-15.PMC4447251.pdf
Science 301: 640 – 643. http://dx.doi.org/10.1126/ science.1087262 .,Non-OADS,/arxiv_data1/oa_pdf/8a/2d/mBio.00638-15.PMC4447251.pdf
Immunity 34:866 – 878. http://dx.doi.org/10.1016/ j.immuni.2011.03.027 .,OADS,/arxiv_data1/oa_pdf/8a/2d/mBio.00638-15.PMC4447251.pdf
http://dx.doi.org/10.1074/jbc.M305790200 .,Non-OADS,/arxiv_data1/oa_pdf/8a/2d/mBio.00638-15.PMC4447251.pdf
http://dx.doi.org/10.1074/jbc.M308093200 .,Non-OADS,/arxiv_data1/oa_pdf/8a/2d/mBio.00638-15.PMC4447251.pdf
http://dx.doi.org/10.1038/nri2079 .,Non-OADS,/arxiv_data1/oa_pdf/8a/2d/mBio.00638-15.PMC4447251.pdf
http://dx.doi.org/10.1164/rccm.201401 -0193LE .,Non-OADS,/arxiv_data1/oa_pdf/8a/2d/mBio.00638-15.PMC4447251.pdf
JVirol 83:8946 – 8956. http://dx.doi.org/10.1128/JVI.01857-08 .,OADS,/arxiv_data1/oa_pdf/8a/2d/mBio.00638-15.PMC4447251.pdf
Rapid generation of a mouse model for Middle East respiratory syndrome.Proc Natl Acad Sc iUSA 111: 4970 – 4975. http://dx.doi.org/10.1073/ pnas.1323279111 .,Non-OADS,/arxiv_data1/oa_pdf/8a/2d/mBio.00638-15.PMC4447251.pdf
http://dx.doi.org/10.1128/mBio.00271-13 .,Non-OADS,/arxiv_data1/oa_pdf/8a/2d/mBio.00638-15.PMC4447251.pdf
http://dx.doi.org/10.1371/ journal.pone.0069374 .,Non-OADS,/arxiv_data1/oa_pdf/8a/2d/mBio.00638-15.PMC4447251.pdf
http://dx.doi.org/10.1086/504262 .,Non-OADS,/arxiv_data1/oa_pdf/8a/2d/mBio.00638-15.PMC4447251.pdf
http://dx.doi.org/10.1172/JCI119516 .,Non-OADS,/arxiv_data1/oa_pdf/8a/2d/mBio.00638-15.PMC4447251.pdf
J Virol 88:4251– 4264. http://dx.doi.org/ 10.1128/JVI.03571-13 .,Non-OADS,/arxiv_data1/oa_pdf/8a/2d/mBio.00638-15.PMC4447251.pdf
http://dx.doi.org/10.1016/j.resp.2012.11.010 .,OADS,/arxiv_data1/oa_pdf/8a/2d/mBio.00638-15.PMC4447251.pdf
J Virol 81:8692– 8706. http://dx.doi.org/ 10.1128/JVI.00527-07 .,Non-OADS,/arxiv_data1/oa_pdf/8a/2d/mBio.00638-15.PMC4447251.pdf
http://dx.doi.org/ 10.1371/journal.pone.0088716 .,Non-OADS,/arxiv_data1/oa_pdf/8a/2d/mBio.00638-15.PMC4447251.pdf
http://dx.doi.org/10.1128/JVI.00591-13 .,Non-OADS,/arxiv_data1/oa_pdf/8a/2d/mBio.00638-15.PMC4447251.pdf
http://dx.doi.org/10.1128/JVI.01675-10 .,Non-OADS,/arxiv_data1/oa_pdf/8a/2d/mBio.00638-15.PMC4447251.pdf
http://dx.doi.org/10.1128/mBio.01174-14 .,Non-OADS,/arxiv_data1/oa_pdf/8a/2d/mBio.00638-15.PMC4447251.pdf
http://dx.doi.org/10.1152/ajplung.00311.2013 .,Non-OADS,/arxiv_data1/oa_pdf/8a/2d/mBio.00638-15.PMC4447251.pdf
http://dx.doi.org/10.1371/ journal.ppat.1000115 .,Non-OADS,/arxiv_data1/oa_pdf/8a/2d/mBio.00638-15.PMC4447251.pdf
http://dx.doi.org/10.1371/journal.ppat.1001304 .,Non-OADS,/arxiv_data1/oa_pdf/8a/2d/mBio.00638-15.PMC4447251.pdf
http://dx.doi.org/10.1038/ nri3070 .,Non-OADS,/arxiv_data1/oa_pdf/8a/2d/mBio.00638-15.PMC4447251.pdf
http://dx.doi.org/10.1371/journal.ppat.1000849 .,Non-OADS,/arxiv_data1/oa_pdf/8a/2d/mBio.00638-15.PMC4447251.pdf
http://dx.doi.org/10.1099/vir.0.066258-0 .,Non-OADS,/arxiv_data1/oa_pdf/8a/2d/mBio.00638-15.PMC4447251.pdf
http://dx.doi.org/10.1128/JVI.00935-08 .,Non-OADS,/arxiv_data1/oa_pdf/8a/2d/mBio.00638-15.PMC4447251.pdf
http://dx.doi.org/ 10.1038/nm1140 .,OADS,/arxiv_data1/oa_pdf/8a/2d/mBio.00638-15.PMC4447251.pdf
J Immunol180:683– 687. http://dx.doi.org/10.4049/jimmunol.180.2.683 .,Non-OADS,/arxiv_data1/oa_pdf/8a/2d/mBio.00638-15.PMC4447251.pdf
JImmunol 192:4303– 4315. http://dx.doi.org/10.4049/jimmunol.1302244 .,Non-OADS,/arxiv_data1/oa_pdf/8a/2d/mBio.00638-15.PMC4447251.pdf
http://dx.doi.org/ 10.1371/journal.ppat.0030005 .61.,Non-OADS,/arxiv_data1/oa_pdf/8a/2d/mBio.00638-15.PMC4447251.pdf
http://dx.doi.org/10.1128/mBio.00047-14 .,Non-OADS,/arxiv_data1/oa_pdf/8a/2d/mBio.00638-15.PMC4447251.pdf
http://dx.doi.org/10.1164/ajrccm.156.3.9606031 .,Non-OADS,/arxiv_data1/oa_pdf/8a/2d/mBio.00638-15.PMC4447251.pdf
http://dx.doi.org/10.1016/j.antiviral.2014.05.002 .Totura et al.,OADS,/arxiv_data1/oa_pdf/8a/2d/mBio.00638-15.PMC4447251.pdf
http://dx.doi.org/10.1099/0022-1317-51-1-45 .,Non-OADS,/arxiv_data1/oa_pdf/e7/ba/mBio.00345-15.PMC4447252.pdf
http://dx.doi.org/10.1128/JVI.78.18.10178 -10186.2004 .,Non-OADS,/arxiv_data1/oa_pdf/e7/ba/mBio.00345-15.PMC4447252.pdf
ProcNatl Acad Sc iUSA 85:6347– 6351. http://dx.doi.org/10.1073/ pnas.85.17.6347 .,Non-OADS,/arxiv_data1/oa_pdf/e7/ba/mBio.00345-15.PMC4447252.pdf
http://dx.doi.org/10.3390/v5051272 .,Non-OADS,/arxiv_data1/oa_pdf/e7/ba/mBio.00345-15.PMC4447252.pdf
http://dx.doi.org/10.1126/ science.277.5330.1310 .,Non-OADS,/arxiv_data1/oa_pdf/e7/ba/mBio.00345-15.PMC4447252.pdf
http://dx.doi.org/10.1038/353569a0 .,Non-OADS,/arxiv_data1/oa_pdf/e7/ba/mBio.00345-15.PMC4447252.pdf
http://dx.doi.org/10.1038/345783a0 .,Non-OADS,/arxiv_data1/oa_pdf/e7/ba/mBio.00345-15.PMC4447252.pdf
http://dx.doi.org/10.1038/351588a0 .,Non-OADS,/arxiv_data1/oa_pdf/e7/ba/mBio.00345-15.PMC4447252.pdf
http://dx.doi.org/ 10.1016/S1097-2765(00)80463-3 .,OADS,/arxiv_data1/oa_pdf/e7/ba/mBio.00345-15.PMC4447252.pdf
Mol CellBiol 20:8709 – 8719. http://dx.doi.org/10.1128/MCB.20.23.8709 -8719.2000 .,OADS,/arxiv_data1/oa_pdf/e7/ba/mBio.00345-15.PMC4447252.pdf
EMBO J 22:6494 – 6504. http://dx.doi.org/10.1093/emboj/cdg619 .,OADS,/arxiv_data1/oa_pdf/e7/ba/mBio.00345-15.PMC4447252.pdf
http://dx.doi.org/10.1023/A:1007177623283 .,Non-OADS,/arxiv_data1/oa_pdf/e7/ba/mBio.00345-15.PMC4447252.pdf
EMBO J 19:683– 690. http://dx.doi.org/10.1093/emboj/ 19.4.683 .,OADS,/arxiv_data1/oa_pdf/e7/ba/mBio.00345-15.PMC4447252.pdf
ProcNatl Acad Sc iUSA 103: 6817– 6822. http://dx.doi.org/10.1073/ pnas.0602109103 .,Non-OADS,/arxiv_data1/oa_pdf/e7/ba/mBio.00345-15.PMC4447252.pdf
http://dx.doi.org/10.1101/ gad.252103 .22.,Non-OADS,/arxiv_data1/oa_pdf/e7/ba/mBio.00345-15.PMC4447252.pdf
http://dx.doi.org/10.1126/scitranslmed.3005145 .,Non-OADS,/arxiv_data1/oa_pdf/e7/ba/mBio.00345-15.PMC4447252.pdf
Cell 55:857– 868. http://dx.doi.org/10.1016/0092-8674(88)90141-9 .,OADS,/arxiv_data1/oa_pdf/e7/ba/mBio.00345-15.PMC4447252.pdf
http://dx.doi.org/10.1128/ JVI.79.8.5078-5089.2005 .,Non-OADS,/arxiv_data1/oa_pdf/e7/ba/mBio.00345-15.PMC4447252.pdf
http://dx.doi.org/10.1371/journal.ppat.1000071 .,Non-OADS,/arxiv_data1/oa_pdf/e7/ba/mBio.00345-15.PMC4447252.pdf
http://dx.doi.org/10.1128/mBio.00300-11 .,Non-OADS,/arxiv_data1/oa_pdf/e7/ba/mBio.00345-15.PMC4447252.pdf
J Virol 82:8094 – 8104. http://dx.doi.org/10.1128/ JVI.00874-08 .,Non-OADS,/arxiv_data1/oa_pdf/e7/ba/mBio.00345-15.PMC4447252.pdf
Immun Ageing 6:4. http://dx.doi.org/10.1186/1742 -4933-6-4 .,Non-OADS,/arxiv_data1/oa_pdf/e7/ba/mBio.00345-15.PMC4447252.pdf
http://dx.doi.org/10.1038/2345 .,Non-OADS,/arxiv_data1/oa_pdf/e7/ba/mBio.00345-15.PMC4447252.pdf
http://dx.doi.org/10.1016/j.tcb.2007.02.004 .,OADS,/arxiv_data1/oa_pdf/e7/ba/mBio.00345-15.PMC4447252.pdf
http://dx.doi.org/10.1021/bi000572w .,Non-OADS,/arxiv_data1/oa_pdf/e7/ba/mBio.00345-15.PMC4447252.pdf
http://dx.doi.org/10.1038/nsmb989 .,Non-OADS,/arxiv_data1/oa_pdf/e7/ba/mBio.00345-15.PMC4447252.pdf
J Biol Chem 277:43288 – 43300. http://dx.doi.org/ 10.1074/jbc.M207952200 .,OADS,/arxiv_data1/oa_pdf/e7/ba/mBio.00345-15.PMC4447252.pdf
J Biol Chem 280: 42252– 42262. http://dx.doi.org/ 10.1074/jbc.M509917200 .,OADS,/arxiv_data1/oa_pdf/e7/ba/mBio.00345-15.PMC4447252.pdf
http://dx.doi.org/10.1371/ journal.pone.0007050 .,Non-OADS,/arxiv_data1/oa_pdf/e7/ba/mBio.00345-15.PMC4447252.pdf
http://dx.doi.org/10.1242/jcs.03461 .,Non-OADS,/arxiv_data1/oa_pdf/e7/ba/mBio.00345-15.PMC4447252.pdf
http://dx.doi.org/10.1038/sj.emboj.7601470 .,Non-OADS,/arxiv_data1/oa_pdf/e7/ba/mBio.00345-15.PMC4447252.pdf
http://dx.doi.org/10.1016/ j.cell.2012.04.043 .,OADS,/arxiv_data1/oa_pdf/e7/ba/mBio.00345-15.PMC4447252.pdf
http://dx.doi.org/10.1074/ jbc.M113.492777 .,Non-OADS,/arxiv_data1/oa_pdf/e7/ba/mBio.00345-15.PMC4447252.pdf
http://dx.doi.org/ 10.1091/mbc.E13-10-0603 .,Non-OADS,/arxiv_data1/oa_pdf/e7/ba/mBio.00345-15.PMC4447252.pdf
http://dx.doi.org/10.1073/ pnas.0408364102 .,Non-OADS,/arxiv_data1/oa_pdf/e7/ba/mBio.00345-15.PMC4447252.pdf
http://dx.doi.org/ 10.1242/jcs.083238 .,Non-OADS,/arxiv_data1/oa_pdf/e7/ba/mBio.00345-15.PMC4447252.pdf
http://dx.doi.org/10.1002/ ajmg.a.34249 .,Non-OADS,/arxiv_data1/oa_pdf/e7/ba/mBio.00345-15.PMC4447252.pdf
Genes Dev 22: 832– 853. http://dx.doi.org/10.1101/gad.1652708 .,OADS,/arxiv_data1/oa_pdf/e7/ba/mBio.00345-15.PMC4447252.pdf
http://dx.doi.org/10.1128/ JVI.77.8.5030-5036.2003 .,Non-OADS,/arxiv_data1/oa_pdf/e7/ba/mBio.00345-15.PMC4447252.pdf
http://dx.doi.org/10.1016/j.chom.2007.03.007 .59.,OADS,/arxiv_data1/oa_pdf/e7/ba/mBio.00345-15.PMC4447252.pdf
http://dx.doi.org/10.1371/ journal.pone.0100511 .,Non-OADS,/arxiv_data1/oa_pdf/e7/ba/mBio.00345-15.PMC4447252.pdf
http://dx.doi.org/10.4161/nucl.2.6.17960 .,Non-OADS,/arxiv_data1/oa_pdf/e7/ba/mBio.00345-15.PMC4447252.pdf
http://dx.doi.org/10.1128/JVI.01575-08 .,Non-OADS,/arxiv_data1/oa_pdf/e7/ba/mBio.00345-15.PMC4447252.pdf
http://dx.doi.org/10.1128/JVI.00169-06 .,Non-OADS,/arxiv_data1/oa_pdf/e7/ba/mBio.00345-15.PMC4447252.pdf
http://dx.doi.org/10.1128/ JVI.00641-11 .,Non-OADS,/arxiv_data1/oa_pdf/e7/ba/mBio.00345-15.PMC4447252.pdf
http://dx.doi.org/10.4161/nucl.28825 .,Non-OADS,/arxiv_data1/oa_pdf/e7/ba/mBio.00345-15.PMC4447252.pdf
Proteomic analysis of the herpes simplex virus 1 virion protein 16 transactivator protein in infected cells.Proteomics http://dx.doi.org/10.1002/pmic.201500020 .,Non-OADS,/arxiv_data1/oa_pdf/e7/ba/mBio.00345-15.PMC4447252.pdf
http://dx.doi.org/10.1128/JVI.01727-09 .,Non-OADS,/arxiv_data1/oa_pdf/e7/ba/mBio.00345-15.PMC4447252.pdf
http://dx.doi.org/10.1083/jcb.200511149 .,Non-OADS,/arxiv_data1/oa_pdf/e7/ba/mBio.00345-15.PMC4447252.pdf
http://dx.doi.org/10.1083/ jcb.200511149 .,Non-OADS,/arxiv_data1/oa_pdf/e7/ba/mBio.00345-15.PMC4447252.pdf
http://dx.doi.org/10.1038/sj.emboj.7601230 .,Non-OADS,/arxiv_data1/oa_pdf/e7/ba/mBio.00345-15.PMC4447252.pdf
J Biol Chem 278:6969 – 6975. http://dx.doi.org/10.1074/jbc.M208811200 .,OADS,/arxiv_data1/oa_pdf/e7/ba/mBio.00345-15.PMC4447252.pdf
http://dx.doi.org/10.1074/ jbc.M609809200 .,Non-OADS,/arxiv_data1/oa_pdf/e7/ba/mBio.00345-15.PMC4447252.pdf
http://dx.doi.org/10.1242/dev.098152 .,Non-OADS,/arxiv_data1/oa_pdf/e7/ba/mBio.00345-15.PMC4447252.pdf
http://dx.doi.org/10.1371/journal.pbio.1000453 .,Non-OADS,/arxiv_data1/oa_pdf/e7/ba/mBio.00345-15.PMC4447252.pdf
Cell Biosci 3:39. http://dx.doi.org/10.1186/2045-3701-3-39 .,OADS,/arxiv_data1/oa_pdf/e7/ba/mBio.00345-15.PMC4447252.pdf
SET for life: biochemical activities and biological functions of SET domain-containing proteins.Trends Biochem Sci 38:621– 639. http://dx.doi.org/10.1016/ j.tibs.2013.09.004 .,OADS,/arxiv_data1/oa_pdf/e7/ba/mBio.00345-15.PMC4447252.pdf
http://dx.doi.org/10.1128/mBio.01086-13 .,Non-OADS,/arxiv_data1/oa_pdf/e7/ba/mBio.00345-15.PMC4447252.pdf
http://dx.doi.org/10.1128/mBio.00590-12 .,Non-OADS,/arxiv_data1/oa_pdf/e7/ba/mBio.00345-15.PMC4447252.pdf
http://dx.doi.org/10.1073/ pnas.0505850102 .,Non-OADS,/arxiv_data1/oa_pdf/e7/ba/mBio.00345-15.PMC4447252.pdf
http://dx.doi.org/10.1038/nprot.2006.98 .Role of BAF in Histone Modiﬁcations on HSV Promoters May/June 2015 Volume 6 Issue 3 e00345-15®mbio.asm.org 13,Non-OADS,/arxiv_data1/oa_pdf/e7/ba/mBio.00345-15.PMC4447252.pdf
Nature 176:121. http://dx.doi.org/10.1038/176121a0 .,Non-OADS,/arxiv_data1/oa_pdf/72/52/mBio.02559-14.PMC4447253.pdf
Ann N Y Acad Sci 81:887– 898. http://dx.doi.org/ 10.1111/j.1749-6632.1959.tb49374.x .,Non-OADS,/arxiv_data1/oa_pdf/72/52/mBio.02559-14.PMC4447253.pdf
http://dx.doi.org/10.4161/mge.1.3.18066 .,Non-OADS,/arxiv_data1/oa_pdf/72/52/mBio.02559-14.PMC4447253.pdf
http://dx.doi.org/10.1046/ j.1365-2958.2001.02618.x .,Non-OADS,/arxiv_data1/oa_pdf/72/52/mBio.02559-14.PMC4447253.pdf
http://dx.doi.org/10.1111/ j.1365-2958.1994.tb00487.x .,Non-OADS,/arxiv_data1/oa_pdf/72/52/mBio.02559-14.PMC4447253.pdf
Mol Micro-biol61:436 – 446. http://dx.doi.org/10.1111/j.1365-2958.2006.05258.x .,OADS,/arxiv_data1/oa_pdf/72/52/mBio.02559-14.PMC4447253.pdf
http://dx.doi.org/10.1016/S0147-619X(03)00063-5 .,OADS,/arxiv_data1/oa_pdf/72/52/mBio.02559-14.PMC4447253.pdf
http://dx.doi.org/10.1038/ emboj.2011.121 .,Non-OADS,/arxiv_data1/oa_pdf/72/52/mBio.02559-14.PMC4447253.pdf
J Gen Mi- crobiol 126:427– 442. http://dx.doi.org/10.1099/00221287-126-2-427 .,OADS,/arxiv_data1/oa_pdf/72/52/mBio.02559-14.PMC4447253.pdf
http://dx.doi.org/10.1007/BF00330791 .,Non-OADS,/arxiv_data1/oa_pdf/72/52/mBio.02559-14.PMC4447253.pdf
http://dx.doi.org/ 10.1099/mic.0.2006/005413-0 .,Non-OADS,/arxiv_data1/oa_pdf/72/52/mBio.02559-14.PMC4447253.pdf
Front Mi-crobiol 5:499. http://dx.doi.org/10.3389/fmicb.2014.00499 .,Non-OADS,/arxiv_data1/oa_pdf/72/52/mBio.02559-14.PMC4447253.pdf
http://dx.doi.org/ 10.1016/j.ijmm.2014.12.020 .Streptomyces DNA Translocation Apparatus May/June 2015 Volume 6 Issue 3 e02559-14®mbio.asm.org 9,OADS,/arxiv_data1/oa_pdf/72/52/mBio.02559-14.PMC4447253.pdf
http://dx.doi.org/10.1073/ pnas.95.10.5752 .,Non-OADS,/arxiv_data1/oa_pdf/72/52/mBio.02559-14.PMC4447253.pdf
http://dx.doi.org/10.1099/13500872-141-10-2499 .,Non-OADS,/arxiv_data1/oa_pdf/72/52/mBio.02559-14.PMC4447253.pdf
J Bacteriol 182: 4500 – 4504. http://dx.doi.org/10.1128/JB.182.16.4500-4504.2000 .,Non-OADS,/arxiv_data1/oa_pdf/72/52/mBio.02559-14.PMC4447253.pdf
http://dx.doi.org/10.1093/nar/27.10.2145 .,Non-OADS,/arxiv_data1/oa_pdf/72/52/mBio.02559-14.PMC4447253.pdf
http://dx.doi.org/10.1016/j.virol.2004.10.028 .,OADS,/arxiv_data1/oa_pdf/72/52/mBio.02559-14.PMC4447253.pdf
J Bacteriol 186: 6728 – 6737. http://dx.doi.org/10.1128/JB.186.20.6728-6737.2004 .,Non-OADS,/arxiv_data1/oa_pdf/72/52/mBio.02559-14.PMC4447253.pdf
http://dx.doi.org/10.1128/ JB.00160-13 .,Non-OADS,/arxiv_data1/oa_pdf/72/52/mBio.02559-14.PMC4447253.pdf
http://dx.doi.org/10.1146/ annurev-genet-102808-114910 .,Non-OADS,/arxiv_data1/oa_pdf/9c/4b/mBio.02567-14.PMC4447254.pdf
http://dx.doi.org/10.1038/ nrmicro3160 .,OADS,/arxiv_data1/oa_pdf/9c/4b/mBio.02567-14.PMC4447254.pdf
http://dx.doi.org/ 10.1126/science.1235771 .,Non-OADS,/arxiv_data1/oa_pdf/9c/4b/mBio.02567-14.PMC4447254.pdf
Cells 1:396 – 408. http://dx.doi.org/10.3390/ cells1030396 .,OADS,/arxiv_data1/oa_pdf/9c/4b/mBio.02567-14.PMC4447254.pdf
http://dx.doi.org/10.1371/journal.pone.0017852 .,Non-OADS,/arxiv_data1/oa_pdf/9c/4b/mBio.02567-14.PMC4447254.pdf
http://dx.doi.org/10.1126/ science.1090124 .,Non-OADS,/arxiv_data1/oa_pdf/9c/4b/mBio.02567-14.PMC4447254.pdf
J Cell Biol 147: 683– 693. http://dx.doi.org/10.1083/jcb.147.3.683 .,OADS,/arxiv_data1/oa_pdf/9c/4b/mBio.02567-14.PMC4447254.pdf
Mol Microbiol 11:619 – 627. http://dx.doi.org/10.1111/j.1365 -2958.1994.tb00341.x .,OADS,/arxiv_data1/oa_pdf/9c/4b/mBio.02567-14.PMC4447254.pdf
http://dx.doi.org/10.1111/j.1462-5822.2009.01415.x .,Non-OADS,/arxiv_data1/oa_pdf/9c/4b/mBio.02567-14.PMC4447254.pdf
http://dx.doi.org/10.1016/j.chom.2009.07.005 .,OADS,/arxiv_data1/oa_pdf/9c/4b/mBio.02567-14.PMC4447254.pdf
http://dx.doi.org/ 10.1073/pnas.86.10.3867 .,Non-OADS,/arxiv_data1/oa_pdf/9c/4b/mBio.02567-14.PMC4447254.pdf
Mol Microbiol 34:675– 689. http://dx.doi.org/10.1046/j.1365 -2958.1999.01627.x .,OADS,/arxiv_data1/oa_pdf/9c/4b/mBio.02567-14.PMC4447254.pdf
http://dx.doi.org/10.1046/j.1462-5822.1999.00019.x .,Non-OADS,/arxiv_data1/oa_pdf/9c/4b/mBio.02567-14.PMC4447254.pdf
Cell 76:829 – 839. http://dx.doi.org/10.1016/0092-8674(94)90358-1 .,OADS,/arxiv_data1/oa_pdf/9c/4b/mBio.02567-14.PMC4447254.pdf
Infect Immun 82: 4447– 4457. http://dx.doi.org/10.1128/IAI.02078-14 .,Non-OADS,/arxiv_data1/oa_pdf/9c/4b/mBio.02567-14.PMC4447254.pdf
http://dx.doi.org/ 10.1016/j.chom.2014.01.005 .,OADS,/arxiv_data1/oa_pdf/9c/4b/mBio.02567-14.PMC4447254.pdf
http://dx.doi.org/10.1126/science.1106036 .,Non-OADS,/arxiv_data1/oa_pdf/9c/4b/mBio.02567-14.PMC4447254.pdf
http://dx.doi.org/10.1016/ j.cell.2012.06.050 .,OADS,/arxiv_data1/oa_pdf/9c/4b/mBio.02567-14.PMC4447254.pdf
http://dx.doi.org/10.1046/j.1365 -2958.2000.01770.x .,Non-OADS,/arxiv_data1/oa_pdf/9c/4b/mBio.02567-14.PMC4447254.pdf
http://dx.doi.org/10.1016/j.micinf.2010.06.006 .,OADS,/arxiv_data1/oa_pdf/9c/4b/mBio.02567-14.PMC4447254.pdf
J Cell Biol115: 31– 43. http://dx.doi.org/10.1083/jcb.115.1.31 .,OADS,/arxiv_data1/oa_pdf/9c/4b/mBio.02567-14.PMC4447254.pdf
http://dx.doi.org/ 10.1074/mcp.M111.016378 .,Non-OADS,/arxiv_data1/oa_pdf/9c/4b/mBio.02567-14.PMC4447254.pdf
http://dx.doi.org/10.1111/ j.1600-0854.2010.01086.x .,Non-OADS,/arxiv_data1/oa_pdf/9c/4b/mBio.02567-14.PMC4447254.pdf
http://dx.doi.org/10.1371/journal.pone.0094653 .,Non-OADS,/arxiv_data1/oa_pdf/9c/4b/mBio.02567-14.PMC4447254.pdf
http://dx.doi.org/10.1038/sj.emboj.7601511 .,Non-OADS,/arxiv_data1/oa_pdf/9c/4b/mBio.02567-14.PMC4447254.pdf
Proteins 77:413– 419. http://dx.doi.org/10.1002/prot.22447 .,OADS,/arxiv_data1/oa_pdf/9c/4b/mBio.02567-14.PMC4447254.pdf
Nature 482: 414 – 418. http://dx.doi.org/ 10.1038/nature10744 .,Non-OADS,/arxiv_data1/oa_pdf/9c/4b/mBio.02567-14.PMC4447254.pdf
http://dx.doi.org/10.1074/jbc.M111.223610 .,Non-OADS,/arxiv_data1/oa_pdf/9c/4b/mBio.02567-14.PMC4447254.pdf
http://dx.doi.org/ 10.1126/science.1205405 .,Non-OADS,/arxiv_data1/oa_pdf/9c/4b/mBio.02567-14.PMC4447254.pdf
http://dx.doi.org/10.1016/ j.chom.2012.04.012 .,OADS,/arxiv_data1/oa_pdf/9c/4b/mBio.02567-14.PMC4447254.pdf
Cell Host Microbe 8:433– 444. http://dx.doi.org/ 10.1016/j.chom.2010.10.009 .,OADS,/arxiv_data1/oa_pdf/9c/4b/mBio.02567-14.PMC4447254.pdf
http://dx.doi.org/10.4161/auto.29411 .,Non-OADS,/arxiv_data1/oa_pdf/9c/4b/mBio.02567-14.PMC4447254.pdf
http://dx.doi.org/10.1038/ nature06421 .,Non-OADS,/arxiv_data1/oa_pdf/9c/4b/mBio.02567-14.PMC4447254.pdf
http://www.bio-protocol.org/e1270 .,Non-OADS,/arxiv_data1/oa_pdf/9c/4b/mBio.02567-14.PMC4447254.pdf
http://dx.doi.org/10.1371/journal.pone.0032862 .,Non-OADS,/arxiv_data1/oa_pdf/9c/4b/mBio.02567-14.PMC4447254.pdf
"creativecommons.org/licenses/by-nc/3.0/) which permits non-commercial use, reproduction and distribution of the work without further permiss ion provided the original work is attributed as specified on the SAGE and Open Access page (http://www.uk.sagepub.com/aboutus/openaccess.htm).",Non-OADS,/arxiv_data1/oa_pdf/00/ec/10.1177_2058460115578600.PMC4447635.pdf
"creativecommons.org/licenses/by-nc/3.0/) which permits non-commercial use, reproduction and distribution of the work without further permiss ion provided the original work is attributed as specified on the SAGE and Open Access page (http://www.uk.sagepub.com/aboutus/openaccess.htm).",Non-OADS,/arxiv_data1/oa_pdf/da/38/10.1177_2058460115577566.PMC4447636.pdf
"In addition, the programming language and environment  R (http://www.r-project.org) was used for Hardy-Weinberg and linkage  disequilibrium (LD) testing.",OADS,/arxiv_data1/oa_pdf/5a/be/JBS-32-1144416.PMC4447760.pdf
2009;  Retrieved from: http://www.dailymail.,Non-OADS,/arxiv_data1/oa_pdf/dd/3d/JBS-32-1144417.PMC4447761.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), permitting all non-commercial use , distribution, and reproduction in any medium, provided the original work is properly cited.1 Citation: Journal of Extracellular Vesicles 2015, 4: 26883 - http://dx.doi.org/10.3402/jev.v4.26883 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/db/59/JEV-4-26883.PMC4447833.pdf
"2 (page number not for citation purpose)Citation: Journal of Extracellular Vesicles 2015, 4: 26883 - http://dx.doi.org/10.3402/jev.v4.26883",OADS,/arxiv_data1/oa_pdf/db/59/JEV-4-26883.PMC4447833.pdf
"The pellet at each fraction was then re-suspended in 20 mL PBS and used for western blotting analysis.Serum-free culture influences EVs Citation: Journal of Extracellular Vesicles 2015, 4: 26883 - http://dx.doi.org/10.3402/jev.v4.26883 3 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/db/59/JEV-4-26883.PMC4447833.pdf
"4 (page number not for citation purpose)Citation: Journal of Extracellular Vesicles 2015, 4: 26883 - http://dx.doi.org/10.3402/jev.v4.26883",OADS,/arxiv_data1/oa_pdf/db/59/JEV-4-26883.PMC4447833.pdf
"(j) Concentration of particles derived from N2a cells conditioned media after 48 h. (k) Representative western blotting pictures showing the appearance of EV markers (Alix and Tsg101) and ER marker (Calnexin) in the particles isolated after 48 h.Serum-free culture influences EVs Citation: Journal of Extracellular Vesicles 2015, 4: 26883 - http://dx.doi.org/10.3402/jev.v4.26883 5 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/db/59/JEV-4-26883.PMC4447833.pdf
"6 (page number not for citation purpose)Citation: Journal of Extracellular Vesicles 2015, 4: 26883 - http://dx.doi.org/10.3402/jev.v4.26883",OADS,/arxiv_data1/oa_pdf/db/59/JEV-4-26883.PMC4447833.pdf
"(b) Representative western blotting pictures showing the appearance of EV markers and Calnexin at 1.10 /C11.18 g/mL after ﬂoating EVs on a continuous sucrose gradient for 16 h.Serum-free culture influences EVs Citation: Journal of Extracellular Vesicles 2015, 4: 26883 - http://dx.doi.org/10.3402/jev.v4.26883 7 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/db/59/JEV-4-26883.PMC4447833.pdf
"8 (page number not for citation purpose)Citation: Journal of Extracellular Vesicles 2015, 4: 26883 - http://dx.doi.org/10.3402/jev.v4.26883",OADS,/arxiv_data1/oa_pdf/db/59/JEV-4-26883.PMC4447833.pdf
"(e) Representative western blots on these selected validation targets in both cells and EVs cultured and collected under either OptiMEM or pre-spun conditions.Serum-free culture influences EVs Citation: Journal of Extracellular Vesicles 2015, 4: 26883 - http://dx.doi.org/10.3402/jev.v4.26883 9 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/db/59/JEV-4-26883.PMC4447833.pdf
"10 (page number not for citation purpose)Citation: Journal of Extracellular Vesicles 2015, 4: 26883 - http://dx.doi.org/10.3402/jev.v4.26883",OADS,/arxiv_data1/oa_pdf/db/59/JEV-4-26883.PMC4447833.pdf
"J Extracell Vesicles.2013;2:20389, doi: http://dx.doi.org/10.3402/jev.v2i0.20389 20.",OADS,/arxiv_data1/oa_pdf/db/59/JEV-4-26883.PMC4447833.pdf
"2014;3:24783, doi: http://dx.doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/db/59/JEV-4-26883.PMC4447833.pdf
"2010;12:3 /C14.Serum-free culture influences EVs Citation: Journal of Extracellular Vesicles 2015, 4: 26883 - http://dx.doi.org/10.3402/jev.v4.26883 11 (page number not for citation purpose)",Non-OADS,/arxiv_data1/oa_pdf/db/59/JEV-4-26883.PMC4447833.pdf
"2012;1:18396, doi: http://dx.doi.org/10.3402/jev.v1i0.18396 49.",Non-OADS,/arxiv_data1/oa_pdf/db/59/JEV-4-26883.PMC4447833.pdf
"12 (page number not for citation purpose)Citation: Journal of Extracellular Vesicles 2015, 4: 26883 - http://dx.doi.org/10.3402/jev.v4.26883",OADS,/arxiv_data1/oa_pdf/db/59/JEV-4-26883.PMC4447833.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/af/10/gav016.PMC4447994.pdf
"Procedures   Randomization was performed online (http://randomization.com) by a study investi- gator, using a randomization plan stratified by blocks of varyi ng sizes (blocks of 2, 4, or 6).",OADS,/arxiv_data1/oa_pdf/6e/6b/cee-0005-0031.PMC4448047.pdf
"http://tabnet.datasus.gov.br/ cgi/deftohtm.exe?idb2010/c08.def (accessed  August 20, 2012).",OADS,/arxiv_data1/oa_pdf/6e/6b/cee-0005-0031.PMC4448047.pdf
"http://www.obsan.admin.ch/bfs/obsan/fr/ index/ (accessed June 15, 2013).",Non-OADS,/arxiv_data1/oa_pdf/b9/55/dee-0005-0176.PMC4448058.pdf
"http://www.orpha.net/data/   patho/ GB/ uk-POEMS.pdf (acc essed  December  4, 2014 ).",Non-OADS,/arxiv_data1/oa_pdf/06/c6/cde-0007-0061.PMC4448059.pdf
"Ghosh et al., 2015, Developmental Cell 33, 478–488 May 26, 2015 ª2015 The Authors http://dx.doi.org/10.1016/j.devcel.2015.03.014",Non-OADS,/arxiv_data1/oa_pdf/82/dd/main.PMC4448147.pdf
"140306, India *Correspondence: lolitika@iisermohali.ac.in http://dx.doi.org/10.1016/j.devcel.2015.03.014This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).",Non-OADS,/arxiv_data1/oa_pdf/82/dd/main.PMC4448147.pdf
"SUPPLEMENTAL INFORMATION Supplemental Information includes Supplemental Experimental Procedures, four ﬁgures, and three movies and can be found with this article online athttp://dx.doi.org/10.1016/j.devcel.2015.03.014 .",Non-OADS,/arxiv_data1/oa_pdf/82/dd/main.PMC4448147.pdf
Available at: http://www.editorial- unit.cochrane.org/sites/editorial-unit.cochrane.org/ﬁle s/ uploads/MECIR˙conduct˙standards%202.1.pdf (accessed on 4 November 2012).,Non-OADS,/arxiv_data1/oa_pdf/4b/8a/CD006404-0001.PMC4448218.pdf
"VL also searched the metaRegister of Controlled T rials (mRCT; http://www.controlled-trials.com/) and the search portal of t he World Health Organization (WHO) International Clinical T ria ls Registry Platform (www.who.int/trialsearch), to identify on going trials, and ProQuest Dissertations & Theses A&I to identify rele- vant dissertations.",OADS,/arxiv_data1/oa_pdf/ad/0a/CD010705-0001.PMC4448219.pdf
Genotype MTBDRsl product information sheet Version 2.0. http://www.tbevidence.org/ documents/rescentre/sop/MTBDRsl.pdf (accessed 02 July 2012):1–16.,Non-OADS,/arxiv_data1/oa_pdf/ad/0a/CD010705-0001.PMC4448219.pdf
Genotype MTBDRsl product information sheet Version 2.0. http://www.hain- lifescience.co.za/products/microbiology/mycobacteria / genotype-mtbdrsl.html (accessed 02 July 2012):1–16.,Non-OADS,/arxiv_data1/oa_pdf/ad/0a/CD010705-0001.PMC4448219.pdf
Available from: http://srdta.cochrane.org/.,OADS,/arxiv_data1/oa_pdf/ad/0a/CD010705-0001.PMC4448219.pdf
"Summary report of the Expert Group Meeting on the use of liquid culture media, Geneva, 26 March 2007. http://www.who.int/tb/laboratory/ use˙of˙liquid˙tb˙culture˙summary˙report.pdf (accessed 15 August 2014).",Non-OADS,/arxiv_data1/oa_pdf/ad/0a/CD010705-0001.PMC4448219.pdf
Global tuberculosis report 2013. http://www.who.int/tb/publications/global˙report/ en/ (accessed 15 August 2014):1–100.,Non-OADS,/arxiv_data1/oa_pdf/ad/0a/CD010705-0001.PMC4448219.pdf
"Expert group meeting report, Geneva: February 2013. http://apps.who.int/iris/bitstream/10665/78099/1/ WHO˙HTM˙TB˙2013.01.eng.pdf (accessed 12 June 2014).",Non-OADS,/arxiv_data1/oa_pdf/ad/0a/CD010705-0001.PMC4448219.pdf
http://apps.who.int/trialsearch/T rial2.aspx?T rialID= IRCT2013072314117N1 (accessed 10 February 2015).,OADS,/arxiv_data1/oa_pdf/9d/b7/CD008138-0001.PMC4448221.pdf
This scale is recommended by the  Cochrane Non‑randomized Studies Methods Working  Group available at the electronic address (http://www.ohri.,Non-OADS,/arxiv_data1/oa_pdf/84/26/IJO-63-227.PMC4448235.pdf
Available from: http://www.who.int/csr/don/2014_04_01_ebola/en/.,OADS,/arxiv_data1/oa_pdf/a3/98/JGID-7-53.PMC4448324.pdf
Available from: http://www.who.int/csr/don/2014_03_30_ebola_lbr/en/.,OADS,/arxiv_data1/oa_pdf/a3/98/JGID-7-53.PMC4448324.pdf
Available from: http://www.who.int/csr/don/2012_11_17/en/.,OADS,/arxiv_data1/oa_pdf/a3/98/JGID-7-53.PMC4448324.pdf
Available from: http://www.who.int/csr/don/2012_11_23_ebola/en/.,OADS,/arxiv_data1/oa_pdf/a3/98/JGID-7-53.PMC4448324.pdf
Available from: http://www.who.int/entity/csr/don/2012_11_30_ebola/en/index.html.,OADS,/arxiv_data1/oa_pdf/a3/98/JGID-7-53.PMC4448324.pdf
Available from: http://apps.who.int/ebola/en/ebola-situation-report/situation-reports/ebola-situation-report-11-february-2015.,Non-OADS,/arxiv_data1/oa_pdf/a3/98/JGID-7-53.PMC4448324.pdf
Available from: http://www.washingtonpost.com/posteverything/wp/2014/10/08/john-kerry-other-countries-need-to-do-more-to-stop-ebola/.,Non-OADS,/arxiv_data1/oa_pdf/a3/98/JGID-7-53.PMC4448324.pdf
Available from: http://www.afp.com/es/noticias/eeuu-alerta-de-una-crisis-mundial-por-el-ebola [Last accessed on 2014 Dec 20].,Non-OADS,/arxiv_data1/oa_pdf/a3/98/JGID-7-53.PMC4448324.pdf
Available from: http://www.cdc.gov/nchs/nhis.htm.,OADS,/arxiv_data1/oa_pdf/a3/98/JGID-7-53.PMC4448324.pdf
Available from: http://www.census.gov/prod/2013pubs/p60-245.pdf.,OADS,/arxiv_data1/oa_pdf/a3/98/JGID-7-53.PMC4448324.pdf
Available from: http://mohfw.nic.in/show ﬁ le.,Non-OADS,/arxiv_data1/oa_pdf/01/18/JGID-7-56.PMC4448325.pdf
Available from: http://www.mohfw.nic.in/show ﬁ le.,Non-OADS,/arxiv_data1/oa_pdf/01/18/JGID-7-56.PMC4448325.pdf
Available from:  http://www.cdc.gov/ ﬂ u/nivw/pledge/index.html [Last accessed on 2015  Mar 8].,Non-OADS,/arxiv_data1/oa_pdf/01/18/JGID-7-56.PMC4448325.pdf
Available from: http://www.mohfw.nic.in/show ﬁ le.php?lid = 3073  [Last accessed on 2015 Mar 8].,Non-OADS,/arxiv_data1/oa_pdf/01/18/JGID-7-56.PMC4448325.pdf
Available from: http://www.tbcindia.org.,Non-OADS,/arxiv_data1/oa_pdf/a5/27/JGID-7-60.PMC4448326.pdf
Available from: http://www.tbcindia.nic.in/pdfs/Training%20manual%20 M%20tuberculosis%20C%20DST.pdf  [Last accessed on 2012 Jan 12].,Non-OADS,/arxiv_data1/oa_pdf/a5/27/JGID-7-60.PMC4448326.pdf
Available from: http://www.newbornwhocc.org/pdf/nnpd_report_2002-03.PDF.,Non-OADS,/arxiv_data1/oa_pdf/38/3d/JGID-7-75.PMC4448329.pdf
http://www.hcup-us.ahrq.gov/reports/statbriefs/sb35.pdf 9.,OADS,/arxiv_data1/oa_pdf/d2/c4/JGID-7-78.PMC4448330.pdf
World Health Organization Regional Of ﬁ ce For The Western Paci ﬁ c. Fact  Sheets — Streptococcus suis August 1 2005. http://www.wpro.who.int.,Non-OADS,/arxiv_data1/oa_pdf/7b/81/JGID-7-93.PMC4448337.pdf
Available from: http://www.wpro.who.int/mediacentre/factsheets/fs_20050802/en/ 5.,Non-OADS,/arxiv_data1/oa_pdf/7b/81/JGID-7-93.PMC4448337.pdf
Available from URL:http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx.,Non-OADS,/arxiv_data1/oa_pdf/eb/5d/tca0006-0307.PMC4448375.pdf
Available from URL:http://www.who.int/mediacent re/factsheets/fs313/en/.,OADS,/arxiv_data1/oa_pdf/eb/5d/tca0006-0307.PMC4448375.pdf
Available from URL: http://www.iarc.fr/en/publications/books/sp161/index.php.,Non-OADS,/arxiv_data1/oa_pdf/eb/5d/tca0006-0307.PMC4448375.pdf
]Available from URL: http://pubs.healtheffects.org/view.php?id =334.,Non-OADS,/arxiv_data1/oa_pdf/eb/5d/tca0006-0307.PMC4448375.pdf
]Available from URL: http://www.euro.who.int/document/e79097.pdf.,Non-OADS,/arxiv_data1/oa_pdf/eb/5d/tca0006-0307.PMC4448375.pdf
]Available from URL: http://www.mep.gov.cn/gkml/hbb/bgg/201308/t20130820_257686.htm.,Non-OADS,/arxiv_data1/oa_pdf/eb/5d/tca0006-0307.PMC4448375.pdf
Available from URL: http://kjs.mep.gov.cn/hjbhbz/bzwb/dqhjbh/dqydywrwpfbz/201309/t20130917_260352.htm.,Non-OADS,/arxiv_data1/oa_pdf/eb/5d/tca0006-0307.PMC4448375.pdf
Available from URL:http://globocan.iarc.fr.,Non-OADS,/arxiv_data1/oa_pdf/ef/50/tca0006-0233.PMC4448384.pdf
Available from URL:http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#nscl.,Non-OADS,/arxiv_data1/oa_pdf/ef/50/tca0006-0233.PMC4448384.pdf
Available from URL: http://globocan.iarc.fr 3 Parkin D. Global cancer statistics in the year 2000.,Non-OADS,/arxiv_data1/oa_pdf/8c/6e/tca0006-0334.PMC4448394.pdf
Available from URL: http://en.wikipedia.org/wiki/Otto_Heinrich_Warburg.,Non-OADS,/arxiv_data1/oa_pdf/d1/88/tca0006-0017.PMC4448463.pdf
Available from URL:http://nutritionaloncology.org/cancerCellMetabolism.html.,Non-OADS,/arxiv_data1/oa_pdf/d1/88/tca0006-0017.PMC4448463.pdf
Available from URL: http://www.cellsignal.com/pathways/glucose-metabolism.jsp.,Non-OADS,/arxiv_data1/oa_pdf/d1/88/tca0006-0017.PMC4448463.pdf
"Material and method Messenger ribonucleic acid (mRNA) expression proﬁle The mRNA expression proﬁle GSE40275, published on 25 August 2012 from the Gene Expression Omnibus (GEO,http://www.ncbi.nlm.nih.gov/geo/) focused on the differ-ences in gene expression proﬁles among SCLC, NSCLC, andnormal lung samples regarding the expression of gene encod-ing for proteins with G protein-coupled receptor activity.",OADS,/arxiv_data1/oa_pdf/b5/1e/tca0006-0070.PMC4448473.pdf
"We downloaded the miRNAfrom miRBase (Release 20: June 2013, http://www.mirbase.org/), and selected the miRNAs that targeted the differentexpressed genes of SCLC and NSCLC.",OADS,/arxiv_data1/oa_pdf/b5/1e/tca0006-0070.PMC4448473.pdf
Available from URL: http://www.cancer.gov/cancertopics/factsheet/detection/staging.6 National Cancer Institute/National Institutes of Health.,Non-OADS,/arxiv_data1/oa_pdf/b5/1e/tca0006-0070.PMC4448473.pdf
Available from URL: http://www.cancer.gov/cancertopics/pdq/treatment/non-small-cell-lung/Patient.,Non-OADS,/arxiv_data1/oa_pdf/b5/1e/tca0006-0070.PMC4448473.pdf
Available from URL: http://www.cancer.gov/cancertopics/pdq/treatment/small-cell-lung/healthprofessional.,Non-OADS,/arxiv_data1/oa_pdf/b5/1e/tca0006-0070.PMC4448473.pdf
Available from URL:http://www.nlm.nih.gov/medlineplus/ency/article/007194.htm.,OADS,/arxiv_data1/oa_pdf/b5/1e/tca0006-0070.PMC4448473.pdf
Available from URL:http://www.cancer.org/cancer/lungcancer-non-smallcell/detailedguide/non-small-cell-lung-cancer-survival-rates.,Non-OADS,/arxiv_data1/oa_pdf/b5/1e/tca0006-0070.PMC4448473.pdf
Available from URL: http://www.cancer.gov/cancertopics/pdq/treatment/non-small-cell-lung/Patient.,Non-OADS,/arxiv_data1/oa_pdf/b5/1e/tca0006-0070.PMC4448473.pdf
Available from URL: http://www.cancer.org/cancer/lungcancer-non-smallcell/detailedguide/non-small-cell-lung-cancer -what-is-non-small-cell-lung -cancer.,Non-OADS,/arxiv_data1/oa_pdf/b5/1e/tca0006-0070.PMC4448473.pdf
Available from URL:http://globocan.iarc.fr 2 National Cancer Institute.,Non-OADS,/arxiv_data1/oa_pdf/b5/2e/tca0006-0010.PMC4448475.pdf
Available from URL:http://seer.cancer.gov 3 U.S. National Institutes of Health.,Non-OADS,/arxiv_data1/oa_pdf/b5/2e/tca0006-0010.PMC4448475.pdf
Available from URL: http://clinicaltrials.gov 4 Camidge DR. Icotinib: kick-starting the Chinese anticancer drug industry.,Non-OADS,/arxiv_data1/oa_pdf/b5/2e/tca0006-0010.PMC4448475.pdf
]: Available from URL: http://www.nccn.com/patient-guidelines.html.,Non-OADS,/arxiv_data1/oa_pdf/c1/c8/tca0006-0224.PMC4448482.pdf
"]Available from URL: http://srdta.cochrane.org/ 49 Jaeschke R, Guyatt G, Sackett DL.",OADS,/arxiv_data1/oa_pdf/ae/a6/tca0006-0123.PMC4448484.pdf
"Available fromURL: http://globocan.iarc.fr/Default.aspx 8 Chen W, Zheng R, Zhang S et al.",OADS,/arxiv_data1/oa_pdf/58/69/tca0006-0209.PMC4448492.pdf
Available from URL:http://ci5.iarc.fr/Default.aspx.,OADS,/arxiv_data1/oa_pdf/58/69/tca0006-0209.PMC4448492.pdf
Available from URL:http://www.nccn.org.,Non-OADS,/arxiv_data1/oa_pdf/57/7d/tca0006-0146.PMC4448496.pdf
"Surgical Neurology InternationalEditor: James I. Ausman, MD, PhD   University of California, Los  Angeles, CA, USAOPEN ACCESS For entire Editorial Board visit :    http://www.surgicalneurologyint.comBook Review A fascinating look at primitive and ancient medicine by medical  historian and classical scholar Plinio Prioreschi, MD, PhD Miguel A. Faria Clinical Professor of Neurosurgery (ret.)",Non-OADS,/arxiv_data1/oa_pdf/75/e1/SNI-6-87.PMC4448513.pdf
Available FREE in open access from: http://www.surgicalneurologyint.com/text.asp?2015/6/1/87/157623 Copyright: © 2015 Faria MA.,Non-OADS,/arxiv_data1/oa_pdf/75/e1/SNI-6-87.PMC4448513.pdf
"Surgical Neurology International 2015, 6:87  http://www.surgicalneurologyint.com/content/6/1/87prose.",Non-OADS,/arxiv_data1/oa_pdf/75/e1/SNI-6-87.PMC4448513.pdf
"Surgical Neurology International 2015, 6:87  http://www.surgicalneurologyint.com/content/6/1/87This discussion includes the most salient aspects of the  medical and public health practices of the Sumerian,  Akkadian, Assyrian, and Babylonian (Chaldean)  civilizations.",Non-OADS,/arxiv_data1/oa_pdf/75/e1/SNI-6-87.PMC4448513.pdf
"Surgical Neurology International 2015, 6:87  http://www.surgicalneurologyint.com/content/6/1/87propounded by the pre‑Socratic Greek philosopher  Empedocles (c. 490–430 B.C.)",Non-OADS,/arxiv_data1/oa_pdf/75/e1/SNI-6-87.PMC4448513.pdf
"Surgical Neurology International 2015, 6:87  http://www.surgicalneurologyint.com/content/6/1/87The ka, the person’s spiritual double and soul, needed a  body for survival after death, so the body needed to be  desiccated and embalmed to prevent its destruction.",Non-OADS,/arxiv_data1/oa_pdf/75/e1/SNI-6-87.PMC4448513.pdf
Surg Neurol Int 2015;6:72  Available from: http://www.surgicalneurologyint.,Non-OADS,/arxiv_data1/oa_pdf/75/e1/SNI-6-87.PMC4448513.pdf
"Surgical Neurology InternationalEditor: James I. Ausman, MD, PhD   University of California, Los  Angeles, CA, USAOPEN ACCESS For entire Editorial Board visit :    http://www.surgicalneurologyint.comDear Editor, The occurrence of postoperative visual loss (POVL) after  spine surgery in prone position, although rare, has been  described.",Non-OADS,/arxiv_data1/oa_pdf/b3/55/SNI-6-86.PMC4448514.pdf
"Available FREE in open access from: http://www.surgicalneurologyint.com/text.asp?2015/6/1/86/157622 Copyright: © 2015 Sodhi SBH This is an open‑access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use,   distribution, and reproduction in any medium, provided the original author and source are credited.",Non-OADS,/arxiv_data1/oa_pdf/b3/55/SNI-6-86.PMC4448514.pdf
"Surgical Neurology International 2015, 6:86  http://www.surgicalneurologyint.com/content/6/1/86After the emergency measures, there was no change in  the symptoms of the patient.",Non-OADS,/arxiv_data1/oa_pdf/b3/55/SNI-6-86.PMC4448514.pdf
"Surgical Neurology International 2015, 6:86  http://www.surgicalneurologyint.com/content/6/1/86visual loss may be reversible, provided it is detected early.",Non-OADS,/arxiv_data1/oa_pdf/b3/55/SNI-6-86.PMC4448514.pdf
"Surgical Neurology InternationalEditor: James I. Ausman, MD, PhD   University of California, Los  Angeles, CA, USAOPEN ACCESS For entire Editorial Board visit :    http://www.surgicalneurologyint.comCase Report Lateral supraorbital approach to ipsilateral PCA‑P1 and ICA‑PCoA  aneurysms Felix Goehre1, Behnam Rezai Jahromi, Ahmed Elsharkawy, Hanna Lehto, Oleg Shekhtman2,   Hugo Andrade‑Barazarte, Francisco Munoz, Ferzat Hijazy, Makhkam Makhkamov , Juha Hernesniemi Department of Neurosurgery, Helsinki University Central Hospital, Helsinki, Finland, 1Department of Neurosurgery, Bergmannstrost Hospital Halle, Halle,  Germany, 2Burdenko Neurosurgical Institute, Russian Academy of Medical Sciences, Moscow , Russia E-mail: Felix Goehre * - fgoehre@gmail.com; Behnam Rezai Jahromi - behnam.rezai@hus.fi; Ahmed Elsharkawy - ahmed.elsharkawy@med.tanta.edu.eg;   Hanna Lehto - hanna.lehto@hus.fi; Oleg Shekhtman - oshekhtman@gmail.com; Hugo Andrade-Barazarte - hugoandrade2@yahoo.es;   Francisco Munoz - francisco.munozg@icloud.com; Ferzat Hijazy - ferzat4@hotmail.com; Makhkam Makhkamov - makhkammakhkamov@gmail.com;   Juha Hernesniemi - juha.hernesniemi@hus.fi   *Corresponding author Received: 31 December 14  Accepted: 13 February 15  Published: 28 May 15 Access this article  online Website: www.surgicalneurologyint.com DOI:   10.4103/2152-7806.157793  Quick Response Code: Abstract Background: Aneurysms of the posterior cerebral artery (PCA) are rare and  often associated with anterior circulation aneurysms.",Non-OADS,/arxiv_data1/oa_pdf/a0/ae/SNI-6-91.PMC4448515.pdf
Available FREE in open access from: http://www.surgicalneurologyint.com/text.asp?2015/6/1/91/157793 Copyright: © 2015 Goehre F .,Non-OADS,/arxiv_data1/oa_pdf/a0/ae/SNI-6-91.PMC4448515.pdf
"Surgical Neurology International 2015, 6:91  http://www.surgicalneurologyint.com/content/6/1/91INTRODUCTION Aneurysms of the posterior cerebral artery (PCA) are  rare; less than 2% of all cerebral aneurysms involve the  PCA.",Non-OADS,/arxiv_data1/oa_pdf/a0/ae/SNI-6-91.PMC4448515.pdf
"Surgical Neurology International 2015, 6:91  http://www.surgicalneurologyint.com/content/6/1/91visible.",Non-OADS,/arxiv_data1/oa_pdf/a0/ae/SNI-6-91.PMC4448515.pdf
"Surgical Neurology International 2015, 6:91  http://www.surgicalneurologyint.com/content/6/1/91surrounded by several sensitive structures.",Non-OADS,/arxiv_data1/oa_pdf/a0/ae/SNI-6-91.PMC4448515.pdf
"Surgical Neurology International 2015, 6:91  http://www.surgicalneurologyint.com/content/6/1/91anterior temporal approach for microsurgical thromboembolectomy of  an acute proximal posterior cerebral artery occlusion.",Non-OADS,/arxiv_data1/oa_pdf/a0/ae/SNI-6-91.PMC4448515.pdf
"Surgical Neurology InternationalEditor: James I. Ausman, MD, PhD   University of California, Los  Angeles, CA, USAOPEN ACCESS For entire Editorial Board visit :    http://www.surgicalneurologyint.comOriginal Article Efficacy of arachnoid plasty with collagen sheets and fibrin glue:  An in vitro  experiment and a case review Junya Abe, T sutomu Ichinose1, Yuzo Terakawa, Naohiro T suyuguchi, Takashi T suruno1, Kenji Ohata Department of Neurosurgery, Osaka City University Graduate School of Medicine, 1‑4‑3 Asahi‑machi, Abeno‑ku, Osaka 545 ‑ 8585, 1Department of Neurosurgery,  Yao T okushukai General Hospital, 1‑11 Wakakusa‑cho, Yao city, Osaka, 581 ‑ 0011, Japan E‑mail: *Junya Abe ‑ abe0801@gmail.com; Tsutomu Ichinose ‑ ichinosetsutomu@gmail.com; Yuzo T erakawa ‑ terakawa@med.osaka‑cu.ac.jp;   Naohiro Tsuyuguchi ‑ nao@med.osaka‑cu.ac.jp; Takashi Tsuruno ‑ tsuruno‑0745@nike.eonet.ne.jp; Kenji Ohata ‑ kohata@med.osaka‑cu.ac.jp   *Corresponding author Received: 29 October 14  Accepted: 29 January 15  Published:  28 May 15 Abstract Background:  Postoperative subdural fluid collection sometimes occurs after clipping  of cerebral aneurysms.",Non-OADS,/arxiv_data1/oa_pdf/9d/dc/SNI-6-90.PMC4448516.pdf
Available FREE in open access from: http://www.surgicalneurologyint.com/text.asp?2015/6/1/90/157792 Copyright: © 2015 Abe J.,Non-OADS,/arxiv_data1/oa_pdf/9d/dc/SNI-6-90.PMC4448516.pdf
"Surgical Neurology International 2015, 6:90  http://www.surgicalneurologyint.com/content/6/1/90of arachnoid plasty performed with collagen sheets and  fibrin glue after clipping of unruptured aneurysms.",Non-OADS,/arxiv_data1/oa_pdf/9d/dc/SNI-6-90.PMC4448516.pdf
"Surgical Neurology International 2015, 6:90  http://www.surgicalneurologyint.com/content/6/1/90RESULTS In vitro  experiment of water pressure resistant The results of the water pressure resistance experiment  are shown in [Figure 2].",Non-OADS,/arxiv_data1/oa_pdf/9d/dc/SNI-6-90.PMC4448516.pdf
"Surgical Neurology International 2015, 6:90  http://www.surgicalneurologyint.com/content/6/1/90instruments has led to better treatment outcome of  craniotomy.",Non-OADS,/arxiv_data1/oa_pdf/9d/dc/SNI-6-90.PMC4448516.pdf
"Surgical Neurology InternationalEditor: James I. Ausman, MD, PhD   University of California, Los  Angeles, CA, USAOPEN ACCESS For entire Editorial Board visit :    http://www.surgicalneurologyint.comAbstract Background:  The elderly represent a unique challenge for the effects of regional  anesthesia, and very few cases of block onset delay have been described.",Non-OADS,/arxiv_data1/oa_pdf/d8/5d/SNI-6-88.PMC4448518.pdf
Available FREE in open access from: http://www.surgicalneurologyint.com/text.asp?2015/6/1/88/157658 Copyright: © 2015 Ghaly RF .,Non-OADS,/arxiv_data1/oa_pdf/d8/5d/SNI-6-88.PMC4448518.pdf
"Surgical Neurology International 2015, 6:88  http://www.surgicalneurologyint.com/content/6/1/88blockade reduced the events of postoperative  complications such as thromboembolism, bleeding,  infection, respiratory depression, and renal failure.",Non-OADS,/arxiv_data1/oa_pdf/d8/5d/SNI-6-88.PMC4448518.pdf
"Surgical Neurology International 2015, 6:88  http://www.surgicalneurologyint.com/content/6/1/88inection to avoid the aforementioned adverse effects  and the delay might be explained by the anatomical and  physiological changes of advanced age.",Non-OADS,/arxiv_data1/oa_pdf/d8/5d/SNI-6-88.PMC4448518.pdf
"Surgical Neurology International 2015, 6:88  http://www.surgicalneurologyint.com/content/6/1/889.",Non-OADS,/arxiv_data1/oa_pdf/d8/5d/SNI-6-88.PMC4448518.pdf
"Article, supplemental material, and publi- cation date are at http://www.genome.org/cgi/doi/10.1101/gr.187450.114.© 2015 Buchner and Nadeau This article is distributed exclusively by Cold Spring Harbor Laboratory Press for the first six months after the full-issue publi-cation date (see http://genome.cshlp.org/site/misc/terms.xhtml).",Non-OADS,/arxiv_data1/oa_pdf/a5/17/775.PMC4448675.pdf
"Other examples of phenotypic variation among inbred strains in- clude M. tuberculosis infection (susceptible: CBA, DBA/2, C3H, 129/X1; resistant: BALB/c, C57BL/6J) and atherosclerosis (suscep-tible: DBA/2, C57BL/6J; resistant: BALB/c, C3H) among many oth- ers (http://www.jax.org/phenome) (Paigen et al.",Non-OADS,/arxiv_data1/oa_pdf/a5/17/775.PMC4448675.pdf
"Websites providing details for resources to study complex traits in mice Panel Websites OS Heterogeneous stockhttp://mus.well.ox.ac.uk/mouse/HS/ Commercially availableAvailable from various commercial vendors including Harlan, Charles River, Taconic, among others(Yalcin and Flint 2012)http://www.harlan.com/products_and_services/research_models_and_services/research_models-outbred-mice http://www.criver.com/find-a-model?",Non-OADS,/arxiv_data1/oa_pdf/a5/17/775.PMC4448675.pdf
animal_type=Mice http://www.taconic.com/find-your-model/non-gems Diversity outbredhttp://jaxmice.jax.org/strain/009376.html HMDP http://systems.genetics.ucla.edu CC http://csbio.unc.edu/CCstatus/index.pyCSS http://www.jax.org/smsr/csstrain.html http://jaxmice.jax.org/list/cat481361.htmlhttp://www.shigen.nig.ac.jp/mouse/nig/ (CC) Collaborative Cross; (OS) Outbred Stock; (HMDP) Hybrid Mouse Diversity Panel; (CSS) Chromosome Substitution Strain.Contrasting genetic architectures Genome Research 777 www.genome.org,Non-OADS,/arxiv_data1/oa_pdf/a5/17/775.PMC4448675.pdf
"Article, supplemental material, and publi- cation date are at http://www.genome.org/cgi/doi/10.1101/gr.185041.114.© 2015 Kloosterman et al.",OADS,/arxiv_data1/oa_pdf/e0/67/792.PMC4448676.pdf
This article is distributed exclusively by Cold Spring Harbor Laboratory Press for the first six months after the full-issue publicationdate (see http://genome.cshlp.org/site/misc/terms.xhtml).,Non-OADS,/arxiv_data1/oa_pdf/e0/67/792.PMC4448676.pdf
"After six months, itis available under a Creative Commons License (Attribution-NonCommercial4.0 International), as described at http://creativecommons.org/licenses/by- nc/4.0/.Research 792 Genome Research 25:792 –801 Published by Cold Spring Harbor Laboratory Press; ISSN 1088-9051/15; www.genome.org www.genome.org",OADS,/arxiv_data1/oa_pdf/e0/67/792.PMC4448676.pdf
"2011): Duplicate reads were marked using Picard tools (http://picard.sourceforge.net), reads were realignedaround indels using GATK IndelRealigner, and base quality scores were recalibrated using GATK BaseRecalibrator.",OADS,/arxiv_data1/oa_pdf/e0/67/792.PMC4448676.pdf
"2011], DWAC- seq [http://tools.genomes.nl/dwac-seq.html], FACADE [Coe et al.",OADS,/arxiv_data1/oa_pdf/e0/67/792.PMC4448676.pdf
Data access Sequence data have been submitted to the European Genome-phe- nome Archive (EGA; https://www.ebi.ac.uk/ega/home) under ac- cession number EGAS00001000644.,OADS,/arxiv_data1/oa_pdf/e0/67/792.PMC4448676.pdf
"Article, supplemental material, and publi- cation date are at http://www.genome.org/cgi/doi/10.1101/gr.184325.114.© 2015 Andrews et al.",OADS,/arxiv_data1/oa_pdf/ad/fe/802.PMC4448677.pdf
This article is distributed exclusively by Cold Spring Harbor Laboratory Press for the first six months after the full-issue publicationdate (see http://genome.cshlp.org/site/misc/terms.xhtml).,Non-OADS,/arxiv_data1/oa_pdf/ad/fe/802.PMC4448677.pdf
"After six months, itis available under a Creative Commons License (Attribution-NonCommercial4.0 International), as described at http://creativecommons.org/licenses/by- nc/4.0/.Research 802 Genome Research 25:802 –813 Published by Cold Spring Harbor Laboratory Press; ISSN 1088-9051/15; www.genome.org www.genome.org",OADS,/arxiv_data1/oa_pdf/ad/fe/802.PMC4448677.pdf
2012) (http://www.human-phenotype-ontology.org/contao/index.php/downloads.html) andused the most general mapping for each term if matches werenot 1 –1.,Non-OADS,/arxiv_data1/oa_pdf/ad/fe/802.PMC4448677.pdf
A full list of the centers that contributed to the gen- eration of the data is available from http://decipher.sanger.ac.uk and via email from decipher@sanger.ac.uk.,OADS,/arxiv_data1/oa_pdf/ad/fe/802.PMC4448677.pdf
http://www.human-phenotype-ontology.org/contao/index.php/downloads.html.,Non-OADS,/arxiv_data1/oa_pdf/ad/fe/802.PMC4448677.pdf
http://www.omim.org/.,Non-OADS,/arxiv_data1/oa_pdf/ad/fe/802.PMC4448677.pdf
"Article, supplemental material, and publi- cation date are at http://www.genome.org/cgi/doi/10.1101/gr.188581.114.© 2015 Lim et al.",OADS,/arxiv_data1/oa_pdf/85/dc/836.PMC4448680.pdf
This article is distributed exclusively by Cold Spring Harbor Laboratory Press for the first six months after the full-issue publication date (seehttp://genome.cshlp.org/site/misc/terms.xhtml).,Non-OADS,/arxiv_data1/oa_pdf/85/dc/836.PMC4448680.pdf
"After six months, it is avail-able under a Creative Commons License (Attribution-NonCommercial 4.0 Inter- national), as described at http://creativecommons.org/licenses/by-nc/4.0/.Research 836 Genome Research 25:836 –844 Published by Cold Spring Harbor Laboratory Press; ISSN 1088-9051/15; www.genome.org www.genome.org",Non-OADS,/arxiv_data1/oa_pdf/85/dc/836.PMC4448680.pdf
Data access Genome-wide data sets from this study have been submitted to the NCBI Gene Expression Omnibus (GEO; http://www.ncbi.,OADS,/arxiv_data1/oa_pdf/85/dc/836.PMC4448680.pdf
"Article, supplemental material, and publi- cation date are at http://www.genome.org/cgi/doi/10.1101/gr.184168.114.© 2015 Stavreva et al.",OADS,/arxiv_data1/oa_pdf/01/d5/845.PMC4448681.pdf
This article is distributed exclusively by Cold Spring Harbor Laboratory Press for the first six months after the full-issue publicationdate (see http://genome.cshlp.org/site/misc/terms.xhtml).,Non-OADS,/arxiv_data1/oa_pdf/01/d5/845.PMC4448681.pdf
"After six months, itis available under a Creative Commons License (Attribution-NonCommercial4.0 International), as described at http://creativecommons.org/licenses/by- nc/4.0/.",Non-OADS,/arxiv_data1/oa_pdf/01/d5/845.PMC4448681.pdf
Data access ChIP-seq and DNase-seq data from this study have been submitted to the NCBI Gene Expression Omnibus (GEO; http://www.ncbi.,OADS,/arxiv_data1/oa_pdf/01/d5/845.PMC4448681.pdf
http://www.R-project.org/.,Non-OADS,/arxiv_data1/oa_pdf/01/d5/845.PMC4448681.pdf
"Article, supplemental material, and publi- cation date are at http://www.genome.org/cgi/doi/10.1101/gr.188870.114.© 2015 Svensson et al.",OADS,/arxiv_data1/oa_pdf/ae/3b/872.PMC4448683.pdf
This article is distributed exclusively by Cold Spring Harbor Laboratory Press for the first six months after the full-issue publicationdate (see http://genome.cshlp.org/site/misc/terms.xhtml).,Non-OADS,/arxiv_data1/oa_pdf/ae/3b/872.PMC4448683.pdf
"After six months, itis available under a Creative Commons License (Attribution-NonCommercial4.0 International), as described at http://creativecommons.org/licenses/by- nc/4.0/.Research 872 Genome Research 25:872 –883 Published by Cold Spring Harbor Laboratory Press; ISSN 1088-9051/15; www.genome.org www.genome.org",OADS,/arxiv_data1/oa_pdf/ae/3b/872.PMC4448683.pdf
Data access The sequencing and microarray data from this study havebeen submitted to the NCBI Gene Expression Omnibus (GEO;http://www.ncbi.nlm.nih.gov/geo/) under accession number GSE66866.,OADS,/arxiv_data1/oa_pdf/ae/3b/872.PMC4448683.pdf
"Article, supplemental material, and publi-cation date are at http://www.genome.org/cgi/doi/10.1101/gr.185793.114.",OADS,/arxiv_data1/oa_pdf/2c/2c/897.PMC4448685.pdf
"This article, published in Genome Research , is avail- able under a Creative Commons License (Attribution-NonCommercial 4.0 Inter- national), as described at http://creativecommons.org/licenses/by-nc/4.0/.Research 25:897 –906 Published by Cold Spring Harbor Laboratory Press; ISSN 1088-9051/15; www.genome.org Genome Research 897 www.genome.org",Non-OADS,/arxiv_data1/oa_pdf/2c/2c/897.PMC4448685.pdf
Data access All high-throughput sequencing data have been submitted to the European Nucleotide Archive (ENA; http://www.ebi.ac.uk/ena).,OADS,/arxiv_data1/oa_pdf/2c/2c/897.PMC4448685.pdf
"Article, supplemental material, and publi- cation date are at http://www.genome.org/cgi/doi/10.1101/gr.183749.114.© 2015 Kaplow et al.",OADS,/arxiv_data1/oa_pdf/eb/c4/907.PMC4448686.pdf
This article is distributed exclusively by Cold Spring Harbor Laboratory Press for the first six months after the full-issue publicationdate (see http://genome.cshlp.org/site/misc/terms.xhtml).,Non-OADS,/arxiv_data1/oa_pdf/eb/c4/907.PMC4448686.pdf
"After six months, itis available under a Creative Commons License (Attribution-NonCommercial4.0 International), as described at http://creativecommons.org/licenses/ by-nc/4.0/.Method 25:907 –917 Published by Cold Spring Harbor Laboratory Press; ISSN 1088-9051/15; www.genome.org Genome Research 907 www.genome.org",OADS,/arxiv_data1/oa_pdf/eb/c4/907.PMC4448686.pdf
"We used Fisher ’s exact test, implemented in MATLAB using Michael Boedigheimer ’s fexact function (http://www.mathworks.",Non-OADS,/arxiv_data1/oa_pdf/eb/c4/907.PMC4448686.pdf
"Weused a 2 × 3 Fisher ’s exact test to compute the associations between genotype and average methylation status, which was implement- ed in MATLAB using Giuseppe Cardillo ’s myfisher23 function (http://www.mathworks.com/matlabcentral/fileexchange/15399-myfisher23).",OADS,/arxiv_data1/oa_pdf/eb/c4/907.PMC4448686.pdf
"To test whether mQTLs associate with open chromatin in var- ious cell types, we intersected the variants we tested for mQTLswith Joseph Pickrell ’s list of SNPs in open chromatin regions in var- ious cell types, which were downloaded from https://github.com/ joepickrell/1000-genomes (Bernstein et al.",OADS,/arxiv_data1/oa_pdf/eb/c4/907.PMC4448686.pdf
Data access Whole-genome bisulfite sequencing data generated in this study have been submitted to the NCBI Sequence Read Archive (SRA; http://www.ncbi.nlm.nih.gov/sra) under accession number SRP045408.,OADS,/arxiv_data1/oa_pdf/eb/c4/907.PMC4448686.pdf
"Article, supplemental material, and publi- cation date are at http://www.genome.org/cgi/doi/10.1101/gr.176552.114.© 2015 Jun et al.",OADS,/arxiv_data1/oa_pdf/26/b2/918.PMC4448687.pdf
This article is distributed exclusively by Cold Spring Harbor Laboratory Press for the first six months after the full-issue publication date (seehttp://genome.cshlp.org/site/misc/terms.xhtml).,Non-OADS,/arxiv_data1/oa_pdf/26/b2/918.PMC4448687.pdf
"After six months, it is availableunder a Creative Commons License (Attribution-NonCommercial 4.0 In- ternational), as described at http://creativecommons.org/licenses/by-nc/4.0/.Method 918 Genome Research 25:918 –925 Published by Cold Spring Harbor Laboratory Press; ISSN 1088-9051/15; www.genome.org www.genome.org",Non-OADS,/arxiv_data1/oa_pdf/26/b2/918.PMC4448687.pdf
"Forunusual scenarios such as drastic changes in sequencing technol-ogies used, we provide detailed guidelines for parameter tuningin the user ’s manual (http://www.gotcloud.org).",Non-OADS,/arxiv_data1/oa_pdf/26/b2/918.PMC4448687.pdf
"Software availability The GotCloud pipeline is available for public download (http://www.gotcloud.org) and is prepared for several different cloud com- puting environments, including the Amazon Web Services (AWS) Elastic Computer Cloud (EC2).",OADS,/arxiv_data1/oa_pdf/26/b2/918.PMC4448687.pdf
"ImageJ software (Rasband W. S., National Institutes of Health, USA; http://rsb.info.nih.gov/ij/) was used to first threshold and then select all Neurotrace-positive cells with a minimum pixel number of 175 reflecting a threshold diameter of ~25 µm.",OADS,/arxiv_data1/oa_pdf/53/db/mtm201451.PMC4448732.pdf
http://theassr.org/abstract/suboccipital-puncture-of- the-cisterna-magna-under-ct-guidance-with-intravenous-enhancement-in-order-to- circumvent-anomalous-course-of-posterior-inferior-cerebellar-artery-pica/ 23.,Non-OADS,/arxiv_data1/oa_pdf/53/db/mtm201451.PMC4448732.pdf
"To view a copy of this license, visit http://creativecommons.org/ licenses/by-nc-nd/3.0/ Supplementary Information accompanies this paper on the Molecular Therapy—Methods & Clinical Development website (http://www.nature.com/mtm)",Non-OADS,/arxiv_data1/oa_pdf/53/db/mtm201451.PMC4448732.pdf
"To view a copy of this license, visit http://creativecommons.org/ licenses/by-nc-sa/3.0/  Supplementary Information accompanies this paper on the Molecular Therapy—Methods & Clinical Development website (http://www.nature.com/mtm)",Non-OADS,/arxiv_data1/oa_pdf/47/ab/mtm201452.PMC4448734.pdf
"The human EF1α  promoter CpG Island prediction mapping was  done using the online tool from the Li Lab in the Department of Urology, UCSF (http://www.urogene.org/cgi-bin/methprimer/methprimer.cgi).",OADS,/arxiv_data1/oa_pdf/66/c8/mtm201453.PMC4448736.pdf
"To view a copy of this license, visit http://creativecommons.org/ licenses/by-nc-nd/3.0/ Supplementary Information accompanies this paper on the Molecular Therapy—Methods & Clinical Development website (http://www.nature.com/mtm)",Non-OADS,/arxiv_data1/oa_pdf/66/c8/mtm201453.PMC4448736.pdf
"To view a copy of this license, visit http://creativecommons.org/ licenses/by-nc-nd/3.0/",Non-OADS,/arxiv_data1/oa_pdf/fe/31/mtm201454.PMC4448738.pdf
"To view a copy of this license, visit http://creativecommons.org/ licenses/by-nc-nd/3.0/",Non-OADS,/arxiv_data1/oa_pdf/1a/91/mtm201458.PMC4448742.pdf
(Cell Mol Gastroenterol Hepatol 2015;1:295 –310; http://dx.doi.org/ 10.1016/j.jcmgh.2015.01.002 )Keywords: Experimental Colitis; IBD; Immunoregulation; Reg- ulatory B Cells.,Non-OADS,/arxiv_data1/oa_pdf/19/02/main.PMC4448782.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/19/02/main.PMC4448782.pdf
2352-345X http://dx.doi.org/10.1016/j.jcmgh.2015.01.002,OADS,/arxiv_data1/oa_pdf/19/02/main.PMC4448782.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/66/3d/imcrj-8-111.PMC4448920.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pInternational Medical Case Reports Journal 2015:8 111–116International Medical Case Reports Journal Dove press submit your manuscript | www.dovepress.co m Dove press  111Case Repo Rtopen access to scientific and medical research open access Full text article http: //dx.doi.org/10.2147/IMCRJ.S6134 8Unusual mechanism of myocardial infarction   in prosthetic valve endocarditis Fernando a atik1  Vanessa G Campos2 Claudio R da Cunha1 Felipe Bezerra Martins de  oliveira1 Maria estefânia Bosco  otto2 Guilherme U Monte2 1Department of Cardiovascular  surgery, Instituto de Cardiologia  do Distrito Federal, Fundação  Universitária de Cardiologia, Brasília,   Distrito Federal, Brazil;  2Department  of Cardiovascular Medicine,   Instituto de Cardiologia do Distrito  Federal, Fundação Universitária de  Cardiologia, Brasília, Distrito Federal,   Brazil Correspondence: Fernando a atik   sQsW  102 Bl D apto  508,   70670-204 Brasília, Distrito   Federal, Brazil   tel +55 61 3222 5110  email atikf@mac.co mAbstract:  A 46-year-old man with bicuspid aortic valve and severe calcific aortic stenosis was  submitted to aortic valve replacement with a stented bioprosthesis.",Non-OADS,/arxiv_data1/oa_pdf/66/3d/imcrj-8-111.PMC4448920.pdf
"International Medical Case Reports Journal Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-medical-case-reports-journal-journa lThe International Medical Case Reports Journal is an international,  peer-reviewed open-access journal publishing original case reports  from all medical specialties.",Non-OADS,/arxiv_data1/oa_pdf/66/3d/imcrj-8-111.PMC4448920.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/66/3d/imcrj-8-111.PMC4448920.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/87/2e/ijn-10-3751.PMC4448921.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pInternational Journal of Nanomedicine 2015:10 3751–3760International Journal of Nanomedicine Dove press submit your manuscript | www.dovepress.co m Dove press  3751OrIg INal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/IJN.S8205 0Nanoalumina induces apoptosis by impairing  antioxidant enzyme systems in human  hepatocarcinoma cells saud alarifi Daoud ali saad alkahtani Department of Zoology, college of  science, King saud University, riyadh,   saudi arabiaAbstract:  Alumina nanoparticles (Al2O3NPs) are gradually used in various areas, including  nanomedicine, biosensors, and electronics.",Non-OADS,/arxiv_data1/oa_pdf/87/2e/ijn-10-3751.PMC4448921.pdf
"Their potential toxicological  impacts are still a matter of investigation, and our actual knowledge on the effects of correspondence: Daoud ali Department of Zoology, college of  science, King saud University, Box 2455,  riyadh 11451, saudi arabia Mob +966 55 890 4621 Fax +467 8514 email daudali.ksu12@yahoo.co m Journal name: International Journal of Nanomedicine Article Designation: Original Research Y ear: 2015 Volume: 10 Running head verso: Alarifi et al Running head recto: Al2O3NPs induce apoptosis by impairing antioxidant systems in HepG2 DOI: http://dx.doi.org/10.2147/IJN.S82050",Non-OADS,/arxiv_data1/oa_pdf/87/2e/ijn-10-3751.PMC4448921.pdf
"International Journal of Nanomedicine Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-nanomedicine-journa lThe International Journal of Nanomedicine is an international, peer- reviewed journal focusing on the application of nanotechnology   in diagnostics, therapeutics, and drug delivery systems throughout   the biomedical field.",Non-OADS,/arxiv_data1/oa_pdf/87/2e/ijn-10-3751.PMC4448921.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/87/2e/ijn-10-3751.PMC4448921.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/ff/41/jaa-8-051.PMC4448922.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pJournal of Asthma and Allergy 2015:8 51–61Journal of Asthma and Allergy Dove press submit your manuscript | www.dovepress.co m Dove press  51OriginAl reseArchopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/JAA.S8024 5The impact of parental history on children’s risk  of asthma: a study based on the national health  and nutrition examination survey-iii rengyi Xu1 sara B DeMauro2 rui Feng1 1Department of Biostatistics and  epidemiology, Perelman school  of Medicine at the University of  Pennsylvania, Philadelphia, PA, UsA;   2Division of neonatology, Perelman  school of Medicine at the University  of Pennsylvania and The children’s  hospital of Philadelphia, Philadelphia,  PA, UsA correspondence: rui Feng   Department of Biostatistics and  epidemiology, University of Pennsylvania  Perelman school of Medicine,   209 Blockley hall,  423 guardian Drive,  Philadelphia, PA  19104, UsA   Tel +1 215 746 4473  Fax +1 215 573 1050  email ruifeng@mail.med.upenn.ed uPurpose:  This study aimed to examine the separate effects of maternal and paternal history  on the onset of asthma in children and evaluate the relationship between age of asthma onset  in parents and risk of asthma in their children.",Non-OADS,/arxiv_data1/oa_pdf/ff/41/jaa-8-051.PMC4448922.pdf
Available at: http://www.cdc.gov/healthyweight/ assessing/bmi/adult_bmi/index.html?s_cid =tw_ob06 4.,Non-OADS,/arxiv_data1/oa_pdf/ff/41/jaa-8-051.PMC4448922.pdf
"Journal of Asthma and Allergy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/journal-of-asthma-and-allergy-journa lThe Journal of Asthma and Allergy is an international, peer-reviewed  open-access journal publishing original research, reports, editorials  and commentaries on the following topics: Asthma; Pulmonary physi - ology; Asthma related clinical health; Clinical immunology and the  immunological basis of disease; Pharmacological interventions and new therapies.",Non-OADS,/arxiv_data1/oa_pdf/ff/41/jaa-8-051.PMC4448922.pdf
Visit http://www.dovepress.com/testimonials.ph p to read  real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/ff/41/jaa-8-051.PMC4448922.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/c8/7d/ott-8-1185.PMC4448923.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pOncoTargets and Therapy 2015:8 1185–1191OncoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  1185Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OTT .S7811 6hgF and nrg1 protein expression are not poor  prognostic markers in surgically resected lung  adenocarcinoma Bin Pan1,2 rui Wang1,2 Yangle huang1,2 David garfield3 Jie Zhang1,2 haiquan chen1,2 1Department of Thoracic surgery,   Fudan University shanghai cancer  center, shanghai, People’s republic  of china; 2Department of Oncology,   shanghai Medical college, Fudan  University, shanghai, People’s republic  of china; 3University of colorado  comprehensive cancer center,   aurora, cO, UsaPurpose:  Although over-expression of hepatocyte growth factor (HGF) and neuregulin-1  (NRG1) are important mechanisms involved in acquired drug-resistance in many cancers, few  reports have evaluated their clinicopathologic features and prognostic significance.",Non-OADS,/arxiv_data1/oa_pdf/c8/7d/ott-8-1185.PMC4448923.pdf
"In that regard, some receptor tyrosine kinase (RTK) ligands known to be correspondences: Jie Zhang;  haiquan chen Department of Thoracic surgery, Fudan  University shanghai cancer center,  270 Dong’an road, shanghai 200032,  People’s republic of china Tel +86 21 6417 5590 2500; +86 21 6417 5590 1707 email zhangjie2289@hotmail.co m;  hqchen1@yahoo.co mJournal name: OncoTargets and Therapy Article Designation: Original Research Y ear: 2015 Volume: 8 Running head verso: Pan et al Running head recto: HGF and NRG1 protein expression are not poor prognostic markers DOI: http://dx.doi.org/10.2147/OTT.S78116",Non-OADS,/arxiv_data1/oa_pdf/c8/7d/ott-8-1185.PMC4448923.pdf
"OncoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncotargets-and-therapy-journa lOncoTargets and Therapy is an international, peer-reviewed, open  access journal focusing on the pathological basis of all cancers, potential  targets for therapy and treatment protocols employed to improve the  management of cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/c8/7d/ott-8-1185.PMC4448923.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/c8/7d/ott-8-1185.PMC4448923.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/54/00/dddt-9-2705.PMC4448924.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pDrug Design, Development and Therapy 2015:9 2705–2719Drug Design, Development and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  2705Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/DDDT .S8094 8synthesis and characterization of tumor-targeted  copolymer nanocarrier modified by transferrin ran liu1,2 Y onglu Wang1,3 Xueming li3 Wen Bao1,2 guohua Xia1,2 Wei chen3 Jian cheng1,2 Yuanlong Xu3 liting guo1,2 Baoan chen1,2 1Department of hematology  (Key Department of Jiangsu Medicine),   Zhongda hospital, Medical school,   2Faculty of Oncology, Medical school,   southeast University, 3college of  Pharmacy, nanjing University of  Technology, Nanjing, People’s Republic  of chinaAbstract:  To increase the encapsulation of hydrophilic antitumor agent daunorubicin (DNR)  and multidrug resistance reversal agent tetrandrine (Tet) in the drug delivery system of nano - particles (NPs), a functional copolymer NP composed of poly(lactic- co-glycolic acid) (PLGA),  poly- l-lysine (PLL), and polyethylene glycol (PEG) was synthesized and then loaded with  DNR and Tet simultaneously to construct DNR/Tet–PLGA–PLL–PEG-NPs using a modified  double-emulsion solvent evaporation/diffusion method.",Non-OADS,/arxiv_data1/oa_pdf/54/00/dddt-9-2705.PMC4448924.pdf
"Compared to verapamil and cyclosporin A, Tet exhibited a stronger activity to correspondence: Baoan chen Department of hematology, Zhongda  hospital, Medical school, southeast  University, Dingjiaqiao no 87, gulou  District, nanjing, Jiangsu, 210009,  People’s Republic of China Tel +86 25 8327 2006 Fax +86 25 8327 2011 email cba8888@hotmail.co m Journal name: Drug Design, Development and Therapy Article Designation: Original Research Y ear: 2015 Volume: 9 Running head verso: Liu et al Running head recto: Tumor-targeted copolymer nanocarrier DOI: http://dx.doi.org/10.2147/DDDT.S80948",Non-OADS,/arxiv_data1/oa_pdf/54/00/dddt-9-2705.PMC4448924.pdf
"Drug Design, Development and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/drug-design-development-and-therapy-journa lDrug Design, Development and Therapy is an international, peer- reviewed open-access journal that spans the spectrum of drug design  and development through to clinical applications.",Non-OADS,/arxiv_data1/oa_pdf/54/00/dddt-9-2705.PMC4448924.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/54/00/dddt-9-2705.PMC4448924.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/27/6f/dddt-9-2745.PMC4448925.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpDrug Design, Development and Therapy 2015:9 2745–2756Drug Design, Development and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  2745Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/DDDT .S8407 0soluplus®/TPgs-based solid dispersions prepared  by hot-melt extrusion equipped with twin-screw  systems for enhancing oral bioavailability  of valsartan Jae-Y oung lee1,* Wie-soo Kang2,* Jingpei Piao2 in-soo Y oon3 Dae-Duk Kim1 hyun-Jong cho4 1college of Pharmacy and research  institute of Pharmaceutical sciences,    seoul national University, seoul,   2school of Bioscience and   Biotechnology, Kangwon national  University, chuncheon, 3college  of Pharmacy and natural Medicine  research institute, Mokpo national  University, Jeonnam, 4college  of Pharmacy, Kangwon national  University, chuncheon, republic  of Korea *These authors contributed equally  to this workBackground:  Soluplus® (SP) and d-alpha-tocopherol polyethylene glycol 1000 succinate  (TPGS)–based solid dispersion (SD) formulations were developed by hot-melt extrusion (HME)  to improve oral bioavailability of valsartan (VST).",Non-OADS,/arxiv_data1/oa_pdf/27/6f/dddt-9-2745.PMC4448925.pdf
"The mixing and dispersing of the drugs and polymers correspondence: Dae-Duk Kim college of Pharmacy and research  institute of Pharmaceutical sciences,  seoul national University, 1 gwanak-ro,  gwanak-gu, seoul 151-742, republic  of Korea Tel +82 2 880 7870 Fax +82 2 873 9177 email ddkim@snu.ac.k r  hyun-Jong cho college of Pharmacy, Kangwon national  University, 1 Kangwondaehak-gil,  chuncheon 200-701, republic of Korea Tel +82 33 250 6916 Fax +82 33 259 5631 email hjcho@kangwon.ac.k r Journal name: Drug Design, Development and Therapy Article Designation: Original Research Y ear: 2015 Volume: 9 Running head verso: Lee et al Running head recto: Soluplus®/TPGS-based solid dispersion DOI: http://dx.doi.org/10.2147/DDDT.S84070",Non-OADS,/arxiv_data1/oa_pdf/27/6f/dddt-9-2745.PMC4448925.pdf
"Drug Design, Development and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/drug-design-development-and-therapy-journa lDrug Design, Development and Therapy is an international, peer- reviewed open-access journal that spans the spectrum of drug design  and development through to clinical applications.",Non-OADS,/arxiv_data1/oa_pdf/27/6f/dddt-9-2745.PMC4448925.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/27/6f/dddt-9-2745.PMC4448925.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/a0/fc/tcrm-11-837.PMC4448926.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pTherapeutics and Clinical Risk Management 2015:11 837–850Therapeutics and Clinical Risk Management Dove press submit your manuscript | www.dovepress.co m Dove press  837PERSPECTIVESopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/TCRM.S8323 0Transtracheal single-point stent fixation in  posttracheotomy tracheomalacia under cone-beam  computer tomography guidance by transmural  suturing with the Berci needle – a perspective on a  new tool to avoid stent migration of Dumon stents Wolfgang Hohenforst-Schmidt1,9 Bernd Linsmeier2 Paul Zarogoulidis3 Lutz Freitag4 Kaid Darwiche4 Robert Browning5 J Francis T urner6 Haidong Huang7 Qiang Li7 Thomas Vogl8 Konstantinos Zarogoulidis3 Johannes Brachmann9 Harald Rittger1 1Medical Clinic I, “Fuerth” Hospital, University  of Erlangen, Fuerth, Germany; 2Department of  Thoracic Surgery, Medinos Clinic Sonneberg,   Sonnerberg, Germany; 3Pulmonary Department- Oncology Unit, “G.",Non-OADS,/arxiv_data1/oa_pdf/a0/fc/tcrm-11-837.PMC4448926.pdf
"Papanikolaou” General Hospital, Aristotle  University of Thessaloniki, Thessaloniki, Greece Fax +30 23 1099 2424 Tel +30 69 7727 1974 Email pzarog@hotmail.co m Journal name: Therapeutics and Clinical Risk Management Article Designation: PERSPECTIVES Y ear: 2015 Volume: 11 Running head verso: Hohenforst-Schmidt et al Running head recto: Transtracheal single-point stent fixation in posttracheotomy tracheomalacia DOI: http://dx.doi.org/10.2147/TCRM.S83230",Non-OADS,/arxiv_data1/oa_pdf/a0/fc/tcrm-11-837.PMC4448926.pdf
"Therapeutics and Clinical Risk Management Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/therapeutics-and-clinical-risk-management-journa lTherapeutics and Clinical Risk Management is an international, peer- reviewed journal of clinical therapeutics and risk management, focusing  on concise rapid reporting of clinical studies in all therapeutic areas,  outcomes, safety, and programs for the effective, safe, and sustained  use of medicines.",Non-OADS,/arxiv_data1/oa_pdf/a0/fc/tcrm-11-837.PMC4448926.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/a0/fc/tcrm-11-837.PMC4448926.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/cd/39/dddt-9-2757.PMC4448927.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pDrug Design, Development and Therapy 2015:9 2757–2766Drug Design, Development and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  2757Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/DDDT .S7983 7Combination therapy of fenofibrate and  ursodeoxycholic acid in patients with primary  biliary cirrhosis who respond incompletely  to UDCA monotherapy: a meta-analysis Yan Zhang1,2,* Sainan Li1,* Lei He1 Fan wang1 Kan Chen1 Jingjing Li1 T ong Liu1 Yuanyuan Zheng1 Jianrong wang1,3 wenxia Lu1,3 Yuqing Zhou1,4 Qin Yin1,4 Yujing Xia1 Yingqun Zhou1 Jie Lu1 Chuanyong Guo1 1Department of Gastroenterology,  Shanghai T enth People’s Hospital,  T ongji University School of Medicine,  Shanghai, 2Sir Run Run Shaw Hospital,  Zhejiang University School of  Medicine, Hangzhou, 3The First Clinical  Medical College of Nanjing Medical  University, Nanjing, 4The First Affiliated  Hospital of Soochow University,  Suzhou, People’s Republic of China *These authors contributed equally  to this workBackground:  Although the effectiveness of treatment with ursodeoxycholic acid (UDCA) and  fenofibrate for primary biliary cirrhosis (PBC) has been suggested by small trials, a systematic  review to summarize the evidence has not yet been carried out.",Non-OADS,/arxiv_data1/oa_pdf/cd/39/dddt-9-2757.PMC4448927.pdf
"Keywords:  randomized controlled trials, combination therapy, monotherapy, fibrates, odds  ratio, risk difference Introduction Primary biliary cirrhosis (PBC) is a chronic progressive inflammatory autoimmune- mediated cholestatic disease that mainly occurs in elderly women and is character - ized by progressive inflammatory destruction of the interlobular bile duct, and the  subsequent development of liver fibrosis and cirrhosis, eventually leading to liver  failure.1 The etiology and exact pathogenesis of PBC are still not entirely clear, and  may be related to genetic factors, viral and bacterial infections, autoimmune status,  and environmental factors.2 Ursodeoxycholic acid (UDCA) is currently the only  United States Food and Drug Administration (FDA)-approved and the 2009 American  Association for the Study of Liver Diseases Practice Guidelines-recommended drug  for the treatment of PBC.3 UDCA therapy for PBC is very safe, and it can improve Correspondences: Chuanyong Guo; Jie Lu Department of Gastroenterology,  Shanghai Tenth People’s Hospital,  Tongji University School of Medicine,  Shanghai 200072, People’s Republic  of China email guochuanyong@hotmail.co m;  kennisren@hotmail.co mJournal name: Drug Design, Development and Therapy Article Designation: Review Y ear: 2015 Volume: 9 Running head verso: Zhang et al Running head recto: UDCA and primary biliary cirrhosis DOI: http://dx.doi.org/10.2147/DDDT.S79837",Non-OADS,/arxiv_data1/oa_pdf/cd/39/dddt-9-2757.PMC4448927.pdf
"Drug Design, Development and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/drug-design-development-and-therapy-journa lDrug Design, Development and Therapy is an international, peer- reviewed open-access journal that spans the spectrum of drug design  and development through to clinical applications.",Non-OADS,/arxiv_data1/oa_pdf/cd/39/dddt-9-2757.PMC4448927.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/cd/39/dddt-9-2757.PMC4448927.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/36/70/opth-9-929.PMC4448928.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pClinical Ophthalmology 2015:9 929–933Clinical Ophthalmology Dove press submit your manuscript | www.dovepress.co m Dove press  929Case repO rtopen access to scientific and medical research Open access Full text article http: //dx.doi.org/10.2147/OPTH.S8085 0Diabetic glomerulosclerosis can be the  pathogenesis of refractory diabetic macular  edema eman saeed al Kahtani King Khaled eye specialist Hospital,   riyadh, saudi arabiaBackground:  Kidney failure provoked by glomerulosclerosis leads to fluid filtration deficits and  other disorders of kidney function.",Non-OADS,/arxiv_data1/oa_pdf/36/70/opth-9-929.PMC4448928.pdf
"The patient was diagnosed with diabetic glomerulosclerosis Correspondence: eman saeed al Kahtani King Khaled eye specialist Hospital,  pO Box 7191, riyadh 11462,  Kingdom of saudi arabia tel +966 11 482 1234 ext 2049 Fax +966 11 482 1234 ext 2044 email ekahtani@kkesh.med.s aJournal name: Clinical Ophthalmology Article Designation: Case report Y ear: 2015 Volume: 9 Running head verso: Al Kahtani Running head recto: Diabetic glomerulosclerosis and refractory diabetic macular edema DOI: http://dx.doi.org/10.2147/OPTH.S80850",Non-OADS,/arxiv_data1/oa_pdf/36/70/opth-9-929.PMC4448928.pdf
"Clinical Ophthalmology Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-ophthalmology-journa lClinical Ophthalmology is an international, peer-reviewed journal  covering all subspecialties within ophthalmology.",Non-OADS,/arxiv_data1/oa_pdf/36/70/opth-9-929.PMC4448928.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/36/70/opth-9-929.PMC4448928.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/92/85/opth-9-935.PMC4448929.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pClinical Ophthalmology 2015:9 935–942Clinical Ophthalmology Dove press submit your manuscript | www.dovepress.co m Dove press  935Original researChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OPTH.S8379 8Optical coherence tomography to evaluate  the interaction of different edge designs  of four different silicone hydrogel lenses  with the ocular surface semra akkaya T urhan ebru T oker Department of Ophthalmology,   school of Medicine, University  of Marmara, istanbul, T urkeyPurpose:  To evaluate the lens edge interaction with the ocular surface with different edge  designs using optical coherence tomography and to examine the effect of lens power on the  lens edge interactions.",Non-OADS,/arxiv_data1/oa_pdf/92/85/opth-9-935.PMC4448929.pdf
"Inappropriate lens fit is responsible for 7% of contact  lens discontinuations.1 The primary reasons for discontinuation of contact lens wear  over time have been reported to be discomfort, dryness, and red eyes.2,3 Comfort may  be the most important factor in determining success versus failure of a contact lens Correspondence: ebru Toker Department of Ophthalmology, school  of Medicine, University of Marmara,  Fevzi Çakmak Mah, Muhsin Yazıcıog ˘lu  Cad, no 10 Üst Kaynarca, Pendik,  istanbul 34899, Turkey Tel +90 532 694 6212 email dretoker@gmail.co m Journal name: Clinical Ophthalmology Article Designation: Original Research Y ear: 2015 Volume: 9 Running head verso: Turhan and Toker Running head recto: Optical coherence tomography of silicone hydrogel lenses DOI: http://dx.doi.org/10.2147/OPTH.S83798",Non-OADS,/arxiv_data1/oa_pdf/92/85/opth-9-935.PMC4448929.pdf
"Clinical Ophthalmology Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-ophthalmology-journa lClinical Ophthalmology is an international, peer-reviewed journal  covering all subspecialties within ophthalmology.",Non-OADS,/arxiv_data1/oa_pdf/92/85/opth-9-935.PMC4448929.pdf
Visit http://www.dovepress.com/ testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/92/85/opth-9-935.PMC4448929.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/77/66/ppa-9-707.PMC4448930.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pPatient Preference and Adherence 2015:9 707–714Patient Preference and Adherence Dove press submit your manuscript | www.dovepress.co m Dove press  707OriginAl reseArchopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/PPA.S7295 2contraceptive prevalence and preference in   a cohort of south–east nigerian women John Okafor egede1 robinson chukwudi Onoh1 Odidika Ugochukwu  Joannes Umeora1 chukwuemeka Anthony  iyoke2 ikechukwu Benedict  Okechukwu Dimejesi1 lucky Osaheni lawani1 1Department of Obstetrics and  gynecology, Federal T eaching hospital,   Abakaliki, ebonyi state, n igeria;   2Department of Obstetrics and  gynaecology, University of nigeria  T eaching hospital, ituku-Ozalla,   enugu,  nigeriaBackground:  Rates of fertility, population growth, and maternal deaths in Nigeria are among the  highest in the world, with an estimated 4% of all births being unwanted and 7% mistimed.",Non-OADS,/arxiv_data1/oa_pdf/77/66/ppa-9-707.PMC4448930.pdf
"Keywords:  barrier method, contraceptive methods, market women, Nigeria, prevalence Introduction Unexpected or unplanned pregnancy poses a major public health challenge for women  of reproductive age, especially in developing countries.1 It is estimated that approxi - mately 210 million pregnancies occur annually worldwide, with 80 million (38%) being  unplanned and 46 million (22%) ending in abortion.2 Nigeria, with a population close  to 160 million, an estimated national growth rate of 3.2%, and a total fertility rate of  5.7 and 6.3 in urban and rural areas, respectively, has an estimated maternal death rate  of 545 per 100,000 live births and 6.8 million pregnancies annually, of which 16% end  in spontaneous miscarriage and 11% in induced abortion.3,4 Overall, 4% of all births in  Nigeria are unwanted, while 7% are mistimed (wanted later).3 More than 200 million  women in developing countries would like to delay their next pregnancy or even stop correspondence: robinson chukwudi  Onoh Department of Obstetrics and  gynecology, Federal Teaching hospital,  Pmb 102, Abakaliki, ebonyi state,  480001 nigeria Tel +23 480 3700 7519 email drrobonoh@gmail.co m Journal name: Patient Preference and Adherence Article Designation: Original Research Y ear: 2015 Volume: 9 Running head verso: Egede et al Running head recto: Contraceptive prevalence and preference in Nigeria DOI: http://dx.doi.org/10.2147/PPA.S72952",Non-OADS,/arxiv_data1/oa_pdf/77/66/ppa-9-707.PMC4448930.pdf
"Available  from: http://dhsprogram.com/pubs/pdf/fr222/fr222.pd f. Accessed April 26,   2015.",OADS,/arxiv_data1/oa_pdf/77/66/ppa-9-707.PMC4448930.pdf
"Patient Preference and Adherence Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/patient-preference-and-adherence-journa lPatient Preference and Adherence is an international, peer-reviewed,  open access journal that focuses on the growing importance of patient   preference  and adherence throughout the therapeutic continuum.",Non-OADS,/arxiv_data1/oa_pdf/77/66/ppa-9-707.PMC4448930.pdf
"Available from: http://www.un.org/popin/icpd5.ht m. Accessed  April 30, 2015.",Non-OADS,/arxiv_data1/oa_pdf/77/66/ppa-9-707.PMC4448930.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/84/1c/jpr-8-247.PMC4448931.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.ph pJournal of Pain Research 2015:8 247–252Journal of Pain Research Dove press submit your manuscript | www.dovepress.co m Dove press  247ORiginal ReseaRchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/JPR.S8437 6T wo-year follow-up of low-level laser therapy   for elderly with painful adhesive capsulitis   of the shoulder David ip nga-Yue Fu asia Medical Pain centre,    Mong Kok, hong Kong,    People’s Republic of china correspondence: David ip   asia Medical Pain centre,  4/F Tower  2   grand Plaza, Mong Kok, hong Kong,  People’s Republic of china   Tel +852 2388 0389  email ipdavid@hotmail.com.h kIntroduction:  This paper reports on the medium-term mean  2-year prospective follow-up of  a patient cohort of  35 unselected elderly patients with mean age of  65 years who visited our  tertiary referral pain center for painful adhesive capsulitis of the shoulder managed with low- level laser therapy (LLLT).",Non-OADS,/arxiv_data1/oa_pdf/84/1c/jpr-8-247.PMC4448931.pdf
"Journal of Pain Research Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/journal-of-pain-research-journa lThe Journal of Pain Research is an international, peer-reviewed, open  access, online journal that welcomes laboratory and clinical findings  in the fields of pain research and the prevention and management  of pain.",Non-OADS,/arxiv_data1/oa_pdf/84/1c/jpr-8-247.PMC4448931.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/84/1c/jpr-8-247.PMC4448931.pdf
"Journal of Visualized Experiments www.jove.com Copyright © 2014  Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported LicenseAugust 2014 |  90  | e51673 | Page 1 of 15Video Article From Voxels to Knowledge: A Practical Guide to the Segmentation of Complex Electron Microscopy 3D-Data Wen-Ting Tsai1, Ahmed Hassan1, Purbasha Sarkar2, Joaquin Correa1,3, Zoltan Metlagel1, Danielle M. Jorgens1, Manfred Auer1,2 1Life Sciences Division, Lawrence Berkeley National Laboratory 2Joint Bioenergy Institute, Physical Biosciences Division, Lawrence Berkeley National Laboratory 3National Energy Research Scientific Computing Center, Lawrence Berkeley National Laboratory Correspondence to: Manfred Auer at mauer@lbl.gov URL: http://www.jove.com/video/51673 DOI: doi:10.3791/51673 Keywords: Bioengineering, Issue 90, 3D electron microscopy, feature extraction, segmentation, image analysis, reconstruction, manual tracing, thresholding Date Published: 8/13/2014 Citation: Tsai, W.T., Hassan, A., Sarkar, P., Correa, J., Metlagel, Z., Jorgens, D.M., Auer, M. From Voxels to Knowledge: A Practical Guide to the Segmentation of Complex Electron Microscopy 3D-Data.",Non-OADS,/arxiv_data1/oa_pdf/92/78/jove-90-51673.PMC4448944.pdf
"Video Link The video component of this article can be found at http://www.jove.com/video/51673/ Introduction Traditionally, the electron microscopy (EM) field has been divided into 1) the structural biology branch using high and super-high resolution TEM, typically combined with implicit or explicit data averaging to investigate the three-dimensional (3D) structure of macromolecular complexes with a defined composition and typically a relatively small size1-4, and 2) the cellular imaging branch in which entire cellular sceneries are visualized1,5,6.",Non-OADS,/arxiv_data1/oa_pdf/92/78/jove-90-51673.PMC4448944.pdf
"For an example of software with manual abstracted model generation, please visit Chimera’s detailed user guide online at http://www.cgl.ucsf.edu/chimera/current/docs/UsersGuide/index.html.",Non-OADS,/arxiv_data1/oa_pdf/92/78/jove-90-51673.PMC4448944.pdf
"For an example of software with manual tracing, please visit Amira’s detailed user guide online at http://www.vsg3d.com/sites/default/files/Amira_Users_Guide.pdf.",Non-OADS,/arxiv_data1/oa_pdf/92/78/jove-90-51673.PMC4448944.pdf
"For an example of software with automated density-based segmentation, please visit Amira’s detailed user guide online at http://www.vsg3d.com/sites/default/files/Amira_Users_Guide.pdf.",Non-OADS,/arxiv_data1/oa_pdf/92/78/jove-90-51673.PMC4448944.pdf
The 3D structure of human ADA1 was obtained from Protein Data Bank(http://www.rcsb.org/pdb).,OADS,/arxiv_data1/oa_pdf/74/62/prp20003-e00121.PMC4448975.pdf
"Available at: http://chem.sis.nlm.nih.gov/chemidplus/ chemidlite.jsp Cho JS, Kim TH, Lim J-M, Song J-H (2008).",OADS,/arxiv_data1/oa_pdf/69/8d/prp20003-e00127.PMC4448976.pdf
"Simulation, data handling, and plotting were performed in R (http://cran.r-project.org/, version 2.10.0).Model estimation was performed with nonlinear mixed-effects modeling implemented in NONMEM VI level 2.0or NONMEM VII (both ICON Development Solutions,Ellicott City, MD; Beal and Sheiner 1989).",OADS,/arxiv_data1/oa_pdf/e3/ec/prp20003-e00131.PMC4448983.pdf
Disclosures The clinical trial from which the actual PK data set was obtained was sponsored by Eisai Co. All authors havecompleted the Uniﬁed Competing Interest form athttp://www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: R. J. K. was supported by a grant from the Eisai network ofcompanies; no ﬁnancial relationships with any organiza-tions that might have an interest in the submitted workin the previous 3 years; no other relationships or activi- ties that could appear to have inﬂuenced the submitted work.,Non-OADS,/arxiv_data1/oa_pdf/e3/ec/prp20003-e00131.PMC4448983.pdf
"FDA, http://www.fda.gov/downloads/Drugs/ Guidances/ucm070107.pdf.",Non-OADS,/arxiv_data1/oa_pdf/e3/ec/prp20003-e00131.PMC4448983.pdf
Available at http://www.ncbi.nlm.nih.gov/pubmed/20122883 [Internet].,OADS,/arxiv_data1/oa_pdf/e3/ec/prp20003-e00131.PMC4448983.pdf
Available at http://www.ncbi.nlm.nih.gov/pubmed/18712503 [Internet].,Non-OADS,/arxiv_data1/oa_pdf/e3/ec/prp20003-e00131.PMC4448983.pdf
"To view a copy of this license, visit http://creativecommons.org/ licenses/by-nc-sa/3.0/  Supplementary Information accompanies this paper on the Molecular Therapy—Methods & Clinical Development website (http://www.nature.com/mtm)",Non-OADS,/arxiv_data1/oa_pdf/c6/e6/mtm201456.PMC4448995.pdf
"To view a copy of this license, visit http://creativecommons.org/ licenses/by-nc-sa/3.0/  Supplementary Information accompanies this paper on the Molecular Therapy—Methods & Clinical Development website (http://www.nature.com/mtm)",Non-OADS,/arxiv_data1/oa_pdf/50/67/mtm201457.PMC4448996.pdf
"To view a copy of this license, visit http://creativecommons.org/ licenses/by-nc-sa/3.0/",Non-OADS,/arxiv_data1/oa_pdf/31/40/mtm201459.PMC4448997.pdf
"To view a copy of this license, visit http://creativecommons.org/ licenses/by-nc-nd/4.0/ Supplementary Information accompanies this paper on the Molecular Therapy—Methods & Clinical Development website (http://www.nature.com/mtm)",Non-OADS,/arxiv_data1/oa_pdf/a8/60/mtm201461.PMC4449016.pdf
